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Immune cell therapies have revolutionized our idea of a drug. Essentially they are a 
living drug becoming increasingly used because of their specificity (antigen targeting), 
durability (memory cells), and success seen in the clinic. Yet immune cell therapies, such 
as T cell immunotherapies, face substantial challenges for widespread adoption, including 
difficulty in target identification, complexity, cost, and inability to maintain and control 
cell function ex vivo. To solve issues facing T cell immunotherapies I engineered several 
novel biomaterials. I engineered magnetic particles to enrich and detect antigen-specific 
T cells in high-throughput which extends our capability to detect hundreds of antigen-
specific T cells at once. This enables a greater understanding of the adaptive immune 
responses and also facilitates tailoring a precision medicine approach to antigen-specific 
T cell therapies. I also engineered extracellular matrix hydrogels for ex vivo and for in 
vivo stimulation, which preserves and improves cellular function and reduces the cost and 
labor, decreasing barriers to patients in the future. Finally, the engineering process for 
optimal properties of these biomaterials also revealed key biology of T cells such as 
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Chapter 1. Summary and Organization of the 
Dissertation 
The organization of the dissertation is as follows: 
 Chapter 2 provides an overview of the importance of T cells in the adaptive 
immune response and their current clinical importance. Furthermore, it focuses as a broad 
introduction to the field of what has been done in terms of engineering T cells with 
techniques such as biomaterials. Finally, it distills critical design constraints to consider 
when designing and engineering a platform to interact or modulate T cells. This was 
published as a book chapter with the following information: “Hickey, John W., Alyssa K. 
Kosmides, and Jonathan P. Schneck. "Engineering Platforms for T Cell Modulation." 
International review of cell and molecular biology 341 (2018): 277-362.” 
 Chapter 3 is the manuscript: Hickey, John W., et al. "Biologically inspired design 
of nanoparticle artificial antigen-presenting cells for immunomodulation." Nano letters 
17.11 (2017): 7045-7054. The data and story center around using information about 
nano-scale organization of cell receptors and designing effective cell-
modulating/signaling nanoparticles. More specifically, we engineered artificial antigen 
presenting cells (aAPCs) by both size and ligand density that can activate antigen-specific 
CD8+ T cells for immunotherapeutic applications. 
 Chapter 4 is the manuscript: Hickey, John W., et al. "Efficient magnetic 
enrichment of antigen-specific T cells by engineering particle properties." Biomaterials 
187 (2018): 105-116. The data and story center around probing the nanoparticle 
biomaterial design space (size, ligand density, ligand choice, concentration) to increase 
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antigen-specific T cell enrichment while considering T cell biology. Here we create 
nanoparticle artificial antigen-presenting cells (aAPCs) that both enrich and expand 
antigen-specific CD8+ T cells to levels necessary for both diagnostic and therapeutic 
applications. This quantitative analysis and investigation to nanoparticle design properties 
was lacking within both the fields of cell-modulating/enriching particles and aAPC 
technology. 
 Chapter 5 is the manuscript Hickey, John W., et al. "Increasing the Throughput 
and Adaptability of Nanoparticle Tools to Isolate and Identify Many Antigen-specific T 
cells." In Preparation. The data and story center around engineering both magnetic 
particle properties and the methods of enriching and expanding rare antigen-specific T 
cells for detection. We build off our work in Chapters 3 and 4 to use larger, more 
effective 300 nm aAPCs to enrich and expand antigen-specific T cells in a higher-
throughput 96-well plate. What’s more, we create universal aAPC and detection beads to 
multiplex the system further. This work provides a platform to increase the throughput of 
enrichment and expansion and increase its adaptability and adoption by other 
laboratories.  
 Chapter 6 is the manuscript Hickey, John W., et al. "Engineering an Artificial T-
Cell Stimulating Matrix for Immunotherapy." Advanced Materials. Resubmitted. The 
data and story center around the creation of a novel, artificial T cell stimulating Matrix 
(aTM) from extracellular matrix (ECM) hydrogels for immunotherapy applications. We 
use a clinically relevant model of adoptive T cell transfer, to test T cells stimulated by our 
new material and compare to traditional materials used to activate T cells. We show 
significant tumor burden delay in an established, aggressive, immunosuppressive murine 
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melanoma with endogenous, antigen-specific T cells stimulated on the aTM compared to 
traditional methods of T cell activation. We investigated important material properties 
key for the significant increase in tumor efficacy. We found both the stiffness of the aTM 
was critical due to the mechanically sensitive signaling through the TCR (T cell receptor) 
in both murine and human T cells. Furthermore, we explored the how the extracellular 
matrix (ECM) influences T cell stimulation and memory phenotype, which has not been 
previously explored in the context of T cell stimulation. It is the unique combination of 
both of these parameters that increases T cell activation and skew the phenotype 
polarization during T cell expansion producing more functional, phenotypically memory 
T cells. What’s more, we utilized this new material with an optimized parameter set, to 
provide both antigen-specific and pan-T cell activation in both murine and human 
systems, which has important implications for both CAR T cell and adoptive T cell 
therapy, ACT. 
 Chapter 7 is a summary of my contributions to other projects not directly my own. 
This includes the work I have done in collaboration with Dr. Green’s lab in creating and 
testing polymeric, biodegradable aAPCs for T cell activation and immunotherapy and my 
contribution to other student’s projects within the lab. Here I will summarize major 
findings rather than in great detail and will not show data as these were not my primary 
thesis projects.  
 Chapter 8 is a general summary of my chapters and outlines potential future work 




Chapter 2. Engineering Platforms for T Cell 
Modulation1 
2.1 Introduction 
The immune system is a complex organization of many different cell types that 
protect the human body from infection and disease. This cellular network is made up of 
innate and adaptive immune cells that can detect and eliminate pathogens with extreme 
precision. The ability of immune cells to provide constant surveillance and protection 
throughout the entire human body makes it a powerful shield against foreign material. 
However, deficiencies in this system can expose vulnerabilities or result in disease. In 
these cases, therapeutics have been developed to modulate the immune response for more 
favorable outcomes.  
Within the adaptive compartment exist T cells, a subset of lymphocytes 
responsible for cell-mediated immunity. T cells can detect and destroy infected cells 
while leaving other nearby healthy cells unharmed. Their precision and cytotoxic ability 
make T cells a popular target for immunotherapies. Because of their complex activation 
pathways, interaction with other cell types, and biodistribution, many emerging 
therapeutics utilize engineering concepts to mimic or alter their normal response. Here, 
we will review these immunoengineering approaches for modulating the T cell response.  
                                                          
1 This chapter is reprinted (adapted) with permission from “Hickey, John W., Alyssa K. Kosmides, and 
Jonathan P. Schneck. "Engineering Platforms for T Cell Modulation." International review of cell and 
molecular biology 341 (2018): 277-362.” Copyright 2018 Elsevier. 
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2.1.1 The T cell response 
Minimally, T cells require two signals for activation—signal 1, a specific peptide 
presented in the context of the major histocompatibility complex (MHC), and signal 2, a 
co-stimulatory signal such as B7/anti-CD28 monoclonal antibody (mAb).1 The peptide-
MHC complex presented by an antigen presenting cell interacts with the T cell via its T 
cell receptor (TCR) and is what confers the specificity of the T cell's activation. Signal 2 
provides co-stimulation and is required for the activation of naïve T cells. B7 on an 
antigen presenting cell, which interacts with CD28 on the T cell, is thought of as the 
prototypical co-stimulatory molecule, although many different co-stimulatory molecules 
exist that modulate the T cell expansion, phenotype, and functionality.2–11 T cells are also 
exposed to a third soluble signal, signal 3, that modulates their activity, including pro-
inflammatory or anti-inflammatory cytokines, which are released in an autocrine and 
paracrine fashion.12 
Before activation, TCR are pre-clustered in small 35-70 nm islands with 7-30 
TCRs per island.13 Upon recognition of cognate antigen, these nanoclusters begin to 
concatenate and form what is known as the immune synapse.14 The lateral organization of 
the microscale immune synapse is defined by supramolecular activation clusters, or 
SMACs. TCR and CD28 co-localize within the central SMAC (cSMAC), with a TCR-
rich core surrounded by a CD28-rich periphery.15,16 Larger adhesion molecules, such as 
LFA-1, localize within the peripheral SMAC (pSMAC).17 This nanoscale co-localization 
of TCR and CD28 is necessary for activation, as separating signal 1 and signal 2 
activation by several microns inhibits T cell activation.18 
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There are two major subsets of T cells—CD4+ and CD8+ T cells, otherwise 
known as T helper cells and cytotoxic T cells, respectively. Upon activation, CD4+ T 
cells differentiate into different subtypes and can carry out multiple functions, from 
activating B lymphocytes to suppressing the immune reaction.19,20 The major subtypes 
include Th1 and Th2, type 1 and 2 T helper cells,19 Th17 cells that play roles in allergy 
and autoimmunity,21 and Treg cells22 that play important roles in immune response 
homeostasis. Cytotoxic CD8+ T cells secrete cytokines and kill target cells upon 
activation.23 This subtype is responsible for selectively eliminating virally infected cells. 
Upon activation, T cells clonally divide, secrete cytokines, and most importantly, 
maintain a memory response that provides long-term protection.  
In most cases, the immune system is a powerful defense against infection and 
disease. However, dysfunctions or deficiencies in any part of the system can reduce its 
effectiveness or even create disease itself. Cancer’s ability to evade immune recognition, 
chronic infection, and autoimmune diseases provide opportunities to intercept and correct 
the immune response. 
2.1.2 The Cancer-Immunity Cycle 
Cancer arises from the culmination of a series of mutations that lead to a break in 
normal cell-regulating functions, including enhanced proliferation or a lack of normal 
apoptotic processes. This can lead to the expression of mutated neo-antigens,24,25 
differentiation antigens, viral antigens, or cancer-testis antigens that can be recognized as 
foreign by the immune system.26 These antigens are presented on major 
histocompatibility class I molecules (MHC-I) by resident dendritic cells (DCs) and 
subsequently activate tumor antigen-specific T cells. While a T cell response can often be 
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mounted against these tumor-antigens, mechanisms of central and peripheral tolerance 
and immunosuppressive actions of the tumor micro-environment often hinder an effective 
immune response.27 
The interplay between cancer and the immune system can be viewed as a 
potentially self-propagating cycle, termed the Cancer-Immunity Cycle, which has been 
elegantly reviewed by Chen and colleagues.28 To achieve effective anti-tumor immunity, 
antigens released upon cancer cell death are processed and presented by antigen 
presenting cells to activate cognate T cells. These T cells may then recognize and kill the 
tumor cells, leading to a positive feedback loop for immune activation. Cancer occurs 
when there is a blockade in a step of this cycle that shields the tumor from immune 
recognition or attack.  
In many cases, tumor antigens do not differ sufficiently from self antigens to be 
recognized as foreign by the immune system. This is evidenced by the fact that tumors 
with higher frequencies of neo-antigens, tumor-specific antigens derived from tumor 
mutations, correlate with better prognosis following immunotherapy.24,29–31 Despite 
mutational load, the immunosuppressive tumor microenvironment also limits the immune 
response. There are three major pathways by which tumor cells evade immune attack—
reduced MHC expression of tumor antigens, secretion of immunosuppressive factors, and 
the upregulation of negative costimulatory pathways within the tumor 
microenvironment.32 Downregulation of MHC expression can protect tumor cell 
recognition by T cells and is often a method of tumor immune escape.33 Tumor or stromal 
cells also can secrete soluble factors, including TGF-β, IL-10, and PGE2, or express 
inhibitory molecules that suppress immune function. Tumor cells that upregulate 
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immunosuppressive TIM family proteins or programmed death ligand 1 (PD-L1) are 
correlated with poor prognosis.34,35 Immunoengineering therapeutics thus often target 
these pathways to establish a more robust T cell response against the tumor.  
2.1.3 Chronic Infection 
Pathogens are usually rapidly eliminated by an adaptive immune response, to 
which effector T cells contribute in large numbers but then quickly contract to a smaller 
subset of memory T cells once the infection has been cleared. However, similar to cancer, 
chronic infection prolongs T cell exposure to antigen and inflammatory signals. This can 
cause ‘exhaustion’ of T cells, limiting their effectiveness.36–38 Exhausted T cells have 
impaired effector function, lose the ability to secrete cytokines, and upregulate expression 
of immunoinhibitory molecules like PD-1 and CTLA-4.  
Examples of chronic infection include viral infections like cytomegalovirus, HIV, 
and hepatitis C virus. T cell exhaustion prevents effective clearance of pathogenic 
infection.39 However, this is not a permanent state as small molecule drugs or checkpoint 
molecules have been shown to reverse T cell functionality.40,41 This provides inspiration 
and hope for engineering approaches to contribute to preventing and rescuing exhausted 
T cells for fighting chronic infection.   
2.1.4 Autoimmunity 
Auotimmunity arises when some level of self-tolerance is broken.42–44 There are 
several mechanisms of generating immunological tolerance, which many times muddles 
the elucidation of direct causes of autoimmunity. Main mechanisms of controlling self-
reactivity include central tolerance, antigen segregation, peripheral tolerance, regulatory 
T cells, and activation-induced cell death.  
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Central tolerance occurs as antigen-specific T cells first go through positive and 
negative selection in the thymus where T cells with strong-affinity TCRs for self-antigen 
are eliminated and those with intermediate binding are selected for. In some cases, strong 
affinity TCRs for self-antigen are selected for and are caused to differentiate into 
regulatory T cells. These cells can dampen the response of other self-reactive antigen-
specific T cells that escape central tolerance. Additionally, self-reactive T cells that 
escape central tolerance can be eliminated by anergy or deletion by stimulation of the 
TCR without co-stimulatory signals.  
Autoimmunity can be triggered by environmental factors, such as an infection, 
but also requires genetic factors. Examples of autoimmune disorders include type 1 
diabetes, rheumatoid arthritis, Chron’s disease, and multiple sclerosis. Severity can be 
manageable to life threatening, and, affecting nearly 8% of the population, it is a critical 
immunological problem to solve, at the root of which are T cells. Many therapies for 
autoimmune diseases are general immunosuppressants that globally downregulate the 
immune system.  However, new therapies that utilize engineering approaches and can 
target specific activation receptors on T cells, activate Tregs for adoptive transfer, and 
engineer cytokine delivery and structure have the potential to work more specifically and 




2.2. T cell Modulation – Properties to consider when 
choosing and designing a T cell modulating platform 
The dynamics of the immune synapse make T cell activation sensitive to many 
micro- and nano-scale properties.46 The organization and composition of signaling 
molecules, as well as substrate size, shape, and stiffness, all play intricate roles in 
modulating T cell activation and resulting phenotype. Immunoengineering approaches 
allow for these factors to be individually varied and optimized. Here, we will review 
many of these properties to consider when engineering a platform to modulate T cell 




Figure 2-1: Properties to consider when choosing and designing a platform for modulating T cell activity. 
Ligand plays a role both in the endogenous density of localized receptors on the T cell surface and the type 
of receptor which could either inhibit or potentiate T cell responses. Size of the platform could influence its 
ability to i) navigate extracellular environment and reach T cells in vivo, ii) be taken up by T cells, or iii) 
enable multiple receptor interactions from the same particle. Shape of the platform could influence the 
number of ligand interactions with increased aspect ratios and limit uptake by non-specific cells. Material 
can a) influence the mechanical interactions with the T cell which can lead to beneficial mechanotraduction 
signaling, b) be utilized for controlled release of immunomodulatory molecules, or c) allow external control 








 Most fundamentally, T cell activation is modulated through different co-
stimulatory and co-inhibitory pathways. When developing a therapeutic, one first has to 
Engineering 
Design Parameter
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Nanoparticle artificial antigen 
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nanoparticles
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Sustained local release of IL-2 and 
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determine which specific signaling pathways to activate or inhibit. In addition to pathway 
choice, ligand nano- and micro-scale arrangement, density, strength, and duration can 
have a great impact on T cell activation.   
 T cells require a signal 1 for activation. This can be provided through stimulating 
the cognate TCR or CD3, which is constitutively associated with the TCR and is 
responsible for its intracellular signaling.47 pMHC stimulation of TCR provides 
activation of only cognate antigen-specific T cells, whereas activation through CD3, with 
an anti-CD3 monoclonal antibody (mAb) for example, activates all T cells regardless of 
specificity.1  
While signal 1 is required for activation to occur, the T cell response to that signal 
is modulated by dozens of types of co-stimulatory and co-inhibitory molecules.48 In the 
absence of any co-stimulation, T cells develop an anergic, under-responsive state. CD28 
is the prototypical co-stimulatory molecule, although several other co-stimulatory 
molecules exist that modify T cell proliferation and phenotype. For example, 4-1BB co-
stimulation has been shown to preferentially activate CD8+ T cells over CD4+ T cells,49 
preferentially activate memory CD8+ T cell populations,6 increase T cell maintenance of 
CD28 expression,5 and increase CD8+ T cell secretion of IL-2.7 Stimulation through the 
co-stimulatory molecules OX40 and CD27 expressed by T cells has also been shown to 
enhance activation.3,4 Importantly, altering the combinations and ratios of different co-
stimulatory molecules without varying total co-stimulation can have tremendous impacts 
on activation.4,8 
Several co-inhibitory pathways exist that diminish T cell activation. Many of 
these pathways are involved with maintaining homeostasis and establishing a self-
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regulated immune response following pathogen removal.50 However, these inhibitory 
pathways can be utilized by cancer to cause immune evasion or be inhibitory or 
dysfunctional in autoimmune diseases and chronic infection and are thus often targets of 
immunotherapeutics. Programmed death 1 (PD-1) and CTLA-4 expressed by T cells are 
two commonly targeted checkpoint molecules.51,52 Monoclonal antibodies blocking these 
checkpoint pathways as well as other immuno-inhibitory molecules such as IDO can 
rescue exhausted T cells.53 Blocking inhibitory pathways along with activating co-
stimulatory pathways can also further augment the T cell response in cancer54,55 and in 
chronic infection.56 
The nano- and micro-scale arrangement of signaling ligands plays an important 
role in modulating the T cell response by engineered platforms as would be speculated 
from the formation of an immune synapse during endogenous activation. At the 
microscale, a focal co-clustering of signal 1 and signal 2 molecules is necessary to initiate 
activation. When anti-CD3 mAb is patterned on a planar substrate in focal spots, T cells 
proliferate and secrete cytokines.57 However, T cell activation is reduced when the same 
anti-CD3 mAb is tethered in an annular pattern that precludes centralized TCR clustering. 
Signal 2 must also be co-clustered with signal 1 during stimulation. Separating anti-CD3 
and anti-CD28 by a distance of several microns inhibits IL-2 cytokine production.18  
In addition to the microscale organization of stimulatory molecules, the TCR 
intermolecular distance must be sufficiently small to induce activation. When anti-CD3 is 
patterned on planar substrates at defined densities, only surfaces displaying anti-CD3 
with intermolecular distances smaller than approximately 60 nm induce optimal 
activation.58,59 Interestingly, the minimum intermolecular distance for CD4+ T cell-
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specific activation with MHC II is close to 115 nm,60 indicating that ligand organization 
may need to be modulated based on the T cell subset to be affected.  
While TCR and CD28 organization have been more extensively studied, some 
data indicate that signaling through other co-stimulatory and co-inhibitory pathways may 
also be sensitive to nanoscale arrangement. T cell inhibition through PD-1 signaling has 
been shown to depend on the formation of microclusters within the immune synapse.61,62 
When the extracellular domain of PD-1 was extended to preclude its co-localization 
within the immune synapse, inhibition was reversed. 4-1BB has also been shown to 
localize within the immune synapse along with CD28 during co-stimulation.63 
2.2.1.1 Density and Impacts on Signal Strength and Duration 
The spatial arrangement of ligands on the surface of both naïve and activated T 
cells also affects the local density of ligands, which in turn has impacts on molecular and 
cellular interactions. TCRs are locally arranged on the surface of quiescent T cells in 
protein islands of about 35-70 nm in diameter and 300 nm in the longest dimension, with 
7-20 TCRs found in one island.13 Indeed, disruption of T cell lipid rafts by cholesterol 
depletion disrupts T cell activation further demonstrating the need for multivalent TCR 
clusters.64 Upon TCR engagement and activation, these TCR nanoislands coalesce to 
form larger microclusters and eventually develop into the central supramolecular 
activation cluster (cSMAC) of the immune synapse.13,65–67 Interestingly, the cognate 
ligand, MHC molecule, is organized similarly on endogenous APCs. As many as 25-125 
MHCs are grouped in 70-600 nm protein patch.68,69 Additionally, it has been shown that 
even specific protein-MHC complexes are clustered on the surface of APCs.70,71 
This nanometer organization is important to modulating the sensitivity of T cell 
signaling. MHC and TCR binding is a low-affinity interaction with µM Kd as compared 
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to nM Kd for antibody-antigen interactions. Kd is a useful description of binding kinetics 
where it is the equilibrium concentration of ligand where half of the ligand is bound to its 
receptor, thus a lower concentration such as a nM Kd has much higher affinity for its 
receptor.72 Consequently, the binding of several MHC and TCR complexes 
simultaneously is beneficial to initiate engagement of cognate APCs and T cells. 
Mathematical models of TCR and MHC binding events also show a need for multiple 
receptors in close proximity.73 The models suggest that the reversible binding between 
MHC and TCR leads to activation when serial binding can occur. 
In addition to initiating signaling between APCs and T cells, multivalent 
interactions would be important to providing sustained signaling.74 Sustained signaling is 
essential for effective T cell activation and can influence the fate and function of resultant 
T cells.75,76 In vivo experiments have shown that once T cells encounter antigen-specific 
APCs in the lymph node, they form stable connections for several hours.77 These studies 
also demonstrated that this sustained connection is dependent on stable pMHC-TCR 
interactions.  
In addition to these biological findings, researchers have corroborated these 
findings through directly modifying MHC density. First, researchers have artificially 
clustered the MHC on APCs and observed enhanced T cell activation with lower levels of 
MHC.78 Second, the density of cognate MHC can be modulated by the dose of antigen 
given to APCs, and as density of surface cognate MHC decreased, so did the in vivo T 
cell response.79 Third, MHC ligands were patterned on surfaces at varying densities, but 
the number presented to a T cell was controlled.80 Here they found that the density was 
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more important than the number of presented ligands with at least four ligands in close 
proximity needed to activate a T cell.  
In summary, TCRs and MHCs are naturally localized into dense regions, which 
allows increased cognate recognition and sustained signaling to occur because of serial 
engagement and multivalent interactions. Though we have focused our analysis how 
ligand density affects the MHC-TCR interaction, other ligands such as those in the 
immunological synapse also have distinct spatial locations and densities.65,81 Therefore, T 
cell-modulating technologies should be designed with consideration given to the density 
and location of the ligand. 
2.2.2 Size Considerations 
In designing cell-modulating technologies, physical size is another important 
biological constraint. Like with considerations of ligand properties, size design 
considerations arise from features of T cells. This can arise from molecular size 
limitations like distances between ligands on the T cell as described in 2.1.3, or even due 
to the fact that T cells reside within the lymph node. Here we will review some of those 
interactions and how to design certain technologies based on these scales.  
2.2.2.1 Molecular Interactions 
When interacting in biological environments, both ex vivo and in vivo, the number 
of molecular species in a given environment can be astronomical. And with an equally 
large number of chemical reactions and molecular binding events occurring, it is hard to 
achieve the desired interaction and avoid unintended reactions. This poses unique 
challenges for maintaining the size of synthetic materials created to modulate T cells. 
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As these materials are usually designed on the micro- to nanometer scale, the 
decrease in size increases the free surface energy of the material. As a result of this small 
size, within minutes of being introduced to a biological media or in vivo, most engineered 
materials acquire a shell of adsorbed proteins known as a protein corona.82 This protein 
shell can both determine the fate of the material and cause unintended consequences 
regardless of T cell targeting. For example, proteins can cause aggregation of the 
material, changing its size; increase cell-uptake; or even cause negative biological events, 
such as platelet activation.83–85 Therefore, to control the size, engineers modulate the 
chemical and biological properties of the surfaces to be inert or covert materials, as 
described in 2.4.  
2.2.2.2 Cellular Interactions 
After encountering and interacting with proteins post-administration, therapeutic 
particles or materials will encounter cells. Cells take up volume around them as a form of 
communication and defense and often these materials become subject to this 
phenomenon. Antigen-presenting cells including macrophages phagocytose efficiently to 
clear antigen and also process antigen to elicit T cell responses. T cells on the other hand 
are less efficient at phagocytosis. Thus, careful design of particle properties can effect 
cellular and intracellular destinations of particle and cargo. A few notable principles have 
been able to be distilled from a number of particle size-related studies in cell 
uptake.82,86,87  
First, particle size-dependent cell uptake differences are partially governed by 
required membrane wrapping energy. Larger particles on the scale of 3 µm and above 
require more energy to be taken up than smaller nanoparticles, which results in decreased 
cell uptake.88 In the absence of surface coating, the uptake of small particles (<25 nm) is 
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lower than that of larger particles.89 Here the surface exposed is insufficient to cause cell 
receptor-nanoparticle interactions necessary for endocytosis. This results in lower avidity 
between the cell membrane and particle and makes it more difficult not only for the 
particle to be “gripped” but also for the cell to initiate signaling for endocytosis 
machinery.90   
Second, the cellular process for uptake also depends on particle size.91,92 
Phagocytosis is primarily seen with particles larger than 500 nm and pinocytosis with 
particles smaller than 500 nm.93 Even within pinocytosis, cellular uptake processes can 
differ and have unique vesicle size limits, which then can provide differential 
intracellular delivery based on particle size. For example, micropinocytosis can engulf 
particles greater than 1 µm, whereas clathrin-mediated endocytosis can take up particles 
up to 120 nm, caveolin-mediated up to 60 nm, and clathrin and caveolin-independent 
endocytosis up to 90 nm.94  
Third, cell-uptake parameters differ between different cell types. Cells of the 
mononuclear phagocytic system will exhibit greater cell uptake than endothelial or even 
T cells.95 This could affect not only the volume of material that is taken up but also the 
size dependency trend.96 
Understanding how size affects nanoparticle endocytosis will be especially 
important for the design not only of nanoparticles that can escape cellular uptake but also 
of effective NP therapeutics such as gene delivery vehicles where endocytosis is a critical 
component of the delivery process. To increase cell uptake for applications such as gene 
delivery, nanoparticles can be coated with cell-interacting ligands.97,98 This can determine 
their intracellular destination by methods such as labeling the particle with a microtubule-
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associated sequence (MTAS) and or nuclear localization signaling (NLS) sequence to 
target the nucleus.99 Additionally, ligands can help to differentiate cell types, such as by 
coating the particles with antibodies to cell-specific proteins.100,101  
Besides targeting cells with cell-specific antibodies, particles can be designed to 
directly provide signaling with ligands.102 Here size also plays a role as the local density 
of ligand can be changed by changing the size of a particle. For example, the number of 
bioavailable ligands on a small 50 nm nanoparticle may only be 2, whereas the number 
may be closer to 200 on a larger 5 µm particle with equivalent density because the 
curvature of the particle decreases with increasing size.103 This will affect the local ability 
to cluster receptors from a single particle and may impact T cell modulation as mentioned 
in 2.1.3, where the spatial relationship among cell surface receptors is critical for T cell 
signaling.  
Finally, when engineering implantable materials (>100 µm) for in vivo 
applications, then the foreign-body response should be considered.104 Here since cells 
cannot uptake the material, then the immune system will become activated based on 
adsorbed blood proteins. This will cause a cascade of events that may result in either 1) 
degradation of the material by reactive oxygen species, 2) segregation of the material by 
formation of scar tissue, or 3) integration of the material into the surrounding tissue. 
Recently, it has been suggested that the size of the implant can influence this response 
regardless of material choice, where implants above 1.5 mm in size led to reduced 
immune response and scarring.105  
2.2.2.3 Tissue Interactions 
In addition to the cellular destination of materials, material size also affects tissue 
distribution when injected in vivo.82 T cells are a unique cell type in their mobility and 
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distribution throughout many different compartments.106 They arise from within the bone 
marrow, develop in the thymus, travel from lymph node to lymph node via the lymphatic 
system and use the circulatory system to traffic to sources of infection within tissue and 
can reside there or in lymph nodes for years. Biodistribution will thus affect the ability to 
target specific T cells with engineered materials.  
Broadly speaking, the impact of particle size on biodistribution can be classified 
by whether particles are introduced to the circulation or to tissues directly. Intravenous 
administration would be useful for targeting circulating T cells or for reaching T cells 
systemically. For intravenous administration, particles should be less than 4 µm to 
prevent occlusion of capillaries. Particles smaller than 6 nm will be cleared by the kidney, 
and larger particles will mostly be removed by the mononuclear phagocyte system in the 
liver and spleen. Most particles will end up being cleared from circulation within 
minutes, but a small percentage will enter different tissue compartments. For example, 
nanoparticles 20-200 nm in size have shown increased accumulation in tumor tissues 
based on the increased fenestration of the tumor capillaries—known as the enhanced 
permeability and retention effect.107  
Tissue-based injection would be useful for targeting localized T cells in tissues or 
for reaching T cells in lymph nodes. Injected particles will diffuse or be convected 
through the extracellular matrix (ECM). Particles less than 50 nm can move efficiently 
through spaces in the ECM and be transported via the lymphatics to the lymph node, 
whereas larger particles are sequestered at the tissue injection site.108,109 Upon reaching 
the lymph node, low molecular weight proteins (<70 kDa) will be shuttled to fibroblastic 
reticular cell-lined channels to B cell follicles, while larger proteins and particles will 
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need to be introduced into the lymph node by subcapsular sinus macrophages.110 Similar 
properties govern particle transport in mucosal administration of particles, where 
particles smaller than 100 nm will have greater diffusion rates and penetration through 
mucus matrices.111 Particles larger than 100 nm, may be limited to administration sites 
and undergo phagocytosis by macrophages or antigen presenting cells, which 
subsequently traffic to lymph nodes as mentioned in section 2.2.2. This property could be 
harnessed to mimic infection in design of biomaterial vaccines that lead to potent T cell 
responses.  
In conclusion, particle size is a key design parameter that influences whether cell-
modulating technologies will reach T cells. Additionally, it impacts how the particles 
interact with T cells and modulate T cell signaling. 
2.2.3 Shape 
 When synthesizing synthetic platforms for T cell modulation, particle shape can 
have surprising impacts on their interaction with T cells and macrophages and their 
biodistribution. Spherical and ellipsoidal particles have differing interfacial geometries 
despite their similar length scales and can thus potentially be optimized for T cell 
interactions. By using shape to vary biodistribution, the half-life and cell and organ 
targets can also be modified. 
 Particle shape affects biodistribution in part by modifying phagocytosis by the 
reticuloendothelial system (RES). In contrast to spherical particles, ellipsoidal particles 
reduce nonspecific RES phagocytosis, an important consideration for extending the half-
life of therapeutics injected in vivo.88,112–114 In fact, phagocytosis is more dominantly 
affected by shape than by size in the range of approximately 1-10 μm.112  However, 
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interestingly, receptor-mediated endocytosis of non-spherical particles is enhanced.115 
Thus, elongating particles for applications where targeted internalization is preferred, 
such as drug delivery, may also take advantage of longer circulation times. 
 In addition to affecting biodistribution and half-life, particle geometry plays an 
important role at the T cell-particle interface. While most T cell-interacting particles, 
such as artificial antigen presenting cells (aAPC), are spherical in nature, this shape does 
not recapitulate biological T cell-APC interactions. Spherical particles maximize the 
curvature and thus minimize the surface area of contact between the T cell and particle. 
This is especially detrimental at the nanoscale where ligand avidity decreases as particle 
size decreases, despite biocompatibility incentives to moving to smaller size scales. 
Ellipsoidal microparticle aAPC were shown to preferentially interact with T cells along 
their long axis and significantly increase T cell activation in vitro and in vivo.116 
Ellipsoidal nano-aAPC also result in a similar increase in T cell activation over spherical 
particles of similar size while also taking advantage of the increased biocompatibility and 
superior biodistribution due to small particle size.117  
 Particle shape can directly affect T cell activation by influencing avidity. For 
therapeutics meant to activate a T cell response, ellipsoidal geometries may be preferred 
due to increased interaction with the T cell surface and superior biodistribution. However, 
in addition to micro- and nano-particles, shape may be an important factor to consider in 
larger scaffolds that cannot be directly engulfed by macrophages. The degradation 
products of  implantable T cell-stimulating devices, such as artificial lymph nodes, are 
often fibers or other non-spherical geometries and may be an important design parameter 




The choice of material and control of material properties can impart unique 
functionalities on the T cell modulating technology. For example, in vivo applications 
need to consider biocompatible materials with low clearance, efficient targeting, low 
toxicity, and biodegradability. For ex vivo applications, a broader range of chemistries 
and materials can be employed to modulate and study T cell responses. Examples include 
using magnetic materials to cluster signaling components on the surface of the cell and 
modulating the stiffness of the material to enable study of mechanotransduction 
pathways.  
2.2.4.1 Material Surfaces 
As discussed in section 2.2, stability in biological fluids and the ability to evade 
the mononuclear phagocytic system enable therapeutics to reach and target T cells. To 
this end, reducing the formation of a protein corona on the material is a priority. 
Engineers have primarily utilized a hydrophilic polymer—polyethylene glycol (PEG)—to 
create a water-based shell to prevent protein adsorption and particle aggregation.119–121 
PEG has also been conjugated to protein-based therapeutics to increase solubility, 
stability, and circulation and reduce immunogenicity.122  
Often, therapeutics are more than just a delivery vehicle and are coated with either 
targeting moieties or cell-modulating proteins. In these cases, a PEG layer can help 
improve stability, but it cannot shield attached protein components from initializing a 
protein corona or initiating uptake by the mononuclear phagocytic system. Another 
approach to shielding therapeutics is to use biology as inspiration. For example, 
liposomes are particles derived from biological lipids that form a bi-lipid membrane 
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similar to that of cells and can be used as a coating on particles to prevent aggregation 
and uptake.123,124  
Similarly, particles have recently been coated with cell membranes, such as red 
blood cell membranes,125 tumor cell membranes,126 and leukocyte cell membranes.127 
Besides increasing stability and decreasing clearance, these membranes can confer 
additional advantages such as site-specific targeting for targeting inflammation. Lessons 
learned from these coatings and studying how red blood cells avoid uptake have revealed 
the importance of CD47 as a “don’t eat me” signal.128 Therefore, instead of coating the 
particle with entire membranes, researchers have also attached the CD47 protein to 
nanoparticles, leading to decreased cell uptake and increased circulation.129  
As an alternative to coating materials with chemistries or biologics that prevent 
protein adsorption, these interactions can be taken advantage of intentionally. One 
example is the design of more efficient vaccines by Liu et al.130 They designed their 
vaccine to have a hydrophobic tail so that it would bind to albumin and traffic to the 
lymph node. This approach resulted in a more efficient delivery of their vaccine to the 
lymph node, generating a more robust immune response.  
2.2.4.2 Biointeractive Materials 
Beyond avoiding the mononuclear phagocytic system, materials can also be 
designed to mimic biological properties to engage cells such as T cells. Biomolecules can 
be attached through adsorption, use of biologic interactions such as streptavidin-biotin, or 
direct chemical attachment. Already covered in section 2.1, coating of ligands on 
materials can mimic existing signals in the body enabling specific T cell modulation. 




Beyond cell-surface ligands, biomolecules derived from the extracellular matrix 
or cytokines can be coated onto material surfaces. Utilizing such molecules can enable 
enhanced attachment of cells to synthetic scaffolds.131 Additionally, these molecules such 
as growth factors can be used to polarize differentiation of cells including stem cells.132  
The material stiffness also contributes to the signaling that occurs upon 
engagement by a cell. This is especially important in mechanotransduction-sensitive 
pathways. Mechanotransduction plays a role in cell-cell signaling, sensing aspects of the 
extracellular environment such as fluid flow, and enabling cell attachment and migration 
through the extracellular matrix.133,134 
T cells are a very active and motile, and mechanotransduction plays a role in 
similar ways to other cells in areas of cell attachment and migration. More specifically 
mechanotransduction has also been implicated in TCR signaling.135 As T cells scan the 
antigen presenting cell, the TCR can engage its cognate MHC, and the resulting force 
associated with recognition is necessary for T cell activation.136 It has been hypothesized 
that this is due to a catch-bond-like behavior of the sensor due to conformational changes 
in the proteins that result from the force.137,138  
Additionally, once initial TCR signaling has occurred, the immunological synapse 
develops, which contains integrins and F-actin on the periphery and enables strong 
adhesion between both cells.139 Retrograde flow of actin drives engaged TCRs to the 
center of the immunological synapse, further exerting forces on the TCR-MHC. 
Additionally, APCs provide rigid surfaces by immobilizing intracellular cell adhesion 
molecule 1 (ICAM-1) on its surface, which is necessary for T cell activation.140 
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Therefore, mechanical properties are an important consideration for designing materials 
to directly interact with T cells.  
Finally, the actual material can have immunomodulatory effects on immune cells. 
One noteworthy example is how the polymer poly(beta-amino ester) (PBAE) intrinsically 
activates the immune response as a vaccine particle. Researchers showed that maximal 
stimulation of the immune response was achieved with high molecular weight PBAEs, or 
short degradation time points even in the absence of traditional adjuvants.141  
2.2.4.3 Bioresponsive Materials 
A more recent development in material design is to engineer materials that react 
and respond to biological cues in the body.142 The first example is to increase the 
biodegradation in vivo in targeted locations due to differences in the biological 
environment, such as changes in pH, redox potential, and enzyme content. Increased 
acidity in the stomach, tumor microenvironment, or lysosome can be used to cause 
protonation of the material and trigger to release its cargo.143 Utilizing disulfide linkages, 
one can exploit the reductive environment of the cytosol or the nucleus as compared with 
the extracellular environment as another method of signaling release.144 Finally, enzyme-
reactive sequences can be designed into material to take advantage of the increased level 
of matrix metalloproteinases found in tumors to speed up degradation.145   
Beyond biodegradation, bioresponsive materials can also be designed to respond 
to mechanical forces, heat, magnetic fields, radiation, and ultrasound to change size, 
shape, and chemical structure.146 Mechanical forces, such as the shear stress induced by 
fluid flow in circulation, can be utilized to break up larger fragile materials into smaller 
pieces more amenable to circulation and tissue targeting.147 Certain polymers have lower 
critical solution temperatures close to body temperature, such as N-isopropylacrylamide, 
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which decreases in size due to a phase change.148 Magnetic materials can be controlled ex 
vivo by a magnetic field and caused to locally aggregate149 or generate heat for therapy.150 
Similar control of size change and heat can be generated by gold and light-responsive 
polymers from activation by specific wavelengths of light.151,152 Like magnetic materials, 
ultrasound-sensitive materials can be utilized both as imaging agents and to change the 
size of the material to release cargos locally.153,154   
Bioresponsive material strategies can be leveraged to implement more effective 
modulation of T cells in vivo and ex vivo. First, these material properties could help to 
target T cells within specific compartments, such as the tumor microenvironment, or even 
specific T cell intracellular compartments. Second, control over T cell trafficking and 
response to cargo controlled by temporal external stimuli offers precise control over the 
timing and level of T cell responses. 
2.2.4.4 Biocompatibility 
Material biocompatibility is another important consideration for clinical 
translation.155 Materials already used in FDA-approved devices or applications can make 
the clinical translation more straightforward, though this may limit the functionalities and 
engineering design in the therapy.156 Translation becomes increasingly challenging when 
bioactive proteins and cellular components are added into the material intervention.157  
2.3. Immunoengineering approaches 
Engineering concepts have been applied to immunology to develop platforms that 
alter the T cell response. Scientists and engineers have developed biocompatible 
platforms that mimic antigen presentation, orchestrate the delivery of immune-
modulatory drugs, or prompt a new type of immune interaction. These platforms have 
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been built upon a wide variety of biocompatible platforms, from engineered small 
molecules and cultured cell lines to biodegradable polymers. Many times, 
immunoengineering is used to attempt to more accurately mimic biological interactions, 
while other times, it is used to trigger a new type of interaction that may be more 
favorable to a patient.  Here, we review previously engineered platforms, including 
protein engineering, synthetic particles, cell and genetic engineering, scaffolds and 
surfaces, and combination therapies.  
2.3.1 Protein Engineering 
At the smallest scale, proteins and small molecules can be engineered to target 
specific signals involved with T cell activation. This may involve developing a high 
affinity antibody to activate or block one or more immune-stimulatory or -inhibitory 
pathways, synthesizing modified cytokines that can more effectively bind their targets, or 
utilizing antibodies to target the delivery of a drug or cytokine to a specific anatomical 
site. In this section, we will review various molecular targeting approaches and how 
engineering principles have been applied to their design. We will focus on how these 
engineered molecules have been used as monotherapies, although many are used in 
combination therapies or encapsulated into synthetic particles or scaffolds to further 
modulate their delivery.  
2.3.1.1 Engineered Cytokines 
 During T cell activation, T cells receive soluble pro-inflammatory or anti-
inflammatory signals, often referred to as “signal 3.” These signals help to drive cell 
proliferation, differentiation, and chemotaxis, among other functions. Therapeutic 
administration of pro-inflammatory cytokines important for immune activation, most 
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commonly IL-2, can activate a robust anti-tumor immune response, but systemic 
injection is complicated by life-threatening toxicities.158,159 The clinical use of cytokines 
is also hindered by their rapid clearance from the bloodstream, leading to a typical serum 
half-life on the order of minutes. Longer-acting engineered cytokines that can selectively 
activate immune subsets and antibodies that direct their localization are thus being 
developed.  
 In the field of cytokine engineering, scientists and engineers have developed 
cytokines with altered binding to immune cell subsets to create more clinically-favorable 
therapeutics. IL-2 signaling occurs through either a high affinity (KD~10 pM) trimeric 
receptor complex, consisting of the IL-2Rα, IL-2Rβ, and IL-2Rγ (c) chains or an 
intermediate affinity dimeric complex (KD~1 nM) consisting of only the IL-2Rβ and γc 
chains. Different immune cell subsets modulate their sensitivity to IL-2 signaling by 
altering surface expression of the non-signaling IL-2R chain. Naïve effector T cells only 
express only the IL-2Rβ and γc subunits, whereas activated memory T cells and 
regulatory T cells also express the high affinity IL-2Rα and are thus more sensitive to IL-
2 activation.160 Importantly, pulmonary edema, a major toxicity upon systemic IL-2 
administration, has been shown to be mainly IL-2Rα-dependent.161 An engineered IL-2 
“superkine” was evolved to have 200-fold increased affinity for the IL-2Rβ subunit and 
thus activated cells in an IL-2Rα-independent fashion. As a result, this IL-2 superkine 
significantly increased the expansion of CD8+ T cells in vivo but did not alter regulatory 
T cell expansion compared to the wild type cytokine. By shifting the cellular response to 
favor immunostimulatory subsets, the IL-2 superkine significantly reduced pulmonary 
edema and increase anti-tumor efficacy.162 Further modifications of this engineered IL-2 
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cytokine have demonstrated how modulating binding activity to the other subunits can 
result in development of agents that further manipulate the cellular response, such as IL-2 
partial agonists or antagonists.163  
 
 Superagonists for other cytokine-receptor systems have also been developed. For 
example, IL-15 is a cytokine that contributes to T cell and NK cell development, 
proliferation, and activation.164 Endogenously, IL-15 is bound to IL-15Rα and expressed 
on the cell surface of antigen presenting cells to T cells and NK cells displaying the 
intermediate affinity dimeric IL-2 receptor (IL-2Rβ/γc). Binding of IL-15 to the IL-15R 
subunit on the surface of APCs induces a conformational change that enhances its 
interaction with IL-2Rβ/γc; thus the administration of soluble IL-15 alone has only a 
moderate effect on T cell expansion. Administration of pre-formed complexes of IL-15 
with recombinant IL-15Rα was shown to selectively induce robust expansion of memory 
CD8+ T cells and NK cells.165 Building on this work, IL-15 superagonists were 
engineered by fusing the IL-15 cytokine to a truncated version the IL-15R subunit. 
These engineered fusions exhibited 4-5-fold more potent biological activity than the 
native IL-15 cytokine on IL-2R/c-expressing cells,166 and later iterations of the 
superagonists were linked to Fc binding domains to prolong their effects through 
extension of serum half-life.167 
 While high-affinity superagonist cytokines may have increased potency compared 
to endogenous cytokines, they often do not solve the problem of systemic toxicities. To 
improve selective targeting, cytokines have been bound to tumor-targeting antibodies to 
increase their localization to the tumor microenvironment. Over a dozen types of 
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cytokine-antibody fusion proteins (immunocytokines) have been developed. In the 
simplest terms, cytokines can be linked via the N- or C- terminus of an antibody to 
leverage the spatial relationship between cytokine delivery and antibody binding.168 
Additional modifications of the antibody constant region can also affect how the fusion 
protein interacts with Fcγ receptors or initiates the complement cascade, or they can alter 
the molecular weight and biodistribution of the cytokine-antibody fusion.169 In addition to 
targeting cytokines to the tumor microenvironment, the physical constraint of a tumor-
targeting antibody with a T or other immune cell-targeting cytokine can be synergistic. 
For example, immunocytokines that target tumor-expressed antigens have been shown to 
increase interactions between tumor cells and T cells or natural killer cells much like a 
bispecific antibody that concurrently targets a tumor-associated antigen and an immune 
cell surface marker.168 Other families of immunocytokines that link cytokines with 
tumor-associated extracellular matrix components are thought to mediate an anti-tumor 
effect primarily through localizing cytokine delivery.170 
 Immunocytokines have been developed that incorporate a wide variety of tumor-
associated antigens, but the majority of these constructs utilize the same cytokines: IL-2, 
IL-12, IL-15, or TNF.168 One example of a successful immunocytokine is a fusion 
between the anti-CD20 antibody rituximab and an IL-15 superagonist, which was shown 
to exhibit superior anti-tumor activity to rituximab alone.171,172 By linking the 
superagonist cytokine with a tumor-targeting antibody, the fusion proteins were capable 
of taking advantages of three mechanisms: specific binding to CD20 on tumor cells; 
potent immune cell stimulation through the IL-2Rβ/γc receptor; and recruitment of 
antibody-dependent cellular cytotoxicity and phagocytosis through binding to Fcγ 
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receptors on macrophages and natural killer cells. Other immunocytokines that deliver 
anti-inflammatory cytokines for organ-specific autoimmune disease,173 target cytokine 
delivery to necrotic areas of tumors through incorporation of anti-DNA antibodies,174 or 
enact the blockade of tumor-expressed immune-inhibitory molecules175 have also been 
developed. 
2.3.1.2 Engineered Antibodies 
In addition to the molecular engineering efforts on cytokines, there is great 
interest in engineering antibodies to block or stimulate cell targets, alter cell-mediated 
cytotoxicity and biodistribution, or selectively deliver drugs to the site of disease. 
Monoclonal antibodies can be evolved to selectively bind antigens that may be uniquely 
expressed or upregulated on tumor cells and also have the advantage of longer half-lives 
compared to small molecule drugs.176 Their precision in targeting also mitigates off-target 
toxicities. However, beyond selecting a molecular target, applying engineering principles 
to their design can improve their biodistribution, alter their interaction with immune cells, 
turn them into a vehicle to specifically deliver a drug or nanoparticle to a disease site, or 
target them to multiple cell types simultaneously. The process of monoclonal antibody 
production177,178 and the selection of target antigen179,180 have been reviewed previously. 
Here, we explore how monoclonal antibodies have been engineered to customize their in 
vivo effects.  
2.3.1.2.1 Monospecific Antibodies and Mechanisms of Action 
Three common classes of therapeutic antibodies include: (1) antibodies whose 
major mechanism of action is through the blockade or stimulation of the targeted 
pathway; (2) antibodies that are used to deliver a drug payload; and (3) antibodies whose 
structure has been engineered to engage multiple different cell types simultaneously to 
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redirect functionality. Endogenously, antibodies often bind infected cells or foreign 
pathogens. The exposed constant region of these antibodies can then mediate antibody-
dependent cellular cytotoxicity or complement-dependent cytotoxicity to destroy the 
targeted entity. Thus most fundamentally, antibody engineering often involves 
modification of the Fc region to modulate how the bound antibodies will interact with the 
immune system.181 When antibody-mediated cell killing is desired, such as when 
antibodies target molecules on infected or tumor cells, isotypes such as human IgG1 are 
often incorporated that initiate these effects.182,183 In other cases, an antibody may be 
developed to block or stimulate a certain pathway on a healthy cell-type, such as the 
programmed death 1 (PD-1) inhibitory molecule on T cells. For such cases in which cell 
death would be detrimental, the antibody is engineered to have an IgG2 or IgG4 isotype 
that has limited interaction with Fc receptors.184 In all cases, antibodies are humanized by 
replacing the constant region and sometimes parts of the variable regions with the human 
sequence.185 
The interplay between T cells and cancerous cells is multi-layered and complex. 
While cancerous cells may express mutated neo-antigens that are recognized by the 
immune system, they also often upregulate immunosuppressive molecules that inhibit 
efficient T cell stimulation and lack expression of co-stimulatory molecules.48 Many 
monoclonal antibodies have been developed that block these inhibitory pathways on T 
cells or tumor cells or that directly stimulate signaling pathways on T cells to jumpstart 
the cancer immunity cycle. Clinical administration of soluble antagonist antibodies 
against the inhibitory checkpoint molecules PD-152,186 and its ligand, PD-L1,187 and 
CTLA-451,188,189 have shown tremendous success in recent years. The success of these so-
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called checkpoint blockade antibodies have been correlated with tumor mutation load—
tumors with more mutations and more neoantigens are associated with improved clinical 
benefit from checkpoint molecule inhibitors.190,191 Agonistic antibodies have also been 
developed that stimulate T cell signaling through co-stimulation, such as anti-CD28, anti-
4-1BB, and anti-OX40 antibodies.3,7,192,193 However, because of the structured 
arrangement of the signaling molecules during T cell activation, these synthetic co-
stimulatory molecules are often delivered on particle platforms4,8 that enable formation of 
the immune synapse.  
The direct function of an antibody is often to affect a signaling pathway. 
However, antibodies have also been conjugated with various drugs and utilized as 
carriers to deliver payloads to specific T cells or tumor cells. In cancer immunotherapy, 
many of these so-called antibody-drug conjugates (ADCs) target tumor-expressed 
antigens, such as HER2, CD19, or CD22, and novel strategies have been introduced to 
increase tumor-specificity. For example, an ADC was developed that encodes an 
additional peptide sequence that shields the antibody’s antigen binding site until it is 
cleaved within the tumor microenvironment.194 This method can thus enhance tumor-
specificity when the antigen target is not uniquely expressed by cancerous cells. This type 
of approach could also potentially be used to decrease off-target toxicities of checkpoint 
inhibitors and co-stimulatory antibodies as these are not limited to the cancerous tissue. 
Fusion proteins have also been developed that deliver multiple payloads simultaneously. 
For example, a tri-functional fusion protein linked an antibody against a tumor-associated 
antigen with both the co-stimulatory molecule 4-1BBL and the IL-15 cytokine.195 The 
fusion protein was more efficient than corresponding bifunctional proteins in activating T 
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cells and inducing an anti-tumor response in vivo. The approach to treating lymphoid 
malignancies is slightly different; in this case, antibodies have been developed to deliver 
cytotoxic drugs to the malignant T cells themselves. An ADC targeting IL-7R, which is 
expressed on lymphatic cells, demonstrated how this method could be used to treat 
lymphoid malignancies or autoimmune disorders.196 
2.3.1.2.2 Approaches Antibody Engineering 
Many tools are being developed to speed up and diversify the discovery of novel 
antibody therapies or engineer of antibody variants. One such tool is the development of 
combinatorial antibody libraries.197 There are nearly 1011 unique antibody sequences, and 
being able to screen or probe the unique antibody-antigen binding landscape may enable 
enhanced affinities or unique binding locations which may enable novel mechanisms of 
therapeutic action, ultimately allowing control over therapeutic antibody design. 
Nevertheless, the massive libraries would be unexploited if not for high throughput 
engineering techniques. One such technique is the development of yeast surface display 
affinity engineering.198 Here antibody libraries can be cloned into yeast and fragments 
can be displayed and allowed to bind to a target protein. Antibodies to both the fragment 
and bound target protein identify high binders, which can be selected for and further 
mutated to increase affinity. 
There are many variants in structural engineering of the antibody, with particular 
focus on Fc and Fab portions.199,200 One example that targeted engineering of both ends, 
looked at eliminating non-specific thromboembolism events that occurred when the anti-
CD40L antibody was administered to treat autoimmune diseases.201 Specific targeting 
sequences of the antibody towards CD40L, termed a domain antibody, were fused to an 
Fc domain which was engineered to lack any Fc binding function. Eliminating the Fc, 
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eliminated platelet activation, thus reducing thromboembolism events, and allowing 
effective treatment of both models of transplantation and lupus.  
2.3.1.2.3 Bi-specific Antibodies 
One of the most powerful antibody-based approaches in cancer immunotherapy 
has been the development of bispecific antibodies. Bispecific antibodies are antibodies 
that have been engineered to comprise two different variable portions, each specific for a 
different antigen. Their specific structures encompass many formats, and each varies in 
terms of size, spatial relationship between antigen-binding sites, and synthesis protocol, 
which may affect their in vivo half-life and interactions with their respective ligands.202 
The physical constraint of the two antibody fragments is often central to their function, as 
bispecific antibodies are used to either physically link two different cell types or dimerize 
two different molecules on the surface of the same cell. Larger bispecific formats include 
the individual component antibodies linked by a chemical linker or the a Triomab, which 
maintains the full IgG shape by linking two half antibodies, each with one heavy and one 
light chain.203 These families of bispecific antibodies can be easily synthesized by 
standard protocols to allow for high-throughput manufacturing, and they have extended 
half-lives compared to smaller proteins. However, they also maintain expression of the Fc 
region which may be recognized by Fc receptors and lead to unwanted off-target effects. 
At the opposite end of the spectrum are small bispecific platforms such as tandem single-
chain variable fragments (scFvs), in which the heavy and light chains of two different 
variable domains are linked by a short serine-glycine linker.204 These bispecific 
antibodies preclude Fc receptor recognition, but their small size (approximately 55 kDa) 
reduces half-life and necessitates constant intravenous infusion.205  
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Likely the most well-known type of bispecific antibodies in the field of cancer 
immunotherapy are bispecific T cell engagers (BiTEs). BiTEs link an anti-CD3 antibody 
fragment with an antibody fragment against a tumor-associated antigen, thus 
simultaneously activating T cells and physically linking them with tumor cells to induce 
lysis.206 However, because BiTEs incorporate anti-CD3 rather than a pMHC, they non-
specifically activate all T cells and thus are associated with dose-limiting toxicities 
including cytokine storms.207 BiTEs have been developed linking T cell stimulation with 
various tumor-associated antigens such as CD19,208,209 BCMA,210 and EphA2.211 
However, like many targeted immunotherapies, they require engagement of a tumor-
associated antigen and thus antigen escape is a concern. Interestingly, it was recently 
shown that BiTEs can mediate lysis of bystander tumor cells not expressing the targeted 
antigen.212 
T cell-targeted bispecific antibodies have also been developed that cross-link two 
molecules on the surface of the same immune cell. A recent bispecific antibody, 
synthesized by chemically linking agonistic antibodies against the co-stimulatory 
receptors CD137 and CD134 on T cells, was more effective at activating an anti-tumor T 
cell response than either antibody individually.213 In contrast with monotherapy, the 
platform uniquely induced preferential expansion of effector T cells. Thus, in addition to 
redirecting cells, bispecific antibodies can potentially impact T cell activation by 
physically clustering surface molecules. This approach may be particularly interesting for 
targeting other T cell signaling molecules since the activation process is highly sensitive 
to receptor clustering and spatial localization.  
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With the success of immune-activating bi-specifics, significant resources are 
being dedicated to increase the efficacy of current therapies while limiting toxicity. With 
nearly 60 preclinical drugs and 30 in clinical trials, knowledge gained from therapeutic 
efficacy will impact on our fundamental understanding of what constitutes ideal bi-
specific properties, like pharmacokinetics.214 Indeed techniques such as developing 
multiple-cancer epitopes for T-cell redirecting antibodies could increase the affinity and 
sensitivity of the therapy.215 This would help to reduce non-specific toxicity such as 
cytokine storms that result from these immune-activating bi-specifics.  
In addition to activating the immune system, development of bi-specifics is also 
expanding to other applications such as infectious and autoimmune diseases and 
diagnostic imaging. Besides T cell redirection, these bi-specifics have additional 
mechanisms of action: T cell recruitment, blockade of T-cell acting cytokines, inducing 
apoptosis, and inactivation of proteins. Indeed many autoimmune anti-cytokine therapies 
demonstrate additive effects when combined justifying the development of bi-specific for 
autoimmune diseases. Just one example includes a bi-specific developed towards TNF-α 
and IL-17 for the treatment of rheumatoid arthritis.216 Here the bi-specific was engineered 
such that there were an additional two TNF-α and IL-17 Fab portions linked to Fc regions 
of the antibody, which induced significantly enhanced therapeutic reduction of arthritis 
potentially due to increased avidity. Similar results were found from a bi-specific 
targeting IL-17A and IL-6.217 
HIV is an example of bi-specific design for infectious disease, where diversity 
and mutation lend for the need for combinatorial therapies. One example is a neutralizing 
antibody where one arm of the bi-specific is from antibodies towards either CD4 or 
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CCR5, which the HIV virus uses to enter the cell.218 The other arm is composed of a Fab 
that is specific to viral envelope epitopes. These bi-specifics reduced viral load and 
provided complete protection upon viral challenge. Another example to broaden the 
diversity and increase the avidity of a neutralizing HIV antibody is the development of a 
tri-specific antibody which recognizes the CD4-binding site, V3 glycan patch, and the 
envelope membrane proximal external region.219 The tri-specific antibody demonstrated 
enhanced and broad neutralization in comparison to mono-specific antibody therapies.  
Another avenue for future bi-specific development is improving production and 
yield of the antibody. Here principles of directed evolution, cell engineering of 
hybridomas, and protein engineering of bi-specific structure will aim increase yield to 
decrease high cost associated with these therapies. Alternatively to in vitro production, 
bi-specifics could be produced in vivo through transfection of the bi-specific antibody 
construct. This was recently demonstrated in production of therapeutic levels of an anti-
CD3/CD20 bi-specific in a mouse for effective anti-lymphoma therapeutic responses.220  
 
2.3.2 Synthetic particles 
In contrast to soluble antibodies and small molecules, nanoparticle-based 
therapies can be engineered to affect biodistribution and drug release profiles. Soluble or 
particle-conjugated signals can be conjugated to the surface or encapsulated within 
synthetic particles to directly affect T cell signaling or alter how other cell types interact 
with T cells. By altering the size, shape, material, or injection route of a particle, drugs 
can target specific immune subsets in defined timeframes. Here, we will review previous 
work in this field of immunoengineering and demonstrate how micro- and 
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nanotechnology can be used to deliver extracellular and intracellular signals to modulate 
T cell responses. 
2.3.3.1 aAPC  
Artificial antigen presenting cells (aAPC) are micro- or nano-sized platforms 
designed to mimic endogenous antigen presenting cells for T cell activation. aAPC are 
three dimensional cellular or synthetic platforms that minimally present the two 
necessary signals for T cell activation—peptide MHC, signal 1 (s1), and a co-stimulatory 
molecule, such as B7-1/B7-2 or αCD28 monoclonal antibody, signal 2 (s2).221,222 aAPC 
have been explored in adoptive cell therapy (ACT), ex vivo activation of autologous 
lymphocytes with aAPC expressing tumor-specific peptide-MHC (pMHC), followed by 
re-infusion of the expanded cells into the patient.223 Large numbers of expanded 
lymphocytes, up to 1011, are needed to treat a single patient with ACT.224 Additionally, 
research has shown the importance of not just quantity but, more importantly, quality of 
the resultant cells for a long-lived effector population post-transfer.225  
Acellular aAPC have grown in importance for a variety of reasons. One reason is 
cost. Synthetic platforms can decrease costs by creating a more easily manufactured all-
in-one off-the-shelf therapy. Another reason is that endogenous antigen-presenting cells 
(APCs) can become immunosuppressed and even immunosuppressive in cases such as 
cancer and chronic infection.226–228 This poses problems for the achievement of effective 
innate anti-cancer responses, therapeutic vaccines and immunotherapies, and ex vivo 
activation of T cells for adoptive transfer. Thus, extensive work has been done to 
optimize acellular aAPC. Specifically, we will focus on engineering developments of the 





 aAPC size has implications to mimicking surface engagement of endogenous 
cells, biodistribution, and interaction with the nanoscale arrangement of receptors. 
Historically, micron-sized aAPC platforms were developed to mimic the endogenous 
APCs.8,229–232 Large, micron-scale particles reduce the curvature at the T cell-aAPC 
interface and can thus interact with multiple TCRs and induce robust activation. 
However, spherical microparticles with low MHC signal 1 density cannot activate T cells 
to the same extent as particles with high density despite increasing particle dose.230,233 
Currently, this size is the preferred size for attaching the aCD3 and aC28 molecules used 
to expand polyclonal populations from tumor infiltrating lymphocyte populations for 
adoptive immunotherapy.234  
Previously it was believed that nanoparticle aAPC could not induce robust T cell 
activation similar to large aAPC.230,235 In one case, biodegradable aAPC of 150 nm and 8 
µm were formed and showed that microparticles provided enhanced stimulation to 
antigen-specific T cells, although nanoparticles resulted in some minimal stimulation.235 
In another report, latex particles of 0.5 to 5 µm were engineered, and it was shown that 
larger particles generated greater responses.230 It was hypothesized that the T cells needed 
to interact with a contiguous area of stimulatory ligands as opposed to the smaller areas 
provided by smaller particles. 
However, this large size hinders the ability of aAPC to be used in vivo. Particles 
larger than 2 µm have a chance to cause embolization. Larger particles also have limited 
abilities to diffuse out into target organs where T cells reside and increases the rate of 
uptake by the mononuclear phagocytic system. To address this, researchers developed 
two versions of nanoparticle aAPC from iron oxide and quantum dot materials 30-100 
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nm in size.236 Here, nanoparticles were shown to provide effective antigen-specific 
stimulation of both murine and human CD8+ T cells and provide tumor prevention. 
Furthermore, biodistribution studies were done to show that the smaller aAPC drained 
more efficiently to the lymph node that larger aAPC remained in the subcutaneous 
injection site.  
In an effort to provide mechanistic insight into why these nanoparticles were 
functional, researchers varied both nanoparticle aAPC size and ligand density.103 Here, 
particles of 50 nm, 300 nm, 600 nm, and the traditional 4.5 µm were compared head-to-
head with controlled densities and quantities of signal. Interestingly, the smallest (50 nm) 
aAPC were again found to be less effective; however, aAPC 300 nm and above were just 
as effective as large 4.5 µm particles. Mechanistically this could be due to A) nearby 
clustering of signaling molecules was important and B) that particles larger than 300 nm 
aAPC are able to provide effective local engagement of multiple TCRs, while 50 nm 
aAPC only engage single receptors. This was confirmed by overcoming this limitation by 
both artificially clustering 50 nm aAPC with a magnetic field and adding saturating doses 
of 50 nm aAPC.  
Ligand density can also be an important parameter, which should be considered in 
conjunction with size. Increasing the density of the ligand on smaller 50 nm aAPC did 
not overcome this effect, suggesting a larger particle footprint is needed to engage TCRs 
in protein nanoislands.13,103,237 As the ligand spacing increased to greater than 100 nm, 
the ability to stimulate CD8+ T cells was abolished even for particles larger than 300 nm. 
This was consistent with the ligand requirements found from planar surface 
studies60,238,239 and could explain why nano-aAPC were not stimulatory previously. 
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Therefore, both nano- and micro-sized aAPC can be effective with control of the ligand 
density, as both properties affect the area and number of ligands available to stimulate a 
CD8+ T cell effectively. 
2.3.3.1.2 Shape 
Despite their success in activating T cells at the cell-particle level, microscale 
particles have poor biodistribution and are thus suboptimal for in vivo applications. 
Microparticles cannot take advantage of the enhanced permeability and retention (EPR) 
effect to localize aAPC at the tumor site240 and do not effectively drain to lymph nodes 
where immune stimulation occurs.236,241 Thus, recent work has explored ways to optimize 
aAPC on more biocompatible, nano-scale platforms. 
The spherical shape of aAPC is popular largely because of the ease of synthesis or 
fabrication procedures, such as emulsion techniques for PLGA.242,243 However, spheres 
minimize the contact area at the T cell-aAPC interface despite the importance of 
multivalent pMHC-TCR interactions. Recent work has demonstrated how altering aAPC 
geometry can improve the stimulatory capabilities of both micro- and nano- aAPC. 
Importantly, modifications to aAPC shape have also helped to bring nano-aAPC into the 
playing field.  
Ellipsoidal synthetic aAPC can be developed by physically stretching spherical 
PLGA particles made by standard emulsion techniques.116 These oblong particles can be 
generated with aspect ratios over 6 and conjugated with equivalent protein densities, 
allowing for comparison between them and their spherical counterparts. Increasing the 
micro-aAPC aspect ratio (i.e., degree of stretching) positively correlates with CD8+ T 
cell proliferation and maximally induces a 20-fold stronger T cell response. Interestingly, 
proliferation did not increase linearly with increased particle stretching but rather resulted 
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in more significant gains at specific aspect ratios. This geometry-driven change in T cell 
proliferation was shown to be correlated with changes to the T cell-aAPC interface. 
Ellipsoidal aAPC bound to more T cells, and individual contact areas were larger than 
those in spherical interactions, thus suggesting that increased avidity and interactions 
with multiple TCR may drive their improved efficacy.  
The geometry effect is also maintained on the nanoscale.117 Ellipsoidal nano-
aAPC with spherical diameters on the order of approximately 200 nm induce a five-fold 
stronger T cell response than their corresponding spherical nano-aAPC. As shown with 
other systems,88,112,113 ellipsoidal aAPC resisted uptake by RES cells and thus had longer 
circulation times in vivo. This increased ability to stimulate T cells and longer circulation 
times led to significantly increased T cell proliferation in vivo.  
In contrast to methods that manipulate the geometry of the base particle, magnetic 
fields have also been utilized to alter how nano-aAPC interact with T cells. 
Superparamagnetic spherical iron-dextran aAPC with a diameter of 100 nm do not 
normally activate a robust T cell response. However, when an external magnetic field is 
applied, the nano-aAPC cluster on the T cell surface, changing the perceived shape and 
size of the aAPC by the T cell, and likewise increase proliferation.103,244 This method 
enables nano-aAPC to activate rare endogenous T cell populations for adoptive cell 
transfer.  
2.3.3.1.3 Ligand Choice 
Ligand choice is another critical parameter in the development of aAPC. 
Traditionally, aAPC are conjugated with the two necessary signals for T cell activation—
anti-CD3 mAb or a specific pMHC, signal 1, and B7 or anti-CD28 mAb, signal 2. The 
choice of anti-CD3 mAb or pMHC dictates whether all T cells or only T cells 
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recognizing a specific target are activated. Often, a specific pMHC will be chosen to 
target antigen-specific T cell responses, although interesting work has demonstrated how 
phenotypic markers can be used post-nonspecific activation to select specific T cell 
subsets.245 A great deal of work in antigen discovery and immunogenicity has been 
conducted and is ongoing in the selection of a specific pMHC targets for different 
applications.   
Despite the fact that signaling through CD28 is the main co-stimulatory signal 
provided by synthetic aAPC, the composition of co-stimulatory signals greatly impacts T 
cell activation. There are dozens of different types of co-stimulatory signal 2 molecules, 
and altering the combinations and ratios of these signals can impact proliferation, 
phenotype, and survival in vivo. These T cell co-stimulatory molecules include pathways 
such as CD70-CD27, CD40-CD40L, 4-1BB-4-1BBL, OX40L-OX40, and others 
expressed on the antigen presenting cell and T cell, respectively.48  
Studies have shown that co-stimulation through 4-1BB during the rapid expansion 
protocol for adoptive cell transfer improves the expansion and effector function of tumor-
specific T cells.246 4-1BB co-stimulation has also been associated with the preferential 
expansion of memory T cells, which are often desired for in vivo transfer applications.247 
Combining multiple co-stimulatory signals on the same aAPC also can have significant 
effects on T cell functionality. A study combining CD28, 4-1BB, and CD27 signaling on 
K562 aAPC demonstrated that certain combinations of the co-stimulatory molecules can 
increase proliferation over 10-fold.4 Even when the same total amount of co-stimulation 
is present, simply changing the ratio of signal 2 ligands can impact the resultant T cells. 
In one study, micron-sized polystyrene aAPC conjugated with different ratios of anti-
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CD28 and anti-4-1BB mAb affected antigen-specific proliferation as much as five-fold.8 
Other co-stimulatory molecules, such as activation through OX40192 and CD40L,248,249 
which have been shown to have stimulatory effects on T cells, could also be incorporated 
in next generation aAPC. A new type of aAPC activation platform where each type of 
signaling molecule is separated onto distinct, magnetically clustered nanoparticles allows 
for high throughput customization of signal 2 choice, ratio, and amount by enabling an 
infinite number of activation conditions from a finite number of functionalized 
nanoparticles.250 Using this platform, combinations of anti-CD28, anti-4-1BB, and anti-
CD27 signaling were shown to affect T cell proliferation and phenotype. This approach 
may serve as a useful mechanism to systematically study co-stimulatory composition.  
In addition to the choice of signal 1 and signal 2, aAPC can be conjugated with 
other molecules to enhance their efficacy. CD47 is a molecule ubiquitously expressed by 
normal cells that protects self-cells against phagocytosis.251 aAPC that also display CD47 
have been shown to also be protected from phagocytosis and induce greater stimulation 
of T cells in vivo.252 
2.3.3.1.4 Material 
aAPC have been formed from materials that are inorganic, organic, biologically-
derived, or a combination thereof. Each material choice enables unique functionality and 
imparts distinct aAPC properties. For example, functions include responsiveness to 
external stimuli, ligand mobility, biocompatibility, degradability, biodistribution, 
nanoscale arrangement of receptors, and encapsulation of additional modulators. 
Therefore, the desired function of the aAPC can drive selection of material. 
Iron oxide based aAPC can be effectively used in adoptive immunotherapy 
expansion protocols as they can be easily removed through magnetic field separation, 
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prior to infusion.221,253 Magnetic forces have been used additionally to induce aAPC 
clustering on the surface of CD8+ T cells and enrich antigen-specific cells.244,254 First, 
clustering of nanoparticle iron oxide aAPC within a magnetic field lead to much greater 
stimulation of CD8+ T cells at a much lower dose of aAPC than without the magnetic 
field.244 This increased TCR cluster size on the surface of the T cells has been shown to 
be important for T cell activation.66 The enhanced ex vivo stimulation translated to 
increased in vivo efficacy of adoptively transferred cells in a tumor treatment model. 
More recently, magnetic fields have been used to home magnetic aAPC in vivo to tumor 
sites to mediate effective tumor killing.255 
Beyond clustering, Perica et al. used these antigen-specific nano-aAPC to 
magnetically enrich for antigen-specific CD8+ T cells.254 The approach is to first add the 
aAPC to bind rare antigen-specific CD8+ T cells, then enrich the antigen-specific cells, 
and because the aAPC are still bound to the enriched cells, simultaneously stimulate only 
the enriched cells to proliferate. Impressively, antigen-specific murine and human CD8+ 
T cells were expanded more than 1,000-10,000-fold over their precursor frequency. This 
was used to identify novel neoantigens predicted by tumor sequencing and also used in 
adoptive transfer model of murine melanomas. 
Organic materials are used for improved biocompatibility, biodegradation 
properties, ability to form shapes other than spheres, and capacity to encapsulate 
material.256 This is true as well for the aAPC. Particle aAPC have been made from 
poly(lactic-co-glycolic acid) (PLGA), which is a component of several FDA-approved 
devices and therapeutics and has high biocompatibility, allowing aAPC to be used for 
direct in vivo therapy.257 Direct in vivo therapy with aAPC is desirable not only because it 
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would allow continued modulation and activation of CD8+ T cells in vivo but also 
because it would potentially eliminate the need for ex vivo stimulation. These 
biodegradable aAPC were effective at stimulating CD8+ T cells ex vivo and provided 
enhanced activation in response to a tumor when combined with checkpoint blockade 
molecule anti-PD1. This in vitro finding was confirmed in vivo as the combination of 
aAPC and anti-PD1 was able to delay tumor growth in an aggressive melanoma cancer 
treatment model more than either individual modality alone. Additionally, polymers like 
PLGA are plastic, so they can be formed into different shapes as discussed in section 
3.3.1.2, which may enable enhanced biodistribution and T cell contact.116,258  
Moreover, organic particles formed by emulsion techniques can be utilized for 
encapsulation of soluble signals. T cell stimulation often requires a third signal from 
cytokine IL-2 from CD4+ T cells to become fully activated and have the capacity to 
proliferate.259–261 Steenblock et al. developed a PLGA aAPC with IL-2 encapsulated to 
mediate close paracrine delivery of the cytokine while the aAPC are bound to antigen-
specific CD8+ T cells to mimic signal 3 delivery in vivo.262 Having the IL-2 encapsulated 
improved the CD8+ to CD4+ T cell ratio and enhanced CD8+ T cell activation with 
upregulation of the IL-2 receptor, CD25. Encapsulation of IL-2 was 100 times more 
potent than the simple addition of soluble IL-2 to the culture medium, suggesting the 
advantage of cytokine encapsulation.  
As an alternative to organic materials, biological materials are another 
biocompatible platform to which T cell stimulatory signals can be attached. Beyond 
biocompatibility, these materials may evade the mononuclear phagocytic system more 
effectively and thus provide a more effective in vivo therapeutic. Another advantage for 
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biological materials is the ability to have fluid membranes, which may impact the 
mobility of the signaling receptors and allow for the needed clustering of the receptors 
upon engagement.  
Recently, red blood cells (RBCs) have been utilized as a bio-inspired method for 
cargo delivery or as a depot of imaging agents.263 RBCs have ‘don’t-eat-me’ signals on 
their surface, which enables long circulation times. Sun et al. recently attached signaling 
molecules, including IL-2, to the surface of red blood cells.264 While there was no in vivo 
work demonstrated, these provided effective stimulation to antigen-specific cells that 
were able to mediate cancer-specific killing in vitro.  
Liposomes are particles developed from lipids that form a lipid bilayer similar to 
that of the cell, but the size can be modulated from the nm to µm range. Liposome based 
aAPC were developed to utilize clustering technology derived from lipid rafts to show 
that having distinct, locally dense MHC rather than diffusely spread MHC improved T 
cell activation.265 Additionally, because it has been shown that endogenous MHCs are 
clustered in lipid rafts on DCs, another group has taken natural MHCs from DCs and 
added the molecules to liposomes.266 These RAFTsome aAPC showed effective 
activation in vitro and tumor protection in an immunization model. This could be 
potentially used to load patient-derived MHCs pre-loaded with cancer antigens to induce 
a polyclonal antigen-specific response without characterizing individual antigenic 
specificities.   
Finally, as each material has unique functionalities, researchers have aimed to 
combine materials for more elaborate aAPC designs. One example, is an aAPC 
developed from carbon nanotubes, polymer (PLGA) nanoparticles, and magnetite.267 The 
51 
 
carbon nanotubes were used to form the particle scaffold, which proves the high surface 
area needed for effective multivalent aAPC-T cell interactions. The PLGA nanoparticles 
were loaded with IL-2 to induce paracrine signaling of signal 3. Furthermore, magnetite 
was embedded in these particles to enable magnetic removal of particles following T cell 
stimulation for adoptive immunotherapy. These aAPC provided effective long-term 
stimulation of both murine and human CD8+ T cells and delayed tumor growth in a 
melanoma treatment model. 
2.3.3.2. Particles with ligands for T cells 
In addition to creating artificial antigen presenting cells for activating T cell 
responses, pMHC molecules have been attached to particles for limiting the immune 
response.64,268,269 This approach aims to mimic peripheral tolerance where presentation of 
antigen in the absence of costimulatory molecules leads to anergy, apoptosis, or 
conversion to a regulatory phenotype. Indeed this has been done for both attaching 
pMHC class I and II molecules and inducing both antigen-specific regulatory CD4+ and 
CD8+ T cells with the effect of reducing autoimmunity in multiple models including 
diabetes, multiple sclerosis, and arthritis. To be able to administer these particle 
intravenously, particles less than 20 nm were utilized for engineering studies to identify 
key parameters necessary for both in vivo function and safety.269 Indeed similar to 
artificial antigen-presenting cell studies, density of the pMHC was a key component of 
the efficacy of their particles, where less than 3-6 nm intermolecular spacing was most 
efficacious in eliciting antigen-specific T cell responses. This density may allow 
enhanced binding with TCR nanoclusters and clustered binding in macroclusters is 
observed experimentally and confirmed in silico through modeling.   
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In addition to particles that interact only with T cells (i.e., aAPC) and particles 
that interact only with antigen presenting cells (i.e., particle-based vaccines), particles can 
be engineered to bind multiple cell types simultaneously, inducing new interactions or 
changing existing ones. In these instances, a nanoparticle platform is used to increase 
avidity for the targeted antigens or alter biodistribution. In one study, 50 nm particles 
were used to redirect a T cell response against a specific tumor antigen, similar in 
approach to bispecific T cell engagers.270 These nanoparticles, termed antigen-specific T 
cell redirectors (ATR), were conjugated with an antibody against the CD19 tumor antigen 
and non-tumor peptide-MHC. When MHC-bound ATR were loaded with a human flu 
peptide, human flu-specific T cells were redirected to kill CD19+ tumor cells.  
In contrast to a tumor cell-T cell dual-binding nanoparticle that presents a specific 
peptide MHC complex, nanoparticles that bind to other non-specific cell surface 
molecules on the two cell types have shown similar efficacy. For example, an 80 nm 
particle, termed immunoswitch, links antibodies against the co-stimulatory 4-1BB 
molecule expressed by T cells with antibodies against the co-inhibitory molecule PD-L1 
expressed by tumor cells and thus converts an inhibitory signal into a co-stimulatory 
signal within the tumor microenvironment.271 These particles were shown to increase 
effector-target cell conjugation and induce a more robust CD8+ tumor-infiltrating 
lymphocyte response and delay or eliminate tumor growth in multiple murine tumor 
models.  
2.3.2.2 Particle vaccines for T cell activation 
Synthetic particles can also be engineered to affect which cell types T cells 
interact with, alter a cell interaction that is already present, or alter the phenotype and 
activity of other immune cells that modulate T cell activity. Dendritic cells (DCs) play a 
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central role in orchestrating both the innate and adaptive immune response.272 In an 
optimal response, dendritic cells express peptide fragments of invading pathogens as well 
as express co-stimulatory molecules that enable their efficient activation of T cells. 
However, in the instance of cancer or chronic infection, this process does not always 
occur appropriately. One method to initiate a more robust T cell response is thus to 
enhance antigen presentation or co-stimulation by DCs which can then mediate the T cell 
response. Since our analysis is focused on T cells we will only provide a brief summary 
of particle properties for vaccines, where more detailed reviews analyzing the density of 
antigen, size of particle, and material chemistry have already been completed.273 
Activation of DCs and other antigen presenting cells, like T cell activation, is 
sensitive to the environment. A stimulatory environment with appropriate stimulation 
kinetics is crucial to induce activation rather than tolerance. In order to control the 
stimulatory conditions, DCs can be extracted from a patient, and the signals for activation 
can be fully controlled ex vivo. Cell-based DC vaccines, such Sipuleucel-T,274,275 involve 
this ex vivo activation of DCs against a tumor antigen followed by their re-infusion into 
the patient where they can circulate throughout the body and activate an anti-tumor 
immune response. However, this approach is time-consuming and expensive as it 
involves manipulating cells outside of the human body and often has to be completed at 
non-local sites. Nanoparticles have generated great interest in the field of vaccine 
delivery due to their ability to be engineered to manipulate in vivo biodistribution and 
kinetics of vaccine delivery.276 Biomaterials can also potentially be used to target 
vaccination to specific DC subsets which has an effect on vaccine efficacy.277 
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Various studies have explored using nanoparticles to effectively delivery antigen 
to DCs directly in vivo. In the design of nanoparticle-based vaccination, particle size 
plays an important role in lymph node trafficking. Pluronic copolymer-coated 
nanoparticles (25 nm) injected intradermally were shown to travel to draining lymph 
nodes through interstitial flow and remain there for at least 120 hours where they could 
activate a humoral and cellular immune response against a model antigen.109 In contrast, 
particles just four times larger—100 nm—were approximately 10% as efficient and were 
undetectable in draining lymph nodes within 24 hours. In another study using polystyrene 
particles ranging in size from 20 nm to 2 μm, 40 nm particles most efficiently trafficked 
to lymph nodes and activated resident DCs.278 Similar to spherical nanoparticles, 
nanodiscs have been used for vaccine delivery. Small vaccine-carrying lipoprotein 
nanodiscs approximately 10 nm in diameter were shown to be more effective than soluble 
vaccines.279 These nanodiscs were coupled with antigen peptides and adjuvant and were 
shown to elicit up to 47-fold greater frequency of tumor-specific T cells than soluble 
vaccines. Utilization of a nanodisc carrier allowed antigen and adjuvant to accumulate in 
lymph nodes, where there is a high density of dendritic cells, more than soluble injected 
vaccines. Most successful particle-based vaccines are engineered with sub-100 nm 
particles. Particles larger than approximately 200 nm require cellular transport by DCs in 
the skin to travel to the lymph node.280  
Particle-antigen conjugates have also been used to generate tolerance in the 
setting of autoimmune diseases. These approaches focus on delivering auto-antigen 
similar to particle vaccines, but in the absence of danger signal to generate tolerance. One 
recent example utilized a quantum dot base particle to enable imaging of trafficked 
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particles within lymph nodes and cellular compartments.281 Interestingly, the 
investigators found that higher numbers of low density auto-antigen on the particles were 
more effective than lower numbers of high density auto-antigen in reducing 
autoimmunity in a model of multiple sclerosis in mice by increasing regulatory T cells. 
Potentially the therapeutic effect could be similar to how peripheral tolerance is 
developed through high systemic levels of auto-antigen in the absence of danger signal.  
In addition to controlling antigen density and dose, co-delivery of 
immunosuppressive agents has been key for mediating effective regulatory immune 
responses in autoimmune therapies. One example is the use of adjuvants for toll-like 
receptors (TLRs) such as GpG, which promotes tolerance through TLR9. Because it is 
electrostatic it has been complexed with self-antigen to form polyelectrolyte multi-layer 
particles and used to effectively eliminate disease in a mouse model of multiple 
sclerosis.282 Another example, utilized different sized microparticles, where a smaller 0.5-
2 µm microparticle could be phagocytosed with either vitamin D3 or insulin B peptide, 
and a larger 30 µm microparticle could be a depot of immune-regulatory signal such as 
TGF-β or GM-CSF.283 The combination of all four particles enabled prevention of 
diabetes through controlling dendritic cell phenotype and antigen presentation. In 
addition to the many various strategies to deliver self-antigen with particles,284 
researchers are also conjugating self-antigen to the surface of red blood cells to utilize a 
natural pathway for tolerance through the clearing of apoptotic cells.285 Using this 
approach, there were benefits in alleviating multiple sclerosis and diabetes in mice both 
as a preventative and therapeutic treatment.  
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Various other similar techniques have been utilized that take advantage of 
nanoparticle trafficking to secondary lymphoid organs by altering size or the biomaterial 
or by incorporating specific receptors. Nanoparticle “backpacks” have been developed 
that deliver vaccines to lymph node DCs by binding DC receptors, such as CD40 or 
DEC-205, or by binding endogenous albumin.130,286–289  In addition to modulating the 
biodistribution of the vaccine, approaches have been developed to alter how the delivered 
peptide is presented by the DC. During normal activation, intracellular antigens are 
presented on MHC-I and activate a cell-mediated CD8+ T cell response, whereas 
endocytosed antigens are presented on MHC-II and activate a humoral CD4+ T cell 
mediated response.  To induce presentation by DC on MHC-I, nanoparticle-based 
vaccines have been developed that are capable of escaping the endosome upon 
internalization.290  
2.3.2.3 Drug carrier particles 
 Synthetic particles that allow for the engineering of shape, modulation of 
biodegradation properties, and conjugation with or encapsulation of drugs that affect 
these various pathways provide a mechanism to direct drug release kinetics with defined 
distribution throughout the body. In terms of extracellular T cell modulation, conjugating 
artificial antigen presenting cells with the necessary signals for T cell activation is the 
main approach. However, biodegradable particles can also be used to selectively deliver 
soluble signals that affect T cell activation.  
 During endogenous T cell stimulation, T cells receive soluble “signal 3” 
molecules that drive proliferation and cytotoxicity.12 These soluble mediators are secreted 
in a localized paracrine or autocrine fashion that increases their local concentration and 
limits exposure to the desired cells. Because these signals are often broadly immune 
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activating, local delivery ensures that only the target cells are affected to avoid 
undesirable autoimmune responses. This important aspect of local immune stimulation 
cannot generally be achieved when immune-activating drugs are administered 
systemically. To more closely mimic the endogenous process and enable maximum T cell 
expansion, nanoparticles have been used to selectively deliver stimulatory signals in a 
paracrine manner to T cells of interest. Biodegradable polymers are often the material of 
choice because their degradation and intracellular delivery properties can be manipulated.  
 Local delivery can be crucial especially in the context of autoimmune and allergic 
disease, where current therapies are systemic immunosuppression, though majority of the 
disease is not. One example of particle delivery of immunomodulatory agents, was the 
delivery of IL-2, TGF-β1, and Rapamycin biodegradable particles to suppress allergic 
contact dermatitis.291 This combination mimic and potentiate the signals given by DCs to 
expand regulatory T cells in vivo. Encapsulation of these agents into particle allows co-
delivery to eliminate potential immune activating effects of IL-2, local delivery to target 
inflamed areas, and prevent future allergic responses. Another example is biodegradable 
particle delivery of CCL22, a chemokine that recruits regulatory T cells, to treat 
autoimmune mediated dry eye disease,292 transplant rejection,293 and periodontal 
disease.294  
Various methods have been developed to target these drug-delivery particles to 
specific immune subsets. One approach is to combine drug delivery with an aAPC to take 
advantage of both aAPC-based extracellular stimulation as well as localized drug 
delivery, as is the case with IL-2-encapsulated aAPC.235,262 Biodegradable particles 
58 
 
decorated with specific pMHC have also been used to selectively deliver cytotoxic drugs 
to cognate T cells for applications in autoimmunity.295  
Similarly, nanoparticles conjugated with T cell signaling molecules have been 
used to simply target the nanoparticles to T cells with the goal of intracellular drug 
delivery. Gelatin nanoparticles approximately 200 nm in diameter conjugated with anti-
CD3 mAb have been shown to be selectively internalized by T cells.296 Over 80% of T 
cell leukemia cells were observed to take up the particles, demonstrating the potential for 
nanoparticles for the delivery of intracellular signals. More recently, this approach has 
demonstrated success in transfecting T cells with genetic material. Anti-CD3 mAb-coated 
biodegradable nanoparticles approximately 150 nm in diameter were engineered to 
encapsulate a DNA plasmid encoding for a specific chimeric antigen receptor (CAR).101 
The particles showed specific transfection of T cells with approximately only 5% of non-
T cells showing uptake following intravenous administration. Remarkably, systemic 
administration of these nanoparticles resulted in the same degree of anti-leukemia activity 
when compared to adoptive cell transfer of ex vivo transfected CAR T cells, which will 
be discussed below in greater detail. Thus, the nanoparticle approach was able to 
significantly reduce the cost and time requirements of lymphodepletion and ex vivo T cell 
manipulation. More specific targeting of T cell subsets is also possible, as anti-CD4 mAb 
conjugated lipid nanoparticles have been shown to selectively target CD4+ T cells in 
vitro and in vivo.297 These nanoparticles selectively delivered CD45 siRNA and induced 
gene silencing up to 20% in CD4+ T cells five days post intravenous administration.  
Localized drug delivery to T cells can also be achieved through combination with 
adoptive cell therapy. For example, nanoparticles can be covalently linked to T cells 
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expanded in vitro prior to re-infusion. In one study, drug-releasing nanoparticles were 
covalently linked to the surface of tumor-targeting T cells prior to adoptive cell 
transfer.298 Using nanoparticles that released an inhibitor of immune-inhibitory signals, 
nanoparticle-functionalized T cells achieved greater expansion at the tumor site compared 
to systemic administration of the drug, achieving a 14 day survival advantage. 
Importantly, this study also demonstrated that the nanoparticles were translocated into the 
immune synapse during T cell activation. To further modulate not just the cell-proximity 
of drug release but also its temporal profile, T cell-bound nanoparticles have been 
developed that release drug only upon T cell stimulation.299 When CD8+ T cells become 
activated, they release lytic granules, and this property has recently been used to trigger 
nanoparticle degradation. These nanoparticles, when bound to HIV-specific CD8+ T 
cells, were shown to enable the delivery of an immunotherapeutic to a site of high viral 
replication. 
Most T cell-targeting nanoparticles for local drug delivery to date have targeted 
CD4, CD3, or TCR expression. However, it is important to appropriately select the 
targeting molecule for the most effective response. Whether or not a targeting molecule is 
internalized can significantly affect the T cell response to nanoparticle-mediated drug 
delivery. A study that investigated targeting nanoparticles that released a TGF-β inhibitor 
to T cell internalizing versus non-internalizing receptors showed differing responses, and 
this effect changed if T cells were conjugated with nanoparticles prior to adoptive cell 
transfer or targeted directly by intravenously administered particles.300 
When widespread circulation of a drug is important, smaller particles or 
molecules are often preferred due to their superior biodistribution. However, in some 
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cases, limiting the circulation of a drug may be desired, such as with non-specific 
immune activators meant to target T cells infiltrating a tumor. Systemic administration of 
stimulatory molecules such as IL-2 and anti-4-1BB mAb are associated with various off-
target toxicities due to widespread immune activation.301,302 Thus, a different approach to 
drug delivery is to anchor drugs to particles and inject them locally at the site of interest 
for the purpose of prolonging drug retention. Studies have shown that anchoring IL-2 and 
anti-4-1BB mAb to the surface of liposomes approximately 160 nm in diameter 
significantly reduces off-target toxicities when injected intratumorally.303,304 Even when 
injected intratumorally, the soluble antibody and cytokine were detectable at high levels 
18 hours post-injection and resulted in significant weight loss of treated mice. In contrast, 
the nanoparticle-anchored drugs limited drug exposure to the tumor site and were shown 
to treat murine melanoma. Similar results have been observed with locally administered 
nanoparticles functionalized with anti-4-1BB and anti-PD-L1 mAbs.271 
2.3.3 Cellular and Genetic Engineering 
The ability to directly engineer cellular function through genetic techniques has 
increased due to new molecular tools such as CRISPR system (Clustered Regularly 
Interspaced Short Palindromic Repeats). Additionally, the motivation to engineer cells 
has increased with the recent success and approvals of chimeric antigen receptor (CAR) 
T cell therapy. Again, this section will look at engineering principles that enable 




2.3.3.1 Cell-based Artificial Antigen Presenting Cells  
In addition to synthetic substrates, cell lines have been used to develop artificial 
antigen-presenting cells (aAPC) with the aim of eliminating the burden of using 
endogenous APCs for stimulating T cells for adoptive immunotherapy.305 This cellular 
approach enables greater biomimicry than synthetic aAPC; however, standardization and 
stability of the construct can be difficult to control. Additionally, cells used for aAPC are 
often not APCs and do not express important co-stimulatory molecules or cytokines 
needed for effective T cell activation. Therefore, cell-based aAPC will need to be 
efficiently transfected, stably express manipulated genes, and downregulate all other non-
specific HLA molecules to avoid activation of allospecific T cells. 
A popular choice of cell line to manipulate is the K562 erythromyeloid cell line 
by retroviral transfection. Researchers have transduced this cell line to stably express Fcγ 
receptors and 41BB ligand.306 Anti-CD3 and Anti-CD28 were added to form the 
complete aAPC to provide polyclonal T cell expansion. The addition of 41BB ligand 
induced effective T cell proliferation and limited CD8+ T cell apoptosis. Another group 
also showed the incorporation of the 41BB ligand improved stimulation with other co-
stimulatory ligands, including CD70 and CD80.4 Co-stimulation including CD83 was 
able to stimulate T cells without the addition of exogenous cytokines.307 Thus, the choice 
of co-stimulatory molecule(s) for cell-based aAPC impacts the ability to provide effective 
T cell stimulation. 
Cytokines act as a third signal in T cell stimulation and are expensive to add to 
cultures. Therefore, work is being done to incorporate the expression of T cell stimulating 
cytokines into cell-based aAPC. IL-21, a cytokine that signals through the IL-2Rγ 
receptor, has been included into the membrane of aAPC and increased the number of 
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CAR T cells and improved tumor killing in vivo.308 Similarly, IL-15 has been stably 
expressed on the membrane of cell-based aAPC.309 Although soluble IL-15 enhanced T 
cell activation and cytotoxicity, membrane-bound IL-15 established greater levels of 
activation, proliferation, and maintenance of the central memory phenotype, as well as 
nearly three times the cytotoxicity.  
Researchers have also used cell-based aAPC to stimulate CMV 
(cytomegalovirus)-specific T cell responses.310 Here they transduced their aAPC to 
express HLA-A2, CMV peptide, co-stimulatory marker CD80, and adhesion ligands 
ICAM-1 and LFA-3. This aAPC produced similar levels of antigen-specific cells 
compared to endogenous APCs and transfected primary B cells used as APCs. Similarly, 
this antigen-specific activation has also been applied to CD4+ T cells for 
immunotherapy.311  
Beyond polyclonal and virus-specific antigens, these aAPC are primarily designed 
for adoptive immunotherapy in cancer therapy. To this end, cells were engineered to 
activate cancer-specific T cells recognizing the MART-1 antigen found within 
melanoma.312 Importantly, these cells were developed under Good Manufacturing 
Practices (GMP) guidelines, enabling the potential translation to the clinic. Another 
example of generating tumor-specific T cells is the manipulation of another popular cell 
line, fibroblast NIH 3T3 cells. Telomerase-specific CD8+ T cells were activated by 
engineered 3T3 fibroblasts in an effort to target tumors overexpressing the protein.313 T 
cells stimulated by these aAPC were cytotoxic in a chromium release assay against 
human telomerase reverse transcriptase expressing tumor cell lines. 
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2.3.3.2 CAR T cells  
Chimeric Antigen Receptor (CAR) T cells are T cells that have been genetically 
engineered to express a receptor with two major functions: 1) antigen recognition, 
typically through antibody binding, and 2) T cell activation through phosphorylation of 
canonical intracellular domains.314 These CAR T cells have had tremendous clinical 
success in treating B cell tumors.315–317 Recently, Tisagenlecleucel became the first FDA-
approved CAR T cell therapy for pediatric patients with recurrent B cell acute 
lymphoblastic leukemia after failing two previous therapies.318 This has spurred 
development of CAR T cell construct for applications other than cancer including 
regulatory CAR T cells for autoimmune disease and tissue transplantation.319 Despite 
incredible clinical progress, major hurdles face the translation of this technology, 
including safety, specificity, and cost.320,321 Here we will highlight some of the more 
recent engineering approaches used to address these issues.  
One of the main toxicities associated with CAR T cell therapy is the severe 
cytokine release syndrome or cytokine storm, leading to complications and death.322–324 
Clinically, groups have managed the toxicities by using biomarkers, such as cytokine 
levels, as an indication for early intervention.322 More recently, researchers have 
developed techniques to “turn off” CAR T cells to limit the toxicity. One example is the 
incorporation of the Caspase-9 gene into the CAR T cell construct.325 When the small 
molecule AP1903 is administered, this dimerizes to cause apoptosis in CAR T cells.  
Another method of decreasing the toxicity of CAR T cells is to increase the 
specificity of the construct. For current therapies, the construct identifies CD19, which is 
expressed on both healthy and malignant B cells. To target cancers specifically, 
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researchers are targeting antigens like HER2, NY-ESO-1, ROR-1, and MUC16 that are 
overexpressed within tumor tissues.324,326–328  
An additional method to increase the specificity is to engineer the CAR construct 
to recognize tumor-specific antigens expressed in HLA molecules similar to how TCR 
molecules recognize antigens. The majority of CAR T cells are developed from single-
chain variable fragments (scFvs). Early scFvs originated with tumor-specific monoclonal 
antibodies; however, utilizing scFvs have much higher affinity than TCRs which can 
cause issues in intracellular signaling and may not recognize intracellular antigens. 
Indeed scFvs have been made to recognize cancer antigens in the context of HLA, but the 
affinity of the construct limited efficacy as compared to a low affinity TCR construct 
recognizing the same HLA-antigen construct.329 To accomplish scFv design, researchers 
employed antibody engineering techniques as mentioned in section 3.1.2 such as phage 
display to fine tune antibody specificity and affinity towards the desired peptide HLA 
complex. This limits discovery to affinity and specificity, but does not inform on cell 
activity upon ligation or even expression. Researchers have recently developed another 
screening technique which includes transduction of T cells with scFv libraries, such that 
structural design and specificity can be linked back to function and phenotype.330,331 
Further specificity and control can be programmed by development of a “two 
signal” approach, similar to canonical T cell stimulation where co-stimulation is needed. 
However, in this case CAR T cell co-stimulatory constructs are designed to recognize a 
second antigen to enhance the specificity of tumor killing.332,333 Similarly, instead of an 
AND-gate, a NOT-switch can be developed by adding a second signal that is present on 
normal cells to act as an inhibitory signal, similar to canonical PD-1 signaling.334 An On-
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switch has also been reported, where CAR T cells can only be activated in the presence 
of a small-molecule to crosslink signaling domains.335 Indeed the repertoire engineering 
approaches to regulate CAR signaling through modifying the signal inputs or 
interpretation is a growing field.314  
Density can also be used to regulate specificity, with the design of lower affinity 
CAR constructs. One group decreased the affinity of EGFR-targeting CAR T cells to 
demonstrate lower toxicity to in normal cells that express a lower density of EGFR than 
cancer cells.336 Additionally, the TCR-MHC interaction is lower affinity than antibody-
antigen interactions and is proposed to confer increased sensitivity to lower density of 
antigens through serially signaling.73 This fact may also help in targeting lower density 
antigens where increased sensitivity is required and has been shown to result in increased 
efficacy of CAR T cells in comparison to higher affinity antibody-based CAR T cells.329  
Ultimate specificity could be achieved by targeting neoantigens. Neoantigens are 
novel antigens that are produced by mutations in the tumor.337,338 Adoptive transfer of 
endogenously activated neoantigen-specific T cells has also shown good clinical 
responses.339,340 However, adopting this approach to CAR T cell therapy is difficult 
because each patient has unique mutations, identifying the reactivity to mutations is time-
consuming, and development of a CAR-T cell with a TCR is less established.  
While limiting toxicity is a primary aim of advancing CAR T cell therapy, there 
are developments being investigated in tandem to increase its efficacy. One main 
challenge facing all immunotherapies is the tumor immunosuppressive environment. To 
combat this, CAR T cells can be used in conjunction with checkpoint blockade 
molecules341 or be programmed to decrease inhibitory markers like PD-1,342 secrete pro-
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inflammatory cytokines,343 and create OR-switches to target multiple antigens 
independently.344  
Exhaustion is a challenge that faces CAR T cells in addition to adoptively 
transferred cells. To overcome exhaustion and increase the functionality of their CAR T 
cells, researchers have adopted the more recent CRISPR/Cas9 genome editing 
technology.345 CRISPR/Cas9 allowed the insertion of the CAR T-cell receptor α constant 
region of the genome to more accurately mimic T cell receptor expression. Indeed CAR 
constructs were downregulated following stimulation and then re-expressed similar to 
TCRs upon T cell activation, which led to a decrease in exhaustion markers. Doing so 
generated CAR T cells that were much more potent than conventionally retrovirally 
transduced CAR T cells in treating a mouse model of acute lymphoblastic leukemia.  
Additionally, standardizing cell source and maintenance of cell phenotype ex vivo 
have been challenges for efficacy, particularly for regulatory CAR T cell development. In 
a recent study researchers isolated regulatory T cells that were CD25+CD45RA+, which 
show more stable maintenance of regulatory phenotype and confirmed the phenotype 
stability by examining epigenetic markers close to FOXP3.346 These cells were effective 
at preventing graft-versus-host disease in a mouse model; however, development and 
expansion of these cells still required substantial time, multiple processes, and feeder 
cells.  
Finally, cost and technical challenges are major hurdles to translating this therapy 
for widespread adoption. One reason is all the ex vivo manipulation of patient cells, 
limiting this therapy to specific certified locations. To eliminate the need for ex vivo 
handling of cells, Smith et al. developed nanoparticles that transfected immune cells in 
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vivo by targeting the CD3 receptor on T cells.101 They demonstrated effective in vivo 
transfection and tumor treatment in model murine tumors.  
2.3.3.3 Other Genetic Engineering Applications  
Genetic engineering of T cells goes beyond CAR T cells in the fields of infectious 
disease and autoimmunity. The HIV virus targets CD4+ T cells through human 
chemokine receptor 5 gene (CCR5). To minimize HIV disease spreading and latency in 
patients, researchers knocked out the CCR5 gene in ex vivo manipulated CD4+ T cells 
and reintroduced into patients.347 CD4+ T cells without CCR5 persisted longer than 
untreated cells and patients who received the therapy had increased levels of CD4+ T 
cells and lower levels of viremia.  
Another example of knocking-down a gene takes inspiration from the success that 
checkpoint blockade therapy has experienced. Researchers used a CRISPR Cas9 
approach to eliminate expression of PD-1 by CAR T cells.342 Gene editing produced 
much more functional CAR T cells in completely eliminating established tumors that 
expressed PD-L1. Finally, engineering of cytokine and chemokine receptors has been 
used to study cytokine pathways and also to control activation of T cells in vivo.348,349  
Genetic engineering has been used to convert and maintain T cell phenotype. 
CD4+ regulatory T cells are an example of this genetic manipulation because the stable 
expression of regulatory constructs play a crucial role at establishing and maintaining 
tolerance; however, when isolated and cultured in vitro often may lose their phenotype or 
effector T cells will dominate. To solve this, lentiviral transduction of CD4+ T cells with 
FOXP3 enabled sustained suppressor activity by naïve and memory T cells.350 
Transduced CD4+ T cells with FOXP3 or IL-10 have demonstrated tolerance induction in 
models of tissue transplantation.351,352 In addition to FOXP3, CD4+ T cells have been 
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transduced to express class II MHC loaded with autoantigen and FOXP3 and enhanced 
suppression of autoimmune arthritis in mice.353  
2.3.4 Scaffolds and Surfaces 
Similar to particle-based technologies, scaffolds and surfaces are materials that 
can be engineered to directly modulate T cell responses. What makes scaffolds and 
surface technologies unique are the a) ability to directly pattern and coat with proteins in 
distinct geometric locations, b) ability to tune unique biophysical properties such as 
stiffness, c) size of the material enabling development of multicellular interactions, d) 
capacity to move to three dimensional interactions and potential to create artificial 
organs. Here we will focus on both 2D and 3D technologies that can be utilized both in 
vitro and in vivo to modulate T cell function.  
2.3.4.1 2D  
2.3.4.1.1 Patterning and Coatings 
Modern lithographic techniques have enabled precise geometric patterning on the 
micron scale. This has been utilized by researchers in developing biocoatings and 
micron-sized structures to further probe T cell biology. Additionally, with the rise of 
tissue and stem cell engineering, biomaterial engineers have developed materials that can 
vary in stiffness to probe mechanotransduction pathways. Researchers have also 
employed these materials to study TCR signaling. 
The geometric organization of stimulatory and non-stimulatory molecules during 
T cell activation is highly regulated as seen in the immune synapse needed for T cell 
activation.65,66 By using multiple rounds of microcontact printing, researchers were able 
to control locations of signal 1 (anti-CD3) and signal 2 (anti-CD28) on planar surfaces.354 
T cells stimulated with the two signals segregated demonstrated enhanced signaling 
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rather than when they are co-clustered. The geometry was distinguished by signal 2 
activation pathways such as PKC-θ and LcK.18,354 Similar results were demonstrated with 
signal 1 and adhesion molecule ICAM-1.57 If signal 1 (anti-CD3) was not clustered in a 
centralized format, T cells did not form efficient contacts or fully activate. Microcontact 
printing is a technology that has elucidated important microscale geometric arrangements 
of receptors.  
Another technique is block copolymer micellar nanolithography. This technique 
allows nanometer resolution of biomolecule printing, where gold nanoparticles are 
hexagonally packed and coated with a distinct layer of polymer that can be removed, to 
which biological compounds can be attached.355 A number of researchers have used this 
technique to probe the question of the influence of nanoscale signal 1 density on T cell 
activation. Interestingly, the reports found commonly that when using antigen-
independent signal 1 with anti-CD3, efficient T cell activation required ligands to be 
spaced below 60-70 nm apart.58,59 When using antigen-specific signal 1 (peptide-loaded 
MHC class II), the threshold was even higher at around 100 nm spacing.60 Although these 
articles did not include co-stimulatory or adhesion molecules, they demonstrate the 
importance of ligand density in providing effective T cell stimulation. 
In addition to confining biomolecules my micro or nanoprinting, biomolecules 
can be coated with lipid bilayers onto surfaces to mimic the fluidity of the cell 
membrane.356 Researchers have used this technique to coat silica surfaces with a lipid 
bilayer with signal 1 (peptide loaded MHC) and adhesion molecule ICAM-1.357 
However, these molecules were constrained by microfabricating barriers of differing 
sizes and shapes to observe the effects of restricting ligand mobility. By observing how 
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signaling molecules formed, moved, and clustered helped elucidate processes of the 
immune synapse formation such as the process of TCR microclusters developing before 
transfer to the c-SMAC.  
2.3.4.1.2 Mechanical Manipulation of Materials 
Beyond microfabrication to enable ligand location, this technique can form 
structures to help probe additional biophysical properties such as creating elastomer 
micropillars for mechanical signaling processes. TCR signaling has been implicated to be 
a mechanosensitive process,135 so researchers have attached signal 1 and signal 2 to 
micropillar arrays to observe the force generation of T cells in engagement with 
activation signals.358 They found that nearly a 100 pN force was generated through the 
TCR, though CD28 signaling assisted to increase the forces generated. The localization 
of intracellular proteins regulating contractility suggested interaction of the TCR with 
intracellular cytoskeleton similar to focal adhesions.  
Additionally, bulk material stiffness has been modified to study the 
mechanosensitive TCR signaling. T cell stimulating ligands have been attached to two 
different surfaces—polyacrylamide and poly(dimethylsiloxane)—were manufactured to 
have stiffness vary from 10 kPa-2 mPa.359,360 In both studies optimal stiffness was found 
to be around 100 kPa. The stiffness additionally was found to impact T cell 
differentiation and functionality of the T cells, highlighting this important consideration 
for T cell-stimulating surfaces.  
2.3.4.2 3D  
2.3.4.2.1 3D Scaffolds for T Cell Immunotherapy 
Increasing the porosity of materials can lead to cells sensing three dimensional 
environment. Dimension can be utilized to create environments which deliver protein or 
cell products in a more controlled fashion or promote additional cell-cell interactions 
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needed for functional T cell development. Three dimensional in vitro environments can 
also be used to more accurately mimic interactions that occur within the body. These 
organ mimics could be further developed to replace resected or dysfunctional immune 
organs.  
Like their particle counterparts, scaffolds can be developed from biocompatible 
and biodegradable materials that have the potential to release cargo in a controlled 
fashion. However, when injected, scaffolds are not motile and rather act as a depot 
delivery system. This is effective in cases where localized delivery is needed.  
A specific example is cytokine delivery, as it can be delivered locally to avoid the 
many off-target effects of systemic administration. IL-2, a cytokine that influences T cell 
responses and is an FDA-approved therapy but has significant toxicities and side 
effects.361 To minimize off-target effects, researchers have encapsulated IL-2 into 
polymeric biodegradable scaffolds.362 This product could be injected, sustained release of 
IL-2 over days, and enabled cell infiltration to the scaffold.  
Besides loading scaffolds with cytokines, cells can be transferred as well. Early 
on, antigen presenting cells were the focus of adoptive transfers. DCs have been loaded 
or recruited to a variety of scaffolds loaded with chemokines, adjuvants, and antigen with 
the purpose of stimulating and recruiting antigen-specific T cells.363,364 Beyond DCs T 
cells have recently been transferred in vivo in the form of scaffolds.365–367 The first 
example demonstrated that loading regulatory T cells (Tregs) onto a PLGA scaffold with 
islets was effective at protecting grafts from autoimmune rejection in a type 1 diabetes 
model.365 Co-localization and retention of the Tregs and islets was necessary to skew the 
local microenvironment to immunoinhibitory, thus enabled by the scaffold technology. 
72 
 
This further eliminated non-specific systemic immunosuppressive effects of Treg 
adoptive transfer. 
Another example is the delivery effector T cells to destroy cancer cells.366,367 T 
cells were loaded on an alginate hydrogel along with co-stimulatory aAPC loaded with 
IL-15 superagonist.367 Here scaffolds were utilized to deliver and further activate T cells 
in the resection bed or in the tumor local microenvironment. Drastic differences were 
observed. T cells delivered locally and with additional stimulation were able to cure mice 
of established tumors, while adoptively transferred T cells did not eliminate tumors. In 
another study, CAR T cells were loaded into the scaffold and demonstrated similar 
efficacy in combination with a stimulator of IFN genes (STING agonist).366 The 
controlled release of STING agonists created a vaccine-like environment which 
prevented the escape of heterogenous tumor cells not expressing antigens recognized by 
CAR T cells. 
In addition to in vivo delivery and stimulation of T cells for adoptive therapy, 3D 
environments have been created ex vivo to enhance T cell stimulation.368 High-aspect-
ratio mesoporous silica micro-rods (MSRs) were coated with lipid bilayers, signal 1 and 
signal 2, and IL-2  to induce T cell stimulation. T cells migrated into the scaffolds and 
formed more dense clusters of cells than traditional microparticle aAPC and produced 
higher levels of proliferation and produce anti-tumor treatment.  
2.3.4.2.2 Tissue Engineering Lymphoid Organs 
Three dimensional scaffolds are utilized frequently to create ex vivo organoids 
which enable more complex analysis of multiple cell types in a more physiological 
manner.369 However, 3D ex vivo culture is not without challenges including difficulty of 
working with multiple cell types, large requirements for nutrients, extended culture times, 
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and ability to analyze with current techniques. To tackle some of these issues in 
developing a human artificial lymph node, Giese et al. compared different bioreactors, 
source of immune cells, and material for scaffolds.370 Based on T cell activation and 
lymphocyte swarming, they determined nonwoven polyamide fibers and collagen 
performed best as scaffolds inside disposable bioreactors. Similarly, researchers found 
that collagen infused scaffolds provided T cells with the best environment to migrate in 
3D.371 These scaffolds were used to study how T cell and DC migration differed in 
response to the chemokine CCL21. 
Collagen based scaffolds have also been used to develop artificial lymph nodes in 
vivo.372–374 Collagen sponge matrices were loaded with transfected thymus-derived 
stromal cells to express lymphotoxin α and activated DCs.374 Implanted into the renal 
subcapsular space, these matrices recruited B cells, DCs, T cells, and endothelial cells to 
form tertiary lymphoid structures in vivo. Taken from these mice, these artificial lymph 
nodes could generate an immune response to a model OVA antigen when transferred into 
SCID mice. The responses were also shown to generate memory T and B cells that 
migrated to other secondary lymphoid organs such as the spleen.373 Similar results were 
recently generated by implanting the scaffold with incorporating lymphotoxin-α1β2, 
CCL19, CCL21, CXCL12, CXCL13, and soluble RANK ligand (sRANKL) in place of 
the transfected cells.372   
Collagen has also been employed in three dimensional scaffolds to generate 
human artificial lymphoid organs such as an artificial thymus.375,376 The collagen coated a 
tantalum carbon coated matrix, to which a mixture of keratinocytes and fibroblasts were 
added ex vivo. Hematopoietic stem cells were added to the matrix, which initiated the 
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maturation of both CD4+ and CD8+ T cells with a diverse repertoire of TCRs similar to a 
natural thymus. The resultant T cells generated effector based responses when stimulated, 
yet were tolerant to self MHC. Development of artificial lymphoid organs can thus 
elucidate our understanding of how endogenous organs are formed, their function, 
provide models for testing immunotherapies, and potentially replace dysfunctional 
immune organs altogether. 
 
2.3.5. Combination immunotherapies 
Methods of both direct T cell activation and blockade of inhibitory checkpoint 
pathways have resulted in exciting results in preclinical studies and clinical trials. 
However, there remains a large population of patients who do not respond to 
monotherapies. Thus, it has become evident that targeting a single stage of the Cancer-
Immunity Cycle is not sufficient and that combination therapies that target multiple 
complementary pathways will have a greater chance of capturing a large response pool. 
Because there is a diverse array of inhibitory and stimulatory pathways that affect T cell 
activation, monotherapies often allow for tumor escape through the upregulation of 
alternative pathways.  
Combination therapies against multiple checkpoint molecules can de-activate 
multiple different T cell inhibitory pathways. Notably, anti-PD-1 mAbs have been co-
administered with anti-CTLA-4 mAb in several clinical trials. Because these two 
pathways are non-redundant, blocking both can synergize T cell activation. The 
combination therapy significantly enhances the objective response rate to as high as 60%, 
but also increases the amount of adverse toxicities associated with widespread immune 
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activation.51 Importantly, the efficacy of combination checkpoint blockade in comparison 
to monotherapy is stratified by biomarker expression, such as PD-L1, in a patient’s tumor 
and indicates the importance of using biomarkers to guide therapeutic interventions to 
reduce costs due to unnecessary combinations.188 Additional combinations of inhibitory 
molecule blockades have also demonstrated improved efficacy. Doublets of anti-CTLA-
4, anti-PD-L1, and an IDO inhibitor all enhanced the re-activation of tumor infiltrating 
lymphocytes in a murine melanoma model. These studies demonstrated that the 
combination therapies were effective by re-activating tumor infiltrating lymphocytes 
rather than inducing new T cell migration.53 Thus, in tumors lacking T cell infiltration, 
combination therapies that also induce migration into the tumor may be more effective. 
Combination therapies that link T cell stimulation with checkpoint blockade aim 
to intervene at the two major ways by which T cell activation is modulated. T cell 
stimulation can be mediated directly through the administration of co-stimulatory 
antibodies, or indirectly through a DC-based vaccine. Even when an anti-tumor or anti-
viral T cell population is present, however, activated T cells upregulate inhibitory 
molecules such as PD-1 and CTLA-4 in a homeostatic fashion. Tumor cells can also 
upregulate inhibitory ligands such as PD-L1, especially in response to T cell secretion of 
IFN-γ, which diminish the activity of these cells.  
Checkpoint blockade has now been combined with almost every approach to T 
cell stimulation to maintain activation. In chronic viral infection, co-administration of 
antagonistic antibodies against PD-L1 and agonistic antibodies against 4-1BB were 
shown to enhance the expansion of viral-specific CD8+ T cells compared to 
monotherapy.56 The combination therapy also impacted the kinetics of the T cell 
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response, indicating that combination therapies may be used to modulate how quickly T 
cells are expanded against a certain antigen. In cancer immunotherapy, anti-PD-1 mAb 
checkpoint blockade synergizes with in vivo aAPC administration to activate CD8+ T 
cells against a tumor-expressed antigen.257 The combination therapy, but neither 
monotherapy, was able to inhibit the growth of palpable murine melanoma and was 
shown to be mediated by a decrease in PD-1 expression and increase in tumor-specific T 
cell expansion. Similarly, co-administration of anti-PD-1 and anti-4-1BB can enhance an 
anti-tumor response by modulating T cell phenotype and density of tumor infiltrating 
lymphocytes.54,55 Checkpoint blockade has also been shown to increase the efficacy of 
peptide-pulsed DC vaccination, in this case blocking inhibitory molecules on 
DCs.377Various other approaches have shown synergy between the combination of anti-
PD-1 checkpoint blockade and granulocyte macrophage colony-stimulating factor,378 
OX40 and CD27 co-stimulation with anti-PD-L1 checkpoint blockade,3 and anti-OX40 
co-stimulation and vaccination.192 
Checkpoint blockade has also been combined with therapeutics that enhance 
tumor immunogenicity. Treatments that induce tumor cell death or increase mutational 
load, including oncolytic viruses, radiation, or chemotherapy, can enhance antigen 
presentation and activation to tumor-specific T cells.379 However, the anti-tumor T cell 
response is often still limited by the expression of inhibitory molecules by both tumor and 
immune cells. Radiation has been shown to synergize with anti-CTLA-4 checkpoint 
blockade, with local radiation leading to the regression of even distant metastases.380,381 
However, resistance to this dual treatment was shown to be mediated at least partially by 
tumor upregulation of PD-L1. In response to this observation, combination therapy 
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comprised of radiation, anti-CTLA-4, and anti-PD-L1 was shown to increase the 
response rate and minimize tumor immune escape.382 Checkpoint blockade also can 
increase the efficacy of oncolytic viruses that preferentially infect and lyses cancerous 
cells. A study with the oncolytic Newcastle Disease Virus demonstrated that its 
combination with anti-CTLA-4 could completely eliminate established murine melanoma 
and even lead to an improved abscopal effect.383 
While combination therapies often involve the co-administration of multiple 
therapeutics, another approach to combination therapy is to develop a single therapeutic 
with multiple mechanisms of action. CD80, the ligand expressed by antigen presenting 
cells that induces T cell proliferation upon ligation with T cell expressed CD28, has 
additional binding partners. CD80 has also been shown to bind PD-L1 and plays a role in 
inducing apoptosis of activated CD8+ T cells.384,385 This dual interaction has been taken 
advantage of in a soluble form of CD80 as a therapeutic.386 This CD80-Fc fusion protein 
was shown to both neutralize the inhibitory PD-1/PD-L1 interaction while simultaneously 
stimulating T cells through CD28.  
While combining stimulatory and inhibitory molecules in a single all-in-one 
therapeutic may be desirable from an engineering perspective, the immunological 
mechanisms behind their success may indicate that sequential delivery may be more 
effective. In one study, anti-PD-1 administration following anti-OX40 co-stimulation was 
effective at delaying tumor growth, but not vise-versa or co-injection—it was necessary 
for the co-stimulation to first boost the T cell response to a state where checkpoint 
molecules played a role in inhibiting the response.387 Thus, sequential delivery or 
biodegradable particles that can mediate this type of release may be beneficial.  
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Most recently, a combination therapy clinical trial including the indoleamine 2,3-
dioxygenase (IDO) inhibitor, epacadostat, with an anti-PD1 antibdoy, pembrolizumab, 
failed a phase III clinical trial.388 This combination which targets to block both 
immunosuppressive metabolic signals and surface ligands from the tumor 
microenvironment that diminish T cell activity. However, there was no improvement in 
progression-free survival when compared with pembrolizumab alone. Consequently, 
while many combinations do have rational pairings, much is to be learned about how 
combinatorial pairings should be prioritized and tested as therapies to increase the 
success rate of costly clinical trials.  
 
2.4. Summary and Next-Generation Therapies 
Over the past two decades, we have seen a dynamic interaction between our 
interest in developing new immune-based therapeutics and our understanding of 
pathogenesis of disease such as cancer and chronic infection. As our understanding 
grows, so does our capacity to engineer desired T cell responses. This has also provided 
enthusiasm for developing novel therapies with T cells. Here we have reviewed general 
salient engineering principles to control T cells based on basic concepts of T cell biology. 
We have provided analysis and examples of researchers using these basic principles to 
control T cells with protein engineering, synthetic particles, cellular and genetic 
engineering, and scaffolds and surfaces.  
Going forward, several areas will continue to be improved using engineering 
principles. Frequently unintended consequences like autoimmunity, cytotoxicity, or 
premature cell death result due to a number of unidentified variables activated by 
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engineered inputs. Control over T cell outputs will come from greater understanding of T 
cell signaling and increased precision in the therapeutic. For example, CAR T cell 
therapy will benefit from greater systems biology approaches to study complex T cell 
activation networks and also from development of more sophisticated CAR constructs 
such as AND, OR, and NOT switches or kill-switches.  
On the other hand, many T cell-based therapies and modulators have extremely 
high price tags, and as we increase the precision or functionality, this caveat should be 
kept in mind. Engineered solutions which decrease cost of therapy will enable 
widespread translation of therapy that is still personalized. An example may be to 
engineer methods that successfully manipulate T cells in vivo instead of requiring 
prohibitively expensive procedures, equipment, personnel, and centers to handle cells ex 
vivo.   
While we have spent time focusing on engineering T cells, progress in T cell 
therapy will come as other cell types are considered or even simultaneously targeted. T 
cells are a part of both a broader immune system, spend time traveling through several 
other organ systems, and require communication and activation from other cells. 
Additionally, other cell types contribute to the pathogenesis and cure of a disease. For 
example, the requirement necessary to eliminate large, aggressive, immunoinhibiting 
tumors required checkpoint blockade, recombinant IL-2, tumor antigen antibody, and a T 
cell vaccine enabling NK, DC, CD4+, and CD8+ T cell interactions and killing of tumor 
cells.389  
Many current advancements have come through cross-disciplinary efforts to 
tackle important clinical problems. Success has generated clinical, academic, and 
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industrial interest with contributors from immunology and engineering fields. Continued 
improvements will come with similar engineering approaches as described here, but 
hinge on interdisciplinary collaborations and dissemination of progress. In conclusion, 
control over T cells will enable further control over disease and enhanced understanding 




Chapter 3. Biologically Inspired Design of 
Nanoparticle Artificial Antigen-Presenting Cells for 
Immunomodulation2 
3.1 Introduction  
Engineering the body’s immune system is an attractive approach to treating and 
preventing diseases. CD8+ T cells are good targets for implementing precision 
immunomodulation against pathogens and tumors with antigen-specificity. Furthermore, 
the memory response of these cells gives this approach potential long-term durability. As 
a consequence, controlling CD8+ T cell responses is one of the goals of adoptive cell 
therapy (ACT) for cancer immunotherapy.390 However, the activation of CD8+ T cells for 
therapy is costly and technically challenging. One of the main hurdles of ACT is 
generating enough functional antigen presenting cells (APCs) to stimulate anti-tumor 
CD8+ T cells. Endogenous APCs from cancer patients are frequently dysfunctional due 
to immunosuppression from the tumor microenvironment. Additionally, ACT often 
requires multiple leukophoreses; and yet the outcomes vary significantly from patient to 
patient.226–228  
 
                                                          
2 Sections of this chapter are reprinted (adapted) with permission from “Hickey, John W., et al. "Biologically 
inspired design of nanoparticle artificial antigen-presenting cells for immunomodulation." Nano letters 17.11 




3.2.1 Engineering different sized aAPCs with both similar and varying 
ligand densities 
To bypass cell-based endogenous APCs, we have developed particle-based 
artificial antigen presenting cells (aAPCs).28,231 These particles are coated with the two 
stimulatory signals needed for effective CD8+ T cell activation—peptide loaded major 
histocompatibility complex (pMHC) (Signal 1) and co-stimulatory anti-CD28 (Signal 2) 
(Figure 3-1a). Using a particle-based system offers a convenient off-the-shelf product 
and cellular replacement for ACT, ultimately leading to the control and standardization of 




Furthermore, particle-based aAPC properties can be engineered to more 
efficiently activate and modulate antigen-specific T cells.222 For example, the shape of 
the particle can be changed to promote increased attachment with the T cells,116,267 
biodegradable particles can be used to modulate T cells in vivo,258 particles can 
encapsulate and deliver other cell modulators such as cytokines,262,267 and can be used in 
combination therapies such as with checkpoint blockade molecules.257  
Particle size and stimulatory ligand surface density are important determinants 
that influence the interaction of particles and cells.82 Our original designs of aAPCs were 
Figure 3-1: Particle aAPCs are made with different sizes and ligand surface densities. (a) Schematic showing 
interaction between particle-based aAPC and cognate antigen-specific T cell. Stimulation is mediated 
through two signals. Signal 1 is antigen-specific and is between peptide loaded MHC-Ig (pMHC) and cognate 
TCR. Signal 2 is a costimulatory signal mediated between the binding of anti-CD28 and CD28 ligand on the 
T cell. (b) Schematic depicting relative sizes and ligand densities of aAPCs to a T cell. Scale bar = 500 nm. 
(c) Dynamic light scattering (DLS) measurements showing size distributions of nanoparticle aAPCs. 4500-
nm aAPC size was analyzed by light microscopy (d) Zeta potential measurements for different sized particles 
in PBS (error bars show s.e.m., n=3). (e) The surface density of ligand defined as the number of Signal 1 and 
2 molecules per µm2 of the aAPC particle surface area, measured by fluorescent antibody detection (error 
bars show s.e.m., n=4). 
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based on particles of several microns in diameter—chosen to mimic the endogenous 
APCs.231 However, using micron-sized particles presents a challenge for in vivo 
application due to the issue of potential embolization. Nanoparticles offer enhanced 
biodistribution to reach lymph nodes if injected subcutaneously,109 or to reach tumors if 
injected intravenously.391 More recently, we have demonstrated that nanoparticle (NP) 
aAPCs with an average size of 50 nm can provide therapeutic benefit in adoptive cell 
transfer models.244,254 Also, others have recently employed nanoparticles with only 
pMHC conjugated (no co-stimulation) to induce a regulatory response instead of 
activating T cells for autoimmune applications.64 Here the size was also explored, but in a 
limited size range between 4-20 nm.269 Therefore, the detailed effect of particle size on T-
cell activation efficiency has not yet been well defined.  
Differences in particle dimensions could have implications due to nanometer-
scale structures of signaling molecules at the surfaces of T cells and APCs. It has been 
shown, for example, that T cell receptors (TCRs) are pre-clustered into protein islands of 
around 35-70 nm in radius and 300 nm at the longest length scale with 7-30 TCRs per 
island.13,392 Furthermore, pMHC patches have also been observed on APCs with radii 
from 70-600 nm and about 25-125 pMHC per patch.69 Therefore, we hypothesized that 
nanoparticles with similar size dimensions to TCR islands and pMHC patches would 
result in more effective engagement and activation of T cells.  
Another parameter important to T cell activation is stimulatory ligand density. 
CD4+ T cells are insensitive to activation when the density of Signal 1 (pMHC) is too 
low. Interestingly, for antigen-independent stimulation with anti-CD3, the activation 
threshold was a maximum linear distance of 60-70 nm;59,238 however, the linear distance 
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was close to 115 nm for pMHC class II molecules.60  Thus, nanometer scale distances 
and ligand densities have clear implications for nanoparticle aAPC design and may offer 
novel insights to how the influence of ligand density is impacted by being attached to a 
mobile platform. 
In this study, we tailored size, stimulatory ligand density, and concentration of 
particle aAPCs to modulate T cell activation (Figure 3-1b). Our strategy is based from an 
effort to see whether design considerations of T cell biology, such as TCR organization, 
will improve the efficiency of nano-sized aAPCs. These findings will provide important 
guidance to control the efficiency of T cell stimulation using nanoparticle-based aAPCs 
for immunotherapeutic applications. 
We prepared aAPCs from superparamagnetic iron oxide nanoparticles (SPIONs). 
SPIONs can be formulated to have a defined size range and can be manipulated in a 
magnetic field. We conjugated chimeric pMHC-Ig loaded with model antigen SIY 
(Signal 1) and anti-CD28 antibody (Signal 2) at a 1:1 molar ratio to particles of different 
average sizes—50 nm, 300 nm, 600 nm, and 4500 nm. All aAPC particles were stable 
post-conjugation and maintained distinct size populations (Figure 3-1c, Figure 
3-2,Table 3-1). All nanoparticle aAPCs across sizes and densities had between -1 and -10 
mV zeta potential when measured in PBS at a pH of 7.4 (Figure 3-1d). While the density 
of stimulatory signals between different sized aAPCs varied slightly, for the 50-nm 
aAPCs we were able to make a high (HD) and low density (LD) version where the ligand 
density differed by 100-fold (Figure 3-1e, Figure 3-2,Table 3-1).  
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Figure 3-2: Further characterization of formed particle aAPCs. (a) Dynamic light scattering (DLS) 
measurements showing size distributions of nanoparticle aAPCs by Intensity Percent. (b-e) Representative 
images of functionalized aAPCs. (b-d) TEM images of (b) HD 50-nm (scale bar = 200 nm), (c) 300-nm 
(scale bar = 1 µm), (d) 600-nm (scale bar = 500 nm), and (e) of 4500-nm aAPCs with light microscopy 





3.2.2 The influence of aAPC particle size on T cell activation 
Using the panel of well-defined, nanoparticle-based aAPCs, we found a size-
dependent association with T cell activation. At a concentration of 2 pM of particle-
bound Signal 1, Kb-SIY, we observed a significant decrease in the ability for 50-nm 
aAPCs to stimulate their cognate 2C CD8+ T cells compared to particles larger than 300 
nm (Figure 3-3a). We controlled for the total number of bound pMHCs in all 
experiments because this parameter has been a critical factor in T cell activation in past 
studies, and not the number of aAPCs.236 Although we kept the surface ligand 
concentration constant in each condition, a greater number of smaller aAPCs were added 
than larger aAPCs because larger aAPCs had more surface-bound ligand per particle. At 
2 pM, 50-nm aAPCs only produced a 5-fold CD8+ T cell expansion, which statistically 
differed from all larger particles. All particles larger than 300 nm produced around 12-
fold T cell expansion—a value indicative of a robust stimulation of T cells for a 7-day 
culture period—and were not statistically different from one another. The differences 
between 50-nm and larger aAPCs to provide stimulation were consistent with the need to 
engage local islands of Signals 1 (pMHC) and 2 (aCD28) greater than 50 nm in diameter 





Figure 3-3: Particle aAPC size influences ability to activate CD8+ T cells. (a) Antigen-specific T cells are 
cultured with aAPCs at a controlled total dose of 2 pM conjugated pMHC and fold proliferation is measured 
7 days later (error bars show s.e.m.; ***p < 0.0005, **p < 0.005, *p < 0.05, n = 9, one-way ANOVA with 
Tukey’s post test). (b-c) Mean fluorescent intensity (MFI) for (b) phosphorylated ERK and (c) 
phosphorylated ribosomal protein S6 of CD8+ T cells cultured with aAPCs at 37 °C for 30 minutes (error 
bars show s.e.m.; ***p < 0.0005, **p < 0.005, *p < 0.05, n = 3, one-way ANOVA with Dunnett’s post test). 
(d) MFI for TCRβ of CD8+ T cells cultured with aAPCs at 37 °C for 5 hours (error bars show s.e.m.; **p < 
0.005, *p < 0.05, n = 3, Student’s T test). (e) Transmission electron microscopy (TEM) of 2C CD8+ T cells 
incubated with 50-, 300-, 600-nm aAPCs for 1 hour at 4 °C (scale bar = 500 nm). 
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To show this size-dependent effect is independent of particle preparation, we 
formulated aAPCs from another set of iron-oxide particles of 50-, 300-, and 600-nm 
diameters (Figure 3-4, Table 3-1). We observed ineffective stimulation with the 50-nm 
aAPCs when compared to the larger aAPCs (Figure 3-5a). Importantly, we did not 
observe any activation by aAPCs with non-cognate pMHC (Kb-TRP2) and anti-CD28 of 
any size (Figure 3-5b). Repeating this experiment in another particle system 
substantiated the evidence of a size-dependent effect observed with nanoparticle aAPCs. 
 
Figure 3-4: Particle characterization of formed aAPCs derived from another company (Micromod). (a-b) 
Dynamic light scattering (DLS) measurements showing size distributions of nanoparticle aAPCs by (a) 
Number Percent and (b) Intensity Percent. (c-e) Representative TEM images of functionalized aAPCs of 




These first two experiments examined proliferation as a functional readout for T 
cell activation; however, early signaling events may provide additional insight into the 
mechanism of the aAPC-T cell interaction. To do so we stimulated T cells for 30 minutes 
and examined MAPK signaling by staining for phosphorylated ERK1/2 (pERK). Similar 
to our proliferation results, we observed robust early signaling by 300-nm and larger 
aAPCs as indicated by the mean fluorescent intensity (MFI) of pERK, yet 50-nm aAPCs 
did not produce a detectable signal (Figure 3-3b, Figure 3-6a). Others have recently 
shown that local clusters of TCR-pMHC interactions are necessary both for T cell 
activation and for effective initial phosphorylation of ERK.393 This result provided 
additional support to our hypothesis that 50-nm aAPCs are unable to cluster local TCRs 
to achieve robust T cell activation.  
Figure 3-5: Size dependent effect is still observed when using another source of iron oxide particles, but not 
with non-cognate aAPCs. (a-b) Antigen-specific T cells are cultured with 2 pM of aAPC-bound pMHC and 
fold proliferation is measured 7 days later for (a) cognate (error bars show s.e.m.; ***p < 0.0005, **p < 




Figure 3-6: Isotype control staining for phosphorylation studies. (a-b) Example of isotype (grey) and 
phosphorylation (blue) staining for CD8+ T cells stimulated with 4500 nm aAPC at a 2 pM dose for (a) 
pERK and (b) pS6.   
Another indicator of early, robust T cell activation is through effective mTOR 
signaling, where phosphorylated ribosomal protein S6 (pS6) is a downstream target of 
activated mTOR.394,395 We stained for pS6 after activating the T cells for 30 minutes, and 
found consistent results between both proliferation and pERK data. Levels of pS6 for 
300-nm and larger aAPCs were significantly higher than those produced by either 50-nm 
aAPCs or the non-stimulated negative control (Figure 3-3c, Figure 3-6b). Recently, it 
has been shown that effective pS6 staining is correlated to the duration of the APC-T cell 
contact.396 Therefore, larger aAPCs may be able to contact CD8+ T cells longer because 
of greater multi-valent binding and thus provides another mechanism to the observed 
size-dependent effect.  
Shorter signaling duration has been associated anergy in CD4+ T cells.396 We did 
not expect the aAPCs to induce anergy because we have conjugated a Signal 2, co-
stimulation (anti-CD28) in addition to pMHC, which has been shown to induce activation 
rather than anergy in T cells.397,398 Nevertheless, we wanted to confirm whether the 
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reduced activity of CD8+ T cells from 50-nm aAPCs was due to suboptimal signaling or 
just ineffective engagement of the CD8+ T cell. We first examined TCR downregulation, 
which is associated with TCR engagement and T cell activation.399,400 We stimulated T 
cells with 2 pM dose of the aAPCs and observed a significant decrease in TCR 
expression for cells stimulated with 300-, 600-, 4500-nm aAPCs, but not 50-nm aAPCs 
when compared to non-cognate aAPCs and no stimulation controls (Figure 3-3d). 
Additionally, we probed for a regulatory phenotype at day 7 as defined by other 
researchers who use pMHC-only (no co-stimulation) and have induced an 
immunoregulatory CD8+ T cell response, which are both CD122+ and CD44+.64,269 After 
stimulating with aAPCs, we found no significant difference in the percentages between 
all aAPCs (Figure 3-7). Moreover, we formulated a 300-nm particle with only pMHC 
(which we term 300 S1), to replicate the type of particle used in previous studies. 
Importantly, here we found that there was a significant increase in the percent of a 
regulatory phenotype at day 7 (Figure 3-7)—further substantiating evidence for the 
importance of having both pMHC (Signal 1) and co-stimulatory anti-CD28 (Signal 2) on 
the particle for an immune activating response. These data point to ineffective 





Figure 3-7: Only aAPCs with only pMHC KbSIY attached (no anti-CD28), 300 S1, showed a significant 
increase in the percent of CD122+, CD44+, CD8+ T cells after 7 days of culture with aAPCs at a 2 pM 
dose of aAPCs (error bars show s.e.m.; *p < 0.05, n = 3, One way ANOVA with Dunnett’s post test). 
To better understand the interaction of different sized particle aAPCs and T cells 
we imaged the aAPCs and T cells using transmission electron microscopy (TEM). 
Interestingly, very few 50-nm aAPCs attached to the T cells, where on average only 
about one particle attached to a T cell in the 70-nm slice, whereas many more 300- and 
600-nm aAPCs attached to the surface of the T cells (Figure 3-3e). Additionally, the 300- 
and 600-nm aAPCs were distributed over the surface of the T cell, yet there seemed to be 
areas where multiple particles attached near each other. These images support both of our 
proposed mechanisms for why we observe the size dependent effect—size of TCR 
clusters and duration of attachment via increased avidity. More specifically, we observed 
that the 50-nm aAPCs were not clustered, nor attached well to the T cell compared to the 
larger 300- and 600-nm aAPCs.  
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3.2.3 Minimum aAPC dose for T cell expansion reveals size-dependent 
properties 
To further probe the size-dependent phenomenon we asked if we could overcome 
the restriction with increasing the dose of pMHC and thus total particle numbers. 
Schematically we are testing if by adding excess aAPCs, then multiple 50-nm aAPCs 
could diffuse and engage a single TCR cluster and achieve similar T cell activation, or if 
clusters need to be ligated by a single larger nanoparticle (Figure 3-8a). Furthermore, by 
adding more aAPCs, this may increase the number of aAPCs bound at one time and 
increase the signaling duration. Indeed, at surface saturating concentrations of 50-nm 
aAPCs (18 pM of particle-bound Kb-SIY), 50-nm aAPCs were able to stimulate the 
CD8+ T cells just as well as the larger particles (Figure 3-8b). All aAPCs produced 
around 12-fold CD8+ T cell expansion with no statistical difference between any of the 
groups. We confirmed that this saturating dose of nanoparticle-based aAPC stimulation 
resulted in similar final CD8+ T cell phenotype (surface markers) and functionality 
(cytokine analysis), further supporting that TCR clusters may be activated by multiple 











Figure 3-8: Particle aAPC concentration reveals saturating concentration of 50-nm aAPCs needed to activate 
CD8+ T cells. (a) Schematic depicting hypothesis that saturating the T cell with 50-nm aAPCs is needed for 
the same nanoisland cluster-based activation as lower concentration larger 300 nm particles (600-nm aAPCs 
are depicted). (b) 18 pM dose of particle-conjugated pMHC is used to stimulate CD8+ T cells for 7 days and 
fold expansion is measured (no significant differences between aAPCs, one-way ANOVA, n=13). (c-d) 
Dose-titrating amounts of particle aAPCs to activate T cells for 7 days determined lowest dose or (c) ratio of 




Figure 3-9: CD8+ T cells stimulated with particle aAPCs of different sizes result in similar CD8+ T cell 
phenotype and functionality. (a, b) CD8+ T cells were stimulated by particles of different sizes for 7 days at 
a concentration of 18 pM of particle-bound Kb-SIY and (a) phenotypic cell surface markers (CD62L, 
CD44) and (b) intracellular cytokine production as measured by triple, double, and single positive cells 
(IFNγ, TNFα, IL-2) were measured as a percent of CD8+ (n=3). 
We extended this finding by quantitating the minimum number of aAPCs required 
for activation at each aAPC size. Interestingly, this revealed three separate patterns in the 
number of aAPCs needed to provide effective T cell signaling (Figure 3-8c). First, the 
minimum number of 50-nm aAPCs needed to activate T cells is similar to the number of 
TCRs per T cell, which is reported to be around 0.5 – 1  105 per T cell.401 Second, larger 
aAPCs, 300- and 600-nm, require many fewer aAPCs than the number of TCR per T cell, 
and much lower than the estimated number of nano-islands per T cell — ca. 15,000, 
assuming about 30 TCR per island. Third, the 4500-nm aAPCs required even fewer 
aAPCs — less than one per T cell.  
The high number of 50-nm aAPCs required for activation further confirms that 
there is a need for a surface saturating amount of aAPCs, since nanoparticle aAPCs 
diffuse through solution, their binding with TCRs will be stochastically distributed over 
the surface of the CD8+ T cell. Estimating the T cell to have around 50,000 TCRs, to 
achieve complete nano-island ligation, all or most TCRs should be bound by 50-nm 
aAPCs (Figure 3-10a). Furthermore, the need for many fewer 300- and 600-nm aAPCs 
supports the idea that individual particle aAPCs can bind multiple TCRs in TCR nano-
islands to achieve local stimulation with only one particle per island. Finally, the low 
numbers of 4500-nm aAPCs points to a different signaling mechanism where multiple 
TCR clusters are bound by a single particle; and multiple T cells can be stimulated by the 
same particle. The need for a surface saturating amount of 50-nm aAPCs can also be 
examined by plotting the ratio of particle aAPC surface area to cell surface area (Figure 
97 
 
3-10b). Consequently, this shows that 50-nm nanoparticles need nearly a 1:1 ratio of 
particle surface area to T cell area to activate T cells, whereas aAPCs larger than 50 nm 
need less than a 1:5 ratio of particle to T cell surface area.  
 
Figure 3-10: 50-nm aAPC require saturating dose of particles to provide T cell activation. (a-b) Dose-
titrating amounts of particle aAPCs to activate T cells for 7 days determined lowest dose (number of 
aAPCs) and therefore (a) number of estimated TCRs per particle aAPC needed. The number of TCRs per T 
cell was estimated to be 50,000 based on literature values, and (b) surface area ratio of particle aAPC to T 
cell needed. The size of the T cell was simulated to be 10 µm (error bars show s.e.m., n=4). 
 
To connect our findings involving synthetic aAPCs to studies with endogenous 
APCs, we calculated the average number of available pMHCs per T cell (Figure 3-8d). 
Previous studies have reported between 1-400 pMHCs are needed to activate a CD8+ T 
cell.402–409 While for aAPCs the pMHC is conjugated to a solid scaffold and not within a 
mobile lipid bilayer with additional signaling molecules, the results seen are consistent 
with previous reports. We found that the “cell-sized” 4500-nm aAPCs required about 3 
pMHCs per T cell. These averages were also similar to numbers found through direct 
observation of cell-based APCs, where 10 pMHCs were needed to activate a CD8+ T cell 
and only 3 pMHCs were needed to activate for killing.407 The 300- and 600-nm aAPCs 
both required close to 200 pMHCs per T cell, which also falls within the range that has 
been calculated by indirect averages of endogenous APCs. In contrast, 50-nm aAPCs 
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required more than 10,000 pMHCs per T cell—pointing to the spatial relation or on-rate 
of the pMHCs when engaged may be important parameters for activation rather than total 
pMHCs available to a T cell.  
 
3.2.4 Magnetic clustering of 50-nm aAPCs reveals need for receptor 
clustering  
Cells are able to dynamically rearrange and cluster receptors on their surface for 
enhanced function and signaling.78,410,411  We sought to mimic receptor clustering of the 
diffusely bound 50-nm magnetic particles on the surface of the T cell by applying a 
magnetic field (Figure 3-11a). Thus, if individually bound TCRs by 50-nm aAPCs can 
be physically made to cluster using magnetic force, and effective signaling is generated, 
then this would strengthen our hypothesis of the importance of spatially activating TCRs 





To artificially cluster TCRs, we placed T cells with 50-nm SPION aAPCs within 
a static magnetic field.244 Indeed, artificially clustering 50-nm aAPCs at sub-surface 
saturating amounts stimulates CD8+ T cells to the same level as surface saturating 
conditions (Figure 3-8b, Figure 3-11b). Within a magnetic field 50-nm aAPCs produce 
Figure 3-11: Particle aAPC can be artificially magnetically clustered at sub-saturating concentrations. (a) 
Schematic demonstrating the effect of magnetic fields on the 50-nm particle aAPCs to achieve artificial 
clustering. (b, c) CD8+ T cells and particle aAPCs were cultured for 7 days with or without the presence of 
a magnetic field and counted for fold expansion at either (b) 2 pM or (c) 18 pM dose of particle-conjugated 
pMHC (error bars show s.e.m.; **p < 0.005, n = 5-7, Student’s T test). 
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approximately a 12-fold, statistically different CD8+ T cell expansion in contrast to the 3-
fold expansion without a magnetic field. Artificial clustering of 50-nm aAPCs were 
comparable to larger aAPCs without artificial clustering. Magnetic clustering of larger 
aAPCs and surface saturating amounts of 50-nm aAPCs did not further increase CD8+ T 
cell stimulation, suggesting there is no added benefit to the magnetic field other than 
providing artificial clustering of diffuse 50-nm particles (Figure 3-11c).  
 
3.2.5 The influence of ligand density and size on T cell activation 
This result demonstrated that artificial clustering of Signals 1 (pMHC) and 2 
(anti-CD28) improved signal activation, suggesting a particle size-dependent signaling 
effect that is linked with stimulatory signaling molecule clusters. However, taking a 
reductionist approach and modeling the surfaces of the particle and the T cells as spheres 
we determined that a confounding variable is the number of ligands available from 
particle aAPCs to interact with T cells (Error! Reference source not found.a, Figure 
3-13, Table 3-1). Even if there are similar densities of ligands for particles of different 
sizes, differences in geometry can lead to differences in number of ligands actually 
available to engage T cells. We calculated the number of available ligands for each 
spherical particle at the initial contact (Figure 3-12a). As the particle size decreases, 
there is an increase in particle curvature and a decrease in ligands available to interact 








Figure 3-13: Spherical geometry of particle aAPC limits the actual size and number of ligands interacting 
with the T cell. (a) Schematic showing the defined effective radius (reff) of the particle aAPC. This is 
governed by the separation distance (sd) between the pMHC on the surface of the aAPC. This is the 
distance that prevents attached pMHC from engaging TCR on the surface of the T cell due to distance. We 
find the reff using Equation 1, which is defined from the geometry of a circle. In order to define effective 
surface area as a percent of surface area we used Equations 2 and 3.  Equation 2 finds the angle of the 
effective surface by using the sides of the defined triangle reff and sd. We then use the effective surface 
area and nanoparticle ligand density to find the effective number of stimulatory ligands/particle from 
Equation 4. (b) Calculated effective diameters are plotted versus actual diameters to show estimated size of 
interaction for aAPCs. Lightly shaded blue region indicates estimated T cell receptor nano-island 
estimations previously described. 
Figure 3-12: Normalizing the effective available activating ligands does not overcome size-dependent 
stimulation capacity of aAPCs. (a) Calculated values of number of effective stimulatory ligands per particle. 
The square represents the HD 50 nm aAPCs made. (b) CD8+ T cells were incubated with equivalent doses 
aAPC-bound pMHC of either 50 nm or HD 50 nm aAPCs for 7 days and fold expansion was measured (error 
bars show s.e.m.; ***p < 0.0005, **p < 0.005, *p < 0.05, n = 10-13, Student’s t test). (c) Schematic showing 
how aAPC size influences ligand-TCR interaction (spaced at ~30 nm) in TCR islands, where larger particles 
facilitate more effective TCR ligand interactions, thus promoting T cell activation. (d) The effect of a 
magnetic field for either aAPC amounts at 2 pM or 18 pM of particle-bound pMHC (error bars show s.e.m.; 
*p < 0.05, n = 5, Student’s t test). (e)  600-nm aAPCs with different ligand densities were incubated with T 
cells at 2 pM of particle-bound pMHC and fold expansion of CD8+ T cells was measured on day 7; 50 nm 




To decouple the effect of multiple-ligands per TCR nanocluster and stimulation 
signal cluster size, we prepared 50-nm aAPCs with a higher density of Signals 1 and 2 
(HD 50-nm). HD 50-nm aAPCs have the same effective radius (reff) as their 50-nm 
counterparts (Figure 3-13a) but a shorter distance between ligands—thus, presenting 
comparable numbers of effective stimulatory molecules as larger aAPCs (Figure 3-12a). 
Using these HD 50-nm aAPCs, we confirmed the size-dependent constraints of 50-nm 
aAPCs as they are also unable to stimulate T cells effectively at 2 pM of particle-bound 
pMHC in terms of cellular proliferation (Figure 3-12b) and in early activation events like 
ERK phosphorylation, mTOR signaling, and TCR downregulation (Figure 3-14). HD 50-
nm aAPCs were even less efficient in activating T cells than the regular density 50-nm 
aAPCs at the 18 pM dose, and required a total dose of 90 pM of particle-bound pMHC to 
produce a similar maximal T cell expansion. This is to be expected as a large number of 
HD 50-nm aAPCs is still needed to achieve saturation binding of nanoparticles to T cells. 
Interestingly at the higher dose of 90 pM, HD 50-nm aAPCs produced a greater apparent 
expansion of T cells than their regular density 50-nm counterpart. This could be due to 
particle toxicity or to activation-induced T cell death evoked by adding so many regular 
density 50-nm aAPCs. Non-cognate 50-nm particle aAPCs at the same dose did not cause 
any additional toxicities as compared to a traditional 4500-nm aAPC stimulation (Figure 
3-15a), ruling out toxicity due to particle numbers. Proliferation analysis by CFSE 
dilution at the 90 pM dose demonstrated effective cell stimulation and division with the 
50-nm aAPCs at an earlier time point than that observed with HD 50-nm aAPCs, 




Figure 3-14: Ineffective activation of CD8+ T cells also observed for HD 50 nm aAPCs at a 2 pM dose 
with early activation events. (a-b) MFI of phosphorylation of (a) ERK and (b) ribosomal protein S6 for HD 
50 nm aAPCs. Other groups were replotted for comparison purposes. (c) MFI for TCRβ of CD8+ T cells 
cultured with aAPCs at 37 °C for 5 hours for cognate and non-cognate aAPCs. Negative control was 
replotted for comparison purposes. 
 
 
Figure 3-15: High concentrations of 50-nm aAPCs are not toxic due to particle doses, but to 
overactivation-induced cell death. (a) CD8+ T cells were incubated with 90 pM controlled non-cognate 
pMHC aAPCs for 7 days and viability was measured. T cells without aAPCs and T cells stimulated with 
traditional 4500 nm aAPCs are shown for comparison purposes for a normal antigen-specific stimulation 
(n=3). (b) CD8+ T cells were stimulated for three days and proliferation is characterized by CFSE dilution 
and characterization of percent of cells in each generation (n=3). (c) Representative flow cytometry plot of 
CFSE dilution experiment. 
Thus, even with normalized ligand availability, 50-nm aAPCs were less effective 
than larger aAPCs at stimulating T cells under sub-saturating conditions. These findings 
support the notion that the size of the aAPCs is particularly important in achieving T cell 
activation rather than differences in ligand availability. This could be explained by TCR 
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density, as it has been reported to be on the order of 1,200 TCR/µm2.13 Linearly, this 
translates to about 30 nm spacing between TCRs, which means that even if small 
particles have a high density of ligand, all available ligands may not be beneficially 
engaged over the entire surface of the TCR island. Consequently, small particles result in 
fewer TCR-MHC interactions, and fail to result in sustained activation of the TCR island 
by an individual particle (Figure 3-12c). In contrast, larger particles can have multivalent 
binding with nanoclusters leading to a rapid on-rate of local TCRs.412–414  
To further investigate the relationship between the observed size-dependent effect 
and potential mechanism of TCR cluster activation we again used a magnetic field to 
artificially cluster the HD 50-nm aAPCs at sub-saturating concentrations. We observed 
effective CD8+ T cell stimulation at both the 2 pM and 18 pM concentrations only when 
the particles were artificially clustered in a magnetic field (Figure 3-12d). These results 
further indicate that activation of TCRs in clusters is important for effective T cell 
activation and agrees with previous studies that demonstrate the importance of pMHC 
clustering on endogenous APCs for T cell activation.78  
This study shows that in addition to ligand spacing (Figure 3-16a), size of the 
stimulatory island (particle size) is also important for T cell activation. Previous studies 
with T cells involving TCR nano-arrays have shown a stimulatory molecule spacing 
requirement for T cell activation of around 70-120 nm.59,60,238 We observe differences 
from this reported trend with 50-nm aAPCs. Even when using 16 nm linear spacing 
between ligands we did not observe as effective stimulation as with larger particles with 




Figure 3-16: Linear ligand density and size of nanoparticle aAPCs are important for T cell stimulation. (a) 
Linear spacing between stimulatory molecules on the surface of the aAPC for different sized aAPCs. (b) 
Graph representing the relationship between the linear ligand density and the number of effective ligands 
presented from a 600-nm aAPC. (c) 600-nm aAPCs with different ligand densities were incubated with T 
cells at 2 pM concentration and fold expansion of CD8+ T cells was measured on day 7 and 50 nm, 300 
nm, and 4500 nm data replotted for comparison (error bars show s.e.m.; n = 5). 
Since the size of the particle appears to be a driving factor in our findings, we 
probed how ligand density influenced T cell stimulation with 600-nm aAPCs. 
Theoretically, 600-nm aAPCs are able to engage multiple receptors with a linear ligand 
spacing up to about 150 nm (Figure 3-16b). Since this is close to the values reported 
from TCR nanoarrays, we hypothesized that we would notice a drop-off in T cell 
activation with ligand densities in this regime. To test this hypothesis, we formulated 
600-nm aAPCs with seven different ligand densities (distance between ligands), ranging 





Table 3-2: Tabular summary of 50- and 600-nm aAPC particle properties and conditions used to examine 
the impacts of ligand density and spacing. 
 
We observe that for 600-nm aAPCs, expansion of CD8+ T cells began to decrease 
substantially at spacing of about 100 nm (Figure 3-12e, Figure 3-16c), which is similar 
to values reported for TCR nano-arrays. Therefore, this shows the importance of 
engineering ligand spacing as well as size of aAPCs for effective T cell activation. 
3.3 Discussion 
Our ability to provide a mobile stimulatory unit by conjugating the stimulatory 
ligands to a particle instead of a nano-array allowed us to probe unique mechanisms of T 
cell activation. This particle-based aAPC system enables simultaneous control of both the 
number of stimulatory molecules and the density of these molecules, something that is 
difficult to achieve with substrate-conjugated signals. Additionally, whereas substrate-
conjugated signals allow the study of how T cells might adapt to a fixed stimulation, 
particle-conjugated signals allow the study of native T cell biology where stimulation 
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signals are also mobile. Another distinction between this and previous studies is that here 
we study CD8+ T cells, where previous studies have investigated the effect of ligand 
spacing and density on CD4+ T cells. 
This study provides a systematic understanding of how particle aAPC parameters 
such as particle size, surface ligand density, and concentration collectively influence T 
cell activation. We demonstrate that aAPCs larger than 300 nm were more effective at 
activating CD8+ T cells, presumably due to their ability to initiate clustering of pMHC-
TCR and costimulatory interactions due to their size. Mechanistically, once particles bind 
to TCR nanoclusters, larger particles have an enhanced ability to bind other TCRs with 
pMHCs and CD28 with anti-CD28 leading to multivalent binding of receptors and 
sustained signaling necessary for T cell activation.412–414 This is consistent with recent 
data from 1) immunoregulatory pMHC-only nanoparticles, 2) DNA chimeric antigen 
receptors, and 3) endogenous antigen presenting cells. For immunoregulatory pMHC-
only nanoparticles, higher ligand densities led to increased activity of the particles and 
clustered attachment to T cells.20 Indirectly, we also observed this as non-cognate aAPCs 
(with anti-CD28) prevented full activation of CD8+ T cells co-cultured with cognate 
aAPCs—presumably because they compete for CD28 binding and decrease the ability for 
multivalent binding (Supplemental Fig. 12). For DNA chimeric antigen receptor T cells, 
it was necessary that a small group of the receptors be clustered by the counterpart DNA 
(pMHC) for effective activation.393 For endogenous APCs, pMHC molecules containing 
identical peptide sequences are found clustered on the surface of APCs and lead to 
effective T cell activation.68,70,71 Furthermore, effective nanocluster signaling has been 
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shown to be necessary for T cell activation prior to the formation of supramolecular 
activation centers.415  
 
Figure 3-17: Addition of non-cognate aAPCs decreases the activation of antigen-specific T cells in a dose 
dependent manner. 600-nm cognate (Kb-SIY/anti-CD28) and 600-nm non-cognate (Kb-TRP2/anti-CD28) 
were mixed at the indicated ratios respectively and cultured for 7 days (error bars show s.e.m.; ***p < 
0.0005, **p < 0.005, *p < 0.05, n = 3, one-way ANOVA with Dunnett’s post test). 
 
In this systematic and quantitative analysis of aAPC particle size, we revealed the 
importance of designing cell-modulating nanoparticles with biology in mind. Here we 
considered both APC and T cell biology where primarily the field has been focusing on 
mimicking APCs. Furthermore, these mechanistic studies have implications for aAPC 
design for optimal therapeutic applications. One application is in utilizing the magnetic 
properties of the SPION aAPCs for magnetic enrichment of antigen-specific cells. 
Antigen-specific T cells occur at very low frequencies—at about 1 in every 105 to 106 T 
cells—and are therefore difficult to detect.416 As immunotherapies have continued to 
develop, techniques surrounding identification and isolation of rare antigen-specific T 
cell have grown in importance. Additionally, previous work has indicated that an 
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enriched cell population can be activated to have therapeutic potential.254 Therefore, 
aAPCs that are able to bind multiple TCRs may result in greater specificity and avidity 
and in greater enrichment of antigen-specific T cells. Our studies lay a foundation of 
quantitative analysis of particle aAPC size that pave the way for similar studies in the 
development of optimal aAPCs for magnetic enrichment.   
Furthermore, these findings can provide aAPC design guidance in the in vivo 
activation of antigen-specific T cells. Using aAPCs to stimulate CD8+ T cells in vivo 
overcomes several challenges of the cancer immunity cycle and adoptive T cell transfer 
(ACT).417 Endogenous APCs, such as dendritic cells (DCs), are immunosuppressed, and 
can even be skewed to be immunosuppressive themselves.418–420 This results in either 
deficient activation or immunosuppression of CD8+ T cells. Using aAPCs would bypass 
the need for DCs and allow effective and precise stimulation of antigen-specific CD8+ T 
cells. Additionally, in ACT, T cells are taken from a patient and cultured ex vivo then 
injected back into the body.390 This process of ex vivo culture is time-consuming, 
technically challenging, and costly.421–423 Therefore, in vivo activation of antigen-specific 
T cells is a primary goal of the field. Yet, achieving saturating conditions of 50-nm 
aAPCs in vivo may be impractical due to both poor nanoparticle-based biodistribution 
and retention, and low frequency of antigen-specific T cells.82,416 Thus, the goal is to 
engineer a particle that could achieve optimal biodistribution yet not require saturating 
amounts of aAPCs to activate a T cell. Our studies provide the basis for development of 




In conclusion, we demonstrated how biologically inspired design of nanoparticle 
aAPCs to mimic a cell can lead to increased functionality of the particle and reveal 
aspects of cellular function. We utilized a reductionist approach to isolate the important 
properties of particle size and ligand density. Though we studied this in a model system 
with CD8+ T cells for immunotherapeutic applications, our findings and quantitative 
approach can impact and be implemented in other areas of cell modulation and 
mimicry.82,424  
3.5 Experimental Methods 
Mice and Reagents. 2C TCR transgenic mice were kept as heterozygotes by 
breeding on a C57/BL6 background. C57BL/6j mice were purchased from Jackson 
Laboratories (Bar Harbor, ME).  All mice were maintained per guidelines approved by the 
Johns Hopkins University’s Institutional Review Board.  
Particle Fabrication. Soluble MHC-Ig dimers, Kb-Ig, was produced in-house and 
loaded with peptides as described1 and anti-CD28 antibody was purchased from Biolegend 
(37.51; BioLegend, San Diego, CA, USA). NHS (NHS) labeled super paramagnetic iron-
oxide particles (SPIONs) were purchased from OceanNanotech (Springdale, AR, USA). 
Conjugation of MHC-Ig dimer and anti-CD28 proteins to the particles was carried out per 
manufacturer’s recommendations (Figure 3-18). Briefly, SPIONs were washed while on a 
STEM-cell magnetic column (Vancouver, Canada) with PBS three times and then 
incubated with equimolar amounts of MHC-Ig and anti-CD28 at ratios of 0.1 mg of total 
protein to 1 mg of SPIONs. SPIONs and protein were allowed to react for 24 hours at 4°C. 
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Tris-HCl buffer was added to the SPIONs to quench any unreacted functional groups and 
SPIONs were subsequently magnetically washed three times with PBS with 2% bovine 
serum albumin (BSA). 4500 nm particles—Dynal Particles—were purchased from 
ThermoFisher (Halethorpe, MD). MHC-Ig and anti-CD28 were conjugated to the surface 
as established previously2.  
 
Using NHS labeled magnetic nanoparticles worked effectively for a facile 
conjugation with our pMHC-Ig and anti-CD28; however, we were not able to substantially 
increase the density of the ligand by adding additional ligand to the reaction. To control 
the density and increase the ligand density on the particles we aimed to functionalize 
amine-coated iron oxide particles with a higher density of reactive groups. SPIONS were 
purchased from Micromod (Rostock, Germany) and functionalized according to 
manufacturer’s recommendations (see 
https://www.micromod.de/daten/File/Technotes/Technote_202_1.pdf and 
https://www.micromod.de/daten/File/Technotes/Technote_201_2.pdf) (Figure 3-19). 
Briefly, amines were then reacted with Sulfo-SMCC (Proteochem, Hurricane, UT) and 
then magnetically washed. MHC-Ig and anti-CD28 were modified with 2-iminothiolane 
(Traut’s reagent) purchased from Sigma Aldrich (St. Louis, MO). Excess 2-iminothiolane 
Figure 3-18: Scheme 1 
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was washed away from protein solution by using a Vivaspin 20 50kDa MWCO 
concentrator (GE Healthcare, Little Chalfont, United Kingdom). Traut’s reagent targets the 
same free amines that would be targeted in the conjugation of the antibodies to NHS-
labeled particles. Therefore, the orientation of the antibodies or Signals does not change 
between chemistries, only the linkers. Washed and activated particles and MHC-Ig and 
anti-CD28 were then mixed and reacted. The resultant product was washed and stored at 
4°C.  HD 50 nm aAPCs were conjugated by Miltenyi Biotec (Cologne, Germany).  
 
Particle Characterization. NP size and zeta potential was measured using a 
Zetasizer DLS. Protein surface density was measured through a fluorescent detection assay. 
Briefly, particles were either stained with FITC-conjugated rat anti-mouse Ig λ1, λ2, λ3 
light chain, clone R26-46, or FITC-conjugated mouse anti-armenian/syrian hamster IgG, 
clone G192-1 (BD Pharmingen, Franklin Lakes, New Jersey) for 1 hour at 4°C. Particles 
were washed three times with 1x PBS. Particles were then collected in 1x PBS and 
subsequently the fluorescence was quantified using a Synergy HTX Multi-mode florescent 
plate reader (BioTek, Winooski, VT, USA). Particle concentration was measured using a 
Figure 3-19: Scheme 2 
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spectrophotometer at a 405 nm reference. Imaging of particle aAPCs by Transmission 
Electron Microscopy (TEM), was done on a FEI Tecnai 12 and Philips EM 420 electron 
microscopes. Samples were allowed to adhere to discharged nickel grid covered with 
carbon film for 30 minutes. Solution was removed with a Kim wipe and then the samples 
were stained with 2% uranyl acetate for 45 seconds. The grids were then washed three 
times and allowed to dry at room temperature.  
In Vitro T Cell Activation. Lymphocyte isolations were completed as previously 
described3. Briefly, CD8+ T cells were isolated from the spleen and lymph node from a 2C 
transgenic mouse by using a mouse CD8+ T cell negative isolation kit from Miltenyi Biotec 
(Cologne, Germany) and following manufacturer’s instructions. 2C transgenic mice have 
CD8+ T cells with identical TCRs, which recognize the SIY peptide loaded into the mouse 
pMHC Kb. All aAPCs had pMHC Kb loaded with SIY and co-stimulatory molecule anti-
CD28, except for non-cognate aAPCs which had an irrelevant peptide, TRP2, loaded into 
pMHC Kb and co-stimulatory molecule anti-CD28, and 300 s1 particles which only 
contained pMHC (no costimulatory molecules). CD8+ T cells were activated by NPs at 
indicated doses as previously described.254 Briefly CD8+ T cells were plated with nano-
aAPCs at 100,000 cells/mL in complete RPMI-1640 medium supplemented with 10% fetal 
bovine serum and T cell growth factor, a cytokine cocktail derived from condition media 
produced from stimulated human PBMC as previously described.425 T cells were fed with 
media with double concentration of T cell growth factor on day 3. Fold expansion and 
viability was determined by harvesting and counting cells by Trypan Blue staining and 
hemocytometry. For magnetic stimulations, T cells were isolated and plated as described 
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above, but tissue culture plates were set between two neodymium N52 disk magnets (K&J 
Magnetics, Jamison, PA, USA) as described previously.244 
For experiments determining the minimum surface area ratio of NP aAPC to CD8+ 
T cells, T cells were incubated with decreasing ratios of NP aAPCs. The activation cut-off 
was defined as CD8+ proliferation above 1-fold the initial number of CD8+ T cells as 
measured on day 7. The graphs were generated by a custom-MATLAB script, with the grid 
size showing the representative surface area of a NP aAPC and the shading demonstrating 
NP aAPC needed for activation. 
Cell proliferation was also characterized by dilution of CellTrace™ CFSE Cell Dye 
per manufacturer’s recommendations (ThermoFisher). Briefly, isolated CD8+ T cells were 
suspended in 1 mL of PBS, and 1 µL of CellTrace™ CFSE Cell Dye suspended at 5 mM 
was added to the solution and placed in a cell incubator for 20 minutes at 37°C. Then 5 mL 
of complete RPMI-1640 medium supplemented with 10% fetal bovine serum was added 
and allowed to incubate in a cell incubator for 5 minutes at 37°C. Cells were then washed 
twice in complete RPMI-1640 medium supplemented with 10% fetal bovine serum and 
counted. Cells were then stimulated for three days. On day 3, cells were counted and 
200,000 cells were taken and stained with a solution of 1:100 APC-conjugated rat anti-
mouse CD8a, clone 53-6.7 (BD Pharmingen) for 15 minutes at 4°C. Cells were then 
washed with FACS was buffer and read on a BD FACSCalibur.  
T Cell Phosphorylation Analysis. 2C CD8+ T cells were isolated as described 
above and particle aAPCs were incubated with T cells for 30 minutes at 4°C and then 
activated for 30 minutes at 37°C. Samples were then washed in a 96 well plate with PBS 
and fixed with pre-warmed (37°C) BD Phosflow 1x Lyse/Fix Buffer (BD Biosciences, San 
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Jose, CA) for 10 minutes at 37°C. Fixative was washed twice from the samples with PBS 
and pre-chilled (-20 °C) BD Phosflow Perm Buffer III was added dropwise to each sample 
and gently mixed and incubated at -20 °C for 30 minutes. This mixture was spun down and 
the supernatant was removed and then washed three times with FACS wash buffer. 
Samples were then stained with a solution of FACS wash buffer with 1:50 PE-conjugated 
rat anti-mouse CD8a, clone 53-6.7 (BD Pharmingen) and either a 1:100 Rabbit anti-
Phospho-S6 Ribosomal Protein (Ser235/236), clone D57.2.2E, or Rabbit anti-Phospho-
p44/42 MAPK (Erk1/2) (Thr202/Tyr204), clone 9101, or Rabbit IgG Isotype Control, 
clone DA1E (Cell Signaling Technology, Danvers, Massachusetts) for 45 minutes at room 
temperature. Samples were then washed with FACS wash buffer and then stained with a 
solution of FACS wash buffer with 1:250 of Alexa Fluor 647-conjugated Goat anti-Rabbit 
IgG, polyclonal (ThermoFisher) for 45 minutes at room temperature. Samples were washed 
and resuspended with FACS wash buffer and read on a BD FACSCalibur.  
T Cell Receptor Downregulation. 2C CD8+ T cells were isolated as described 
above and particle aAPCs were incubated with T cells for 30 minutes at 4°C and then 
activated for 5 hours at 37°C. Cells were washed with FACS wash buffer in a 96 well plate 
and then stained with a solution of FACS wash buffer with 1:100 PE-conjugated rat anti-
mouse CD8a, clone 53-6.7 (BD Pharmingen) and 1:100 Alexa Fluor 647-conjugated anti-
mouse TCR β chain, clone H57-597 (Biolegend) for 30 minutes at 4°C. Samples were then 
washed and resuspended with FACS wash buffer and read on a BD FACSCalibur.  
T Cell Phenotype Characterization. After 7 days of culture, T cells were counted 
using a hemocytometer. 200,000 T cells were taken to stain for phenotypic markers. Cells 
were stained with a 1:100 solution of PE-conjugated rat anti-mouse CD62L, clone MEL-
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14 (BD Pharmingen), APC-conjugated rat anti-mouse CD8a, clone 53-6.7 (BD 
Pharmingen), PerCP-conjugated rat anti-mouse CD44, clone IM7 (Biolegend), and 1:1000 
of LIVE/DEAD® Fixable Green Dead Cell Stain (ThermoFisher) for 15 minutes at 4°C. 
Cells were then washed with FACS wash buffer and read on a BD FACSCalibur. For 
CD122+, CD44+, CD8+ T cell experiments, the same protocol was followed, but a 1:100 
solution of PE-conjugated Rat Anti-Mouse CD122, clone TM-Beta 1 (BD Pharmingen) 
was used instead of the PE-conjugated anti-mouse CD62L.  
T Cell Cytokine Functionality Characterization. After 7 days of culture, T cells 
were counted using a hemocytometer. 500,000 T cells were taken per condition and 
separated into restimulation or no-stimulation groups. A solution of 1:350 BD GolgiStop 
Protein Transport Inhibitor (BD Biosciences) and 1:350 BD GolgiPlug Protein Transport 
Inhibitor (BD Biosciences) was added to the cells in RPMI-1640 medium supplemented 
with 10% fetal bovine serum. Microparticle Dyanl-based aAPCs were added to cells to be 
restimulated at a 1:1 ratio. Cells were then allowed to incubate in a cell incubator for 6 
hours at 37°C. Following the incubation, cells were washed and then stained with 50 µL 
of a 1:100 solution of PerCP-conjugated rat anti-mouse CD8a, clone 53-6.7 (Biolegend) 
and 1:1000 LIVE/DEAD® Fixable Aqua Dead Cell Stain (ThermoFisher) for 30 minutes 
at 4°C. Cells were then washed with PBS and 100 µL of BD Cytofix/Cytoperm Fixation 
and Permeabilization Solution was added to the cells and allowed to sit overnight at 4°C. 
Following the fixation step, 100 µL of 1x BD Perm/Wash Buffer (10x solution diluted to 
1x in a solution of 2% bovine serum albumin in PBS) was added to the cells and washed. 
Cells were again washed with 200 µL 1x BD Perm/Wash Buffer. Cells were then stained 
with a solution of 1:100 solution of PE-conjugated rat anti-mouse IFNγ, clone XMG1.2 
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(BD Pharmingen), APC-conjugated rat anti-mouse IL2, clone JES6-5H4 (BD 
Pharmingen), and PE-Cy7-conjugated rat anti-mouse TNFα, clone MP6-XT22 (Biolegend) 
for 1 hour at 4°C. Cells were washed with FACS wash buffer and then read on a BD LSR 
II flow cytometer. Background cytokine staining was accounted for by subtracting cytokine 
positive cells in non-stimulated conditions from the re-stimulated cells.  
Transmission Electron Microscopy (TEM) of T cells and Particles. Thin 
sections, 60 to 90 nm, were cut with a diamond knife on the Reichert-Jung Ultracut E 
ultramicrotome and picked up with Formvar coated 2x1 mm copper slot grids.  Grids were 
stained with 2% uranyl acetate (in 50% methanol) followed by lead citrate, and observed 
with a Philips CM120 at 80 kV.  Images were captured with an AMT XR80 high-resolution 
(16-bit) 8 Mpixel camera.   
Effective Particle Diameter and Ligands Available Calculations. To calculate 
the average number of available ligands it is assumed the particles and the CD8+ T cells 
are spherical. The separation distance from the particle and cell is assumed to be 5 nm to 
be the limit where a productive interaction to occur. This distance is used to calculate the 
effective radius of a particle’s interaction with the CD8+ T cell with Equation 1, where 
𝑟𝑒𝑓𝑓 is the effective radius, 𝑟𝑝𝑎𝑟𝑡 is the radius of the particle and 𝑠𝑑 the separation distance. 
1) 
𝑟𝑒𝑓𝑓 = √𝑟𝑝𝑎𝑟𝑡
2 − (𝑟𝑝𝑎𝑟𝑡 −  𝑠𝑑)
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The effective radius is used to find the angle of interaction between the particle and 
the CD8+ T cells using Equation 2, where 𝜃𝑑 is the angle between the particle and the 
CD8+ T cell to where 𝑠𝑑, and 𝑟𝑒𝑓𝑓 is the effective radius.  







The angle of interaction between the particle and CD8+ T cell can be used to 
calculate the effective surface area engaged between the particle and the CD8+ T cell using 
Equation 3, where 𝑆𝐴𝑒𝑓𝑓 is the effective surface area engaged, 𝜃 is the angle of interaction, 
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The effective number of ligands presented by each particle can then be calculated 
with the effective engaged surface area of each particle with Equation 4, where 
𝑙𝑖𝑔.  𝑑𝑒𝑛𝑠./𝑁𝑃 is the ligand density of each NP aAPC, and 𝑆𝐴𝑒𝑓𝑓 is the effective surface 
area of each particle.  

















Chapter 4. Efficient magnetic enrichment of antigen-
specific T cells by engineering particle properties3 
 
4.1. Introduction 
The clinical success of recent advances in immunotherapies such as checkpoint 
blockade, chimeric antigen receptor T cell therapy, and adoptive cell transfer (ACT) shows 
the critical importance of using the immune system to fight disease. Particularly, finding 
and eliciting antigen-specific responses has gained significance as this minimizes off-target 
side-effects including autoimmunity while creating durable memory.340,390,426 However, 
understanding, diagnosing, and predicting antigen-specific immune cell responses has been 
limited due to the exceptionally low frequency of these cells. For example, antigen-specific 
CD8+ T cells are between 1-in-104 to 1-in-106 CD8+ T cells.416,427 Thus, there is a need 
for techniques to isolate and characterize antigen-specific immune responses for cancer, 
autoimmune, and pathogen responses.  
 We have previously developed an approach to magnetically enrich and expand 
these rare antigen-specific CD8+ T cells to detectable levels for immunotherapy.254 We 
created artificial antigen-presenting cells (aAPCs) by chemically attaching dimeric major 
                                                          
3 Sections of this chapter are reprinted (adapted) with permission from “Hickey, John W., et al. "Efficient 
magnetic enrichment of antigen-specific T cells by engineering particle properties." Biomaterials 187 (2018): 
105-116.” Copyright 2018 Elsevier.  
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histocompatibility complex (MHC-Ig), that can be loaded with antigenic peptide 
sequences, and anti-CD28 monoclonal antibody to the surface of a magnetic nanoparticle 
(Figure 4-1A). The peptide-MHC complex (pMHC) confers antigen-specificity and binds 
the T cell receptor (TCR) while the anti-CD28 promotes stimulation through the co-
stimulatory receptor CD28 on the surface of the T cell.  
 The initial design was based on a 50 nm particle to mimic other current antibody 
cell-based particle isolations. However, this “one size fits all” approach may not be optimal 
for antigen-specific T cell enrichment which depend on lower affinity pMHC-TCR 
interactions. Recently, we and others have studied how aAPC nanoparticle size and ligand 
density affect the stimulation and expansion of antigen-specific T cells,103,428 and have 
found that T cells are sensitive to both size and ligand density due to the necessity for local 
TCR clustering and sustained signaling. Particles larger than 300 nm were able to 
efficiently cluster multiple TCRs presumably through multivalent interaction with TCR-
rich nano-islands.13,392 Consequently, we hypothesized that aAPC nanoparticle size and 
ligand density would also affect the enrichment of antigen-specific T cells due to 
differential particle-T cell interactions such as multivalent binding.  
Here we systematically studied particle properties, which provide the most 
effective enrichment of antigen-specific target cells, with outputs of both cell recovery and 
fold enrichment. We compared different aAPC particle sizes and their abilities to enrich 
antigen-specific T cells and correlated this back to their binding activity. We varied the 
ligand choice and density to determine optimal configurations and examined how the 
concentration of particles affects the recovery and purity of antigen-specific cells. With 
multiple engineering inputs and outputs we revealed that there are competing optima, 
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where enhancing one property may increase one output but decrease another. Study of the 
parameter landscape allowed us to optimize to balance these competing optima to achieve 
higher percentages and numbers of antigen-specific T cells for both detection and 
therapeutic applications.  
 
4.2. Materials and Methods 
Mice. Mice were maintained per guidelines approved by the Johns Hopkins 
University’s Institutional Review Board. C57BL/6J mice were purchased from Jackson 
Laboratories (Bar Harbor, ME).  2C T cell receptor transgenic mice were kept as 
heterozygotes by breeding on a C57BL/6 background. Mice were used between 8–10 
weeks of age. 
Peptide-MHC Dimer Production. Dimeric peptide-loaded MHC-Ig was produced as 
previously described250. Briefly, Kb-Ig was produced using hybridoma cell lines in serum 
free media and captured on a NP sepharose column. Kb-Ig was  loaded with the 
SIYRYYGL peptide (GenScript, Piscataway, NJ) using active protein folding via buffer 
exchange and washed using membrane ultrafiltration with a Vivaspin 20 50 kDa MWCO 
(GE Healthcare). Non-cognate TRP2 peptide (SVYDFFVWL), (GenScript), was loaded in 
the same way.  Fluorescent KbSIY was produced by labeling with Fluorescein-5-
Isothiocyanate (FITC 'Isomer I') (Sigma Aldrich, St. Louis, MO) per manufacturer’s 
recommendations. Briefly, a 1 M carbonate-bicarbonate buffer at a pH of 9.0 was added at 
a 1:10 ratio to the KbSIY. FITC-isothiocyanate was dissolved in DMSO (Sigma Aldrich) 
at a concentration of 1 mg/mL and added to the KbSIY at a 5:1 molar ratio and allowed to 
react for 2 hours at room temperature. FITC-KbSIY was washed using membrane 
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ultrafiltration at a 50 kDa MWCO (GE Healthcare). To make staining MHC-Ig, loaded 
dimeric MHC-Ig was biotinylated by reacting a 20-molar excess of EZ-Link™ Sulfo-NHS-
Biotin (ThermoFisher) for 30 minutes at room temperature and then washing the protein 
using membrane ultrafiltration.    
Artificial Antigen Presenting Cell Production. Artificial antigen-presenting cells 
were produced as previously described.103 Briefly, magnetic particles functionalized with 
NHS surface groups of various sizes were purchased from OceanNanotech (Springdale, 
AR, USA). Loaded antigen-specific dimeric MHC-Ig KbSIY and equimolar anti-CD28, 
clone 37.51 (purchased from BioXCell (West Lebanon, NH)) were conjugated to the 
surface of the particles per manufacturer’s recommendations.  
For higher density aAPCs, magnetic particles with amine surface groups of various 
sizes were purchased from Micromod (Rostock, Germany). Particles were functionalized 
with Sulfo-SMCC (Proteochem, Hurricane, UT) and antigen-specific dimeric MHC-Ig 
KbSIY and equimolar anti-CD28 were thiolated with Traut’s reagent (2-iminothiolane) 
(Sigma Aldrich) and then mixed with the functionalized particles per manufacturer’s 
recommendations. Signal-1 only particles were produced accordingly; however, no anti-
CD28 was included in the reaction with the magnetic particles. Similarly fluorescent 
particle aAPCs were produced by a similar process except that the MHC-Ig KbSIY 
attached was labeled with FITC. 4500 nm  Dynal Particles were purchased from 
ThermoFisher (Halethorpe, MD) and dimeric MHC-Ig KbSIY and equimolar anti-CD28 
were conjugated to the epoxy-coated surface as established previously.231  
To achieve closely equivalent densities of dimeric MHC-Ig and anti-CD28 on the 
surface of different sized particles, the ratio of protein added to the total particle surface 
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area was kept constant. For example, 0.5 mg of 50 nm particles have the same total surface 
area as 4.6 mg of the 300 nm particles. Thus, 0.5 mg of total protein was added to react 
with each of these particle batches respectively. For co-conjugation of Signals 1 and 2, 0.5 
mg of Signals 1 or 2 represents a supersaturating amount for both proteins, i.e. it is 10-fold 
higher than the theoretical maximum amount of protein needed for conjugating to the 
particle surface. The amount of protein to add was determined by increasing the total 
protein added to the conjugation reaction, and choosing the value where the final protein 
density on the particle plateaued.  
Particle Characterization. The amount of protein conjugated successfully to the 
surface of the particles was quantified through fluorescent staining. The amount of MHC-
Ig was quantified by staining with FITC-conjugated rat anti-mouse Ig λ1, λ2, λ3 light chain, 
clone R26-46, and the amount of anti-CD28 was quantified by staining with FITC-
conjugated mouse anti-Armenian/Syrian hamster IgG, clone G192-1 (BD Pharmingen, 
Franklin Lakes, New Jersey). Particles were stained with 1 μL of the antibody for 1 hour 
at 4 °C, then washed three times, and fluorescence was read on Synergy HTX Multi-mode 
florescent plate reader (BioTek, Winooski, VT, USA). Protein was quantified by 
comparison to fluorescent standard curve of staining antibodies, and particle number was 
quantified by absorbance using a spectrophotometer at a 405 nm reference. 
Doped Enrichment. 2C or C57BL/6J CD8+ T cells were obtained by using a mouse 
CD8+ T cell negative isolation kit from Miltenyi Biotec (Cologne, Germany) and 
following manufacturer’s instructions. 2C transgenic mice have CD8+ T cells with the 
same T cell receptor that recognizes the mouse MHC Kb loaded with the SIY peptide. 
These 2C CD8+ T cells were labeled with CellTrace™ CFSE Cell Dye per manufacturer’s 
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recommendations (ThermoFisher). Briefly, CD8+ T cells were suspended in 1 mL of PBS 
and 1 µL of CFSE to make a final concentration of 5 µM. This was incubated at 37 °C for 
20 minutes and then incubated for 5 more minutes with 5 mL of complete RPMI-1640 
medium (ThermoFisher) supplemented with 10% fetal bovine serum (Atlanta Biologicals, 
Flowery Branch, GA). Labeled cells were then washed twice more in RPMI-1640 medium 
supplemented with 10% fetal bovine serum. 
These CFSE-labeled 2C CD8+ T cells were then counted with a hemocytometer and 
added at a 1:1000 ratio to C57BL/6J CD8+ T cells and mixed thoroughly in a PBS buffer 
with 2 mM EDTA and 0.5% Bovine Serum Albumin (Gemini, Sacramento, CA). Particle 
aAPCs were then added to this mixture at the indicated amounts per 1x106 total CD8+ T 
cells and allowed to bind at 4 °C for 1 hour. Binding was done at 4 °C to minimize cell 
uptake of the aAPCs. This particle cell-mixture was then washed magnetically. For smaller 
50 nm particle aAPCs, the cell-particle mixture was washed three times with PBS using a 
Miltenyi MS column which amplifies the magnetic field needed for smaller particles. The 
larger particles larger than 50 nm were washed using a STEM-cell magnetic column 
(Vancouver, Canada) with PBS three times. All particle-cell mixtures were eluted in 500 
µL of PBS and counted via a hemocytometer. This eluted product was then stained with 
the APC-conjugated rat anti-mouse CD8a, clone 53-6.7, antibody (BD Pharmingen) for 15 
minutes at 4 °C, washed, and read on a BD FACSCalibur. 
Fold enrichment was determined by dividing the percent of 2C positive cells in the 
eluted particle-cell mixture by the percent of 2C positive the native 1:1000 doped mixture. 
Percent cell recovery was calculated by dividing the number of 2C positive cells in the 
eluted particle-cell mixture by the number of 2C positive the native 1:1000 doped mixture. 
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The 2C cell counts were calculated by multiplying the number of cells in each mixture by 
the measured percentages from flow cytometry.  
Particle Binding. Particle aAPCs were allowed to bind with 2C CD8+ T cells at 4 °C 
for 1 hour at various ratios of particle aAPCs to T cells. This mixture was washed and then 
stained with a 1:350 ratio of PE labeled rat-anti-mouse IgG for 15 minutes at 4 °C. PE 
labeled polyclonal goat-anti-mouse IgG1 (ThermoFisher) recognizes the mouse IgG of the 
dimeric Kb-Ig on the particles to discriminate and quantitate particles on the surface. 
Excess antibody was washed away from the particle-cell mixture and then the cells were 
read on a BD FACSCalibur to determine the percent of cells bound with respect to the non-
particle-bound 2C CD8+ T cells of background staining.   
Particle Off-rate. Fluorescent aAPCs were allowed to bind with 2C CD8+ T cells in 
FACS wash buffer at 4 °C for 1 hour at a saturating dose particle aAPCs to T cells as 
determined by particle binding experiments. Samples were washed with FACS wash buffer 
and a 0 time point was read on a BD FACSCalibur. Then a super-saturating amount (greater 
than 50 molar excess) of 1B2 anticlonotypic mAb was added to the T cell-particle mixture. 
The 1B2 antibody recognizes the 2C TCR and competes for binding with particle KbSIY. 
Samples of the mixture were taken periodically and read via flow cytometry to quantify 
the number of particles still attached.  
Particle Endocytosis. Fluorescent aAPCs were allowed to bind with 2C CD8+ T cells 
at 4 °C for 1 hour at a saturating dose of particle aAPCs to T cells as determined by particle 
binding experiments. A third of cell-aAPC mixture was taken and stained with a 1:350 
ratio of APC-labeled polyclonal goat-anti-mouse IgG1 for 15 minutes. Stained cells were 
then washed and stained with a 1:100 ratio of PerCP-conjugated rat anti-mouse CD8a, 
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clone 53-6.7, antibody (BD Pharmingen) for 15 minutes at 4 °C, washed, and read on a BD 
FACSCalibur. The other two-thirds of the cell-aAPC mixture was added to a 96 U-
bottomed plate in complete RPMI media supplemented with 10% FBS. The cell-aAPC 
mixture was then incubated for either 3 or 18 hours at 37 °C in a cell incubator. At the 
indicated time points, another third of the cell-aAPC mixture was harvested and stained as 
indicated above and read on a BD FACSCalibur.  
Confocal Microscopy of aAPCs and 2C CD8+ T Cells. The same experimental set-
up was utilized for confocal microscopy as described in the particle endocytosis 
experiments. However, following incubation cells were stained with a 1:100 ratio of APC-
conjugated rat anti-mouse CD8a, clone 53-6.7, antibody (BD Pharmingen) for 15 minutes 
at 4 °C. Then cells were fixed with a solution of 4% paraformaldehyde in PBS for 20 
minutes at room temperature. Cells were then washed and stained with DAPI 
(ThermoFisher) according to manufacturer’s instructions for 10 minutes at room 
temperature. Cells were washed and then imaged on a Zeiss LSM780-FCS confocal 
microscope. 
Development of Particle Binding Model. We attempted to model aAPC-T cell 
binding with a multivalent kinetic model, as described by Stone and group 429. In their 
paper, they developed a kinetic model for a multivalent pMHC complex dissociating from 
T cells. We expanded this model for nanoparticles with given numbers of TCR-pMHC 
contacts, n:  
 
We follow their assumption that the off-rates of TCR-pMHCs (𝒌𝒐𝒇𝒇) and 
multivalent on-rates (𝝁) are independent of the binding of neighboring MHC with TCR, 
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allowing use of stoichiometric coefficients alone to account for avidity effects. These 


















= −𝒏𝒌𝒐𝒇𝒇[𝑳𝒏𝑻] + 𝝁[𝑳𝒏−𝟏𝑻] 
Utilizing this model we derived the equation that was used within this manuscript 
to model T cell-aAPC binding, based on the following assumptions:  
The concentration of nanoparticles bound to TCRs equals:  
 𝑳𝑩 = ∑ [
𝒏
𝒋=𝟏 𝑳𝒋𝑻]                                                                              (1) 






𝑳𝑩 = −𝒌𝒐𝒇𝒇[𝑳𝑻]                                                           (2)                                                     
Finally, to determine what [LT] equals, we assume mass equilibrium of bound 
forms, based on the exponential decay behavior of our particles and µ being at least ten 
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Solving for [𝑳𝑩(𝒕)] in equation (2) and substituting in equation (4) for [𝑳𝑩] in terms 
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Enrichment and Expansion of Endogenous Antigen-specific T cells. CD8+ T cells 
from C57BL/6J mice were obtained with a mouse CD8+ T cell negative isolation kit from 
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Miltenyi Biotec (Cologne, Germany) following manufacturer’s instructions. aAPCs were 
then added to the CD8+ T cells to incubate at 4 °C for 1 hour with mixing. The ratio of 
aAPCs to T cells was controlled based on the total T cell signaling molecules conjugated 
to the surface of the particles—230 fmol of signaling molecules (or 115 fmol of peptide-
loaded MHC) per every 1x106 CD8+ T cells. This ratio was determined from early 
experiments by comparing different sized aAPCs in doped enrichment studies (Fig. 6A), 
and from our previous experience using 50 nm aAPCs for enrichment and expansion of 
rare endogenous antigen-specific T cells 254.  
After incubation with the particles, the mixture was magnetically washed three times. 
For smaller 50 nm particle aAPCs, the cell-particle mixture was washed using a Miltenyi 
MS column, while the 300 nm aAPCs mixtures were washed using a STEM-cell magnetic 
column. The first wash was with a PBS buffer with 2 mM EDTA and 0.5% Bovine Serum 
Albumin. The second wash was with complete RPMI-1640 medium supplemented with 
10% fetal bovine serum. The third was with complete RPMI-1640 medium supplemented 
with 10% fetal bovine serum and T cell growth factor, a cytokine cocktail derived from 
condition media produced from stimulated human PBMC as previously described 425. The 
resulting washed cells were eluted in 0.5 mL of RPMI-1640 medium supplemented with 
10% fetal bovine serum and T cell growth factor. The cells were then counted on a 
hemocytometer, resuspended at a concentration of 250,000 cells/mL, and plated in 96 u-
bottomed plates. On day 3, cells were refed using media (50% of the initial plating volume) 
with a doubled concentration of T cell growth factor.  
On day 7 cells were harvested and stained with Trypan Blue, and viable cells were 
counted via hemocytometry. Samples were divided and stained for antigen-specific CD8+ 
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T cells. The first portion of cells was stained with 1 µg of biotinylated-cognate KbSIY and 
a 1:100 ratio of APC-conjugated rat anti-mouse CD8a, clone 53-6.7 (BD Pharmingen) in 
FACS wash buffer for 1 hour at 4 °C. The second subset of the sample was stained with 1 
µg of biotinylated-noncognate KbTRP2 and a 1:100 ratio of APC-conjugated rat anti-
mouse CD8a, clone 53-6.7 (BD Pharmingen) in FACS wash buffer for 1 hour at 4 °C.  All 
samples were then washed with PBS and then stained with a 1:350 ratio of PE-labeled 
streptavidin (BD Pharmingen) and a 1:1000 ratio of LIVE/DEAD™ Fixable Green Dead 
Cell Stain (ThermoFisher) in PBS for 15 minutes at 4 °C. Cells were then washed and read 
on a BD FACSCalibur. Percent antigen-specific cells were calculated by subtracting the 
percent gated in cognate stained CD8+ T cells from non-cognate stained CD8+ T cells. 
Number of antigen-specific cells was determined from multiplying the percent of antigen-
specific cells by the number counted following cell harvest. For the experiment comparing 
high density (HD) 50 nm and 300 nm expansion of endogenous CD8+ T cells without 
enrichment, the same protocol was followed just excluding the magnetic washing at day 0.  
Functional Analysis of Antigen-specific CD8+ T Cells. On Day 7 of culture, 
approximately 100,000 CD8+ T cells were isolated and stained with either 1 µg of 
biotinylated-cognate KbSIY or 1 µg of biotinylated-non-cognate KbTRP2 in sterile PBS 
for 1 hour at 4 °C. All samples were then washed with PBS and stained with a 1:350 ratio 
of PE-labeled streptavidin (BD Pharmingen) in PBS for 15 minutes at 4 °C. Cells were 
subsequently washed in complete RPMI-1640 medium supplemented with 10% fetal 
bovine serum and resuspended in 100 µL of media. To inhibit protein transport and probe 
for degranulation, 10 µL solution of 1:50 FITC anti-CD107a, 1:350 BD GolgiStop Protein 
Transport Inhibitor (BD Biosciences), and 1:350 BD GolgiPlug Protein Transport Inhibitor 
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(BD Biosciences) in PBS was added to the samples. Cells were incubated at 37 °C for 6 
hours. After incubation, cells were washed and stained with 1:100 PBS solution of PerCP-
conjugated anti-mouse CD8a, clone 53-6.7 (Biolegend) and 1:1000 of LIVE/DEAD® 
AmCyan Fixable Aqua Dead Cell Stain (ThermoFisher) at 4 °C for 30 minutes. Cells were 
subsequently fixed and permeabilized with 100 µL BD Cytofix/Cytoperm Fixation and 
Permeabilization Solution (BD Biosciences) overnight. Cells were washed with 1x BD 
PERM/Wash buffer with 2% BSA the following day and stained with 1:100 solution of 
APC-conjugated rat anti-mouse IFN-γ, clone XMG1.2 (BD Pharmingen) in PERM/Wash 
buffer with 2% BSA at 4 °C for 1 hour. Stained cells were read on BD LSR II flow 
cytometer.  
4.3. Results 
4.3.1 aAPC size impacts antigen-specific T cell enrichment efficiency 
To study how engineering nanoparticle aAPC properties affect the ability to enrich 
antigen-specific T cells, we doped in fluorescently-labeled antigen-specific CD8+ T cells 
at a 1:1000 ratio to CD8+ T cells from a B6 mouse.  The antigen-specific cells were isolated 
from a 2C transgenic mouse that recognizes the SIY peptide loaded into the MHC Kb 
(Figure 4-1B). Using a magnetic field, we enriched antigen-specific cells with our different 
sized magnetic aAPCs. We detected the percent antigen-specific T cells by flow cytometry 




Figure 4-1: Particle aAPC size influences antigen-specific cell enrichment.  (A) Artificial antigen-presenting 
cells (aAPCs) are formed by conjugating Signal 1, which is antigen-loaded dimeric MHC-Ig, and Signal 2, 
which is co-stimulatory antibody towards CD28. Together they provide antigen-specific recognition and 
signaling to activate antigen-specific T cells and proliferate. (B) Experimental set up to identify key particle 
parameters influencing antigen-specific T cell enrichment. Fluorescently labeled transgenic 2C T cells were 
doped in at a 1 to 1000 ratio with wildtype non-specific B6 T cells. Schematic not drawn to scale in order to 
visualize aAPC binding to cells. (C) An example flow plot of fold enrichment that is characterized by 
analyzing pre-enrichment and post-enrichment populations by flow cytometry. (D) Fold enrichment is 
significantly lower in 50 nm aAPCs compared to other sized aAPCs at an amount of particles controlled for 
115 fmol of pMHC-conjugated to the surface per 106 CD8+ T cells (error bars show s.e.m.; ***p < 0.001, 
**p < 0.001, *p < 0.05, n = 3, one-way ANOVA with Tukey’s post test). (E) Binding avidity changes based 
on particle size, where aAPC dose was varied and the percent of transgenic CD8+ T cells bound by particles 





We evaluated the effect of nanoparticle size on the ability to enrich by developing 
particle aAPCs of 50-, 300-, 600-nm, and 4.5-µm diameters with similar ligand densities 
of pMHC and anti-CD28 monoclonal antibody (44, 300, 124, and 392 molecules of Signal 
1 and 2 per µm2 of particle respectively—data originally published in103)  (Figure 4-2). 
Smaller aAPC sizes were chosen with distinct size distributions and at the nanometer 
resolution to enable capability with in vivo administration of aAPCs and enriched antigen-
specific T cells as a therapy, whereas larger 4.5 µm aAPCs were included for comparison, 
as they are the standard anti-CD3/anti-CD28 aAPC used to activate polyclonal T cells in 
ACT 231. We controlled the amount of SIY-loaded MHC and anti-CD28 on the particle 
surface across various particle sizes. This theoretically normalizes the number of binding 
events each TCR should encounter. Particles 300 nm and larger, were effective in enriching 
antigen-specific cells about 20-fold, whereas 50 nm aAPCs were significantly less 
effective, only providing a 1.5-fold enrichment (Figure 4-1D). 
 
Figure 4-2: Schematic demonstrating relative size of particle aAPCs sizes used in the studies to a CD8+ T 
cell. Scale bar = 500 nm. 
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We hypothesized that aAPCs larger than 300 nm have multivalent interactions with 
the TCRs and lead to greater binding with the T cell thereby enhancing enrichment. To test 
this hypothesis, we incubated our different sized aAPCs with cognate 2C CD8+ T cells at 
varying doses to examine their equilibrium binding. Interestingly, we observed a size-
dependent trend with the aAPCs ability to bind to the T cells (Figure 4-1E, Figure 4-3). 
As aAPC size increases, fewer aAPCs are needed to effectively bind to the CD8+ T cell 
indicating a higher avidity of the aAPC for the cognate T cell. For example, to achieve 
greater than 40 percent of the T cells bound to particles, the ratio of particles to T cells for 
4.5 µm, 600 nm, 300 nm, and 50 nm are around 1, 10, 10, and 105 respectively. The increase 
in avidity further substantiates our hypothesis that aAPCs engage clusters of TCR and co-
stimulatory molecules. 
 
Figure 4-3: The ratio of 500 nm aAPCs to CD8+ T cells was varied and particles and T cells were incubated 
for 1 hour at 4 °C and percent of CD8+ T cells bound by NPs was determined by flow cytometry by staining 
for both the CD8+ T cells and particles (n=4 and error bars representing s.e.m.). 
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4.3.2 Decreasing aAPC concentration improves T cell enrichment but 
decreases cell recovery 
Based on the more efficient binding of larger aAPCs, we hypothesized that 
decreasing the total number of aAPCs could reduce enrichment of non-cognate CD8+ T 
cells. We postulated that by eliminating excess particle aAPCs would decrease the number 
of lower affinity non-specific interactions. By decreasing the concentration of the 300 nm 
aAPCs about 20-fold, we were able to increase enrichment from 20-fold to 60-fold (Figure 
4-4A). However, when evaluating enrichment, we recovered much fewer cells in general. 
We thus counted the number of cells that went into each enrichment and also the number 
after enrichment to determine the percent cell recovery of our doped antigen-specific cells. 
While we achieved much greater levels of antigen-specific enrichment, the percent 




Figure 4-4: Particle aAPC concentration affects fold enrichment and percent antigen-specific cell recovery.  
(A) Increased enrichment when decreasing concentration of 300 nm particle aAPCs (n=3). (B) Decreased 
cell recovery when decreasing concentration of particle aAPCs as measured by hemocytometry and flow 
cytometry (error bars show s.e.m.; n = 3). (C) At high concentrations of aAPC particles increase cell recovery 
but also have increased non-specific interactions potentially due to the reason they have both antigen-specific 
signals and non-specific co-stimulatory signals. (D) High cell recovery and high cell enrichment are needed 
for adoptive immunotherapy applications and high cell enrichment is wanted for diagnostic applications. (E) 
Size dependent differences in fold enrichment and antigen-specific cell recovery at a concentration of 115 
fmol aAPC-bound pMHC (error bars show s.e.m.; n = 3). 
 
From these results we observed competing optima, where reducing aAPCs leads to 
greater enrichment, but decreases binding and recovery of total antigen-specific cells 
(Figure 4-4C). Selecting conditions for enrichment depends on the application for antigen-
specific T cell enrichment. For cell therapy applications, high cell recoveries are desired as 
the effectiveness of cell-based therapies increases with increasing number of effector 
cells.417 In contrast, fold enrichment is more important for detection purposes, but still 
requires a threshold of total cell recovery to achieve accurate readouts. When plotting our 
enrichment results on a graph that indicates both antigen-specific cell recovery and 
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enrichment (Figure 4-4D), it is apparent that there is a trade-off between non-specific T 
cell binding and low antigen-specific T cell recovery rates, pointing to the fact that the 
concentration of aAPCs in the enriching solution is an important parameter to optimize 
(Figure 4-5).   
 
Figure 4-5: Tradeoff between fold enrichment and percent antigen-specific T cell recovery in altering the 
concentration of magnetic particle aAPCs. Data from panels Figure 2B and 2C replotted together (error bars 
show s.e.m.; n = 3) 
Based on these results, we quantified the percent of antigen-specific cells recovered 
in enrichment experiments with different-sized aAPCs. Although there were minimal 
differences in fold-enrichment of particles larger than 300 nm (Figure 4-1C), we can 
observe drastic effects of the size of the particle on enrichment and cell recovery (Figure 
4-4E). It appears that there is also a balance between size in both achieving high enrichment 
and high percent cell recovery, with an optimal size of 300 nm aAPCs achieving both the 
highest fold enrichment and highest percent cell recovery.  
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This phenomenon could be due to a balance between collective magnetic strength 
of the particles attached to a T cell and individual magnetic strength of a particle. The first 
requirement to successfully enrich a cell is an adequate magnetic force. Thus, there is a 
need to maximize the aggregate magnetic strength of the particles to successfully 
magnetically isolate the tagged cell. However, there is also a requirement to minimize 
individual particle magnetic strength to prevent particle disassociation from the cell.430,431  
The magnetic strength of an individual particle is related to total iron oxide and thus 
related to volume or diameter cubed. However, the collective magnetic strength of particles 
bound to a given T cell, assuming spherical square-packing, is proportionally related to the 
diameter (Figure 4-6). A square-packing estimate is more conservative biologically, where 
there is less packing per surface area than hexagonal-packing; however, the proportion is 
equivalent, with just a constant difference. Thus, mathematically we also see the competing 
optima between decreasing the diameter to the third power and increasing it proportionally 
to achieve both high percent recovery and high fold enrichment. This could explain why 
we observe an optimal 300-nm size, which achieves both the greatest antigen-specific 




Figure 4-6: Magnetic strength depends on particle volume; too high of individual particle volume (∝ r3) can 
lead to disassociation with target cell and too low of collective attached particle volume (∝ r) can lead to 
inefficient isolation. (A) Schematic of sphere-packing diagram illustrating maximum packing of aAPC on a 
surface from a 2D slice at the location of 50% of the volume of the sphere. Equation 1 indicates volume for 
an aAPC used with raAPC representing the radius of the particle. Equation 2 indicates the equation for surface 
area of the cell that is engaged where rcell represents the radius of the cell and %engaged represents the 
amount of the surface of the T cell available for binding. Equation 3 indicates the maximum number of aAPC 
per T cell given a certain surface area of the T cell that can be engaged. Equation 4 represents the collective 
volume of the bound aAPCs to a given T cell. (B) Using analysis and equations from A we plot the volume 
of an individual particle (primary y axis) or the volume of attached particles assuming a given engaged 




4.3.3 Increasing ligand density increases aAPC avidity and improves 
antigen-specific CD8+ T cell isolation for small 50 nm-sized aAPCs 
Besides particle size, another important design parameter of aAPCs is the density 
of the stimulatory ligand on the surface of the particle (Figure 4-7A). This has been shown 
to influence the ability to activate T cells presumably due to both clustering of nearby TCRs 
and co-stimulatory signals and also increased signal duration due to a more avid 
interaction.60,103,239,432 We similarly hypothesized that increasing the particle avidity would 
increase enrichment of antigen-specific CD8+ T cells.  
 
Figure 4-7: Particle ligand density influences target cell enrichment.  (A) Ligand density of aAPC affects 
local density and thus avidity with T cell. (B) Binding avidity increases for 50 nm particles with increased 
density of ligand. (C) Increasing ligand density improves fold enrichment of 50 nm aAPCs at a concentration 
of 115 fmol aAPC-bound pMHC (error bars show s.e.m.; *p < 0.05, n = 3, Student’s T test). (D–F) Increasing 
the surface ligand density increases the fold enrichment of 50 nm aAPCs (D), but leads to greater non-specific 
enrichment by (E) 300 nm and (F) 600 nm aAPCs (error bars show s.e.m.; n = 3). 
 
 To study this, we developed aAPCs with nearly a 100-fold increase in ligand 
density termed high-density (HD) 50 nm. These HD 50 nm aAPCs bound to cognate CD8+ 
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T cells much more effectively than their lower density counterparts (Figure 4-7B). For 
example, to achieve above 40% of T cells bound to particles, 105 of 50 nm particles per 
cell were required, while only 102 of HD 50 nm particles per cell were needed. We 
hypothesized that this several log difference in binding would lead to greater enrichment. 
Indeed, the HD 50 nm aAPCs enriched more effectively than the 50 nm aAPCs (Figure 
4-7C). However, the 10-fold enrichment was still lower than the 300 nm aAPCs, and even 
by changing the concentration of these HD 50 nm aAPCs we were unable to increase the 
enrichment or percent of antigen-specific recovery (Figure 4-7D). This inability to further 
increase enrichment could be due to either the low magnetic strength of the smaller 
particles, or an increase in non-specific interactions leading to lower enrichments.  
 To further explore the effects of ligand density, we made higher density versions of 
the 300 and 600 nm aAPCs (Figure 4-8A). These higher density versions also exhibited 
enhanced binding compared to normal density aAPCs (Figure 4-8B). However, when 
compared at the same concentration (controlled by total particle-bound protein), the HD 
300 and 600 nm aAPCs provided little to no enrichment (Figure 4-8C). We hypothesized 
that the increase in ligand density also led to an increase in non-specific binding, and that 
by decreasing the concentration we could achieve higher values of enrichment. While 
decreasing the concentration helped improve the enrichment, it also decreased valued of 
cell recovery below 50% (Figure 4-7E, F). This demonstrates the importance of ligand 
density and also in the context of particle size to both achieve effective enrichment and cell 
recovery. This is another illustration of competing optima, where increasing ligand density 
may lead to increased binding with cognate T cells, which will increase cell recovery. 
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However, increasing ligand density may also lead to increased non-specific interactions 
such as binding with CD28 on non-cognate T cells, thus decreasing enrichment. 
 
Figure 4-8: Increasing the ligand density increases avidity of larger aAPCs. (A) Density of Signals 1 and 2 
per µm2 of particle surface area for HD 300 and HD 600 particles (n=2, error bars show s.e.m.). (B) Binding 
avidity increases for increasing the ligand density on 300 nm and 600 nm particles. (C) Fold enrichment 
significantly decreases with high density 300 nm and 600 nm aAPCs compared to regular density aAPCs at 
the same concentration (error bars show s.e.m.; ***p < 0.0005, *p < 0.05,  n = 3, Student T test). 
 
4.3.4 Eliminating signal 2 significantly improves antigen-specific CD8+ T 
cell enrichment 
 Based on all of our previous results where we saw significant non-specific binding 
and lower enrichment values with particles presenting both pMHC and anti-CD28, we 
hypothesized that if we eliminated non-specific anti-CD28 from our particles, we would 
increase specificity as CD28 is expressed by all T cells (Figure 4-9A). Decoupling the co-
stimulatory molecule from T cell stimulation has been shown to lead to anergy and even 
inhibitory phenotypes.269,433,434 However, recently we have shown that the co-stimulatory 
molecule can be separated from the aAPC on the nanoscale and added after enrichment if 
these two particles are co-clustered in a magnetic field.250 Encouraged by these recent 
results we developed particles with only pMHC (Signal 1 or S1 only aAPCs) attached at 





Figure 4-9: Eliminating non-specific co-stimulatory ligand from particle aAPCs to improve enrichment.  (A) 
Signal-1 only aAPCs only have antigen-specific MHC which should eliminate many non-specific 
interactions. (B) Binding avidity is dependent on size of the aAPC and decreases for each size when anti-
CD28 antibody is eliminated. (C–E) Eliminating non-specific co-stimulatory decreases fold enrichment for 
(C) 50 nm aAPCs but increases fold enrichment for (D) 300 nm and (E) 600 nm aAPCs (error bars show 
s.e.m.; n = 3). 
 
 The S1 only particles exhibited the same particle size-dependent increase in binding 
to cognate CD8+ T cells as with the canonical aAPCs (Figure 4-9B). However, eliminating 
anti-CD28 from the particle decreased the particle binding compared to their canonical HD 
S1/S2 aAPC counterparts (Supplemental Fig. 6A–C). This is not surprising as the 
antibody anti-CD28/CD28 interaction is a higher affinity interaction (nanomolar KD) than 
the pMHC-TCR interaction (micromolar KD).400  
 We next probed the ability for the 50, 300, and 600 nm S1 only particles to enrich 
antigen-specific cells. S1 50 nm aAPCs did not provide effective enrichment, where even 
at their highest concentration of particles there was only 2-fold enrichment (Figure 4-9C). 
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However, eliminating signal 2 from 300 nm aAPCs significantly improved specificity, 
where up to 90-fold enrichment was achieved with 40% recovery (Figure 4-9D). This was 
also true for S1 600 nm aAPCs but exhibited lower cell recovery percentages (Figure 
4-9E). In general, cell recovery percentages were lower for S1 only particles at the same 
aAPC concentration than observed for the HD particles with anti-CD28 (Figure 4-9D–F). 
This agrees with our observation that HD S1 particles bind less effectively at the same dose 
than the HD S1 and S2 particles (Figure 4-10). Thus, we would expect increasing cell-
recovery percentages with increased doses of S1-only particles.  
 
Figure 4-10: Eliminating non-specific co-stimulatory signal anti-CD28 from particle aAPCs decreases 
binding affinity even with a high density of ligand for (A) 50 nm, (B) 300 nm, and (C) 600 nm. Data 
presented is replotted for comparison purposes. 
 Achieving 90-fold enrichment is significantly better than enrichments we had 
previously achieved, where at most we were able to enrich up to 10-fold.250,254 This 
increase in cell enrichment efficacy could be utilized to identify rare antigen-specific T 
cells earlier and more accurately. 
 
4.3.5 Multiavidity interactions of larger aAPCs with T cells are seen by both 
experimental and modeling analysis 
Since even S1-only aAPCs showed a size-dependent enrichment, we hypothesized 
that smaller aAPCs have fewer chances for multi-receptor binding leading to faster off-
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rates for our S1 50 nm particles. We also hypothesized that larger particles would 
dissociate more slowly than smaller ones because they have more contact area with the T 
cell and thus more available ligands, schematically illustrated in Figure 4-11. This should 
be even more pronounced for S1 50 nm particles as the spacing of TCRs is estimated 
around 30 nm.13,392  
 
Figure 4-11: Nanoparticle size affects avidity and effective off-rate from T cell surface. (A) Schematic of 
how size of particles affects number of ligands available to interact with T cell receptors. (B) HD S1-only 
50 nm particles dissociate more rapidly than S1-only 300 nm particles, as determined by an off-rate 
experiment. (C) Larger particles have increased numbers of available ligands and longer half-lives (error 
bars show s.e.m., * p<0.05, Student’s t test). 
 
To quantitatively assess this hypothesis, we conducted off-rate experiments by 
incubating 2C CD8+ T cells with saturating amounts of fluorescently labelled 50 and 300 
nm Signal 1 KbSIY particles and then competing them off with 1B2, an anticlonotypic 
antibody for the 2C CD8+ TCR. We then fit the off-rate data for the S1 50 nm and S1 
300 nm particles with an exponential decay function (Figure 4-11B, R2 = 0.98 and 0.89, 
respectively) and found that the effective off rate of 50 nm particles was significantly 
faster than 300 nm particles (p=0.001, unpaired t test).  
To associate these off-rates with multi-ligand binding, we estimated available 
ligands from the aAPCs to the CD8+ T cell based on particle size and total conjugated 
protein as quantified through fluorescent staining (Figure 4-12). S1 300 nm particles had 
a total of 100 ± 29 dimer proteins, while S1 50 nm particles had 8.3 ± 1.5 dimer proteins 
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per particle. The number of available ligands was estimated by assuming as we have done 
previously7 that the ratio of available to total ligands is equal to the ratio of the area of a 
spherical cap of height h to the total surface area of a particle with diameter D, as 
described in Equation [1] and that the distance of interaction between particles and the T 









                                                           (1) 
Based on this conservative, static ratio we determined that S1 50 nm and S1 300 
nm particles had 0.8±0.1 and 1.7±0.3 available ligands, respectively, leading us to 
attribute this difference in effective off-rate and half-life to the 300 nm particle having 
more available ligands despite a slightly lower density (Figure 4-11C).  
 
Figure 4-12: Surface ligand density of pMHC-Ig on S1 only particles. (A) Number and (B) surface density 
of pMHC-Ig on particles (error bars show s.e.m. n = 3–6). 
To explore the design space of aAPC-T cell binding, we decided to 
mathematically model the effect of multi-ligand binding on particle off-rate. This will 
clarify how effective off-rate would change as the number of available ligands increases 
for other particle configurations and ligand densities. To do so we extended a kinetic 
model developed for oligomers with three available binding sites to particles with any 
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given number of available binding sites.429 The model, as shown in Equation [2] below 
relates the effective off rate (𝑘𝑜𝑓𝑓
𝑒𝑓𝑓
) to the number of binding sites (n), the monomeric off 
rate (𝑘𝑜𝑓𝑓) and the multivalent on-rate (𝜇) by assuming mass equilibrium between all 
states of binding and that 𝑘𝑜𝑓𝑓 and 𝜇 are independent of binding of neighboring MHC 













]                                           (2) 
While the first assumption is difficult to validate, the latter assumption about 
rapid interconvertibility and mass-equilibrium is corroborated by the exponential decay 
behavior of our particles from the cell surfaces and that 𝜇 is at least 10 times larger than 
𝑘𝑜𝑓𝑓. By fitting our values for  𝑘𝑜𝑓𝑓
𝑒𝑓𝑓
 according to equation [2], we were able to estimate 
the parameters 𝑘𝑜𝑓𝑓 and 𝜇 and determine the behavior of 𝑘𝑜𝑓𝑓
𝑒𝑓𝑓
 as the number of available 
ligands increases (Figure 4-13). We found that 𝑘𝑜𝑓𝑓
𝑒𝑓𝑓
 decreases very rapidly, as was 
expected based on the significantly different off-rates of our S1 50 and S1 300 nm 
particles. Thus, both experimental and modeling approaches demonstrated that both the 
ligand density and the size of the nanoparticles are crucial to determining the local 
number of ligands affecting the avidity of the T cell and aAPC interaction. These results 
could help explain why there is so much more non-specific binding with our high density 
300 and 600 nm particles that include anti-CD28 on the surface, which has a much higher 




Figure 4-13: Kinetic model (see Supplementary Text) shows rapid decrease in effective off-rate of 
nanoparticles as the number of available ligands increases (error bars show s.e.m, R2 =0.65). 
 
4.3.6 The effects of aAPC size and ligand density on endogenous antigen-
specific enrichment and expansion 
Beyond antigen-specific T cell identification, enriching antigen-specific CD8+ T 
cells can be applied in ACT applications. Magnetic enrichment can benefit ACT by 
eliminating non-specific and regulatory cells in culture, which will also limit off-target 
immune responses in vivo. Therefore, the goal is to achieve the highest percentage and 
number of antigen-specific cells. For this purpose, aAPCs with both Signals 1 and 2 can be 
used to enrich and expand antigen-specific cells taken from patients to large numbers, 
decreasing the time, cost, and technical difficulty to achieve this therapy.254  
Synthesizing what we have learned about particle properties in model systems, we 
aimed to study further how these studies translate to isolating endogenous rare antigen-
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specific T cells. To test how particle size and ligand density affected cell enrichment and 
activation, we chose aAPCs with different fold enrichments, yet similar percent cell 
recoveries. Therefore, we selected 50 nm aAPCs with low enrichment, HD 50 nm aAPCs 
with intermediate enrichment, and 300 nm aAPCs with high enrichment capabilities—all 





Figure 4-14: Particle aAPC size and ligand density influence the isolation and expansion antigen-specific 
CD8+ T cells from wildtype B6 mice. (A) Data replotted from Figures 2E and 3D to demonstrate three levels 
of fold enrichment over similar percentage antigen-specific recovery at an amount of particles controlled for 
115 fmol of pMHC-conjugated to the surface per 106 CD8+ T cells (no statistical difference, error bars show 
s.e.m, n = 3, one-way ANOVA). (B) After 7 days of culture, cells were stained with a viability dye, anti-
CD8+, and pMHC KbSIY (cognate) or pMHC KbSINF (non-cognate) to determine total percent and number 
of antigen-specific CD8+ T cells. (C) Number of SIY-specific T cells after enrichment and 7 days of culture 
differed (error bars show s.e.m.; *p < 0.05, n = 3–6, one-way ANOVA with Tukey’s post test). (D) Percent 
SIY-specific T cells after enrichment and 7 days of culture differed (error bars show s.e.m.; ***p < 0.001, 
**p < 0.01, n = 3–6, one-way ANOVA with Tukey’s post test). (E–F) After 7 days of culture, cells were 
stained with a viability dye, anti-CD8+, and pMHC KbTRP2 (cognate) or pMHC KbSIY (non-cognate) to 
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determine total (E) number and (F) of antigen-specific CD8+ T cells (error bars show s.e.m.; *p < 0.05, **p 
< 0.01, n = 4, Student’s t test). 
 
For these studies we enriched antigen-specific CD8+ T cells from the endogenous 
population representative of how one would approach clinical ACT. First, we expect our 
cell recoveries post-enrichment for high enriching aAPCs to be lower when starting with 
the same total number of CD8+ T cells pre-enrichment. Indeed, the overall number of 
recovered CD8+ T cells was consistent with previous enrichment experiments. The least 
amount of recovered cells was from the 300 nm aAPCs and the most from the 50 nm aAPCs 
(Figure 4-15).  
 
Figure 4-15: Day 0 cell counts from enrichment of endogenous CD8+ T cells mirrors enrichment trends 
from transgenic doped experiments. Particle aAPCs were incubated with CD8+ T cells (each beginning with 
3x10^6 CD8+ T cells) and the enriched fraction was counted to determine the number of antigen-specific T 
cells (error bars show s.e.m.; ***p < 0.001, n = 3, one-way ANOVA with Tukey’s post test). 
 
We then cultured these enriched fractions for seven days to allow for stimulation and 
expansion. The process of enriching antigen-specific T cells should increase nutrient 
supply, stimulus to cell ratio, and room to expand ex vivo. Therefore, we expected that 
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increasing enrichment would also lead to an increase in total antigen-specific cell number 
on day 7.  
On day 7, we stained the cells with anti-CD8 and pMHC KbSIY (cognate) and control 
KbSINF (noncognate) complexes (Figure 4-14B).  The 300 nm aAPCs had significantly 
more antigen-specific cells than 50 nm aAPCs as expected, and more than the HD 50 nm 
while not statistically significant (Figure 4-14C). We also investigated whether antigen-
specific CD8+ T cells generated from the enrichment and expansion process were 
functional by investigating cytokine and degranulation markers associated with enhanced 
killing.39,41,435,436 We first investigated CD107a expression where this is a degranulation 
marker of lytic ability. Both 300 and HD 50 nm produced high percentages functional 
antigen-specific CD8+ T cells, where this resulted in 70% and 88% positive for CD107a 
(Figure 4-16A). Furthermore, upwards of 20% of antigen-specific CD8+ T cells were also 
positive for effector cytokine IFNγ—a marker of the functionality of killer cells (Figure 
4-16B). Both readouts indicate robust expansion of functional antigen-specific CD8+ T 
cells. Frequencies of antigen-specific cells vary from 1-in-104 to 1-in-106; therefore, 
assuming the frequency to be between 0.0001–0.01%, the number of original antigen-
specific cells was between 3 and 300. With the resultant number totaling close to 1.5x105, 




Figure 4-16: Antigen-specific CD8+ T cell resulting from 300 nm and HD 50 nm enrichment and expansions 
are functional. (A) Percent of antigen-specific SIY+ CD8+ T cells that are also positive for CD107a (B) IFNγ 
(error bars show s.d.; ***p < 0.001, n = 6, Student’s T test). 
To decouple how variables affect either enrichment or activation of rare-antigen 
specific cells we eliminated enrichment but still stimulated endogenous CD8+ T cells with 
HD 50 and 300 nm aAPCs. We see significant decreases in total cells generated by both 
the HD 50 nm and 300 nm aAPCs, indicating again the important role of enrichment 
(Figure 4-17A–B). HD 50 nm aAPCs demonstrated a greater reduction in antigen-specific 
cells, nearly 8-fold compared to only 5-fold reduction for the 300 nm aAPCs. This agrees 
with previous studies that demonstrated particles smaller than 300 nm are less effective at 
stimulating T cells, unless artificially clustered in a magnetic field.7 Indeed, clustering HD 
50 nm aAPCs in a magnetic field without enrichment increased the number of antigen-
specific CD8+ T cells to be similar to activating with 300 nm aAPCs without any magnetic 
field (Figure 4-17C–D). Thus, during the enrichment process, the magnetic field may 





Figure 4-17: The importance of enrichment on antigen-specific T cell number and purity and understanding 
the impacts of magnetic clustering without enriching. (A) Number and (B) Percent of antigen-specific T cells 
for endogenous expansions without enrichment after 7 days of culture. Differences were significant from 
HD50 and 300 (error bars show s.e.m.; *p < 0.05, n = 6–9, Student’s T test). (C–D) Culturing endogenous 
CD8+ T cells with HD 50 nm aAPCs in a magnetic field raises the antigen-specific T cells to similar levels 
of (C) number and (D) percent of 300 nm aAPCs cultured without a magnetic field (error bars show s.e.m. n 
= 3). 
We also investigated if differences in particle endocytosis correlate with greater 
proliferation seen with 300 nm aAPCs. We studied this at saturating doses of aAPCs with 
cognate 2C CD8+ T cells across nanoparticle aAPC sizes. After 1 hour of cell incubation 
at 4 °C, particles were not internalized, but bound to the surface (Figure 4-18), which 
agreed with temperature-dependent receptor mediated endocytosis and our own previous 
studies.103,244,250,437,438 After 3 and 18 hours of incubation at 37 °C, most particles 
dissociated from the cells (Figure 4-19A). More specifically, the percent of cognate CD8+ 
T cells bound to aAPCs decreased to below 20% for all conditions (Figure 4-19B). Of 
these aAPC-bound T cells, almost no uptake was observed with HD 50 nm aAPCs (Figure 
4-19C–E). Greater uptake was observed in the 300 and 600 nm aAPCs, where the increased 
avidity of larger particles potentially enabled activation induced TCR-mediated 
endocytosis of particles,439,440 albeit in only 5–10% of total antigen-specific cells (Figure 
4-19C–E). Therefore, endocytosis likely contributes to further signaling in a subset of 
antigen-specific cells441 and needs to be studied further for 300 nm aAPCs, but early cell-




Figure 4-18: aAPCs primarily bind to the surface of cognate 2C CD8+ T cells after 1 hour binding at 4 °C. 
(A) Schematic of experimental set-up. aAPCs are fluorescently labeled with FITC, and then also stained with 
an anti-mouse IgG1 antibody to detect and discriminate extracellular aAPCs from intracellular aAPCs. (B) 
Ratio of percent of amIgG1+ CD8+ T cells over aAPC+ CD8+ T cells that have been incubate for 1 hour at 
4 °C (error bars show s.e.m.; n=3). (C) Confocal microscopy image of 2C (CD8+ = magenta) T cells 





Figure 4-19: aAPCs dissociate from cognate aAPCs following incubation at 37 °C, with greater uptake 
observed for 300 nm and 600 nm aAPCs than HD 50 nm aAPCs. (A) Fold reduction of aAPC mean 
fluorescent intensity (MFI) associated with 2C CD8+ T cells after subsequent incubation for either 3 or 18 
hours at 37 °C, normalized by MFI after 1 hour incubation at 4 °C  (error bars show s.e.m.; n=3). (B) Percent 
of 2C CD8+ T cells bound to aAPCs after 1 hour incubation at 4 °C  and subsequent incubations for either 3 
or 18 hours at 37 °C  (error bars show s.e.m.; n=3). (C) Ratio of percent of amIgG1+ CD8+ T cells over 
aAPC+ CD8+ T cells that have been incubate for 1 hour at 4 °C and subsequent incubations for either 3 or 
18 hours at 37 °C  normalized to initial ratios to account for any bead staining bias (error bars show s.e.m.; 
n=3). Values less than 1 indicate endocytosis with decreasing values indicating more endocytosis. (D–E) 
Confocal microscopy image of 2C (CD8+ = magenta) T cells (DAPI=Blue) that have been incubated with 
HD 50 nm aAPCs (green) for (D) 1 hour at 4 °C, then 3 hours at 37 °C and (E) 1 hour at 4 °C, then 18 hours 
at 37 °C indicate aAPC binding is restricted to the surface of the membrane and decreases association over 
time. 
Finally, the degree of purity of antigen-specific CD8+ T cells is consistent with 
previous enrichment experiments with 300 nm aAPCs providing the highest percentage of 
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antigen-specific T cells (~65%) and the 50 nm aAPCs with the lowest (~15%) (Figure 
4-14D). An increase in antigen-specific purity to nearly 65% is a major advancement for 
two major reasons. First, antigen-specific purity enables tumor-specific CD8+ T cells to 
propagate and fill the immunological space in a lymphodepleted patient, rather than non-
specific CD8+ T cells. Second, the antigen-specific purity of a therapeutic product will 
limit off-target effects such as autoimmunity, where ex vivo stimulation could activate self-
reactive T cells.  
Even more dramatic increases in percentage (3-fold) and number (5-fold) of antigen-
specific T cells were observed when targeting a shared tumor antigen TRP2 when 300 nm 
aAPCs were used and compared to HD 50 nm aAPCs (Figure 4-14E–F). Testing these 
sizes at another antigenic boundary condition validates our size and ligand-dependent 
findings that 300 nm aAPCs enrich and expand antigen-specific CD8+ T cells more 
effectively than smaller 50 nm aAPCs even with increased ligand density.  
 
4.4. DISCUSSION 
This acellular particle platform is an attractive approach because of its ability to be 
modular yet standardized across different patients. First, we do not need to produce and 
maintain variable and costly feeder cells for T cell expansions needed.421,442 Second, this 
can be an off-the-shelf reagent that can be customized with any peptide sequence needed 
for patient specific responses. Third, the ability to use a magnetic field greatly enriches for 
antigen-specific cells and decreases nutrient competition and potential regulatory cells in 
culture. Fourth, with co-stimulation we can activate these cells to divide to create thousands 
of copies of themselves within short periods of time. Fifth, enrichment can increase the 
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purity of antigen-specific T cells in the final cell transfer product limiting the off-target 
side effects.  
Beyond these benefits, the results described herein provide a path towards development 
of a higher throughput version of antigen identification and in vivo activation studies. 
Previously the enrichment and expansion process was developed with the 50 nm particle 
and required Miltenyi columns to enhance the magnetic field for enrichment.254 However, 
with 300 nm particles, this enables the use of plate-based magnets, thus eliminating costly 
columns and enabling multiple enrichments to occur at the same time if done on 96-well 
plate magnets. The 300 nm particles are also still small enough to be injected in vivo as a 
therapy post enrichment or enrichment and expansion.82 Since there is no commercially 
available aAPC, these benefits may enable transfer to other labs and adoption of these 
aAPCs both as a tool to isolate and study antigen-specific CD8+ T cells and as a therapy. 
Finally, we have previously observed enhanced stimulation from particles larger than 300 
nm in vitro,103 which could lead to enhanced in vivo activation of antigen-specific cells—
potentially eliminating the ex vivo activation step after enrichment. 
Cell modulation with particle platforms is becoming a more widely used tool to both 
study biological properties of cells and manipulate cell fate for cell therapy.82,424 These 
studies continue to reveal the importance of heterogeneity in cell types and should drive 
particle design. Here we investigated how important particle parameters such as size, 
concentration, surface ligand density, and surface ligand choice affected enrichment of 
cells in a model system with CD8+ T cells for immunotherapeutic applications. 
To achieve optimal magnetic enrichment of antigen-specific cells, particle 
parameters need to be balanced based on T cell biology. For particle size, the relationship 
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between the potential number of close-packed particles, individual and collective magnetic 
strength of particles, and local T cell ligand clustering need to be considered with an 
experimentally observed maximum for 300 nm sized particles. We further demonstrated 
that increasing ligand density can improve magnetic cellular enrichment, but this avidity 
also increases any non-specific existing interactions. These unwanted interactions can be 
limited by decreasing particle concentration or eliminating non-specific ligand on the 
surface of the particle. Finally, in combining enrichment with stimulation, we were able to 
achieve nearly 65% antigen-specific purity from an endogenous population of less than 
0.01%, and nearly 5 times the number of antigen-specific cells from a shared tumor antigen.   
For immunotherapeutic applications, many current forms of antigen-specific T cell 
identification are either costly or do not allow subsequent culture or manipulation of the 
cells.443 On the other hand enriching antigen-specific T cells with superparamagnetic 
aAPCs could be more affordable, multiplexed, and allow subsequent culture—creating a 
new diagnostic tool and improving expansions of antigen-specific CD8+ T cells potentially 
to be used in antigen-specific therapies.  
 
4.5. CONCLUSION 
In conclusion, we have investigated unexplored biomaterial parameters of 
nanoparticle size, ligand density, particle concentration, and ligand choice in the 
enrichment of rare antigen-specific CD8+ T cells. Previous enrichment with aAPCs have 
been limited to 50 nm with a single ligand density. Quantitative control of parameters 
revealed that 300 nm aAPCs were most effective at both enriching and activating antigen-
specific CD8+ T cells, shedding light on how particle design can be influenced and inspired 
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from T cell biology. This resulted in generating nearly 3-fold increase in the percentage 
and 5-fold in the number of antigen-specific CD8+ T cells for a shared tumor antigen. 
Ultimately, advancing the utility as a tool for identifying, characterizing, and utilizing 
antigen-specific immune responses, and offers a general case study in biomaterial 




Chapter 5. Increasing the Throughput and 
Adaptability of Nanoparticle Tools to Isolate and 
Identify Many Antigen-specific T cells 
5.1 Introduction 
T cells are critical immune cells which play roles in carrying out and bolstering 
immune responses against pathogens, self, allergens, and cancer444. They do so through 
recognizing target-specific peptide sequences presented in major histocompatibility 
complexes (MHC) with their unique T cell receptors (TCRs). Identifying and 
understanding which T cells are involved in immune responses can lead to targeted 
therapies. For example, once antigen-specific T cells are identifies in type 1 diabetes they 
could be targeted and eliminated268,269,445. Also, antigen-specific T cells are involved in 
recognizing and killing tumor and are at the forefront of many anti-cancer 
immunotherapies444. T cells can recognize over-expressed shared tumor antigens, or 
neoantigens which are the result of tumor-generated mutated proteins. Thus, once a target 
neoantigen can be identified a tumor vaccine, adoptive T cell transfer, or genetically 
modified T cells could be given for therapy24,338,446.   
Thus, there is great utility in identifying antigen-specific T cells to understand immune 
responses, disease, and potential therapies; however, identification is not so 
straightforward. Unique TCRs are generated through VDJ recombination with a possible 
1014 unique TCRs 447, and the frequency of any one specific T cell is between 1 in 104 to 
106 of T cells416,427.  
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This diversity and frequency require conventional methods of cellular identification 
like flow or mass cytometry to be adapted443. Approaches to increase the sensitivity of 
staining reagents include multermerizing MHC onto platforms to increase avidity and 
sensitivity of staining reagents448 and co-evaluation with staining intracellular cytokine 
production or phenotypic proteins449–452. Other techniques decrease background cells 
through magnetic enrichment by magnetic particles attached to peptide-loaded MHC 
(pMHC)254,453,454. However, these techniques also suffer from low throughput of the 
number of antigen-specific responses that can be identified at any given time. To improve 
throughput researchers have developed UV-cleavable peptides for more efficient peptide 
loading onto MHC tetramers455 and combinatorial fluorescent labeling456,457. More 
recently, pMHC yeast displays have been developed but require downstream TCR 
sequencing for identification of reactive clones458. In summary, current techniques to 
identify antigen-specific T cells lack either sensitivity, throughput, or ease of use.  
Here we build on previous techniques to enrich and expand rare antigen-specific T 
cells with peptide-loaded MHC (pMHC) and co-stimulatory molecules (such as anti-
CD28)250,254,459. We increase the usability of this platform by eliminating costly cell 
isolation kits and show support from additional immune cells in antigen-specific T cell 
expansion. We adapt this technology platform to be higher throughput with capability to 
evaluate many antigen-specific T cells at once. To increase the sensitivity we also create a 
new detection magnetic particle which enables antigen-specific detection without 
expansion. Our work enables facile adoption of the technology by non-specialists and 





5.2 Results and Discussion 
5.2.1 Enrichment and Expansion from Splenocytes 
While the initial E+E protocol required a CD8+ isolation before incubating 
aAPCs with T cells254, we wanted to attempt to increase the throughput and lower the 
cost of isolating and expanding antigen-specific T cells by enriching antigen-specific 
CD8+ T cells directly from splenocytes, bypassing a CD8+ isolation preparatory step 
(Figure 5-1a). We began by dividing harvested splenocytes in two, one population of 
which that went through a CD8+ isolation and the other that did not.  We then enriched 
for KbSIY specific cells from both splenocytes and CD8+ T cells over a magnetic 
column, using the same number of particles for both conditions, and found that the E+E 
from splenocytes not only still worked but also dramatically improved the purity of the 
expanded population post-expansion (Figure 5-1b). Specifically, the percent and number 
of SIY-specific CD8+ T cells were doubled (Figure 5-1c) and tripled (Figure 5-1d), 
respectively, after seven days of expansion. We found similar results when expanding for 
self-antigen TRP2 (Figure 5-2). We then compared both the phenotype and function of 
antigen-specific cells from E+Es of the two different starting populations, finding that 
both populations post-expansion were predominantly effector memory (Figure 5-1e) and 
antigen-specific cells were similarly functional by intracellular cytokine stain in terms of 






Figure 5-2: Enriching and expanding rare antigen-specific T cell populations directly from splenocytes and 
comparing to starting from purified CD8+ T cell populations. (a) Schematic of experimental set up for 
comparing different starting populations (splenocyte vs. purified CD8+ T cells). (b) Percent and (c) number 
of antigen-specific T cells (TRP2+) resulting from aAPC enrichment and expansion two different starting 
populations of cells (CD8+ T cell purified, splenocytes) at day 7 (error bars show s.e.m.; *p < 0.05, n = 4, 
Student’s t-test, two-tailed). 
 
 
Figure 5-1: Decreasing the cost, time, and technical skill needed to isolate rare antigen-specific T cells and 
boosting activation with co-culture of non-CD8+ T cells. (a) Schematic of eliminating CD8+ T cell isolation 
from protocol for using aAPCs (artificial antigen-presenting cells) for enrichment and expansion of antigen-
specific T cells. (b) Representative flow plot of CD8+ T cells 7 days post enrichment and expansion from 
CD8+ T cells vs. Splenocytes (c) Percent and (d) number of antigen-specific T cells resulting from aAPC 
enrichment and expansion two different starting populations of cells (CD8+ T cell purified, splenocytes) at 
day 7 (error bars show s.e.m.; **p < 0.01, n = 6, Student’s t-test, two-tailed). Enriching from splenocytes 
does not alter antigen-specific (e) phenotype or (f) cytokine production at day 7 (error bars show s.e.m.; ns 
p>0.05, n =3, one-way ANOVA with Tukey’s post-test). 
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5.2.2 Understanding the Mechanism of Enhanced Output from Splenocyte 
'E+E 
 After confirming that enrichment from splenocytes was not functionally altering 
the final cell population but was simply leading to a larger, purer antigen-specific 
population, we next began to probe how this occurred mechanistically. First we compared 
the efficiency of enrichment from both starting populations by doping CFSE labelled 
transgenic 2C or pmel CD8+ T cells into endogenous splenocytes, finding that there was 
no difference in terms of fold enrichment (Figure 5-3a) or percent cell recovery (Figure 
5-3b) compared to CD8+ enrichments.  
 
 
Figure 5-3: Enhancements in enrichment and expansion of antigen-specific CD8+ T cells from splenocyte 
starting populations do not come from increases in levels of fold enrichment or percent cell recovery of 
antigen-specific T cells on day 0. (a-b) Doping antigen-specific CD8+ T cells at (1:104) in endogenous 
splenocytes allow comparison of (a) fold enrichment and (b) percent cell recovery of 50 nm aAPCs that are 
not different from fold enrichment and cell recovery in CD8+ T cell populatinos (error bars show s.e.m., 
n=5). 
We then investigated if splenocyte E+Es nonspecifically enriched non-CD8+ cell 
populations that could contribute to this enhanced expansion.  First, we confirmed that 
our CD8+ isolation truly removed all other lymphocytes, macrophages, dendritic cells, 
and NK cells (Figure 5-4). Next, we compared cell composition-post enrichment on day 
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0 between splenocyte vs. CD8+ groups, finding that while enrichment from both 
populations was predominantly skewed towards CD8+ T cells, the splenocyte E+E 
starting population also included B cells (CD19+), NK cells (NK1.1+), CD4+ T cells, 
dendritic cells (CD11c+), and macrophages (F4/80+) (Figure 5-5a). Despite this 
relatively heterogeneous cell population on day 0, the splenocyte E+E converged to a 
relatively homogenous CD8+ population by day 7 (Figure 5-5b).  
 
 
Figure 5-4: Percentage of different cell types from splenocytes and from CD8+ T cells purified with a no-
touch CD8+ T cell isolation kit (n=1-2). 
To confirm that these other cell populations were contributing to an enhanced 
output from our splenocyte E+E, we compared the percent (Figure 5-6a) and number 
(Figure 5-5c) of antigen-specific cells on day 7 if we added splenocytes to CD8+ T cells 
post-enrichment to dilute them back to their initial frequency, finding that doing so 
168 
 
significantly increased the number of antigen-specific cells. We then depleted various cell 
types pre-enrichment from splenocytes to determine which ones significantly impacted 
the output from the E+E, finding that depletion of dendritic cells (Figure 5-7a) and CD4+ 
T cells (Figure 5-7b) both significantly decreased the number of antigen-specific cells on 
day 7 (Figure 5-5d). As a potential mechanism of how non-CD8+ T cells were being 
enriched, we conducted enrichments from splenocytes using signal 1 only (s1) particles 
and co-clustering with signal 2 (s2) particles for expansion as previously described250. 
We found this approach did not significantly reduce the number of antigen-specific CD8+ 
T cells post-expansion compared to s12 particles (Figure 5-5e), although it did 
significantly reduce their frequency (Figure 5-6c) on day 7. Moreover, when examining 
the enriched populations from splenocytes using s12 vs. s1 particles, there were no 
significant differences between the two (Figure 5-6d), suggesting that the majority of 







Figure 5-5: Splenocyte E+E improves output through presence of specific subsets of non-CD8+ T cells 
(a) Cellular composition of post-enrichment fractions on (a) day 0 and (b) after 7 days of culture (error 
bars show s.e.m, n = 3). (c) Number of antigen-specific T cells resulting from aAPC enrichment and 
expansion of CD8+ T cells, splenocytes, or CD8+ T cells diluted to 10% post-enrichment with 
splenocytes (error bars show s.e.m.; **p<0.01, ***p<0.001)(d) Number of antigen-specific T cells 
resulting from aAPC enrichment and expansion from depletion experiments of splenocytes compared 
to CD8+ T cell purified (error bars show s.e.m.;*p< 0.05, ***p<0.001, n = 3–4, one-way ANOVA with 
Tukey’s post test). (e) Number of antigen-specific T cells resulting from enrichment and expansion of 
splenocytes using S12 particles or from enrichment with S1 particles and expansion through co-
clustering with S2 particles (f) Number of antigen-specific T cells resulting from aAPC enrichment and 
expansion of CD8+ T cells or CD8+ T cells mixed 1:1 with CD4+ T cells at day 7 (error bars show 
s.e.m.; ns p > 0.05, n = 4, Student’s t-test, two-tailed). (g) Number of antigen-specific T cells resulting 
from aAPC enrichment and expansion from two different starting populations of cells (CD8+ T cell 
purified, Pan T cell purified) at day 7 (error bars show s.e.m.; **p < 0.01, n = 6, Student’s t-test, two-
tailed (h) Number of antigen-specific T cells from aAPC enrichment and expansion from CD8+ T cells 
or splenocytes with washed vs. unwashed particles (error bars show s.e.m.;**p< 0.01, n = 3, one-way 




Figure 5-6: Splenocyte E+E improves output through presence of specific subsets of non-CD8+ T cells. (a) 
Percent of antigen-specific T cells resulting from aAPC enrichment and expansion of CD8+ T cells, 
splenocytes, or CD8+ T cells diluted to 10% post-enrichment with splenocytes (error bars show s.e.m.; 
***p<0.001 Student’s t test) (b) Percentage of antigen-specific T cells resulting from aAPC enrichment and 
expansion of CD8+ T cells or CD8+ T cells mixed 1:1 with CD4+ T cells at day 7 (error bars show s.e.m.; 
ns p > 0.05, n = 4, Student’s t-test, two-tailed). (c) Percent of antigen-specific T cells resulting from 
enrichment and expansion of splenocytes using S12 particles or from enrichment with S1 particles and 
expansion through co-clustering with S2 particles (error bars show s.e.m.; **p<0.01, n= 3 Student’s t-test) 
(a) Cellular composition of post-enrichment fractions on day 0 of S1 vs. S12 E+E (error bars show s.e.m, n 
= 2). (e) Percent of antigen-specific T cells resulting from aAPC enrichment and expansion from two 
different starting populations of cells (CD8+ T cell purified, Pan T cell purified) at day 7 (error bars show 
s.e.m.; **p < 0.01, n = 6, Student’s t-test, two-tailed). (f) Percent of antigen-specific T cells from aAPC 
enrichment and expansion from CD8+ T cells or splenocytes with washed vs. unwashed particles (error 





Figure 5-7: Understanding the contribution of other non-CD8+ T cells in enhancing antigen-specific CD8+ 
T cell activation through depleting populations pre-enrichment with aAPCs (a-b) Depletion of (a) CD11c+ 
cells and (b) comparison to splenocytes, Pan T cells, CD8+ isolation, and CD4+ depletion. 
We then examined if CD4+ T cells alone were sufficient to improve the output 
from CD8+ E+Es, finding that mixing CD4+ T cells with CD8+ T cells 1:1 pre-
enrichment slightly but not significantly improved the percentage (Figure 5-6b) and 
number (Figure 5-5f) of antigen specific T cells compared to  CD8+ T cells alone, and 
along similar lines, beginning with the cell population that results from a Pan T cell 
isolation (Figure 5-8 and Figure 5-7b) significantly boosts the number (Figure 5-5g) and 
frequency (Figure 5-6e) of antigen-specific T cells after a week. Finally, to further 
investigate the role of dendritic cells in the improved output, we tested the hypothesis that 
they could present peptide from aAPCs that had accumulated in solution over time by 
testing CD8+ and Splenocyte E+Es with the same number of aAPCs pre vs. post washing 
them over a magnetic column. We found that while washing aAPCs did not significantly 
alter the number (Figure 5-5h) or frequency (Figure 5-6f) of cells that resulted from 
CD8+ E+Es, they did dramatically reduce the output from splenocyte E+Es. Combined, 
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these mechanistic studies suggest that the enhanced output from splenocyte E+E can be 
attributed to both additional CD4+ help and other sources of antigen presentation beyond 
aAPCs alone.  
 
Figure 5-8: Schematic for comparing CD8+ T cell isolations and Pan T cell isolations in enriching and 
expanding antigen-specific T cells. 
 
5.2.3 Increasing the Throughput of Enrichment and Expansion 
Previous efforts for enrichment and expansion of antigen-specific T cells have 
included the use of 50-nm aAPCs254, at which size require additional specially produced 
magnetic bead columns to produce magnetic fields strong enough to retain labeled cells. 
Here this limits the throughput and adaptability of the protocol. Previously, we have studied 
how the size of the aAPC impacts both T cell activation103 and enrichment459 and found 
that particles close to 300 nm were most efficient at activating and enriching antigen-
specific T cells. These 300 nm aAPCs can be magnetically isolated with weaker magnetic 
fields and thus can be pulled by conventional neodymium magnets and thus adapted to a 




Figure 5-9: Increasing the throughput of enrichment and expansion of antigen-specific CD8+ T cells by 
increasing simultaneous parallel processing. (a) Schematic illustrating limitations of current approach to 
enrich rare cells by magnetic columns with 50-100 nm magnetic particles and increasing throughput by 
adapting a 96-well plate magnet approach with larger 300 nm magnetic particles. (b) By doping in Thy1.1+, 
transgenic PMEL CD8+ T cells into Thy1.2+ mice at a 1:1000 ratio, we determine effective aAPC:Cell ratios 
needed for the new enrichment and expansion protocol (error bars show s.e.m.;*p< 0.05, n = 5, one-way 
ANOVA with Tukey’s post test). (c-d) Comparison of (c) percentages and (d) numbers of four different 
antigen-specific T cell populations and comparing having the aAPCs batched versus processing individually 
in parallel (error bars show s.e.m.; n = 7-14). 
 
We have also found that particle concentration is a key factor affecting optimal 
enrichment and expansion of antigen-specific T cells459. Therefore, to screen particle 
concentrations in this 96 well format we doped transgenic pmel CD8+ T cells which 
recognize the gp100 peptide at a 1:10,000 ratio to background splenocytes. Though the 
1820 aAPCs per cell ratio led to the highest fold enrichment and cell recovery on day 0 
(Figure 5-10a,b), expansion after 7 days lessened differences between 680 and 1820 
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conditions with similar total antigen-specific T cells in culture (Figure 5-9b, Figure 
5-10c). Additionally, using a magnet which pulled particle aAPCs into a ring around the 
outside (Ring magnet) instead of the bottom (Bottom magnet) substantially increased 
cellular enrichment and percent cell recovery in doped experiments (Figure 5-11). Thus, 
all other experiments were done with the 1820 aAPC to cell dose on the Ring magnet.  
 
Figure 5-10: Establishing the proper dose of 300 nm aAPCs to use to enrich antigen-specific T cells. (a-b) 
Doping antigen-specific CD8+ T cells at (1:104) in endogenous splenocytes allow comparison of (a) fold 
enrichment and (b) percent cell recovery of 300 nm aAPCs at different ratios of aAPCs to cells (error bars 
show s.e.m.; *p < 0.05, **p<0.01, ***p<0.001, n = 5, one-way ANOVA with Tukey’s post test). (c) Fold 
expansion of doped Thy1.1+ CD8+ T cells by day 7 after enrichment (day 0) and expansion (error bars 




Figure 5-11: Comparing antigen-specific T cell enrichment from a 96-well plate magnet that either focuses 
magnetic particles to the bottom of the well (Bottom Magnet) or in a ring above the bottom of the well (Ring 
Magnet). (a-b) There is no difference in particle retention between bottom and ring magnets. Absorbance of 
particles that have been washed with a magnetic column three times (+) and compared to the original 
concentration of particles that have not been washed (-) at different stock concentrations of particles for both 
96-well plate (a) bottom and (b) ring magnets. (c-d) Doping antigen-specific CD8+ T cells at (1:104) in 
endogenous splenocytes allow comparison of (c) fold enrichment and (d) percent cell recovery of 300 nm 
aAPCs on either bottom or ring magnets (error bars show s.e.m.; *p < 0.05, **p<0.0001, n = 5, Student’s t-
test, two-tailed). 
Next we produced four individual, differentially antigen-loaded aAPCs (gp100, 
SIY, TRP2, OVA) and performed the enrichment and expansion process on an endogenous 
repertoire of T cells. We evaluated whether batching particle aAPCs or separating the cell 
sample into individual isolations would affect ability to enrich and expand antigen-specific 
T cells (Figure 5-12). Interestingly, both conditions produced similar percentages (Figure 
5-9c) and slightly higher numbers of antigen-specific T cells (Figure 5-9d) suggesting that 
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either configuration could be used to identify antigen-specific T cells depending on the 
availability of sample or number of combinatorial staining reagents.    
 
Figure 5-12: Schematic for comparing experimental set-up for comparing batched to individual antigen-





5.2.4 Multiplexed Particle aAPC Production through Passive Loading 
While the 96-well plate format provides a convenient, high-throughput approach to 
enrich antigen-specific T cells, creating individual, antigen-specific aAPCs is labor and 
reagent intensive. Previously, dimeric MHCs were loaded individually and then coupled to 
magnetic nanoparticles (Active Loading). Instead, now empty dimeric MHCs are 
conjugated directly to the magnetic nanoparticles creating a universal reagent, requiring 
only one particle synthesis and standardization amongst reagents (Figure 5-13a). These 
peptide-less aAPCs can be aliquoted into individual wells on 96 well-plates and be loaded 
efficiently through incubation with peptide (Passive Loading) for easily multiplexing the 




Figure 5-13: Increasing the throughput of enrichment and expansion of antigen-specific CD8+ T cells by 
parallel production of different particle aAPCs. (a) Schematic illustrating limitations of current approach to 
create individualized antigen-specific aAPCs and increasing throughput by creating universal aAPCs and 
then loading antigens post-conguation passively and using magnetic field to parallel processing. (b) CFSE 
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dye dilution demonstrates effective antigen-specific activation of passively loaded aAPCs as compared to 
actively loaded aAPCs. (c-d) Comparing the (c) fold enrichment and (d) percent cell recovery from unloaded, 
passive-loaded, and active loaded aAPCs in a doped Thy1.1+ system (error bars show s.e.m, n = 8). (e) 
Cognate and non-cognate staining of antigen-specific cells enriched and expanded for 7 days by passively-
loaded aAPCs (two replicates shown). 
 
To confirm that this universal stock approach to aAPC production produces 
similarly functional aAPCs we evaluated how well they stimulate antigen-specific T cells 
by incubating with pmel CD8+ T cells. Passive loaded aAPCs stimulated T cells just as 
well as active loaded aAPCs by CFSE analysis after 3 days of culture (Figure 5-13b, 
Figure 5-14a). In contrast, aAPCs that were not loaded (Unloaded) did not result in any 
background activation of the cells demonstrating both the specificity and efficiency of the 
peptide loading process. We used this assay to also determine appropriate amounts of 
peptide and incubation duration with aAPCs, where stimulation potential plateaued around 
1 µg of peptide per 1.5 x 1010 aAPCs, and optimal time to incubate at this concentration 




Figure 5-14: Passively loading 300 nm aAPCs with peptide post-conjugation result in antigen-specific 
binding and activation with similar efficacy to actively loaded aAPCs. (a-c) Quantification of CFSE dye 
dilution demonstrates (a) effective antigen-specific activation of passively loaded aAPCs as compared to 
actively loaded aAPCs, (b) amount of peptide and (d) time for incubation to be loaded for effective 
activation of antigen-specific T cells. (d) Mean fluorescent intensity of secondary antibody staining aAPCs 
that have attached to antigen-specific T cells comparing to unloaded (0 µg) aAPCs at various aAPC:T cell 
ratios. 
 
In addition to how well the cells expand we tested the ability to bind and enrich 
antigen-specific T cells. Passively loaded aAPCs bound in a dose dependent manner to 
cognate T cells whereas there was little binding of similar doses of unloaded aAPCs 
(Figure 5-14d). In a doped enrichment experiment we observed similar to higher levels of 
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both fold enrichment (Figure 5-13c) and recovery (Figure 5-13d) of target cells with the 
passive loaded aAPCs compared to traditionally produced aAPCs, where unloaded aAPCs 
produced no antigen-specific enrichment. These results held true at both lower and higher 
aAPC to cell ratios (Figure 5-15). Thus, we tested the passive particles for enrichment and 
expansion of endogenous antigen-specific T cells and resulted in nearly 70-80% antigen-
specific T cells by day 7 (Figure 5-13e). These results demonstrate effective enrichment 
and expansion by these universal particles and will provide a facile method for parallel 




Figure 5-15: Passively loading 300 nm aAPCs with peptide post-conjugation result in effective antigen-
specific enrichment with similar efficacy to actively loaded aAPCs at other doses. (a-d) Comparing the 
(a,c) fold enrichment and (b,d) percent cell recovery from unloaded, passive-loaded, and active loaded 
aAPCs in a doped Thy1.1+ system for (a-b) 10,000 and (c-d) 400 aAPC:Cell ratio (error bars show s.e.m, n 
= 4). 
 
5.2.5 Development of Fluorescent Magnetic Beads for High-throughput 
Detection 
 With a multiplexed process for evaluating many antigen-specific T cells on the 
front-end, it is necessary to be able to also increase the throughput at the back-end of 
detection. The current method to produce detection pMHC complexes requires first 
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biotynylation of dimeric MHC and then loading with each individual antigen that must be 
washed away, which is labor intensive, costly, and results in losses of expensive MHC 
protein. Alternatively, we now produce another universal magnetic bead which we can 
attach the MHC to and then load efficiently with whatever peptide; however, this time the 
bead is also fluorescent (Figure 5-16a). This enables use of our previously established 
work from Figure 4 that passively loading peptides works well for antigen-specific binding 






Figure 5-16: Increasing the throughput of enrichment and expansion of antigen-specific CD8+ T cells by 
parallel production of different particle detection particles. (a) Schematic illustrating limitations of current 
approach to create individualized detection dimers/tetramers and increasing throughput by creating universal 
detection fluorescent particles and then loading antigens post-conjugation passively and using magnetic field 
to parallel processing. (b) Both passive and active loaded fluorescent beads (KbIg loaded with SIY peptide) 
stain cognate antigen-specific transgenic 2C CD8+ T cells but not unloaded fluorescent detection beads 
(KbIg) with little background of non-cognate transgenic PMEL CD8+ T cells. (c) Level of background 
staining can be decreased by decreasing fluorescent bead dose for both DbIg and KbIg particles. (d,e) 
Fluorescent detection beads are at least as sensitive as current detection technology for antigen-specific T 
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cells at low, intermediate, and high frequencies at day 7 of the enrichment and expansion protocol. (f) Percent 
of antigen-specific CD8+ T cells enriched and expanded by passively-loaded aAPCs and detected on day 7 
by fluorescent detection particles (n=4). 
 To create a fluorescent detection bead, we conjugated both unloaded and previously 
loaded dimeric-MHC to the surface of magnetic beads from several different bead types 
(Micromod, Spherotech, and Bangs). To test whether these magnetic fluorescent detection 
beads would work to stain antigen-specific T cells, we began by testing transgenic staining 
of either pmel CD8+ T cells (Dbgp100) or 2C CD8+ T cells (KbSIY). All conjugated beads 
stained antigen-specific T cells efficiently with low background binding to non-cognate 
cells and little to no binding of unloaded beads (Figure 5-17). Comparing across bead 
groups, Micromod most efficiently stained the highest percentage above background 
(~90%) and also the highest mean fluorescent intensity (MFI~1200) compared to 
Spherotech (70%, 600) and Bangs (60%, 400). For these reasons we moved forward with 
optimizing the Micromod magnetic fluorescent bead for detection. As both active and 
passive loaded fluorescent beads bound antigen-specific CD8+ T cells very efficiently with 
little background binding of unloaded fluorescent beads (Figure 5-16b), we further 
reduced the background by decreasing the bead to cell ratio (Figure 5-16c, Figure 5-18a). 
These results were also replicated when starting from a mixed population of immune cells 
and stained antigen-specific CD8+ T cells but not CD8- cells, demonstrating their 




Figure 5-17: Fluorescent detection particles are specific to antigen-specific CD8+ T cells with low 
background binding. (a-f) quantification of (a,c,e) percent and (b,d,f) MFI of CD8+ T cells positive for 
fluorescent detection particles (unloaded, passive-loaded, and active loaded) for (a,b) Micrmod particles, 





Figure 5-18: Fluorescent detection particles are specific to antigen-specific CD8+ T cells with decreasing 
background binding at lower concentrations of particles. (a) MFI of antigen-specific staining with particles 
where level of background staining can be decreased by decreasing fluorescent particle dose for both DbIg 
and KbIg particles. (b-c) Similar staining with fluorescent particles is observed for staining antigen-specific 
CD8+ T cells from a starting population of splenocytes. (b) Gated on CD8+. (c) Gated on CD8- of the same 
samples. 
We then used these fluorescent detection beads at the back-end of our process to 
detect antigen-specific T cells at low, intermediate, and high antigen-specific frequencies. 
Comparing to our traditional biotinylated dimeric pMHC (Dimer), the fluorescent 
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detection beads are very efficient at detecting antigen-specific T cells with relatively low 
background (Figure 5-16d,e). Optimal fluorescent bead dose was found to be 3,000 bead 
to cell ratio for each of the end antigen-specific frequencies (Figure 5-19, Figure 5-20, 
Figure 5-21). With the established staining protocol we coupled our front-end optimized, 
high-throughput aAPC for enrichment and expansion and then detected on day 7 with our 
magnetic, fluorescent detection beads to successfully detect four antigens simultaneously 




Figure 5-19: Titration of detection bead:cell ratios to evaluate optimal staining concentration for staining 
antigen-specific T cells on day 7 of the enrichment and expansion protocol with a low final percentage of 
antigen-specific T cells. (a) Flow cytometry plots of both passively loaded detection particles and unloaded 
detection particles. (b) Percentage of control staining (unloaded/non-cognate) were subtracted to evaluate 






Figure 5-20: Titration of detection bead:cell ratios to evaluate optimal staining concentration for staining 
antigen-specific T cells on day 7 of the enrichment and expansion protocol with a intermediate final 
percentage of antigen-specific T cells. (a) Flow cytometry plots of both passively loaded detection particles 
and unloaded detection particles. (b) Percentage of control staining (unloaded/non-cognate) were subtracted 
to evaluate final percentage of antigen-specific T cells on day 7 and compare to traditional biotynlated 






Figure 5-21: Titration of detection bead:cell ratios to evaluate optimal staining concentration for staining 
antigen-specific T cells on day 7 of the enrichment and expansion protocol with a high final percentage of 
antigen-specific T cells. (a) Flow cytometry plots of both passively loaded detection particles and unloaded 
detection particles. (b) Percentage of control staining (unloaded/non-cognate) were subtracted to evaluate 






Figure 5-22: Average numbers of antigen-specific T cells after enrichment and expansion by passively-
loaded aAPCs and detected on day 7 by fluorescent detection particles (n=4). 
5.2.6 Day 0 Enrichment and Application of High-throughput Platform and 
Process to Human Antigen-specific T cells 
 Because these beads are also magnetic we hypothesized that we should be able to 
both enrich and detect at day 0 and potentially eliminate the need for the seven day culture 
period to expand the antigen-specific T cells to higher percentages. Starting from a 0.1% 
antigen-specific frequency (transgenic pmel cells), we significantly enriched populations 
nearly 70-fold at optimal bead to cell ratios, increasing to nearly 7% antigen-specific T 
cells (Figure 5-23, Figure 5-24a,b). Examining the doped antigen-specific T cells, nearly 
all (98%) of the cells stained positive with the fluorescent detection beads (Figure 5-24c); 
however, there was significant background binding as well where only close to 30% of the 




Figure 5-23: Fold enrichment of antigen-specific T cells with fluorescent magnetic beads.  
 
Figure 5-24: Titration of magnetic, fluorescent detection bead:cell ratios to evaluate optimal enrichment 
and expansion of doped pmel CD8+ T cells. (a) Fold enrichment and (b) percent cell recovery of antigen 
specific T cells post enrichment as analyzed by flow cytometry. (c) Percent of Thy1.1+ (pmel CD8+) that 
also stained positive with fluorescent detection beads. (d) Percent of bead+ that also stained positive with 






Herein we have engineered a system and a magnetic nanoparticle technology to 
substantially improve detection of antigen-specific T cells and extend the throughput and 
adaptability of the process. First, we eliminated the need to enrich and expand antigen-
specific T cells from purified CD8+ T cell populations. This decreased total cost and time 
to perform the assay, and also resulted in drastic increases in both numbers and percentages 
of antigen-specific CD8+ T cells resulting from beneficial interactions with CD4+ T cells 
increasing the sensitivity of the assay. Second, we modified the size of the particle aAPC 
to 300 nm based on previous work where we showed this was most effective in both 
enriching and expanding antigen-specific T cells103,454. Because of the increase in particle 
size we were able to use a conventional neodymium magnet and adapt the process of 
enrichment and expansion to a 96-well plate where multiple antigen-specific T cell 
responses can be processed in parallel. Third, to further increase multiplexing we created 
a universal aAPC where the MHC-Ig is conjugated to the surface of the particle and 
subsequently can be divided and loaded with any desired peptide sequence. Fourth, with 
an increased throughput and capability to multiplex, we also multiplexed our detection of 
antigen-specific T cell responses through creation of a universal fluorescent magnetic bead 
that can be loaded with any peptide to facilitate efficient and easy antigen-specific staining.   
These engineered technologies and streamlined process for enrichment and expansion 
of antigen-specific T cells overcome critical difficulties in processing and identifying 
antigen-specific T cells.  This enables researchers to easily adopt both the technology and 
process to study unprecedented number of antigen-specific T cell responses in infectious 
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disease, autoimmunity, allergy, and cancer. In particular, the ability to investigate multiple 
candidate antigen-specific T cells will be beneficial to cancer immunotherapy for 
neoantigen targeted therapy. Neoantigens are a result of mutated proteins from the tumor 
that the immune system has not been tolerized to; thus, represent unique and specific 
immune cell targets to the tumor24,338. Previous efforts to target neoantigens in therapy has 
led to dramatic clinical results in both adoptive immunotherapy and tumor vaccines460,461. 
However, neoantigen-specific therapies have been limited because of challenges in 
identifying antigen-specific T cell responses. With 100’s to 1,000’s of potential antigen 
candidates for each patient, current techniques can only examine a few antigen-specific 
responses at once and thus rely heavily on prediction algorithms and are labor intensive. 
Our technique overcomes many of these challenges and thus is poised to be used to identify 
neoantigen-specific cells and understand these responses to better use as a therapy. In 
conclusion, our method for identifying antigen-specific T cells will extend our ability to 
enrich, expand, and detect rare antigen-specific T cells enabling further understanding of 






Chapter 6. Engineering an Artificial T-Cell 
Stimulating Matrix for Immunotherapy 
6.1 Introduction 
T lymphocytes are increasingly targeted and utilized in immunotherapies with the 
success of checkpoint blockade, adoptive cell transfer (ACT), and chimeric antigen 
receptor (CAR) T-cell therapy444. For both ACT and CAR T cell therapies, T cells must be 
removed from patients, cultured and stimulated ex vivo, and then reinjected into patients 
for cancer immunotherapy390. This presents two major challenges. First, the number of T 
cells needed is very large, so they are cultured for 6-8 weeks at a time, by which time the 
cells’ functionality and phenotype to mediate effective killing and long-term memory may 
have been lost or altered37,442,462,463. By improving the quality or phenotype and 
functionality ex vivo, therapeutic outcomes can also be improved significantly234. Second, 
antigen-specific stimulations utilize antigen-presenting cells that may be 
immunosuppressed and are often dysfunctional, or non-specific stimulation from synthetic 
surfaces through CD3 can result in expansion of irrelevant and potentially harmful 
clones226–228.  
There are several approaches to address these challenges including altering 
composition of cytokine cocktails, signaling pathway inhibitors, and feeder cells224. 
Additionally, the two signals necessary to stimulate the T cell receptor and costimulatory 
molecules have been conjugated to synthetic materials: inorganic or polymeric 
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particles102,103,257,267 and surfaces359,360,368. While current synthetic T cell stimulation 
platforms are helpful in efficiently enriching and activating antigen-specific T 
cells250,254,454, providing cell membrane-mimetic materials368, and acting as in vitro or in 
vivo stimulators257, however, none provide environmental cues similar to what T cells 
encounter in the lymphoid organs, such as the spleen or lymph node.    
The extracellular matrix (ECM) is an important regulator of cellular function, 
including gene expression, differentiation, migration, proliferation, and morphology464–467. 
T lymphocytes primarily reside in the lymphoid organs. These unique microenvironments 
enable rapid communication, cell differentiation, and allow antigen-specific cells to expand 
thousands-fold in response to infection468–471. Even though it is well demonstrated that cells 
are influenced by ECM properties such as composition, stiffness, and bioactive cues that 
create unique microenvironments suited to the function of each cell and tissue472, the role 
of ECM on T cell activation has not been investigated. Furthermore, bioengineering 
approaches have developed ex vivo culture environments with control over matrix 
properties for cell and tissue engineering applications134,473–479. We hypothesize that a 
biomimetic, engineered artificial T cell stimulating matrix (aTM) can improve the 
functionality and phenotype of ex vivo stimulation of T cells for therapeutic applications.  
Here we generated aTM hydrogels from ECM-based materials with tunable stiffness 
and two types of key signaling molecules for T-cell stimulation of murine or human cells. 
This approach also provides ligands from the hydrogel matrix to ECM receptors on the T 
cell—contributing a potential additional signaling component480—in contrast to other T-
cell stimulating materials. Additionally, the stiffness of the hydrogel matrix can be tuned 
allowing effective mechanotransduction required for effective T cell receptor (TCR) 
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signaling. We examine these unique biophysical properties and study them mechanistically 
for producing more functional antigen-specific T cells and assess their efficacy in 
preclinical models of tumor immunotherapy.  
 
6.2 Results and Discussion 
6.2.1 Engineering an Artificial T Cell Stimulating Matrix (aTM) 
We formed ECM hydrogels by crosslinking thiolated hyaluronic acid (HA) with 
polyethylene glycol diacrylate (PEGDA) (Figure 6-1). HA is a linear polysaccharide and 
is the only non-sulfated glycosaminoglycan found distributed throughout the ECM, 
including lymphoid tissues481 that impacts cell motility and adhesion, differentiation, gene 
expression, and proliferation482–484. Furthermore, we chose HA as an ECM mimic because 
it can be easily modified through tunable chemistry—which enables the addition of 
adhesive ligands485,486, conjugation of drugs or growth factors487, and control of the elastic 




Figure 6-1: Schematic showing the three main components and conjugation chemistry of the hyaluronic 
acid hydrogels to form the artificial T cell stimulating matrix (aTM). Scale bar of photo is 5 mm. 
We engineered this material into an antigen-presenting material by conjugating the 
signals (Signal 1 and Signal 2) needed for T cell activation directly to the scaffold (Figure 
6-2A). We first used anti-CD3 and anti-CD28 antibodies for polyclonal wildtype B6 murine 
CD8+ T cell expansion. This presents a unique approach to use the biophysical properties 
of hydrogels to influence the potency of a stimulatory environment, which we term an 






Figure 6-2: An artificial T cell stimulating matrix (aTM) is engineered by conjugating T cell stimulating 
signals to a hydrogel. (A) Schematic of aTM made from conjugating Signals 1 and 2 to a hyaluronic acid 
hydrogel. Attachment of Signal 1 and 2 enable effective T cell stimulation which leads to T cell proliferation, 
differentiation, and effector function. Receptors bind to ECM hydrogel and also contribute to attachment and 
T cell signaling. (B-D) B6 CD8+ T cell fold expansion measured after seven days of stimulation of the 
antigen-specific T cells on the hydrogels with (B) Signals 1+2 conjugated or soluble (error bars show s.e.m.; 
**p < 0.005, n = 4, Student’s t-test, two-tailed), (C) conjugated together or alone (error bars show s.e.m.; **p 
< 0.005, ***p < 0.0005, n = 5–7, one-way ANOVA with Tukey’s post test), and (D) at varying amounts of 
Signals 1+2, n = 5. (E) Day 7 CD8+ T cell fold expansion measured after seven days of stimulation of the 
antigen-specific T cells on the aTM. T cells were removed from aTM on the day noted and cultured on TCP 




Post-conjugation, nearly all (at least 85%) of the stimulatory signals conjugated 
remained attached to the scaffold post-gelation (Figure 6-3A). Direct conjugation of 
Signals 1 and 2 at 1 µg/mL (i.e. aTM) mediated about 7-fold polyclonal T cell proliferation, 
whereas the same hydrogel substrate with soluble Signals 1 and 2 showed little 
proliferation (Figure 6-2B). Substrates with only Signal 1 or 2 conjugated resulted in much 
lower T cell activation and proliferation (Figure 6-2C). Investigating different ratios of 
Signal 1 to Signal 2 at 1 µg/mL revealed that Signal 1 concentration was most critical, and 
that optimal T cell expansion occurred at a 1:1 ratio, which is used in all subsequent studies 
(Figure 6-3B, C). There are a number of different co-stimulatory molecules which may 
also provide T cell co-stimulation. Incorporation of a different co-stimulatory molecule 
anti-41BB at various ratios to anti-CD28 did not further enhance CD8+ T cell activation 
on the aTM, and also demonstrated the necessity of inclusion of anti-CD28 as a co-




Figure 6-3: Conjugation efficiency and linear estimated ligand spacing on aTM hydrogels (A) Fluorescent 
antibody levels in the hydrogel washes were below level of detection, and show efficient conjugation 
efficiency (error bars show s.e.m., n=5). (B) Quantitation of percentage of T cells in each divisional 
generation based on CFSE proliferation dye dilution for different ratios of Signal 1 to Signal 2. (C) CD8+ T 
cell fold expansion after 7 days of culture with different ratios of Signal 1 to Signal 2, n=2-3. (D) CD8+ T 
cell fold expansion after 7 days of culture with various percentages of anti-41BB as co-stimulatory 
molecule percentage, n=4.(E) Estimated ligand spacing based on the Signal 1 and 2 concentration in the 
aTM solution. 
The density of T cell stimulating signals is an important parameter to control and 
optimize. We and others have shown previously on particle and planar surfaces that 
effective T cell stimulation is observed when the inter-ligand spacing is maintained below 
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75-150 nm60,103,239. As we increased the concentration of stimulatory ligands on the aTM, 
the amount of CD8+ T cell proliferation increased, though it plateaued at around 20-fold 
expansion when 4 µg/mL of Signals 1 and 2 was used (Figure 6-2D). We estimated the 
surface density of the signals attached to the surface of the aTM for each concentration 
(Figure 6-3E). Our findings estimate that the spacing for ligands need to only be at least 
500 nm apart (corresponding to 1 µg/mL), which is larger than previously reported values, 
potentially due to the fact that signals may not be evenly distributed across hydrogel surface 
and could be clustered on ECM polymers, or that compliant surfaces require less dense 
arrays of signal. Additionally, the viability of T cells decreased beyond 4 µg/mL of Signals 
1 and 2 (Figure 6-4A), and thus less than 4 µg/mL or less were used for subsequent studies 
with a cell concentration of 0.1 x 106 cells/mL (Figure 6-4B). aTM also effectively 
stimulated CD8+ T cells from splenocyte starting populations at similar densities of Signals 
1 and 2 (Figure 6-4C). Finally, CD8+ T cells required at least five days to be fully 
stimulated on the aTM surface, where suboptimal activation was observed when cells were 
removed from the hydrogels on days 1 and 3 (Figure 6-2E), indicating a need for dynamic 
engagement of conjugated stimulatory molecules.  
 
Figure 6-4: Density and ratio of stimulatory signals impacts on T cell activation on the aTM. (A) Viability 
of stimulated T cells measured on day 7 by trypan blue staining and hemocytometry for varying amounts of 
Signals 1+2 conjugated to hydrogels, n=4-5. (B-C) CD8+ T cell fold expansion after 7 days of culture with 
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(B) both varying Signals 1+2 conjugated and cell seeding densities, n=3 and (C) either purified CD8+ T 
cells or whole splenocyte populations, n=2. 
 
6.2.2 Stiffness Matters: Soft aTM Favors T Cell Stimulation 
In stem cells, matrix stiffness modulates cell function through mechanotransduction 
signaling mechanisms133,134. Secondary lymphoid tissue is a soft tissue and the stiffness 
has been reported to be between 0.1 to 2 kPa490,491. To control the mechanical stiffness of 
our hydrogel within this range, we altered the amount of crosslinker, varying the elastic 
modulus from 0.2 to 3 kPa and verified overall structures by scanning electron microscopy 
(SEM) (Figure 6-5A, B, Figure 6-6). A softer aTM (0.5 kPa) stimulated CD8+ T cell 
proliferation more effectively than the stiffer aTM (3 kPa) as determined by the dilution of 
the proliferation dye, carboxyfluorescein succinimidyl ester (CFSE) (Figure 6-5C). 
Greater than 80% of the CD8+ T cells divided past the first and second generation when 
stimulated on the 0.5-kPa aTM, while the majority of T cells on 3-kPa aTM did not divide 
at all (Figure 6-7). We further probed the spectrum of substrate stiffness to determine the 
optimal range for T cell stimulation. aTMs with a stiffness below 1 kPa were more effective 
at stimulating CD8+ T cell expansion, where we observed a dramatic decrease in T cell 
expansion occurs with aTM greater than 1 kPa (Figure 6-5D). We verified the integrity of 
gel stiffness after 7 days of incubation with minor changes in stiffness of both the 3 kPa 




Figure 6-5: Tuning the stiffness of the aTM impacts T cell stimulation. (A) Schematic illustrating hypothesis 
that tuning stiffness of aTM may change the ability for cell mechanotransduction. (B) Elastic modulus 
measured by rheometry with varying PEGDA crosslinker weight percent (error bars show s.e.m., n = 3). (C) 
CFSE proliferation dye dilution measured after 3 days of stimulation of T cells comparing a stiff (3 kPa) and 
soft (0.5 kPa) aTM. (D) CD8+ T cell fold expansion measured after seven days of stimulation of the T cells 
on aTMs with varying stiffness (error bars show s.e.m.; *p < 0.05, **p < 0.005, n = 4-12, one-way ANOVA 
with Tukey’s post test). (E) CD8+ T cell fold expansion measured for T cells stimulated on soft aTMs (0.5 
kPa) with or without blebbistatin (error bars show s.e.m.; ***p < 0.0005, n = 4, Student’s t-test, two-tailed). 
(F) Quantitation of percentage of T cells in each divisional generation based on CFSE proliferation dye 
dilution with T cells stimulated on HA hydrogels of different stiffness with aAPC (error bars show s.e.m, n 
= 4-8). (G) Airyscan super-resolution imaging of phalloidin and CD3 of CD8+ T cells cultured on either soft 
or stiff aTM (scale bar=2 µm.), (H) where a total of 515 spots were analyzed from 16 cells in the 0.5 kPa 
condition and 1580 spots were analyzed from 13 cells in the 3kPa condition.  (Error bars show s.e.m.; ****p 
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< 0.0001, Student’s t-test, two-tailed). (I) CD8+ T cell fold expansion measured after seven days of 
stimulation of T cells on the aTMs with either laminin and RGD attached (error bars show s.e.m.; *p < 0.05, 
n = 3-6, one-way ANOVA with Tukey’s post test). 
 
 
Figure 6-6: Structure of both soft and stiff aTM hydrogels as evaluated by macroscale imaging and 
scanning electron microscopy (SEM) of aTM hydrogels for both 3 kPa and 0.5 kPa hydrogels. Scale bars 
indicated in images.    
 
 
Figure 6-7: CD8+ T cell fold expansion measured after three days of stimulation of the T cells on aTMs 
with varying stiffness (error bars show s.e.m.; *p < 0.05, **p < 0.005, n = 4-12, one-way ANOVA with 




Figure 6-8: Stiffness of aTM hydrogels measured both on day 0 and after 7 days of culture with CD8+ T 
cells (error bars show s.e.m.; not significant, two-tailed Student’s t-test). 
 
It was surprising to observe such a dramatic increase in T cell expansion at stiffness 
below 1 kPa. We hypothesized that this expansion was a result of stiffness-dependent TCR 
signaling through the conjugated stimulatory signals more so than T cell-ECM interactions, 
as mechano-transduction may play a role in TCR signaling due to the motile nature of 
interacting cognate T cells and antigen presenting cells135–138,492.  
To evaluate our hypothesis of the role of mechanotransduction of TCR stimulating 
signals, we performed additional experiments where we confirmed similar antibody 
conjugations to the hydrogel, utilized myosin inhibitors, decoupled signaling components 
from the hydrogel, macro and microscale visualized cellular attachment, and added further 
cell-adhesive molecules. First, we confirmed that similar densities of stimulatory signal 
were conjugated to the surface of the different stiffness aTM through fluorescent secondary 
antibody staining (Figure 6-9). Second, we added a blebbistatin, a myosin II inhibitor 
important in the role of T cell mechanotransduction360,493, to the culture of a 0.5-kPa aTM. 
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In the presence of the inhibitor, CD8+ T cell expansion is abolished even with the same 
amount of stimulatory ligand present (Figure 6-5E).  
 
 
Figure 6-9: Similar densities of antibody are detected on both 3 kPa and 0.5 kPa aTM through secondary 
fluorescent staining (error bars show s.e.m.; n = 6-7). 
 
Third, we decoupled the stimulatory agent from the matrix and stimulated with 
cognate artificial antigen presenting cells (aAPC) on different stiffness of hydrogels. The 
nanoparticle aAPC contain both Signals necessary for CD8+ T cell activation—Signal 1: 
peptide loaded major histocompatibility complex (pMHC) and Signal 2: anti-CD28 
costimulatory antibody (Figure 6-10). There were no differences in the CFSE proliferation 
assay or in resultant cell phenotype between soft (0.5 kPa) and stiff (3 kPa) HA hydrogels 
(Figure 6-5F, Figure 6-11). This demonstrates that the mechanotransduction is 
independent of ECM-cell adhesion receptor interactions traditionally investigated, but 

































Figure 6-10: Schematic of artificial antigen-presenting cell (aAPC) with Signal 1 (pMHC) and Signal 2 
(aCD28) attached to a particle platform. 
 
 
Figure 6-11: Activation of CD8+ T cells is not changed by surface stiffness when stimulus is decoupled 
from the surface. (A) CD8+ T cell fold expansion from T cells stimulated by aAPC on different hydrogel 
stiffness (0.5 kPa, 3 kPa) (error bars show s.e.m., n= 14-15). (B) Phenotypic markers (CD62L, CD44) 
measured by flow cytometry after 7 days of stimulation an (error bars show s.e.m.; n = 18, Student’s t-test). 
 
Fourth, we visualized the interaction of the T cells and the aTM hydrogels or HA 
hydrogels (without Signals 1 and 2) with light video microscopy (Figure 6-12). After 24 
hours, only CD8+ T cells remained attached to the soft (0.5 kPa) aTM hydrogel with both 
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stimulatory signals conjugated. Whereas CD8+ T cells did not attach to stiff aTM (3 kPa) 
or soft (0.5 kPa) hydrogels without Signals 1 and 2 attached. Fifth, by doing super 
resolution microscopy we observed significant differences in the CD3 clustering on T cells 
cultured on the soft (0.5 kPa) aTM versus the stiff (3 kPa) aTM with little difference in 
actin co-localization (Figure 6-5G). Indeed by analyzing the CD3 cluster size, T cells 
cultured on the soft aTM had significantly greater CD3 cluster area of 0.05 µm2 compared 
to 0.02 µm2 for that of the T cells stimulated on the stiff aTM (Figure 6-5H). 
 
 
Figure 6-12: T cells attach to aTMs when Signals 1 and 2 are conjugated and are soft (0.5 kPa). Light 
video microscopy over a period of 24 hours was done to track cell movement and attachment to the aTMs 
of (A) 0.5 kPa (B) 3 kPa both with and without Signals 1 and 2 at time points of t=0 and t=24 hr. 
Sixth, adding cell-adhesive ligands has been shown to increase cell attachment to 
surfaces494. We included additional ECM-binding proteins to the aTM scaffold such as 
laminin and cyclic RGD, a sequence derived from ECM-binding proteins to determine 
whether this might improve engagement and stimulation on stiff hydrogels. Even providing 
cell-adhesive ligands did not help stiff aTMs (3 kPa) stimulate antigen-specific PMEL 
CD8+ T cells, whereas RGD further increased T cell proliferation on soft (0.5 kPa) aTM 




Figure 6-13: Light microscopy images of T cell cultures on aTMs at day 3 with different stiffness (0.5, 3 
kPa) and proteins (cyclic RGD, laminin) attached (scale bar = 1 mm).    
 
Taken together, these data indicate that the role of mechanical stimulation is mediated 
through the TCR and the stimulatory ligands conjugated to the matrix, yet cannot be 
overcome with adding additional cell-attachment sequences. This enhanced 
mechanotransduction at lower stiffness could be due to a number of reasons. First, softer 
hydrogels which are more compliant and may enable enhanced clustering of neighboring 
attached Signal 1 molecules on the hydrogel—shown to promote superior TCR signaling, 
which we observe103,495. Second, traditionally T cells are stimulated by surfaces which have 
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stimulatory signals non-specifically adsorbed to surfaces, whereas our signals are 
chemically attached to the matrix, which may contribute to more effective 
mechanotransduction. Third, the stiffness range of the aTM more closely matches the 
stiffness of the secondary lymphoid tissue. To our knowledge this represents the lowest 
stiffness of a surface, orders of magnitude less than T cells have been stimulated with, 
where traditionally the surface is a stiff (~MPa) plastic359,360.  At softer hydrogel surfaces, 
we are approaching the appropriate level of resistance that a T cell may observe at a cellular 
level, where researchers have shown that the minimum adhesion strength to antigen 
presenting cells to be around 90 Pa136,496. In conclusion the stiffness of the aTM is critical 
to enhance mechano-transduction TCR signaling for effective T cell expansion.  
 
6.2.3 Extracellular Matrix Provides Additional Signaling and Phenotype 
Skewing 
Beyond biophysical cues such as stiffness, the ECM can provide molecular signaling 
cues via cellular receptor activation. We were particularly curious to how the base HA 
hydrogel affects both T cell functionality and phenotype, as T cells express CD44—a 
ligand specific for HA483,497. For T cells, CD44 has primarily been utilized as a marker for 
cellular phenotype and not examined as a co-stimulatory molecule498–501. To investigate 
how the HA hydrogel contributes to T cell activation and signaling, we decoupled the other 
unique biophysical variable—having the T cell stimulatory signals attached to the 
surface—by utilizing aAPC for T cell stimulation. In this manner we could mechanistically 
study differences in T cell signaling directly due to the HA hydrogel.  
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To examine the influence of stimulatory environment, transgenic PMEL CD8+ T cells 
and cognate aAPC were co-incubated and then either plated onto ECM-mimic hydrogels 
(HA) or the traditional tissue culture plate (TCP) wells (Figure 6-14A). Interestingly, 
CD8+ T cells that were cultured on HA hydrogel surfaces demonstrate much higher 
antigen-specific T cell proliferation as indicated by CFSE dilution after three days of 
culture (Figure 6-14B). In fact, there are significantly more T cells that have reached the 
second, third, and fourth generations when compared to the T cells cultured on traditional 
tissue culture plates, where the majority of the cells have not yet divided (Figure 6-15). 
There was no inherent signaling or activation without stimulatory aAPC with no effects on 
cell viability on the HA surface (Figure 6-16). Moreover, including soluble HA also 
increased the percent of CD8+ T cells to divide (~35%) as compared to the tissue culture 
plate without hydrogel (~15%), but not as much when it is crosslinked into a hydrogel 
(~65%) (Figure 6-14C). Therefore, the benefit of the HA to early CD8+ T cell proliferation 
is partially mediated through direct interaction with crosslinked HA in combination with 




Figure 6-14: Stimulated T cells are influenced by additional signaling from the HA hydrogel. (A) Schematic 
showing experimental setup testing the difference between activating antigen-specific CD8+ T cells with 
nanoparticle artificial antigens presenting cells (aAPC) on HA hydrogel versus a tissue culture plate (TCP). 
(B) CFSE proliferation dye dilution measured after 3 days of stimulation of antigen-specific T cells 
stimulated by the same dose of aAPC on either TCP or on HA hydrogel surface. (C) Percent of CD8+ T cells 
that have divided by day 3 as measured by CFSE proliferation dye dilution (error bars show s.e.m., *p < 0.05, 
**p < 0.005, ***p < 0.0005 n = 7, one-way ANOVA with Tukey’s post test). (D) Time course experiment 
using p-S6 (S240/S244) as the read out for mTORC1 activation. This relative fold-change pattern represents 
three independent experiments using phospho-flow cytometry. (E) Phenotypic markers (CD62L, CD44) 
measured by flow cytometry after 7 days of stimulation with aAPC on different surfaces (error bars show 
s.e.m.; *p < 0.05, n = 7, Student’s t-test, two-tailed). (F, G) Time course experiment detecting fold change of 
(F) IL15Ra (CD215) and (G) IL7Ra (CD127). Geometric means of each data point are compared first with 
their isotype controls followed by the baseline control. Data represents two independent experiments. (H) T 
cells positive for all four cytokine and functional molecules (IL-2, IFN-γ, TNFα, CD107a) were measured 






Figure 6-15: Quantitation of percentage of T cells in each divisional generation based on CFSE 
proliferation dye dilution for the experiment described in Figure 3B (error bars show s.e.m.; *p < 0.05, **p 





Figure 6-16: The HA hydrogel environment does not provide any inherent stimulation for T cell 
proliferation. (A) CFSE proliferation dye dilution measured after 3 days of culture of T cells on either 
tissue culture plates (TCPs) or on hyaluronic acid hydrogels (HA) without stimulatory signals present. (B) 
Quantitation of percentage of T cells in each divisional generation based on CFSE proliferation dye dilution 
(error bars show s.e.m., n=15). (C) CD8+ T cell fold proliferation (error bars show s.e.m.; *p < 0.05, n = 7, 
Student’s t-test) and (D) viability (error bars show s.e.m., n=8-11) measured after seven days of stimulation 
of the antigen-specific T cells on the hydrogels with or without aAPC. 
 
We investigated the role of HA in signaling and inducing greater early expansion 
of CD8+ T cells in the hydrogel condition. Exploring key signaling pathways related to T 
cell activation and proliferation, we identified a significant increased expression of p-S6K1 
and p-S6 (Figure 6-14D, Figure 6-17), consistent with upregulation of mTORC1 
(mammalian target of rapamycin complex 1), and a downregulation of p-AKT (indicative 
of mTORC2) under the HA culture condition compared to the TCP condition (Figure 
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6-17). Furthermore, CD44-signaling has been shown to trigger Ras-Erk signaling in other 
cell types484, and Ras-Erk and PI3K-mTOR pathways have been shown to crosstalk and 
compensate each other in T cells502. Indeed we observe a significant amount of p-S6 signal 
may come from CD44-induced Ras-Erk signaling (Figure 6-18A,B). CD44 has also been 
shown to directly interact with Src family proteins like Lck503. Lck is involved in early 
phosphorylation the ITAM domains of TCRζ chain and CD3 complex for T cell activation 
upstream of both Ras-Erk and PI3k-mTOR signaling504.  We observe higher 
phosphorylation of p-Src family protein at Y416 (which includes Y934 in p-Lck as an 
activation signal), with equal amounts of inhibiting signal and total protein—p-Lck Y505 
and total Lck, respectively (Figure 6-19). Taken together, the interaction of T cells with 
HA critically influences early T cell priming and activation with noted contributions of 
enhanced Lck phosphorylation and potential crosstalk between Ras-Erk and PI3K-mTOR 
pathways, where mTOR is an important integrator of immune cues for robust T cell 




Figure 6-17: Time course experiment for T cell activation on HA surfaces compared to TCP surfaces for 
mTOR signaling. Cells were collected for western blot at designated time points after activation. Read out 
for mTORC1: p-S6K1 (T389) and p-S6 (S240/244); read out for mTORC2: p-AKT (S473). These images 
represent five independent experiments. 
 
 
Figure 6-18: HA-CD44 signaling induces CD8+ T cell expansion through crosstalk between Ras-Erk and 
PI3K-mTOR pathways.  (A) Isolated CD8+ T cells were treated with different drug conditions. Erki = 
U0126, an inhibitor that specifically targets Erk1/2; Rapa = Rapamycin, an inhibitor that specifically 
targets mTORC1. Image represents three independent experiments. (B) Quantified data from western blot 
representing levels of expression of mTORC1 24 hours after activation, using p-S6 (S240/244) as a 





Figure 6-19: HA-CD44 signaling induces CD8+ T cell expansion by early (15 min – 30 min) 
phosphorylation of Src family kinases for early T cell activation, but not changes in Total Lck protein or 
phosphorylation of LCK inhibition sites (p-LCK Y505), and no changes in beta actin. Phospho-Src family 
Y416 is equivalent to phospho-Lck Y394, which serves as an activation site of Lck activity. 
 
To investigate the long-term role of ECM-mimic hydrogels in enhancing CD8+ T 
cell expansion and hemostasis, we looked at the expression of CD44 after stimulation on 
the two different surfaces. CD44 is expressed by CD8+ T cells in concordance with 
changes in phenotype, where CD44 remains upregulated in activated and memory cells498–
501. We also stained for CD62L to separate CD8+ T cell phenotypes influenced by the HA 
hydrogel—naïve, memory, and effector. 
Stimulation on the HA hydrogel resulted in significantly higher percentage of CD44+ 
T cells (Figure 6-14E). This increase was associated with nearly double the percentage of 
memory T cells (CD62L+, CD44+) and a decrease in effector T cells though not 
statistically significant. Consistent with an increase in memory-like cells, we observed a 
global upregulation of IL-15Ra (Figure 6-14F) and a conditional upregulation of IL-7Ra 
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(Figure 6-14G) at late contraction phases under HA condition, confirmed at the mRNA 
level (Figure 6-20). Both IL-7Ra and IL-15Ra are receptors for cytokines that trigger 
memory T cell homeostasis506, and thus an upregulation of both receptors may induce 
memory T cell formation. In conclusion, this both informs that HA can contribute to 
increased proliferation, and also demonstrates that the ECM hydrogel surface influences 
the final phenotype of the cells.  
 
Figure 6-20: Quantified rt-PCR data of IL7Ra mRNA collected cells at different time points post 
activation in either HA+aAPC or TCP+aAPC conditions. Data are collected using ΔΔCT method. The 
pattern of mRNA matches relatively with the protein fold change level. 
Memory T cells have an increased persistence and potential for proliferation, with 
stem-cell like qualities426, and have been shown  effective in anti-cancer responses for 
ACT507. To test the function and quality of the resultant CD8+ T cells in vitro, we examined 
how well they co-produced multiple cytokines and cytolytic molecules41, which is 
associated with successful immune responses in infection and cancer39,435,436,462. In chronic 
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infections and after extended stimulations such as in ACT and in the cancer 
microenvironment, CD8+ T cells will continue to differentiate and become “exhausted” or 
less potent37,462,508,509. We observed a higher percentage of CD8+ T cells that are co-
positive for all functionality markers—IFN-γ, TNF-α, IL-2, and CD107a—on the HA 
hydrogel, when compared to the TCP condition (Figure 6-14H). Thus, the HA hydrogel 
ECM environment enhances early cell proliferation, memory cell induction, and functional 
T cell generation.  
 
6.2.4 aTM Stimulates and Polarizes Human CD8+ T Cells 
To show that aTM is also capable of stimulating human CD8+ T cells, we attached 
anti-human CD3 (Signal 1) and anti-human CD28 (Signal 2) to the HA hydrogels. We 
observed a similar increase in the fold expansion when increasing the density of the Signal 
1 and 2 to 4 µg/mL (~25 fold CD8+ T cell expansion in 1 week) on 0.5-kPa aTM, but 
beyond this value, the fold proliferation of the cells dramatically decreased where little to 
no expansion was detected in the 25 µg/mL condition (Figure 6-21A), with minimal CFSE 
dilution (Figure 6-22). Nevertheless, phenotypic studies revealed that the cells are still 
proliferating at this dose, albeit at lower frequency (Figure 6-21B). Interestingly, this 
indicates control over phenotype independent of cell proliferation. Additionally, we 
verified the interaction of the T cells with the aTM at higher densities through light video 
microscopy where there is a higher fraction of cells bound to the aTM matrix over the first 
hour of attachment, similar to what we have observed with murine T cells (Figure 6-23). 
After 3 days we observed macroscopically more punctate, smaller cell clusters in the 25 
µg/mL aTMs than in the 4 µg/mL condition, potentially indicating the antibody density 
222 
 
may prevent beneficial multi-cellular interactions from forming due to an inhibition of 
migration necessary for expansion (Figure 6-24).  
Similar matrix stiffness-dependent effects were observed where more effective 
stimulation (>20 fold expansion in 1 week) is observed on aTM hydrogels with an elastic 
modulus less than 1 kPa (Figure 6-21C,D, Figure 6-25, Figure 6-26). By changing the 
stiffness of the aTM, we observed differences in phenotype even within conditions that 
have similar fold expansions (Figure 6-21E). For example, the 0.5 kPa and 1 kPa aTMs 
both provided nearly 20-fold expansion, but the 1 kPa aTM generated a more balanced 
ratio of central memory to effector memory CD8+ T cells than the 0.5 kPa aTM. In 
summary, this demonstrates that we can create an aTM that stimulates and polarizes human 





Figure 6-21: Artificial T cell stimulating matrix hydrogels provide effective stimulation to human CD8+ T 
cells. (A) CD8+ T cell fold expansion measured after seven days of stimulation by aTM with Signals 1+2 
(anti-CD3 and anti-CD28) conjugated at varying amounts, n = 3 independent donors. (B) Phenotype of CD8+ 
T cells after culture on aTM surfaces of varying Signals 1+2 amounts defined by CD45RA and CD62L (error 
bars show s.e.m). (C) CFSE proliferation dye dilution measured after 3 days of stimulation of CD8+ T cells 
comparing a stiff (3 kPa) and soft (0.5 kPa) aTM, n = 3 independent donors.  (D) CD8+ T cell fold expansion 
measured after seven days of stimulation on aTMs with varying stiffness (error bars show s.e.m.; **p < 0.01, 
n = 3 independent donors, one-way ANOVA with Dunnett’s post test comparing to 3 kPa condition). (E) 
Phenotype of CD8+ T cells after culture on aTM surfaces of varying stiffness defined by CD45RA and 





Figure 6-22: Quantitation of percentage of human CD8+ T cells in each divisional generation based on 
CFSE proliferation dye dilution with T cells stimulated on aTM with different density of anti-human 





Figure 6-23: Quantitation of fraction of human CD8+ T cells bound to aTM hydrogels of different anti-





Figure 6-24: Representative light microscopy images of T cell cultures on aTMs with different density of 





Figure 6-25: Quantitation of percentage of human CD8+ T cells in each divisional generation based on 
CFSE proliferation dye dilution with T cells stimulated on aTM with different stiffness with 4 µg/mL anti-





Figure 6-26: Representative light microscopy images of T cell cultures on aTMs with different stiffness 
(0.5, 1, 1.7, 2.5, 3 kPa) (scale bar = 1mm). 
 
 
6.2.5 aTM-stimulated Endogenous, Antigen-specific T Cells Inhibit 
Established Tumor Growth 
A main goal of ACT is to be able expand rare (frequency of 1 in 105 to 106 CD8+ T 
cells), antigen-specific CD8+ T cells to high numbers that are functional. Because of the 
difficulty in obtaining and activating these cells, most studies investigate the antigen-
specific activation of T cells from transgenic mice or the non-specific activation of 
endogenous T cells. This limits clinical relevance because of lack of translatability and the 
monoclonality of these T cells. On the other hand, we investigated an optimized version of 
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the aTM in the setting of activating rare antigen-specific CD8+ T cells. Thus, instead of 
using non-specific Signal 1 (anti-CD3) we conjugate antigen-specific Signal 1 (pMHC: 
Kb-SIY) to aTM with costimulatory anti-CD28, and compared stimulating conditions 
similar to those used with T cells mixed with aAPC cultured on HA hydrogel or TCP 
surface.  
After seven days of stimulation, we determined the antigen-specificity of the cultures 
and found that an average of 22% of the CD8+ T cells were antigen-specific from aTM 
cultures (Figure 6-27A). Indeed, we observed more than double the percentage of antigen-
specific cells and more than quadruple the total number of antigen-specific cells expanded 
on aTM (Figure 6-27B, C). This highlights the importance of studying endogenous T cell 
activation where now differences are much larger between groups than when studying with 
transgenic cells or in non-specific activation. Such a drastic increase in cell number, even 
between the aTM and HA + aAPC groups where the only difference was the location of 
the stimulatory signals, is quite surprising. Therefore, the combination of both engaging 
the TCRs and CD28 from stimulatory signals conjugated to the soft hydrogel and direct 
interaction with the hyaluronic acid ECM hydrogel surface represents important progress 




Figure 6-27: aTM stimulates a greater number and percent of functional antigen-specific CD8+ T cells that 
provide more effective tumor treatment. (A, B) Percentage of antigen-specific T cells after 7 days of 
stimulation is determined by staining with cognate and non-cognate antigen-loaded peptide major 
histocompatibility complex (pMHC) and anti-CD8a. (B, C) Percentages (B) and numbers (C) of antigen-
specific CD8+ T cells stimulated by aTM, or by aAPC on either TCP or HA hydrogel surface (error bars 
show s.e.m.; **p < 0.01, ***p < 0.001,  n = 12-15, one-way ANOVA with Tukey’s post test). (D) Fold IL7Ra 
expression on antigen-specific CD8+ T cells from HA+ aAPC and aTM compared to IL7Ra expression on 
antigen-specific CD8+ T cells from TCP + aAPC (error bars show s.e.m., n = 8–9). (E) T cell functionality 
was measured by the number of functional molecules co-expressed by each antigen-specific cell (IFN-γ, 
TNFα, CD107a) after 7 days of stimulation (n = 5–7). (F) Murine melanoma therapeutic in vivo model for 
adoptively transferred cells. (G) Tumor size measurements indicate that adoptive T cells from aTM 
stimulation significantly delayed tumor growth. Significance measured by two-way ANOVA with 
Bonferroni post-test (p < 0.0001) and (H) significantly extended survival. Significance measured by log-rank 




Since we had observed differences in the IL7Ra expression and functionality of the 
CD8+ T cells cultured on the HA hydrogel, we also probed antigen-specific cells after 
seven days of stimulation for these markers. We again observed an increase in both the 
IL7Ra (Figure 6-27D) and the functionality associated with an increase in the percent of 
SIY+ T cells that were positive for multiple cytokines and degranulation markers (Figure 
6-27E, Figure 6-28), and was confirmed by an in vitro killing assay (Figure 6-29). This is 
significant, because it shows that aTM is capable of generating higher numbers of 
functional antigen-specific CD8+ T cells. We also confirmed that these findings were 
consistent with CD8+ T cells isolated from mice with established tumors (Figure 6-30), 
and that we could expand human antigen-specific T cells with aTM specific for CMV+ 
CD8+ human T cells (Figure 6-31). 
 
 
Figure 6-28: Intracellular cytokine and functionality staining of antigen-specific CD8+ T cells on day 7 
reveals that aTM stimulations provide functional cells by (A) CD107a, (B) IFNγ, (C) TNFα staining (n=5-




Figure 6-29: In vitro killing assay demonstrates that aTM-stimulated antigen-specific CD8+ T cells are 
most effective at killing target cells. 
 
 
Figure 6-30: aTM provides an effective stimulation from tumor-experienced antigen-specific cells. (A) 
Schematic of experimental set up to test if aTM can provide additional support to stimulate tumor-
experienced antigen-specific T cells. (B) Number of antigen-specific CD8+ T cells at day 7 of culture as 
measured by hemocytometry and cognate dimer staining by flow cytometry (error bars show s.e.m.; *p < 
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0.05, **p < 0.01, n = 5, one-way ANOVA with Tukey’s post test). (C) Size of B16-SIY tumors at day 12 
post-injection (n=4). (D) Percent of antigen-specific CD8+ T cells at day 7 of culture as measured by 
cognate dimer staining by flow cytometry (error bars show s.e.m.; **p < 0.01, n = 5, one-way ANOVA 
with Tukey’s post test). 
 
 
Figure 6-31: aTM can stimulate antigen-specific human CD8+ T cells. (A) aTM-stimulated CMV+, CD8+ 
T cells were stained on day 7 of culture with cognate CMV-tetramer and non-cognate M1-tetramer to 
determine the percentage of antigen-specific T cells. (B) aTM produce more than four times as many 
CMV+, CD8+ T cells by day 7 than controls: peptide pulsing without Signal 1 and 2 attached or no-peptide 
with Signal 1 and 2 attached (n = 1). 
 
Finally, we tested the in vivo activity of aTM-stimulated and expanded T cells in an 
ACT model where T cells were transferred into mice with established B16-SIY melanoma 
tumors (Figure 6-27F). T cells stimulated by aTM significantly reduced tumor growth as 
compared to T cells on other surfaces and no treatment controls. Even on day 29, tumors 
in the group receiving aTM-stimulated T cells were stable below 50 mm2 (Figure 6-27G, 
Figure 6-32). This treatment also resulted in improved survival rate. By day 40, none 
among the no treatment group, 16% of TCP + aAPC treated mice, 33% of HA+ aAPC 
treated group survived, in contrast, 66% of mice survived after receiving aTM-stimulated 
T cells at the same dose (Figure 6-27H). Furthermore, there was no significant difference 
in the percentage of transferred cells 21 days after transfer (Figure 6-33). Thus, T cells 
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stimulated on the aTM had significantly increased efficacy compared to those stimulated 
with traditional methods. In conclusion, the aTM offers a unique combination of an ECM 
cue and stiffness-mediated mechanical signaling through the TCR. It was only when these 
two parameters were combined and optimized which resulted in effective antigen-specific 
expansion, phenotype skewing, and effective control of an established, aggressive, 
immunosuppressive murine melanoma. 
 
Figure 6-32: Individual growth curves from mice with tumors for each treatment group (A) No treatment 





Figure 6-33: Percentage of Thy1.1+ (adoptively transferred CD8+ T cells) on day 21 after adoptive 
transfer. No significant differences were observed between groups in the (A) Spleen, (B) lymph nodes, or 
(C) blood compartments by flow cytometry (error bars show s.e.m., n=3). 
6.3 Conclusion 
Herein we have engineered an artificial T cell stimulating matrix (aTM). By 
considering the native T cell biology we designed the aTM through mimicking critical 
features of both the natural extracellular matrix (ECM) and the antigen presenting cells. 
We conjugated T-cell stimulating molecules to develop the first ECM-based T cell 
activation biomaterial. The density of the signal attached and stiffness were key biophysical 
parameters engineered that influenced the ability for both murine and human CD8+ T cells 
to interact and be stimulated by the aTM. Additionally, we utilized a hyaluronic acid (HA) 
as an ECM molecule and found that it provides an additional signaling component 
influencing both the activation and polarization of T cells. By fine-tuning these biophysical 
properties, the aTM produced four times as many functional, therapeutic antigen-specific 
CD8+ T cells than current stimulation materials—resulting in more effective tumor 
inhibition. Additional work will need to be done to continue to study the underlying 
signaling implications for why biophysical properties of the aTM confer improved T cell 
activation. This has implications for adoptive T cell and CAR T cell therapies, where large 
numbers of high quality antigen-specific T cells are needed306,510,511. Engineering the 
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environment with ECM modulation represents a new approach to control T cell activation, 
where previously researchers have focused on cytokine cocktails, and generating artificial 
cells using particles or scaffolds instead of environmental cues103,267,368. Finally, besides 
creating an ex vivo environment for T cell activation, the aTM has the potential to be 







6.4 Experimental Section  
Mice  
B6, 2C, and PMEL transgenic mice were maintained per guidelines approved by the 
Johns Hopkins University’s Institutional Review Board.  
Reagents 
Soluble MHC-Ig dimers loaded with peptides (pMHC-Ig) and artificial antigen 
presenting cells (aAPC) were produced in-house as described103,250. 
Hydrogel Preparation  
Thiol-modified hyaluronic acid (HA) (ESI BIO, Alameda, CA, USA) was resuspended 
with 1 mL sterile dH2O and incubated at 37 °C for 30 minutes until completely dissolved 
to form 1% HA solution in 1 PBS. To form hydrogels, HA was plated immediately after 
getting mixed with polyethylene glycol diacrylate (PEGDA) with a molecular weight of 
3400 (Laysan Bio, Arab, AL) crosslinker at a 4:1 volume ratio to fully cover the well. 
Plated hydrogels were incubated for a minimum of 1 hour prior to cell culture.  
Preparation of aTM  
HA solution was prepared as previously described. Anti-CD3 and anti-CD28 antibodies 
were purchased respectively from BioXCell (145-2C11; West Lebanon, NH, USA) and 
BioLegend (37.51; San Diego, CA, USA). Antibody and MHC-Ig dimers were partially 
reduced with 100 mM dithiothreitol (DTT) for 30 minutes at room temperature to expose 
free thiol groups and thoroughly washed through a centrifugation filtration with a 50-kDa 
MWCO filter. PEGDA crosslinker was added to reduced MHC-Ig dimers, anti-CD3 and 
anti-CD28 antibody solutions to a final concentration of 0.5% PEGDA for preparation for 
238 
 
crosslinking. This results in at least a 200-fold excess of PEGDA to antibody ratio, which 
prevents thiol oxidation and long-term storage of antibody-PEGDA conjugates and that 
antibody can be attached effectively to the thiolated HA hydrogel. Prior to hydrogel 
formation, MHC-Ig dimers or anti-CD3 antibodies and anti-CD28 co-stimulatory signals 
with 0.5% PEGDA were added to the HA solution to directly attach signals on HA 
through thiol-diene chemistry. The HA-antibody solution was then mixed with PEGDA 
crosslinker at a 4:1 ratio to be plated. The aTM was allowed to form within flat-bottomed 
tissue culture plates to form a complete layer for at least 1 hour prior to washing 3 times 
with 1 PBS to remove any unbound stimulatory signal and cells were subsequently 
plated. To investigate the effects of extracellular matrix (ECM) protein attachment, cyclic 
RGD (sequence: CCRRGDWLC), which was synthesized by solid phase methods as 
described previously512 or laminin (ThermoFisher) were added to make a HA solution 
with protein concentration of respectively 100 µM and 20 µg/mL, prior to the hydrogel 
formation. To investigate the stiffness effects of aTMs, we changed the PEGDA 
crosslinker concentration from a final concentration of 0.05 wt/vol% to 2 wt/vol%.  
Characterization of aTM 
To evaluate the mechanical stiffness of aTMs, elastic moduli of hydrogels were measured 
using Ares G2 oscillatory shear rheometer. First, HA solution was mixed with varying 
PEGDA crosslinker concentrations to a final volume of 200 µL and placed immediately 
on the stationary lower plate of the rheometer. The shear storage modulus, G’, and the 
sheer loss modulus, G”, were recorded during in situ hydrogel formation over one hour at 
37 °C. The elastic modulus, E’, was calculated by E’ = 2G’(1+γ) where γ is the Poisson’s 
ratio. For HA hydrogels, we assumed γ to be 0.5 because the Poisson’s ratio of 
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incompressible materials is approximately 0.5 and the hydrogels are used under low 
strain conditions488.  
For scanning electron microscopy (SEM), hydrogels were cross-linked overnight at 37⁰C 
and subsequently flash frozen in liquid nitrogen for 5 minutes. Samples were placed in 
the FreeZone 4.5 Benchtop (LABCONCO) freeze dry system for 72 hours for complete 
dehydration of samples. Samples were coated using a Desk III (Denton Vacuum) Au/Pd 
sputter coater for 2 mins at 25mA before imaging in LEO 435 VP SEM. 
To evaluate the conjugation to the surface of the hydrogel, we stained both HA hydrogels 
with no antibodies attached and HA hydrogels with 10 µg/mL anti-CD3, anti-CD28 in 
black 96-well half area wells. We stained with FITC-anti-Armenian and Syrian Hamster 
IgG, clone G192-1 and FITC-anti-Armenian and Syrian Hamster IgG1, clone G94-56 
(BD Pharminogen) for 5 minutes at 4 °C. Then the surfaces of the hydrogels were 
washed 5 times with PBS and then the fluorescence per well was read on a fluorescent 
plate reader and compared to a standard curve of the fluorescent antibodies titrated down 
the plate. To estimate the density of the ligand on the surface of the aTM, the thickness 
observed by cells was assumed to be 1 µm, and then the density was calculated based off 
the total mass of Signal 1 and 2 within this slab and then dividing by the surface area.  
CD8+ T Lymphocyte Isolation  
Murine cells were obtained from adult mouse lymph nodes and spleens. Obtained cells 
were treated with ACK lysing buffer to lyse red blood cells and filtered through cell 
strainers to isolate splenocytes. PBMCs from healthy donors were isolated by Ficoll-
Paque PLUS gradient centrifugation (GE Healthcare). CD8+ T lymphocytes were then 
isolated from splenocytes or PBMCs by negative selection using CD8+ isolation kits and 
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magnetic columns from Miltenyi Biotech (Auburn, CA, USA) according to the 
manufacturer’s protocol. PBMCs were obtained from blood drawn from healthy males 
and females per JHU IRB approved protocols. 
Ex Vivo T Cell Culture and Activation 
For ex vivo T cell expansion, isolated CD8+ T cells were cultured in the T cell culture 
media (RPMI supplemented with L-glutamine, non- essential amino acids, vitamin 
solution, sodium pyruvate, β-mercaptoethanol, 10% fetal bovine serum, ciproflaxin, and a 
cocktail of T cell growth factors as described previously513). In the case of human T cell 
expansion, 10% AB serum was used instead of 10% fetal bovine serum. On day 3 or 4 of 
culture, cells were fed with half the volume of the initial T cell culture media with twice 
the concentration of T cell growth factor cocktail.  
For activation with aAPC, T cells were co-cultured with a concentration of 75 pM-bound 
pMHC-Ig on the aAPC and then plated on respective surfaces. For stimulation on the 
aTM, cells were plated on the surfaces aTM with concentrations of the stimulatory 
antibody (either anti-CD3 and anti-CD28 or pMHC-Ig and anti-CD28) conjugated to the 
HA hydrogel.  
T Cell Proliferation Assay 
CD8+ T cells were isolated as previous described and resuspended in 1 mL T cell culture 
media. Cells were mixed with 1 µL CellTrace carboxyfluorescein succinimidyl ester 
(CFSE) dye (ThermoFisher) in 1 mL T cell culture media per 3 million cells and 
incubated at 37 °C for 20 minutes. CFSE stained cells were washed with 50 mL T cell 
culture media to remove unstained dye and plated. On day 3 of culture, cells were 
harvested and stained with a 1:100 PBS solution of APC-conjugated rat anti-mouse 
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CD8a, clone 53-6.7 (BD Pharmingen) for 15 minutes at 4 °C. The CFSE fluorescence 
intensity was measured using BD FACSCalibur flow cytometer. Cell proliferation was 
analyzed using FlowJo with diluted CFSE fluorescence peaks signifying population after 
each round of cell division. A subset of the cells were allowed to expand for 7 days and 
viable cells were counted with a hemocytometer to determine fold expansion. Images of 
cell cultures were taken with an Olympus IX71 inverted light microscope at a 4 
magnification on day 3 of cultures.  
Time Course Experiments 
Two million purified CD8+ T cells from either PMEL or 2C mice were cultured on HA 
or TCP conditions. The cells were collected at designated time points. These cells were 
frozen down in liquid nitrogen for western blots, stored in TRIzol for mRNA detection, 
or PFA fixed for phospho-flow. For drugs, the final concentration of rapamycin 
(mTORC1 inhibitor), U-0126 (Erk1/2 inhibitor), blebbistatin, and anti-CD44 (KM201) 
were 0.1 µM, 10 µM, 100 µM, and 5 µg/mL, respectively. Half-volumes of T cell culture 
media is added every other day to keep cells in good condition. For western blot and rt-
PCR, live cells that have been cultured for more than 24 hours were first purified using 
Ficoll-Paque followed by the procedure mentioned above. 
Western Blot 
Frozen cells were lysed in a radioimmunoprecipitation assay (RIPA) buffer-based 
mixture containing proteinase inhibitor, PMSF (phenylmethane sulfonyl fluoride), 
sodium pyrophosphate, sodium fluoride, sodium orthovanadate, and β-glycerophosphate 
to inhibit phosphatases. Then, protein samples underwent standard western blot 
procedure with 1-2 hours of incubation in 5% milk, overnight incubation in primary 
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antibodies (in 4% BSA), and 1hr incubation in secondary antibodies. Films were imaged 
in a UVP BioSpectrum Imaging System, analyzed in UVP VisionWorks and quantified in 
ImageJ. Antibodies used include: 
Target Cat# Vendor 
p-S6 (S240/244) 2215 Cell Signaling 
p-Erk (Y202/204) 4695 Cell Signaling 
Beta-actin 4970 Cell Signaling 
p-S6K1 (T389) 9234 Cell Signaling 
p-AKT (S473) 3787 Cell Signaling 
Total Lck 2752 Cell Signaling 
p-Lck (Y505) 2751 Cell Signaling 
p-Src (Y416) 2101 Cell Signaling 
 
RT-PCR 
Cells were kept in TRIzol in -80℃ for storage. mRNA was purified using Zymo Quick-
RNA MiniPrep Kit. Then, reaction mix was prepared based on standard RT-PCR 
protocol. Probes were from TaqMan FAM/MGB probes with VIC/TAMRA Eukaryotic 
18S rRNA as an endogenous control (ThermoFisher). Samples were run in quintuplicate 
in Applied Biosystems StepOnePlus Real-Time PCR system and analyzed using Excel. 
Phosphorylation Flow Cytometry 
Cells were first stained with Live/Dead stain and then were fixed using BD Phosflow Fix 
Buffer I at room temperature for 10 minutes. After washing, cells were permeabilized 
using ice cold BD Phosflow Perm Buffer II for 30 minutes on ice. Samples were then 
stained with a solution of FACS wash buffer with 1:50 PE conjugated rat anti mouse 
CD8a, clone 53 6.7 (BD Pharmingen) and a 1:100 Rabbit anti Phospho S6 Ribosomal 
Protein (Ser235/236), clone  
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D57.2.2E, or Rabbit IgG Isotype Control, clone DA1E (Cell Signaling Technology, 
Danvers, Massachusetts) for 45 minutes at room temperature. Samples were then washed 
with FACS wash buffer and then stained with a solution of FACS wash buffer with 1:250 
of Alexa Fluor 647-conjugated Goat S22 anti Rabbit IgG, polyclonal (ThermoFisher) for 
45 minutes at room temperature. Samples were washed and resuspended with FACS 
wash buffer and read on a BD FACSCalibur.   
T Cell Phenotype Assay  
On day 7 of culture, the numbers of cells were counted using hemocytometer. After 
counting, less than 500,000 cells were collected and stained with a 1:100 PBS solution of 
APC-conjugated rat anti-mouse CD8a, clone 53-6.7 (BD Pharmingen), PE-conjugated rat 
anti-mouse CD62L, clone MEL-14 (BD Pharmingen), PerCP-conjugated rat anti-mouse 
CD44, clone IM7 (Biolegend), and 1:1000 of LIVE/DEAD® Fixable Green Dead Cell 
Stain (ThermoFisher) for 15 minutes at 4 °C. Cells were then washed with FACS wash 
buffer to be read on BD FACSCalibur flow cytometer and analyzed using FlowJo to 
measure the population of naïve T cells (CD62L+CD44-), effector T cells (CD62L-
CD44+), and memory T cells (CD62L+CD44+). For human phenotype experiments, the 
same protocol was used except, the cells were instead stained with a 1:100 PBS solution 
of APC-conjugated anti-human CD45RA, Clone HI100 (Biolegend), PE-conjugated anti-
human CD62L, clone DREG-56 (Biolegend), PerCP-conjugated anti-human CD8a, clone 
SK-1 (Biolegend), and 1:1000 of LIVE/DEAD® Fixable Green Dead Cell Stain for 15 
minutes at 4 °C. Cells were then washed with FACS wash buffer to be read on BD 
FACSCalibur flow cytometer and analyzed using FlowJo to measure the population of 
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naïve T cells (CD62L-CD45RA-), effector T cells (CD62L-CD45RA+), central memory 
T cells (CD62L+CD45RA-), and effector memory T cells (CD62L-CD45RA-). 
For analysis of IL-7Ra and IL-15Ra expression on cells, on day 7 of culture, the numbers 
of cells were counted using hemocytometer. After counting, samples were divided into 
four tubes (less than 500,000 cells per tube) and stained with a 1:100 PBS solution of 
APC-conjugated rat anti-mouse CD8a, clone 53-6.7 (BD Pharmingen), 1:1000 of 
LIVE/DEAD® Fixable Green Dead Cell Stain (ThermoFisher), and either PE-conjugated 
rat anti-mouse IL7Ra, clone A7R34 (Biolegend), or isotype control PE-conjugated Rat 
IgG2a, κ Isotype Ctrl, clone RTK2758 (Biolegened), or PE-conjugated rat anti-mouse 
IL15Ra, clone DNT15Ra (eBioscience), or isotype control PE-conjugated Rat IgG1, κ 
Isotype Ctrl, clone eBRG1 (eBioscience), for 15 minutes at 4 °C. Cells were then washed 
with FACS wash buffer to be read on BD FACSCalibur flow cytometer and analyzed 
using FlowJo. 
T Cell Cytokine Functionality Assay 
On day 7 of culture, approximately 500,000 CD8+ T cells were isolated from each 
condition and separated into restimulation and no-stimulation groups in 100 µL T cell 
culture media. To inhibit protein transport, 10 µL solution of 1:50 FITC anti-CD107a, 
1:350 BD GolgiStop Protein Transport Inhibitor (BD Biosciences), and 1:350 BD 
GolgiPlug Protein Transport Inhibitor (BD Biosciences) in PBS was added to the 
samples. For the restimulation group, microparticle Dyanl-based aAPC were added at a 
1:1 ratio. Both groups were incubated at 37 °C for 6 hours. After incubation, cells were 
washed and stained with 1:100 PBS solution of PerCP-conjugated anti-mouse CD8a, 
clone 53-6.7 (Biolegend) and 1:1000 of LIVE/DEAD® AmCyan Fixable Aqua Dead Cell 
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Stain (ThermoFisher) at 4 °C for 30 minutes. Cells were then fixed and permeabilized 
with 100 µL BD Cytofix/Cytoperm Fixation and Permeabilization Solution (BD 
Biosciences) overnight. To analyze intracellular cytokines, cells were washed with 1x BD 
PERM/Wash buffer with 2% BSA the following day and stained with 1:100 solution of 
PE-conjugated rat anti-mouse IFN-γ, clone XMG1.2 (BD Pharmingen), APC-conjugated 
rat anti-mouse IL2, clone JES6-5H4 (BD Pharmingen), and PE-Cy7-conjugated rat anti-
mouse TNFα, clone MP6-XT22 (Biolegend) in PERM/Wash buffer with 2% BSA at 4 °C 
for 1 hour. Stained cells were read on BD LSR II flow cytometer and analyzed by 
subtracting cytokine positive cells in the no-stimulation group from the re-stimulation 
group using FlowJo.  
For antigen-specific cells a similar assay was used with the following modifications. 
Instead of a restimulation, cells were simply stained with 1 µg of either cognate or non-
cognate biotinylated pMHC-Ig dimer for 1 hour at 4°C. After washing, samples were 
stained with a 1:350 ratio of PE-labeled streptavidin (BD Pharmingen). Then 10 µL 
solution of 1:50 FITC anti-CD107a, 1:350 BD GolgiStop Protein Transport Inhibitor (BD 
Biosciences), and 1:350 BD GolgiPlug Protein Transport Inhibitor (BD Biosciences) in 
PBS was added to the samples and incubated for 37 °C for 6 hours. Cells were then 
washed and stained with 1:100 PBS solution of PerCP-conjugated anti-mouse CD8a, 
clone 53-6.7 (Biolegend) and 1:1000 of LIVE/DEAD® AmCyan Fixable Aqua Dead Cell 
Stain (ThermoFisher) at 4 °C for 30 minutes. Cells were then fixed and permeabilized 
with 100 µL BD Cytofix/Cytoperm Fixation and Permeabilization Solution (BD 
Biosciences) overnight. Cells were then washed with 1x BD PERM/Wash buffer with 2% 
BSA and stained with 1:100 solution of APC-conjugated rat anti-mouse IFN-γ, clone 
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XMG1.2 (BD Pharmingen) and PE-Cy7-conjugated rat anti-mouse TNFα, clone MP6-
XT22 (Biolegend) in PERM/Wash buffer with 2% BSA at 4 °C for 1 hour. Stained cells 
were read on BD LSR II flow cytometer.  
In Situ Staining and Super-resolution Microscopy 
CD8+ T cells were added to the surface of the aTM hydrogels and allowed to culture at 
37 °C for 1 hour. Gels were fixed with 4% PFA for 20 minutes at room temperature, 
followed by permeabilization, and staining with Alexafluor phalloidin-564 and CD3 
(Novus Biologicals). The secondary antibody used was Alexafluor-488. Gels were 
mounted on coverslips and imaged using the Zeiss 800 confocal microscope equipped 
with an AiryScan detector. Airyscan super-resolution images were processed using Zen 
software. Quantification of CD3 spot area was performed in FIJI/ImageJ using the 
analyze particles function. 
Expansion of Rare Antigen-Specific T cells 
B6 CD8+ T cells were stimulated on aTM surfaces as described previously for 7 days. To 
detect antigen-specific CD8+ T cells, cells were stained with 1 µg of either cognate or 
non-cognate biotinylated pMHC-Ig dimer, with a 1:100 ratio of APC-conjugated rat anti-
mouse CD8a, clone 53-6.7 (BD Pharmingen) in FACS wash buffer for 1 hour at 4°C. 
Samples were washed and then stained with a 1:350 ratio of PE-labeled streptavidin (BD 
Pharmingen) and a 1:1000 ratio of LIVE/DEAD™ Fixable Green Dead Cell Stain 
(ThermoFisher) in PBS for 15 minutes at 4°C. Cells were then washed and read on a BD 
FACSCalibur. Percent antigen-specific cells were calculated by subtracting the percent 
gated in cognate stained CD8+ T cells from non-cognate stained CD8+ T cells. Number 
of antigen-specific cells was determined from multiplying the percent of antigen-specific 
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cells by the number counted following cell harvest. Detection of antigen-specific human 
cells was done similarly, except instead of staining with biotynlated dimer, the antigen-
specific cells were stained with purchased PE-labeled tetramer (MBL International, 
Woburn, MA) for 30 minutes at room temperature, then washed and stained with APC-
conjugated anti-human CD8a, clone SK-1 (Biolegend), and 1:1000 of LIVE/DEAD® 
Fixable Green Dead Cell Stain for 15 minutes at 4 °C. 
For expansion of rare T cells from tumor-experienced mice, mice were injected with 
2  106 B16-SIY melanoma tumor cells expressing the SIY antigen and tumors were 
allowed to grow until on average were around 100 mm2. CD8+ T cells were then 
harvested from the lymph nodes and spleens as previously described and expansion and 
detection were performed as previously described.  
For analysis of IL7Ra of antigen-specific T cells, a similar process was used. Cells were 
stained with 1 µg of either cognate or non-cognate biotinylated pMHC-Ig dimer, with a 
1:100 ratio of PerCP-conjugated rat anti-mouse CD8a, clone 53-6.7 (BD Pharmingen) in 
FACS wash buffer for 1 hour at 4°C. Samples were washed and then stained with a 1:350 
ratio of PE-labeled streptavidin (BD Pharmingen), either APC-conjugated rat anti-mouse 
IL7Ra, clone A7R34 (Biolegend) or isotype control APC-conjugated Rat IgG2a, κ 
Isotype Ctrl, clone RTK2758 (Biolegend), and a 1:1000 ratio of LIVE/DEAD™ Fixable 
Green Dead Cell Stain (ThermoFisher) in PBS for 15 minutes at 4°C.   
In Vitro Killing Assay 
Target cells were harvested from splenocytes of B6 mice. 20 x 106 splenocytes were 
labeled with a high concentration of CFSE (5 µM) and another was labeled with a low 
concentration of CFSE (0.05 µM) in 1 mL of PBS at 37°C for 10 min (Invitrogen, 
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Eugene, OR). Media with FBS was added to quench the reaction and allowed to incubate 
at 37°C for another 5 min and then washed with media. The CFSE-high cells were then 
incubated at 37°C for 1 hour with 1 µM SIY peptide in media without serum. The cells 
were then washed and mixed at a 1:1 ratio with control non-target, CFSE-low 
splenocytes. This mixed population was added to CD8+ T cells which had been 
stimulated for 7 days at a 1:1 ratio and allowed to incubate for 18 hours at 37°C in a cell 
incubator. Then cells were washed, stained with a 1:1000 of LIVE/DEAD® AmCyan 
Fixable Aqua Dead Cell Stain (ThermoFisher) at 4 °C for 30 minutes. The cells were 
washed and read on a BD LSRII flow cytometer. The percent killing was calculated as 
follows: % of in vivo killing = 100 − ([(% specific peptide pulsed cells in treatment/% 
unspecific B6 cells in treatment)/(% specific peptide pulsed in no treatment controls/% 
unspecific B6 cells in no treatment controls)] × 100). 
Therapeutic Adoptive Transfer of T Cells  
On day 0, B6 mice were injected with 2  106 B16-SIY melanoma tumor cells expressing 
the SIY antigen. On day 1, CD8+ T cells were isolated from wildtype B6 mice and 
cultured for 7 days to produce stimulated T cells for adoptive transfer. On day 7, mice 
were given a central dose of 500 cGy, which induces transient lymphopenia similar 
standard approaches within adoptive immunotherapy514. On day 8, T cells cultured ex 
vivo were harvested and adoptively transferred intravenously in volumes of 100 μL. For 
every 3 mice receiving treatment, 1 B6 spleen was used for CD8+ T cell isolation and 
stimulation. This resulted in each mouse receiving 500,000 stimulated CD8+ T cells. 
Tumor sizes were measured using calipers and multiplying the longest measured length 
by the perpendicular direction of the tumor. Mice were sacrificed once tumors grew 
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larger than 200 mm2. For studies involving persistence of cells, Thy1.1+ B6 donor mice 
were used. On day 21 blood, spleen, and lymph nodes were harvested from recipient 
mice and stained with a 1:100 ratio of APC-conjugated rat anti-mouse CD8a, clone 53-
6.7 (BD Pharmingen) and 1:100 ratio of Alexa Fluor 488-conjugated mouse anti-mouse 





Chapter 7. Contributions to Additional Research 
7.1 Introduction 
I was fortunate to be able to participate in a variety of research projects ancillary to 
the goals of the lab and my overall thesis goals in controlling biomaterial properties to 
understand and control T cell responses. Here I will only briefly summarize our major 
findings with these projects as these were not the focus of my PhD thesis. First, I will 
describe the projects I have contributed to for creating biodegradable aAPCs. Second, I 
will describe the projects I have contributed to towards other students in our lab. Finally, I 
will briefly mention some of the projects I have started, but did not progress at the rate that 
I had intended so they were eventually dropped or stopped.  
 
7.2 Biodegradable aAPCs4 
Biomimetic materials that target the immune system and generate an anti-tumor 
responses hold promise in augmenting cancer immunotherapy. These synthetic materials 
can be engineered and optimized for their biodegradability, physical parameters such as 
shape and size, and controlled release of immune-modulators. As these new platforms 
enter the playing field, it is imperative to understand their interaction with existing 
immunotherapies since single-targeted approaches have limited efficacy. Here, we 
investigated the synergy between a PLGA-based artificial antigen presenting cell (aAPC) 
and a checkpoint blockade molecule, anti-PD1 monoclonal antibody (mAb). The 
                                                          
4 Sections of this chapter are reprinted (adapted) with permission from “Kosmides, A. K., et al. "Biomimetic 
biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma." 
Biomaterials 118 (2017): 16-26.” Copyright 2017 Elsevier. 
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combination of antigen-specific aAPC-based activation and anti-PD-1 mAb checkpoint 
blockade induced the greatest IFN-γ secretion by CD8+ T cells in vitro. Combination 
treatment also acted synergistically in an in vivo murine melanoma model to result in 
delayed tumor growth and extended survival, while either treatment alone had no effect. 
This was shown mechanistically to be due to decreased PD-1 expression and increased 
antigen-specific proliferation of CD8+ T cells within the tumor microenvironment and 
spleen. Thus, biomaterial-based therapy can synergize with other immunotherapies and 
motivates the translation of biomimetic combinatorial treatments257. Here my specific 
contribution was to complete the in vivo efficacy of the combination therapy and also 
evaluate the mechanism of action by further analyzing immune cells both within the 
tumor and other immune related organs like the lymph node and spleen.  
We have also recently found that modulation of the base polymer which forms the 
aAPC can significantly increase the efficiency of binding and expansion of cognate T-
cells. By incorporating a poly(beta-amino ester) (PBAE) into the PLGA-based 
microparticles, we have discovered that the resultant microparticles can bind in a targeted 
fashion to cognate T-cells with much greater efficiency than PLGA particles alone. 
Furthermore, this binding demonstrates a much higher capacity to stimulate cognate T 
cells for expansion at 100’s-fold lower particle doses and is able to effectively stimulate 
endogenous antigen-specific T cell responses, something which previous biodegradable 
PLGA aAPCs were unable to do. We found that the PLGA/PBAE aAPCs 
absorb/conjugate a much higher amount of dimer and anti-CD28 potentially pointing to 
this as the mechanism of action of increased functionality. Consequently, we further 
tested these PLGA/PBAE aAPC formulation for activating the endogenous antigen-
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specific T cells in vivo, where previous therapies were always in combination with 
transgenic CD8+ T adoptive T cell responses. From this preliminary trial we saw both a 
reduction in tumor burden and increase in overall survival.  
We have also investigated the differences in particle shape when activating T cells 
because of the polymer flexibility and ability to be shaped when heated. Building off the 
group’s previous work with microparticle aAPCs, we have looked at spherical, 1D-
stretched, and 2D-stretched aAPCs. Interestingly, 1D-stretched aAPCs show most in vivo 
efficacy, while 2D-stretched aAPCs and spherical aAPCs have been less effective, 
although the 2D-stretched aAPCs have been just as effective as 1D-stretched aAPCs in 
vitro. Therefore, the shape of the aAPC influences not only the binding of the aAPC with 
cognate T cells, but also the biodistribution of the particles in vivo potentially causing 
differential in vivo effects.  
 
7.3 Contributions to other Schneck lab projects5  
 T cell activation requires the coordination of a variety of signaling molecules 
including T cell receptor-specific signals and costimulatory signals. Altering the 
composition and distribution of costimulatory molecules during stimulation greatly 
affects T cell functionality for applications such as adoptive cell therapy (ACT), but the 
large diversity in these molecules complicates these studies. Here, we develop and 
validate a reductionist T cell activation platform that enables streamlined customization 
of stimulatory conditions. This platform is useful for the optimization of ACT protocols 
                                                          
5 Sections of this chapter are reprinted (adapted) with permission from “Kosmides, Alyssa K., et al. 
"Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation." 
Nano letters 18.3 (2018): 1916-1924.” Copyright 2018 American Chemical Society. 
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as well as the more general study of immune T cell activation. Rather than decorating 
particles with both signal 1 antigen and signal 2 costimulus, we use distinct, 
monospecific, paramagnetic nanoparticles, which are then clustered on the cell surface by 
a magnetic field. This allows for rapid synthesis and characterization of a small number 
of single-signal nanoparticles which can be systematically combined to explore and 
optimize T cell activation. By increasing cognate T cell enrichment and incorporating 
additional costimulatory molecules using this platform, we find significantly higher 
frequencies and numbers of cognate T cells stimulated from an endogenous population. 
The magnetic field-induced association of separate particles thus provides a tool for 
optimizing T cell activation for adoptive immunotherapy and other immunological 
studies. Involved directly in engineering nanoparticle aAPCs and its properties, I worked 
closely with Alyssa Kosmides as well on her project in creating nanoparticle aAPCs 
which had separated signal 1 and signal 2 aAPCs250. 
 Engineering the aAPC and the system of enrichment and expansion, I created a 
JoVE (Journal of Visualized Experiments) video protocol for the process515 and was 
involved in Ami Bessell’s project with understanding cross-reactive gut microbiota 
antigen-specific T cell responses. Here we used the aAPC process to enrich and expand 
both SIY (foreign/tumor model antige) and SVY (gut microbiota derived protein)-
reactive T cells and understand the influence of the presence of the microbiota on this 
antigen-specific T cell response in the context of tumor immunotherapy. Specifically, we 
also looked at the enrichment of antigen-specific T cells on day 0 with the fluorescent 




7.4 Incomplete Projects 
 This section serves to be a dump for those projects which met dead-ends, yet were 
a significant part of my research during my PhD. First, I tried to give my first 
undergraduate Fernando a project to make a MHC-array detection chip. This was to 
improve upon the work Dr. Schneck had done with Mike Paulitis and try to improve 
antigen-specific CD8+ T cell detection in high throughput. We were able to get antigen-
specific binding on the spots that we printed; however, the sensitivity was not improved 
over that of flow cytometry, so we decided to abandon this project in favor of further 
development of the aAPC for the same purpose.  
Another project included one where I worked with another PhD student in the 
Neuroscience department to create EGFR-targeted magnetic nanoparticles and attempted 
to use a magnetic field to cluster receptors on neural cells to enable magnetic control of 
neuron activity. Unfortunately, the student showed little signal above background and as 
this was a side project, it was discarded without much troubleshooting.  
 I have also tested many other parameters with the hydrogel-T cell culture system. 
First, I obtained decellularized ECM from the Elisseeff lab and incorporated it into the 
stimulation mixture. After several stimulations it did not seem to have major effects on 
the activation, except if there was too high of a concentration of dECM in the hydrogel, 
then this would eliminate any CD8+ T cell activation. Similar results were seen when I 
would add gelatin and heparin at various ratios. I added gelatin to decrease the stiffness 
of the gel and increase CD8+ T cell migration in 3D gels; however, all experiments with 
3D stimulation in these gels did not work because the cells would not move in these gels, 
while they would move very quickly through collagen 3D gels. The reason I was 
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interested in adding heparin is because the heparin is known to bind to cytokines and 
chemokines and keep them as a depot in the ECM. This can provide extended signaling 
and preservation of the cytokines for longer periods of time, and I hypothesized this 
would work for T cell cytokines and further enhance T cell activation.  
 Also, towards the goal of doing 3D stimulation of the T cells ex vivo, I tried to use 
polymeric nanofibers produced through electrospinning as a component to reinforce the 
hydrogel while increasing the porosity. I was able to get this composite material to also 
stimulate antigen-specific CD8+ T cells in 2D effectively, but never get migration or 
expansion in 3D. Optimizing gel properties for 3D stimulation has taken a large portion 
of my time and yielded little success, which is why we have decided to go with producing 
microparticle hydrogels instead. Along the lines of the composite material, I also looked 
at the difference of stimulating CD8+ T cells on fiber mats with different diameter fibers. 
At similar conjugation efficiencies, I did not observe any differential activation of the 






Chapter 8. Conclusions 
8.1 Summary of work 
I have successfully addressed many of the challenges facing T cell 
immunotherapies by systematically engineering novel biomaterials such as magnetic 
nanoparticles and ECM hydrogels (Figure 8-1). Both will be immediate tools to 
researchers and clinicians to use in detecting in high-throughput and controlling the 
expansion and phenotype of rare antigen-specific T cells that will advance our 
understanding of antigen-specific responses. Already they have improved our 
understanding of T cell biology where changing the size of the aAPC demonstrated the 
importance of clustered cognate recognition events needed for T cell activation. 
Additionally, changing the mechanical strength of the aTM elucidated the strict 
mechanical requirements of the T cell receptor needs for effective activation. Further 
demonstrating that the environment influences the cellular therapeutic product is 
paradigm-shifting and delineates the importance of the ECM, providing a case study of 
how to engineer ECM-materials for therapeutic immune stimulation in the future. Finally, 
besides creating an ex vivo environment for T cell activation, the aTM has the potential 
to be applied for direct T cell activation in vivo, thus eliminating the need for ex vivo T 




Figure 8-1: Schematic of biomaterials properties I engineered to solve problems facing T cell 
immunotherapies during my PhD thesis.  
 
8.2  Future directions 
 The work in Chapters 3-5 have mostly been developed with mouse CD8+ T cells. 
Thus, true translation and utility will be the use of these aAPC tools in human CD8+ T 
cells. I will finish out my PhD attempting to translate our findings to human CD8+ T 
cells. Finally, I hope to continue to work with Mekha to understand the role of CD4+ T 
cells in our splenocyte cultures as she is in a lab where they are able to do signle cell 
fluorescent imaging with transgenic mice that express fluorescent phosphorylated ERK. 
Furthermore, other students in the lab will begin to look at some of these engineering 
parameters within the development of Class II aAPCs for CD4+ T cells.   
Chapter 6 mostly focused on the ex vivo stimulation of antigen-specific CD8+ T 
cells. The original main goal for this project was to develop “artificial lymph nodes” or in 
vivo hydrogel activation hubs for antigen-specific CD8+ T cells. Already I have made 
progress towards this goal where we create injectable microparticle hydrogels by passing 
the gel through a stainless steel mesh. Furthermore, we are able to attach 
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immunocytokines or antibody-binding cytokines to the surface of the hydrogel for a 
signal 3 because of the lack of cytokine support in vivo. Next steps are to finish 
optimizing the combination of the three signals and perform in vivo T cell activation and 
tumor models to demonstrate efficacy.  
Similar to the aAPCs, in addition to the use of the aTM in vivo, CD4+ T cell 
activation can be probed on the surface of the hydrogel. CD4+ T cells are much more 
phenotypically sensitive and may prove different in terms of activation and phenotype 
from the HA hydrogels. This also points to another new direction the project could go. 
Here we only extensively investigated one ECM component, HA, but there are dozens 
more that may also differentially influence T cell activation, studying them further could 
improve our overall design of the aTM and also provide more clues to how the 















1. Smith-Garvin, J. E.; Koretzky, G. A.; Jordan, M. S. T Cell Activation. Annu. Rev. Immunol. 2009, 
27, 591–619. 
2. Cannons, J. L.; Lau, P.; Ghumman, B.; DeBenedette, M. A.; Yagita, H.; Okumura, K.; Watts, T. H. 
4-1BB Ligand Induces Cell Division, Sustains Survival, and Enhances Effector Function of CD4 
and CD8 T Cells with Similar Efficacy. J. Immunol. 2001, 167, 1313–1324. 
3. Buchan, S. L.; Manzo, T.; Flutter, B.; Rogel, A.; Edwards, N.; Zhang, L.; Sivakumaran, S.; 
Ghorashian, S.; Carpenter, B.; Bennett, C. L.; Freeman, G. J.; Sykes, M.; Croft, M.; Al-Shamkhani, 
A.; Chakraverty, R. OX40- and CD27-Mediated Costimulation Synergizes with Anti-PD-L1 
Blockade by Forcing Exhausted CD8+ T Cells to Exit Quiescence. J. Immunol. 2015, 194, 125–
133. 
4. Zeng, W.; Su, M.; Anderson, K. S.; Sasada, T. Artificial Antigen-Presenting Cells Expressing 
CD80, CD70, and 4-1BB Ligand Efficiently Expand Functional T Cells Specific to Tumor-
Associated Antigens. Immunobiology 2014, 219, 583–592. 
5. Chacon, J. A.; Wu, R. C.; Sukhumalchandra, P.; Molldrem, J. J.; Sarnaik, A.; Pilon-Thomas, S.; 
Weber, J.; Hwu, P.; Radvanyi, L. Co-Stimulation through 4-1BB/CD137 Improves the Expansion 
and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy. 
PLoS One 2013, 8, e60031. 
6. Zhang, H.; Snyder, K. M.; Suhoski, M. M.; Maus, M. V; Kapoor, V.; June, C. H.; Mackall, C. L. 4-
1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for 
Adoptive Immunotherapy. J. Immunol. 2007, 179, 4910–4918. 
7. Oh, H. S.; Choi, B. K.; Kim, Y. H.; Lee, D. G.; Hwang, S.; Lee, M. J.; Park, S. H.; Bae, Y.-S.; 
Kwon, B. S. 4-1BB Signaling Enhances Primary and Secondary Population Expansion of CD8+ T 
Cells by Maximizing Autocrine IL-2/IL-2 Receptor Signaling. PLoS One 2015, 10, e0126765. 
8. Rudolf, D.; Silberzahn, T.; Walter, S.; Maurer, D.; Engelhard, J.; Wernet, D.; Bühring, H.-J.; Jung, 
G.; Kwon, B. S.; Rammensee, H.-G.; Stevanović, S. Potent Costimulation of Human CD8 T Cells 
by Anti-4-1BB and Anti-CD28 on Synthetic Artificial Antigen Presenting Cells. Cancer Immunol. 
260 
 
Immunother. 2008, 57, 175–183. 
9. Zheng, G.; Wang, B.; Chen, A. The 4-1BB Costimulation Augments the Proliferation of 
CD4+CD25+ Regulatory T Cells. J. Immunol. 2004, 173, 2428–2434. 
10. Resta, R.; Thompson, L. F. T Cell Signalling through CD73. Cell Signal 1997, 9, 131–139. 
11. Debenedette, M. A.; Shahinian, A.; Mak, T. W.; Watts, T. H. Costimulation of CD28- T 
Lymphocytes by 4-1BB Ligand. J. Immunol. 1997, 158, 551–559. 
12. Curtsinger, J. M.; Mescher, M. F. Inflammatory Cytokines as a Third Signal for T Cell Activation 
Julie. Curr Opin Immunol 2011, 22, 333–340. 
13. Lillemeier, B. F.; Mörtelmaier, M. A.; Forstner, M. B.; Huppa, J. B.; Groves, J. T.; Davis, M. M. 
TCR and Lat Are Expressed on Separate Protein Islands on T Cell Membranes and Concatenate 
during Activation. Nat. Immunol. 2010, 11, 90–96. 
14. Hashimoto-Tane, A.; Saito, T. Dynamic Regulation of TCR-Microclusters and the Microsynapse 
for T Cell Activation. Front. Immunol. 2016, 7, 1–8. 
15. Yokosuka, T.; Kobayashi, W.; Sakata-Sogawa, K.; Takamatsu, M.; Hashimoto-Tane, A.; Dustin, 
M. L.; Tokunaga, M.; Saito, T. Spatiotemporal Regulation of T Cell Costimulation by TCR-CD28 
Microclusters and Protein Kinase C Translocation. Immunity 2008, 29, 589–601. 
16. Saito, T.; Yokosuka, T.; Hashimoto-Tane, A. Dynamic Regulation of T Cell Activation and Co-
Stimulation through TCR-Microclusters. FEBS Lett. 2010, 584, 4865–4871. 
17. Dustin, M. L.; Depoil, D. New Insights into the T Cell Synapse from Single Molecule Techniques. 
Nat. Rev. Immunol. 2011, 11, 672–684. 
18. Bashour, K. T.; Tsai, J.; Shen, K.; Lee, J.-H.; Sun, E.; Milone, M. C.; Dustin, M. L.; Kam, L. C. 
Cross Talk between CD3 and CD28 Is Spatially Modulated by Protein Lateral Mobility. Mol. Cell. 
Biol. 2014, 34, 955–964. 
19. Zhu, J. T Helper Cell Differentiation, Heterogeneity, and Plasticity. Cold Spring Harb. Perspect. 
Biol. 2017, a030338. 
20. Luckheeram, R. V.; Zhou, R.; Verma, A. D.; Xia, B. CD4+T Cells: Differentiation and Functions. 
Clin. Dev. Immunol. 2012, 2012. 
21. Tesmer, L. A.; Lundy, S. K.; Sarkar, S.; Fox, D. A. Th17 Cells in Human Disease. Immunol Rev 
261 
 
2008, 223, 87–113. 
22. Josefowicz, S. Z.; Lu, L.-F.; Rudensky, A. Y. Regulatory T Cells: Mechanisms of Differentiation 
and Function. Annu. Rev. Immunol. 2012, 30, 531–564. 
23. Zhang, N.; Bevan, M. J. CD8+ T Cells: Foot Soldiers of the Immune System. Immunity 2011, 35, 
161–168. 
24. Schumacher, T. N.; Schreiber, R. D. Neoantigens in Cancer Immunotherapy. Science (80-. ). 2015, 
348, 69–74. 
25. Bobisse, S.; Foukas, P. G.; Coukos, G.; Harari, A. Neoantigen-Based Cancer Immunotherapy. Ann. 
Transl. Med. 2016, 4, 262–262. 
26. Vigneron, N. Review Article Human Tumor Antigens and Cancer Immunotherapy. Hindawi 2015, 
2015, 1–17. 
27. Vasievich, E. a; Huang, L. The Suppressive Tumor Microenvironment: A Challenge in Cancer 
Immunotherapy. Mol. Pharm. 2011, 8, 635–641. 
28. Chen, D. S.; Mellman, I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity 
2013, 39, 1–10. 
29. Snyder, A.; Makarov, V.; Merghoub, T.; Yuan, J.; Zaretsky, J. M.; Desrichard, A.; Walsh, L. a.; 
Postow, M. a.; Wong, P.; Ho, T. S.; Hollmann, T. J.; Bruggeman, C.; Kannan, K.; Li, Y.; 
Elipenahli, C.; Liu, C.; Harbison, C. T.; Wang, L.; Ribas, A.; et al. Genetic Basis for Clinical 
Response to CTLA-4 Blockade in Melanoma. N. Engl. J. Med. 2014, 371, 2189–2199. 
30. Mcgranahan, N.; Furness, A. J. S.; Rosenthal, R.; Ramskov, S.; Lyngaa, R.; Saini, S. K.; Jamal-
hanjani, M.; Wilson, G. A.; Birkbak, N. J.; Hiley, C. T.; Watkins, T. B. K.; Shafi, S.; Murugaesu, 
N.; Mitter, R.; Akarca, A. U.; Linares, J.; Marafioti, T.; Henry, J. Y.; Allen, E. M. Van. Clonal 
Neoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune Checkpoint Blockade. 
Science (80-. ). 2016, 351, 1463–1469. 
31. Germano, G.; Lamba, S.; Rospo, G.; Barault, L.; Magrì, A.; Maione, F.; Russo, M.; Crisafulli, G.; 
Bartolini, A.; Lerda, G.; Siravegna, G.; Mussolin, B.; Frapolli, R.; Montone, M.; Morano, F.; de 
Braud, F.; Amirouchene-Angelozzi, N.; Marsoni, S.; D’Incalci, M.; et al. Inactivation of DNA 
Repair Triggers Neoantigen Generation and Impairs Tumour Growth. Nature 2017, 552, 116–120. 
262 
 
32. Rabinovich, G. a; Gabrilovich, D.; Sotomayor, E. M. Immunosuppressive Strategies That Are 
Mediated by Tumor Cells. Annu. Rev. Immunol. 2007, 25, 267–296. 
33. Garrido, F.; Algarra, I. MHC Antigens and Tumor Escape from Immune Surveillance. Adv. Cancer 
Res. 2001, 83, 117–158. 
34. Baghdadi, M.; Jinushi, M. The Impact of the TIM Gene Family on Tumor Immunity and 
Immunosuppression. Cell. Mol. Immunol. 2014, 11, 41–48. 
35. Wang, Q.; Liu, F.; Liu, L. Prognostic Significance of PD-L1 in Solid Tumor: An Updated Meta-
Analysis. Medicine (Baltimore). 2017, 96. 
36. Speiser, D. E.; Utzschneider, D. T.; Oberle, S. G.; Münz, C.; Romero, P.; Zehn, D. T Cell 
Differentiation in Chronic Infection and Cancer: Functional Adaptation or Exhaustion? Nat. Rev. 
Immunol. 2014, 14, 768. 
37. Wherry, E. J. T Cell Exhaustion. Nat. Immunol. 2011, 131, 492–499. 
38. Wherry, E. J.; Kurachi, M. Molecular and Cellular Insights into T Cell Exhaustion. Nat. Rev. 
Immunol. 2015, 15, 486. 
39. Almeida, J. R.; Price, D. a; Papagno, L.; Arkoub, Z. A.; Sauce, D.; Bornstein, E.; Asher, T. E.; 
Samri, A.; Schnuriger, A.; Theodorou, I.; Costagliola, D.; Rouzioux, C.; Agut, H.; Marcelin, A.-G.; 
Douek, D.; Autran, B.; Appay, V. Superior Control of HIV-1 Replication by CD8+ T Cells Is 
Reflected by Their Avidity, Polyfunctionality, and Clonal Turnover. J. Exp. Med. 2007, 204, 2473–
2485. 
40. Barber, D. L.; Wherry, E. J.; Masopust, D.; Zhu, B.; Allison, J. P.; Sharpe, A. H.; Freeman, G. J.; 
Ahmed, R. Restoring Function in Exhausted CD8 T Cells during Chronic Viral Infection. Nature 
2006, 439, 682–687. 
41. Chiu, Y.-L. L.; Shan, L.; Huang, H.; Haupt, C.; Bessell, C.; Canaday, D. H.; Zhang, H.; Ho, Y. C.; 
Powell, J. D.; Oelke, M.; Margolick, J. B.; Blankson, J. N.; Griffin, D. E.; Schneck, J. P. Sprouty-2 
Regulates HIV-Specific T Cell Polyfunctionality. J. Clin. Invest. 2014, 124, 198–208. 
42. Buckner, J. H. Mechanisms of Impaired Regulation by CD4+ CD25+ FOXP3+ Regulatory T Cells 
in Human Autoimmune Diseases. Nat. Rev. Immunol. 2010, 10, 849. 
43. Theofilopoulos, A. N.; Kono, D. H.; Baccala, R. The Multiple Pathways to Autoimmunity. Nat. 
263 
 
Immunol. 2017, 18, 716. 
44. Wing, K.; Sakaguchi, S. Regulatory T Cells Exert Checks and Balances on Self Tolerance and 
Autoimmunity. Nat. Immunol. 2010, 11, 7. 
45. Rosenblum, M. D.; Gratz, I. K.; Paw, J. S.; Abbas, A. K. Treating Human Autoimmunity: Current 
Practice and Future Prospects. Sci. Transl. Med. 2012, 4, 125sr1-125sr1. 
46. Perica, K.; Kosmides, A. K.; Schneck, J. P. Linking Form to Function: Biophysical Aspects of 
Artificial Antigen Presenting Cell Design. Biochim. Biophys. Acta 2015, 1853, 781–790. 
47. Birnbaum, M. E.; Berry, R.; Hsiao, Y.-S.; Chen, Z.; Shingu-Vazquez, M. A.; Yu, X.; Waghray, D.; 
Fischer, S.; McCluskey, J.; Rossjohn, J.; Walz, T.; Garcia, K. C. Molecular Architecture of the Αβ 
T Cell Receptor–CD3 Complex. Proc. Natl. Acad. Sci. 2014, 111, 17576–17581. 
48. Chen, L.; Flies, D. B. Molecular Mechanisms of T Cell Co-Stimulation and Co-Inhibition. Nat. 
Rev. Immunol. 2013, 13, 227–242. 
49. Shuford, W. W.; Klussman, K.; Tritchler, D. D.; Loo, D. T.; Chalupny, J.; Siadak,  a W.; Brown, T. 
J.; Emswiler, J.; Raecho, H.; Larsen, C. P.; Pearson, T. C.; Ledbetter, J. a; Aruffo, A.; Mittler, R. S. 
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the 
Amplification in Vivo of Cytotoxic T Cell Responses. J. Exp. Med. 1997, 186, 47–55. 
50. Okazaki, T.; Chikuma, S.; Iwai, Y.; Fagarasan, S.; Honjo, T. A Rheostat for Immune Responses: 
The Unique Properties of PD-1 and Their Advantages for Clinical Application. Nat. Immunol. 
2013, 14, 1212–1218. 
51. Postow, M. A.; Chesney, J.; Pavlick, A. C.; Robert, C.; Grossmann, K.; McDermott, D.; Linette, G. 
P.; Meyer, N.; Giguere, J. K.; Agarwala, S. S.; Shaheen, M.; Ernstoff, M. S.; Minor, D.; Salama, A. 
K.; Taylor, M.; Ott, P. A.; Rollin, L. M.; Horak, C.; Gagnier, P.; et al. Nivolumab and Ipilimumab 
versus Ipilimumab in Untreated Melanoma. N. Engl. J. Med. 2015, 372, 2006–2017. 
52. Callahan, M. K.; Wolchok, J. D. At the Bedside: CTLA-4- and PD-1-Blocking Antibodies in 
Cancer Immunotherapy. J. Leukoc. Biol. 2013, 94, 41–53. 
53. Spranger, S.; Koblish, H. K.; Horton, B.; Scherle, P. a; Newton, R.; Gajewski, T. F. Mechanism of 
Tumor Rejection with Doublets of CTLA-4, PD-1/PD-L1, or IDO Blockade Involves Restored IL-2 
Production and Proliferation of CD8(+) T Cells Directly within the Tumor Microenvironment. J. 
264 
 
Immunother. cancer 2014, 2, 3. 
54. Chen, S.; Lee, L.-F.; Fisher, T. S.; Jessen, B.; Elliott, M.; Evering, W.; Logronio, K.; Tu, G. H.; 
Tsaparikos, K.; Li, X.; Wang, H.; Ying, C.; Xiong, M.; VanArsdale, T.; Lin, J. C. Combination of 
4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a 
Poorly Immunogenic Tumor Model. Cancer Immunol. Res. 2014, 3, 149–160. 
55. Shindo, Y.; Yoshimura, K.; Kuramasu, A.; Watanabe, Y.; Ito, H. H.; Kondo, T.; Oga, A.; Ito, H. 
H.; Yoshino, S.; Hazama, S.; Tamada, K.; Yagita, H.; Oka, M. Combination Immunotherapy with 
4-1BB Activation and PD-1 Blockade Enhances Antitumor Efficacy in a Mouse Model of 
Subcutaneous Tumor. Anticancer Res 2015, 35, 129–136. 
56. Vezys, V.; Penaloza-macmaster, P.; Barber, D. L.; Ha, S.-J.; Konieczny, B.; Freeman, G. J.; 
Mittler, R. S.; Ahmed, R. 4-1BB Signaling Synergizes with Programmed Death Ligand 1 Blockade 
to Augment CD8 T Cell Responses during Chronic Viral Infection. J. Immunol. 2011, 187, 1634–
1642. 
57. Doh, J.; Irvine, D. J. Immunological Synapse Arrays: Patterned Protein Surfaces That Modulate 
Immunological Synapse Structure Formation in T Cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 
5700–5705. 
58. Delcassian, D.; Depoil, D.; Rudnicka, D.; Liu, M.; Davis, D. M.; Dustin, M. L.; Dunlop, I. E. 
Nanoscale Ligand Spacing Influences Receptor Triggering in T Cells and NK Cells. Nano Lett. 
2013, 13, 5608–5614. 
59. Matic, J.; Deeg, J.; Scheffold, A.; Goldstein, I.; Spatz, J. P. Fine Tuning and Efficient T Cell 
Activation with Stimulatory ACD3 Nanoarrays. Nano Lett. 2013, 13, 5090–5097. 
60. Deeg, J.; Axmann, M.; Matic, J.; Liapis, A.; Depoil, D.; Afrose, J.; Curado, S.; Dustin, M. L.; 
Spatz, J. P. T Cell Activation Is Determined by the Number of Presented Antigens. Nano Lett. 
2013, 13, 5619–5626. 
61. Yokosuka, T.; Takamatsu, M.; Kobayashi-Imanishi, W.; Hashimoto-Tane, A.; Azuma, M.; Saito, 
T. Programmed Cell Death 1 Forms Negative Costimulatory Microclusters That Directly Inhibit T 
Cell Receptor Signaling by Recruiting Phosphatase SHP2. J. Exp. Med. 2012, 209, 1201–1217. 
62. Hui, E.; Cheung, J.; Zhu, J.; Su, X.; Taylor, M. J.; Wallweber, H. A.; Sasmal, D. K.; Huang, J.; 
265 
 
Kim, J. M.; Mellman, I.; Vale, R. D. T Cell Costimulatory Receptor CD28 Is a Primary Target for 
PD-1–mediated Inhibition. Science (80-. ). 2017, 355, 1428–1433. 
63. Stephan, M. T.; Ponomarev, V.; Brentjens, R. J.; Chang, A. H.; Dobrenkov, K. V; Heller, G.; 
Sadelain, M. T Cell-Encoded CD80 and 4-1BBL Induce Auto- and Transcostimulation, Resulting 
in Potent Tumor Rejection. Nat. Med. 2007, 13, 1440–1449. 
64. Tsai, S.; Shameli, A.; Yamanouchi, J.; Clemente-Casares, X.; Wang, J.; Serra, P.; Yang, Y.; 
Medarova, Z.; Moore, A.; Santamaria, P. Reversal of Autoimmunity by Boosting Memory-like 
Autoregulatory T Cells. Immunity 2010, 32, 568–580. 
65. Fooksman, D. R.; Vardhana, S.; Vasiliver-Shamis, G.; Liese, J.; Blair, D. A.; Waite, J.; Sacristán, 
C.; Victora, G. D.; Zanin-Zhorov, A.; Dustin, M. L. Functional Anatomy of T Cell Activation and 
Synapse Formation. Annu. Rev. Immunol. 2009, 28, 79–105. 
66. Varma, R.; Campi, G.; Yokosuka, T.; Saito, T.; Dustin, M. L. T Cell Receptor-Proximal Signals 
Are Sustained in Peripheral Microclusters and Terminated in the Central Supramolecular 
Activation Cluster. Immunity 2006, 25, 117–127. 
67. Fahmy, T. M.; Bieler, J. G.; Edidin, M.; Schneck, J. P. Increased TCR Avidity after T Cell 
Activation: A Mechanism for Sensing Low-Density Antigen. Immunity 2001, 14, 135–143. 
68. Bosch, B.; Heipertz, E. L.; Drake, J. R.; Roche, P. A. Major Histocompatibility Complex (MHC) 
Class II-Peptide Complexes Arrive at the Plasma Membrane in Cholesterol-Rich Microclusters. J. 
Biol. Chem. 2013, 288, 13236–13242. 
69. Hwang, J.; Gheber, L. A.; Margolis, L.; Edidin, M. Domains in Cell Plasma Membranes 
Investigated by Near-Field Scanning Optical Microscopy. Biophys. J. 1998, 74, 2184–2190. 
70. Ferez, M.; Castro, M.; Alarcon, B.; van Santen, H. M. Cognate Peptide–MHC Complexes Are 
Expressed as Tightly Apposed Nanoclusters in Virus-Infected Cells to Allow TCR Crosslinking. J. 
Immunol. 2014, 192, 52–58. 
71. Lu, X.; Gibbs, J. S.; Hickman, H. D.; David, A.; Dolan, B. P.; Jin, Y.; Kranz, D. M.; Bennink, J. R.; 
Yewdell, J. W.; Varma, R. Endogenous Viral Antigen Processing Generates Peptide-Specific MHC 
Class I Cell-Surface Clusters. Proc. Natl. Acad. Sci. 2012, 109, 15407–15412. 
72. Matsui, K.; Boniface, J. J.; Reay, P. A.; Schild, H.; Groth, B. F. de S.; Davis, M. M. Low Affinity 
266 
 
Interaction of Peptide-MHC Complexes with T Cell Receptors. Science (80-. ). 1991, 254, 1788–
1792. 
73. Lever, M.; Maini, P. K.; van der Merwe, P. A.; Dushek, O. Phenotypic Models of T Cell 
Activation. Nat. Rev. Immunol. 2014, 14, 619–629. 
74. Bousso, P. T-Cell Activation by Dendritic Cells in the Lymph Node: Lessons from the Movies. 
Nat. Rev. Immunol. 2008, 8, 675–684. 
75. Huppa, J. B.; Gleimer, M.; Sumen, C.; Davis, M. M. Continuous T Cell Receptor Signaling 
Required for Synapse Maintenance and Full Effector Potential. Nat. Immunol. 2003, 4, 749–755. 
76. Iezzi, G.; Karjalainen, K.; Lanzavecchia, A. The Duration of Antigenic Stimulation Determines the 
Fate of Naive and Effector T Cells. Immunity 1998, 8, 89–95. 
77. Celli, S.; Lemaître, F.; Bousso, P. Real-Time Manipulation of T Cell-Dendritic Cell Interactions in 
Vivo Reveals the Importance of Prolonged Contacts for CD4+ T Cell Activation. Immunity 2007, 
27, 625–634. 
78. Fooksman, D. R.; Grönvall, G. K.; Tang, Q.; Edidin, M. Clustering Class I MHC Modulates 
Sensitivity of T Cell Recognition. J. Immunol. 2006, 176, 6673–6680. 
79. Bullock, T. N. J.; Mullins, D. W.; Engelhard, V. H. Antigen Density Presented by Dendritic Cells 
in Vivo Differentially Affects the Number and Avidity of Primary, Memory, and Recall CD8+ T 
Cells. J. Immunol. 2003, 170, 1822–1829. 
80. Manz, B. N.; Jackson, B. L.; Petit, R. S.; Dustin, M. L.; Groves, J. T-Cell Triggering Thresholds 
Are Modulated by the Number of Antigen within Individual T-Cell Receptor Clusters. Proc. Natl. 
Acad. Sci. 2011, 108, 9089–9094. 
81. Bromley, S. K.; Iaboni, A.; Davis, S. J.; Whitty, A.; Green, J. M.; Shaw, A. S.; Weiss, A.; Dustin, 
M. L. The Immunological Synapse and CD28-CD80 Interactions. Nat. Immunol. 2001, 2, 1159–
1166. 
82. Hickey, J. W.; Santos, J. L.; Williford, J.-M.; Mao, H.-Q. Control of Polymeric Nanoparticle Size 
to Improve Therapeutic Delivery. J. Control. Release 2015, 219, 536–547. 
83. Monopoli, M. P.; Åberg, C.; Salvati, A.; Dawson, K. A. Biomolecular Coronas Provide the 
Biological Identity of Nanosized Materials. Nat. Nanotechnol. 2012, 7, 779–786. 
267 
 
84. Nel, A. E.; Mädler, L.; Velegol, D.; Xia, T.; Hoek, E. M. V; Somasundaran, P.; Klaessig, F.; 
Castranova, V.; Thompson, M. Understanding Biophysicochemical Interactions at the Nano–bio 
Interface. Nat. Mater. 2009, 8, 543–557. 
85. Tenzer, S.; Docter, D.; Kuharev, J.; Musyanovych, A.; Fetz, V.; Hecht, R.; Schlenk, F.; Fischer, D.; 
Kiouptsi, K.; Reinhardt, C. Rapid Formation of Plasma Protein Corona Critically Affects 
Nanoparticle Pathophysiology. Nat. Nanotechnol. 2013, 8, 772–781. 
86. Albanese, A.; Tang, P. S.; Chan, W. C. W. The Effect of Nanoparticle Size, Shape, and Surface 
Chemistry on Biological Systems. Annu. Rev. Biomed. Eng. 2012, 14, 1–16. 
87. Shang, L.; Nienhaus, K.; Nienhaus, G. U. Engineered Nanoparticles Interacting with Cells: Size 
Matters. J. Nanobiotechnology 2014, 12, 5. 
88. Gratton, S. E. a; Ropp, P. a; Pohlhaus, P. D.; Luft, J. C.; Madden, V. J.; Napier, M. E.; DeSimone, 
J. M. The Effect of Particle Design on Cellular Internalization Pathways. Proc. Natl. Acad. Sci. U. 
S. A. 2008, 105, 11613–11618. 
89. Shann, S. Y.; Lau, C. M.; Thomas, S. N.; Jerome, W. G.; Maron, D. J.; Dickerson, J. H.; Hubbell, J. 
A.; Giorgio, T. D. Size-and Charge-Dependent Non-Specific Uptake of PEGylated Nanoparticles 
by Macrophages. Int. J. Nanomedicine 2012, 7, 799. 
90. Yuan, H.; Li, J.; Bao, G.; Zhang, S. Variable Nanoparticle-Cell Adhesion Strength Regulates 
Cellular Uptake. Phys. Rev. Lett. 2010, 105, 138101. 
91. Lai, S. K.; Hida, K.; Man, S. T.; Chen, C.; Machamer, C.; Schroer, T. A.; Hanes, J. Privileged 
Delivery of Polymer Nanoparticles to the Perinuclear Region of Live Cells via a Non-Clathrin, 
Non-Degradative Pathway. Biomaterials 2007, 28, 2876–2884. 
92. Rejman, J.; Oberle, V.; Zuhorn, I. S.; Hoekstra, D. Size-Dependent Internalization of Particles via 
the Pathways of Clathrin- and Caveolae-Mediated Endocytosis. Biochem. J. 2004, 377, 159–169. 
93. Kettiger, H.; Schipanski, A.; Wick, P.; Huwyler, J. Engineered Nanomaterial Uptake and Tissue 
Distribution: From Cell to Organism. Int. J. Nanomedicine 2013, 8, 3255. 
94. Conner, S. D.; Schmid, S. L. Regulated Portals of Entry into the Cell. Nature 2003, 422, 37–44. 
95. Zauner, W.; Farrow, N. A.; Haines, A. M. R. In Vitro Uptake of Polystyrene Microspheres: Effect 
of Particle Size, Cell Line and Cell Density. J. Control. Release 2001, 71, 39–51. 
268 
 
96. Choi, J.-S.; Cao, J.; Naeem, M.; Noh, J.; Hasan, N.; Choi, H.-K.; Yoo, J.-W. Size-Controlled 
Biodegradable Nanoparticles: Preparation and Size-Dependent Cellular Uptake and Tumor Cell 
Growth Inhibition. Colloids Surfaces B Biointerfaces 2014, 122, 545–551. 
97. Gao, H.; Shi, W.; Freund, L. B. Mechanics of Receptor-Mediated Endocytosis. Proc. Natl. Acad. 
Sci. U. S. A. 2005, 102, 9469–9474. 
98. Zhang, S.; Li, J.; Lykotrafitis, G.; Bao, G.; Suresh, S. Size‐dependent Endocytosis of Nanoparticles. 
Adv. Mater. 2009, 21, 419–424. 
99. Narayanan, K.; Yen, S. K.; Dou, Q.; Padmanabhan, P.; Sudhaharan, T.; Ahmed, S.; Ying, J. Y.; 
Selvan, S. T. Mimicking Cellular Transport Mechanism in Stem Cells through Endosomal Escape 
of New Peptide-Coated Quantum Dots. Sci. Rep. 2013, 3. 
100. Jung, Y.; Park, H.-J.; Kim, P.-H.; Lee, J.; Hyung, W.; Yang, J.; Ko, H.; Sohn, J.-H.; Kim, J.-H.; 
Huh, Y.-M. Retargeting of Adenoviral Gene Delivery via Herceptin–PEG–adenovirus Conjugates 
to Breast Cancer Cells. J. Control. release 2007, 123, 164–171. 
101. Smith, T. T.; Stephan, S. B.; Moffett, H. F.; McKnight, L. E.; Ji, W.; Reiman, D.; Bonagofski, E.; 
Wohlfahrt, M. E.; Pillai, S. P. S.; Stephan, M. T. In Situ Programming of Leukaemia-Specific T 
Cells Using Synthetic DNA Nanocarriers. Nat. Nanotechnol. 2017, 12, 813. 
102. Oelke, M.; Maus, M. V; Didiano, D.; June, C. H.; Mackensen, A.; Schneck, J. P. Ex Vivo Induction 
and Expansion of Antigen-Specific Cytotoxic T Cells by HLA-Ig-Coated Artificial Antigen-
Presenting Cells. Nat. Med. 2003, 9, 619–624. 
103. Hickey, J. W.; Vicente, F. P.; Howard, G. P.; Mao, H.-Q.; Schneck, J. P. Biologically Inspired 
Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation. Nano Lett. 
2017, 17. 
104. Franz, S.; Rammelt, S.; Scharnweber, D.; Simon, J. C. Immune Responses to Implants–a Review of 
the Implications for the Design of Immunomodulatory Biomaterials. Biomaterials 2011, 32, 6692–
6709. 
105. Veiseh, O.; Doloff, J. C.; Ma, M.; Vegas, A. J.; Tam, H. H.; Bader, A. R.; Li, J.; Langan, E.; 
Wyckoff, J.; Loo, W. S. Size-and Shape-Dependent Foreign Body Immune Response to Materials 
Implanted in Rodents and Non-Human Primates. Nat. Mater. 2015, 14, 643–651. 
269 
 
106. Gong, C.; Linderman, J. J.; Kirschner, D. Harnessing the Heterogeneity of T Cell Differentiation 
Fate to Fine-Tune Generation of Effector and Memory T Cells. Front. Immunol. 2014, 5. 
107. Jain, R. K.; Stylianopoulos, T. Delivering Nanomedicine to Solid Tumors. Nat. Rev. Clin. Oncol. 
2010, 7, 653–664. 
108. Irvine, D. J.; Swartz, M. A.; Szeto, G. L. Engineering Synthetic Vaccines Using Cues from Natural 
Immunity. Nat. Mater. 2013, 12, 978–990. 
109. Reddy, S. T.; Van Der Vlies, A. J. A. J.; Simeoni, E.; Angeli, V.; Randolph, G. J.; O’Neil, C. P.; 
Lee, L. K.; Swartz, M. A.; Hubbell, J. A. Exploiting Lymphatic Transport and Complement 
Activation in Nanoparticle Vaccines. Nat. Biotechnol. 2007, 25, 1159–1164. 
110. Hirosue, S.; Dubrot, J. Modes of Antigen Presentation by Lymph Node Stromal Cells and Their 
Immunological Implications. Front. Immunol. 2015, 6. 
111. Norris, D. A.; Puri, N.; Sinko, P. J. The Effect of Physical Barriers and Properties on the Oral 
Absorption of Particulates. Adv. Drug Deliv. Rev. 1998, 34, 135–154. 
112. Champion, J. a; Mitragotri, S. Role of Target Geometry in Phagocytosis. Proc. Natl. Acad. Sci. U. 
S. A. 2006, 103, 4930–4934. 
113. Sharma, G.; Valenta, D. T.; Altman, Y.; Harvey, S.; Xie, H.; Mitragotri, S.; Smith, J. W. Polymer 
Particle Shape Independently Influences Binding and Internalization by Macrophages. J. Control. 
Release 2010, 147, 408–412. 
114. Yoo, J.-W.; Mitragotri, S. Polymer Particles That Switch Shape in Response to a Stimulus. Proc. 
Natl. Acad. Sci. U. S. A. 2010, 107, 11205–11210. 
115. Barua, S.; Yoo, J.-W.; Kolhar, P.; Wakankar, A.; Gokarn, Y. R.; Mitragotri, S. Particle Shape 
Enhances Specificity of Antibody-Displaying Nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2013, 
110, 3270–3275. 
116. Sunshine, J. C.; Perica, K.; Schneck, J. P.; Green, J. J. Particle Shape Dependence of CD8+ T Cell 
Activation by Artificial Antigen Presenting Cells. Biomaterials 2014, 35, 269–277. 
117. Meyer, R. a.; Sunshine, J. C.; Perica, K.; Kosmides, A. K.; Aje, K.; Schneck, J. P.; Green, J. J. 
Biodegradable Nanoellipsoidal Artificial Antigen Presenting Cells for Antigen Specific T-Cell 
Activation. Small 2014, 11, 1519–1525. 
270 
 
118. Andorko, J. I.; Jewell, C. M. Designing Biomaterials with Immunomodulatory Properties for Tissue 
Engineering and Regenerative Medicine. Bioeng. Transl. Med. 2017, 2, 139–155. 
119. Torchilin, V. P.; Trubetskoy, V. S. Which Polymers Can Make Nanoparticulate Drug Carriers 
Long-Circulating? Adv. Drug Deliv. Rev. 1995, 16, 141–155. 
120. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-
Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of Functionalized PLGA–PEG 
Nanoparticles for in Vivo Targeted Drug Delivery. Biomaterials 2007, 28, 869–876. 
121. Xu, Q.; Ensign, L. M.; Boylan, N. J.; Schön, A.; Gong, X.; Yang, J.-C.; Lamb, N. W.; Cai, S.; Yu, 
T.; Freire, E. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle 
Transport in Mucus Ex Vivo and Distribution in Vivo. ACS Nano 2015, 9, 9217–9227. 
122. Duncan, R. Polymer Conjugates as Anticancer Nanomedicines. Nat. Rev. cancer 2006, 6, 688. 
123. Safra, T.; Muggia, F.; Jeffers, S.; Tsao-Wei, D. D.; Groshen, S.; Lyass, O.; Henderson, R.; Berry, 
G.; Gabizon, A. Pegylated Liposomal Doxorubicin (Doxil): Reduced Clinical Cardiotoxicity in 
Patients Reaching or Exceeding Cumulative Doses of 500 Mg/M2. Ann. Oncol. 2000, 11, 1029–
1033. 
124. Torchilin, V. P. Recent Advances with Liposomes as Pharmaceutical Carriers. Nat. Rev. Drug 
Discov. 2005, 4, 145. 
125. Hu, C.-M. J.; Zhang, L.; Aryal, S.; Cheung, C.; Fang, R. H.; Zhang, L. Erythrocyte Membrane-
Camouflaged Polymeric Nanoparticles as a Biomimetic Delivery Platform. Proc. Natl. Acad. Sci. 
2011, 108, 10980–10985. 
126. Fang, R. H.; Hu, C.-M. J.; Luk, B. T.; Gao, W.; Copp, J. A.; Tai, Y.; O’Connor, D. E.; Zhang, L. 
Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery. Nano 
Lett. 2014, 14, 2181–2188. 
127. Parodi, A.; Quattrocchi, N.; Van De Ven, A. L.; Chiappini, C.; Evangelopoulos, M.; Martinez, J. 
O.; Brown, B. S.; Khaled, S. Z.; Yazdi, I. K.; Enzo, M. V. Synthetic Nanoparticles Functionalized 
with Biomimetic Leukocyte Membranes Possess Cell-like Functions. Nat. Nanotechnol. 2013, 8, 
61. 
128. Oldenborg, P.-A.; Zheleznyak, A.; Fang, Y.-F.; Lagenaur, C. F.; Gresham, H. D.; Lindberg, F. P. 
271 
 
Role of CD47 as a Marker of Self on Red Blood Cells. Science (80-. ). 2000, 288, 2051–2054. 
129. Rodriguez, P. L.; Harada, T.; Christian, D. A.; Pantano, D. A.; Tsai, R. K.; Discher, D. E. Minimal" 
Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles. Science 
(80-. ). 2013, 339, 971–975. 
130. Liu, H.; Moynihan, K. D.; Zheng, Y.; Szeto, G. L.; Li, A. V.; Huang, B.; Van Egeren, D. S.; Park, 
C.; Irvine, D. J. Structure-Based Programming of Lymph-Node Targeting in Molecular Vaccines. 
Nature 2014, 507, 519–522. 
131. Burdick, J. A.; Anseth, K. S. Photoencapsulation of Osteoblasts in Injectable RGD-Modified PEG 
Hydrogels for Bone Tissue Engineering. Biomaterials 2002, 23, 4315–4323. 
132. Discher, D. E.; Mooney, D. J.; Zandstra, P. W. Growth Factors, Matrices, and Forces Combine and 
Control Stem Cells. Science (80-. ). 2009, 324, 1673–1677. 
133. Humphrey, J. D.; Dufresne, E. R.; Schwartz, M. A. Mechanotransduction and Extracellular Matrix 
Homeostasis. Nat. Rev. Mol. cell Biol. 2014, 15, 802. 
134. Jaalouk, D. E.; Lammerding, J. Mechanotransduction Gone Awry. Nat. Rev. Mol. cell Biol. 2009, 
10, 63. 
135. Huse, M. Mechanical Forces in the Immune System. Nat. Rev. Immunol. 2017, 17, 679. 
136. Kim, S. T.; Takeuchi, K.; Sun, Z.-Y. J.; Touma, M.; Castro, C. E.; Fahmy, A.; Lang, M. J.; 
Wagner, G.; Reinherz, E. L. The Αβ T Cell Receptor Is an Anisotropic Mechanosensor. J. Biol. 
Chem. 2009, 284, 31028–31037. 
137. Liu, B.; Chen, W.; Evavold, B. D.; Zhu, C. Accumulation of Dynamic Catch Bonds between TCR 
and Agonist Peptide-MHC Triggers T Cell Signaling. Cell 2014, 157, 357–368. 
138. Das, D. K.; Feng, Y.; Mallis, R. J.; Li, X.; Keskin, D. B.; Hussey, R. E.; Brady, S. K.; Wang, J.-H.; 
Wagner, G.; Reinherz, E. L. Force-Dependent Transition in the T-Cell Receptor β-Subunit 
Allosterically Regulates Peptide Discrimination and PMHC Bond Lifetime. Proc. Natl. Acad. Sci. 
2015, 112, 1517–1522. 
139. Basu, R.; Huse, M. Mechanical Communication at the Immunological Synapse. Trends Cell Biol. 
2017, 27, 241–254. 
140. Comrie, W. A.; Li, S.; Boyle, S.; Burkhardt, J. K. The Dendritic Cell Cytoskeleton Promotes T Cell 
272 
 
Adhesion and Activation by Constraining ICAM-1 Mobility. J Cell Biol 2015, 208, 457–473. 
141. Andorko, J. I.; Hess, K. L.; Pineault, K. G.; Jewell, C. M. Intrinsic Immunogenicity of Rapidly-
Degradable Polymers Evolves during Degradation. Acta Biomater. 2016, 32, 24–34. 
142. Lu, Y.; Aimetti, A. A.; Langer, R.; Gu, Z. Bioresponsive Materials. Nat. Rev. Mater. 2017, 2, 
16075. 
143. Baeza, A.; Colilla, M.; Vallet-Regí, M. Advances in Mesoporous Silica Nanoparticles for Targeted 
Stimuli-Responsive Drug Delivery. Expert Opin. Drug Deliv. 2015, 12, 319–337. 
144. Meng, F.; Hennink, W. E.; Zhong, Z. Reduction-Sensitive Polymers and Bioconjugates for 
Biomedical Applications. Biomaterials 2009, 30, 2180–2198. 
145. Callmann, C. E.; Barback, C. V; Thompson, M. P.; Hall, D. J.; Mattrey, R. F.; Gianneschi, N. C. 
Therapeutic Enzyme‐Responsive Nanoparticles for Targeted Delivery and Accumulation in 
Tumors. Adv. Mater. 2015, 27, 4611–4615. 
146. Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-Responsive Nanocarriers for Drug Delivery. Nat. Mater. 
2013, 12, 991. 
147. Korin, N.; Kanapathipillai, M.; Matthews, B. D.; Crescente, M.; Brill, A.; Mammoto, T.; Ghosh, 
K.; Jurek, S.; Bencherif, S. A.; Bhatta, D. Shear-Activated Nanotherapeutics for Drug Targeting to 
Obstructed Blood Vessels. Science (80-. ). 2012, 1217815. 
148. Schmaljohann, D. Thermo-and PH-Responsive Polymers in Drug Delivery. Adv. Drug Deliv. Rev. 
2006, 58, 1655–1670. 
149. Chertok, B.; Moffat, B. A.; David, A. E.; Yu, F.; Bergemann, C.; Ross, B. D.; Yang, V. C. Iron 
Oxide Nanoparticles as a Drug Delivery Vehicle for MRI Monitored Magnetic Targeting of Brain 
Tumors. Biomaterials 2008, 29, 487–496. 
150. Kumar, C. S. S. R.; Mohammad, F. Magnetic Nanomaterials for Hyperthermia-Based Therapy and 
Controlled Drug Delivery. Adv. Drug Deliv. Rev. 2011, 63, 789–808. 
151. Tong, R.; Hemmati, H. D.; Langer, R.; Kohane, D. S. Photoswitchable Nanoparticles for Triggered 
Tissue Penetration and Drug Delivery. J. Am. Chem. Soc. 2012, 134, 8848–8855. 
152. Han, G.; You, C.; Kim, B.; Turingan, R. S.; Forbes, N. S.; Martin, C. T.; Rotello, V. M. Light‐
regulated Release of DNA and Its Delivery to Nuclei by Means of Photolabile Gold Nanoparticles. 
273 
 
Angew. Chemie 2006, 118, 3237–3241. 
153. Javadi, M.; Pitt, W. G.; Belnap, D. M.; Tsosie, N. H.; Hartley, J. M. Encapsulating Nanoemulsions 
inside ELiposomes for Ultrasonic Drug Delivery. Langmuir 2012, 28, 14720–14729. 
154. Wang, C.-H.; Kang, S.-T.; Lee, Y.-H.; Luo, Y.-L.; Huang, Y.-F.; Yeh, C.-K. Aptamer-Conjugated 
and Drug-Loaded Acoustic Droplets for Ultrasound Theranosis. Biomaterials 2012, 33, 1939–1947. 
155. De Jong, W. H.; Borm, P. J. A. Drug Delivery and Nanoparticles: Applications and Hazards. Int. J. 
Nanomedicine 2008, 3, 133. 
156. Bobo, D.; Robinson, K. J.; Islam, J.; Thurecht, K. J.; Corrie, S. R. Nanoparticle-Based Medicines: 
A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm. Res. 2016, 33, 2373–
2387. 
157. Aguado, B. A.; Grim, J. C.; Rosales, A. M.; Watson-Capps, J. J.; Anseth, K. S. Engineering 
Precision Biomaterials for Personalized Medicine. Sci. Transl. Med. 2018, 10, eaam8645. 
158. Lurie, N.; Slater, J.; McGovern, P.; Ekstrum, J.; Quam, L.; Margolis, K. A Progress Report on the 
Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and 
Interleukin-2 of High-Dose Interleukin-2 Alone. N. Engl. J. Med. 1993, 329, 478–482. 
159. Rosenberg, S. A. IL-2: The First Effective Immunotherapy for Human Cancer. J. Immunol. 2014, 
192, 5451–5458. 
160. Malek, T. R.; Castro, I. Interleukin-2 Receptor Signaling: At the Interface between Tolerance and 
Immunity. Immunity 2010, 33, 153–165. 
161. Krieg, C.; Letourneau, S.; Pantaleo, G.; Boyman, O. Improved IL-2 Immunotherapy by Selective 
Stimulation of IL-2 Receptors on Lymphocytes and Endothelial Cells. Proc. Natl. Acad. Sci. 2010, 
107, 11906–11911. 
162. Levin, A. M.; Bates, D. L.; Ring, A. M.; Krieg, C.; Lin, J. T.; Su, L.; Moraga, I. L.; Raeber, M. E.; 
Bowman, G. R.; Novick, P.; Pande, V. S.; Fathman, C. G.; Boyman, O.; Garcia, K. C.; Vijay, S.; 
Fathman, C. G.; Boyman, O.; Garcia, K. C. Exploiting a Natural Conformational Switch to 
Engineer an Interleukin-2 “Superkine.” Nature 2012, 484, 529–533. 
163. Mitra, S.; Ring, A. M.; Amarnath, S.; Spangler, J. B.; Li, P.; Ju, W.; Fishcer, S.; Oh, J.; Spolski, R.; 
Weiskopf, K.; Kohrt, H.; Foley, J. E.; Rajagopalan, S.; Long, E. O.; Fowler, D. H.; Waldmann, T. 
274 
 
A.; Garcia, K. C.; Leonard, W. J. Interleukin-2 Activity Can Be Fine-Tuned with Engineered 
Receptor Signaling Clamps. Immunity 2015, 42, 826–838. 
164. Mishra, A.; Sullivan, L.; Caligiuri, M. A. Molecular Pathways: Interleukin-15 Signaling in Health 
and in Cancer. Clin Cancer Res 2014, 20, 2044–2050. 
165. Rubinstein, M. P.; Kovar, M.; Purton, J. F.; Cho, J.-H.; Boyman, O.; Surh, C. D.; Sprent, J. 
Converting IL-15 to a Superagonist by Binding to Soluble IL-15Ra. Proc. Natl. Acad. Sci. U. S. A. 
2006, 103, 9166–9171. 
166. Zhu, X.; Marcus, W. D.; Xu, W.; Lee, H.-I.; Han, K.; Egan, J. O.; Yovandich, J. L.; Rhode, P. R.; 
Wong, H. c. Novel Human Interleukin-15 Agonists. J Immunol 2009, 183, 1–27. 
167. Bailey, C. P.; Budak-Alpdogan, T.; Sauter, C. T.; Panis, M. M.; Buyukgoz, C.; Jeng, E. K.; Wong, 
H. C.; Flomenberg, N.; Alpdogan, O. New Interleukin-15 Superagonist (IL-15SA) Significantly 
Enhances Graft-versus-Tumor Activity. Oncotarget 2017, 8, 44366–44378. 
168. Neri, D.; Sondel, P. M. Immunocytokines for Cancer Treatment: Past, Present and Future. Curr 
Opin Immunol 2016, 40, 96–102. 
169. Müller, D. Antibody-Cytokine Fusion Proteins for Cancer Immunotherapy: An Update on Recent 
Developments. BioDrugs 2014, 28, 123–131. 
170. Carnemolla, B.; Borsi, L.; Balza, E.; Castellani, P.; Meazza, R.; Berndt, A.; Ferrini, S.; Kosmehl, 
H.; Neri, D.; Zardi, L. Enhancement of the Antitumor Properties of Interleukin-2 by Its Targeted 
Delivery to the Tumor Blood Vessel Extracellular Matrix Enhancement of the Antitumor Properties 
of Interleukin-2 by Its Targeted Delivery to the Tumor Blood Vessel Extracellular Matr. 2013, 99, 
1659–1665. 
171. Liu, B.; Kong, L.; Han, K.; Hong, H.; Marcus, W. D.; Chen, X.; Jeng, E. K.; Alter, S.; Zhu, X.; 
Rubinstein, M. P.; Shi, S.; Rhode, P. R.; Cai, W.; Wong, H. C. A Novel Fusion of ALT-803 
(Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-Specific Antitumor 
Responses. J. Biol. Chem. 2016, 291, 23869–23881. 
172. Vincent, M.; Teppaz, G.; Lajoie, L.; Solé, V.; Bessard, A.; Maillasson, M.; Loisel, S.; Béchard, D.; 
Clémenceau, B.; Thibault, G.; Garrigue-Antar, L.; Jacques, Y.; Quéméner, A. Highly Potent Anti-
CD20-RLI Immunocytokine Targeting Established Human B Lymphoma in SCID Mouse. MAbs 
275 
 
2014, 6, 1026–1037. 
173. Kawalkowska, J. Z.; Hemmerle, T.; Pretto, F.; Matasci, M.; Neri, D.; Williams, R. O. Targeted IL-
4 Therapy Synergizes with Dexamethasone to Induce a State of Tolerance by Promoting Treg Cells 
and Macrophages in Mice with Arthritis. Eur. J. Immunol. 2016, 46, 1246–1257. 
174. Fallon, J. K.; Vandeveer, A. J.; Schlom, J.; Greiner, J. W. Enhanced Antitumor Effects by 
Combining an IL-12/Anti-DNA Fusion Protein with Avelumab, an Anti-PD-L1 Antibody. 
Oncotarget 2017, 8, 20558–20571. 
175. Chen, X.; Xu, J.; Guo, Q.; Wang, L.; Yang, Y.; Guo, H.; Gu, N.; Zhang, D.; Qian, W.; Hou, S.; Li, 
J.; Dai, J.; Guo, Y.; Wang, H. Therapeutic Efficacy of an Anti-PD-L1 Antibody Based 
Immunocytokine in a Metastatic Mouse Model of Colorectal Cancer. Biochem. Biophys. Res. 
Commun. 2016, 480, 160–165. 
176. Kamath, A. V. Translational Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies. 
Drug Discov. Today Technol. 2016, 21–22, 75–83. 
177. Almagro, J. C.; Daniels-wells, T. R.; Perez-tapia, S. M.; Penichet, M. L. Progress and Challenges in 
the Design and Clinical Development of Antibodies for Cancer Therapy. Front. Immunol. 2018, 8. 
178. Chiu, M. L.; Gilliland, G. L. Engineering Antibody Therapeutics. Curr. Opin. Struct. Biol. 2016, 
38, 163–173. 
179. Sanchez-Martin, D.; Sorensen, M. D.; Lykkemark, S.; Sanz, L.; Kristensen, P.; Ruoslahti, E.; 
Alvarez-Vallina, L. Selection Strategies for Anti-Cancer Antibody Discovery: Searching off the 
Beaten Path. Trends Biotechnol. 2015, 33, 292–301. 
180. Mahoney, K. M.; Rennert, P. D.; Freeman, G. J. Combination Cancer Immunotherapy and New 
Immunomodulatory Targets. Nat. Rev. Drug Discov. 2015, 14, 561–584. 
181. Beers, S. A.; Glennie, M. J.; White, A. L. Influence of Immunoglobulin Isotype on Therapeutic 
Antibody Function. Blood 2016, 127, 1097–1101. 
182. Wang, W.; Erbe, A. K.; Hank, J. A.; Morris, Z. S.; Sondel, P. M. NK Cell-Mediated Antibody-
Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front. Immunol. 2015, 6. 
183. Taylor, R. P.; Lindorfer, M. A. Cytotoxic Mechanisms of Immunotherapy: Harnessing 




184. Gong, Q.; Hazen, M.; Marshall, B.; Crowell, S. R.; Ou, Q.; Wong, A. W.; Phung, W.; Vernes, J. 
M.; Meng, Y. G.; Tejada, M.; Andersen, D.; Kelley, R. F. Increased in Vivo Effector Function of 
Human IgG4 Isotype Antibodies through Afucosylation. MAbs 2016, 8, 1098–1106. 
185. Harding, F. A.; Stickler, M. M.; Razo, J.; DuBridge, R. B. The Immunogenicity of Humanized and 
Fully Human Antibodies: Residual Immunogenicity Resides in the CDR Regions. MAbs 2010, 2, 
256–265. 
186. Hamid, O.; Robert, C.; Daud, A.; Hodi, F. S.; Hwu, W.-J.; Kefford, R.; Wolchok, J. D.; Hersey, P.; 
Joseph, R. W.; Weber, J. S.; Dronca, R.; Gangadhar, T. C.; Patnaik, A.; Zarour, H.; Joshua, A. M.; 
Gergich, K.; Elassaiss-Schaap, J.; Algazi, A.; Mateus, C.; et al. Safety and Tumor Responses with 
Lambrolizumab (Anti-PD-1) in Melanoma. N. Engl. J. Med. 2013, 369, 134–144. 
187. Chen, L.; Han, X. Anti – PD-1 / PD-L1 Therapy of Human Cancer : Past , Present , and Future. J. 
Clin. Invest. 2015, 125. 
188. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Schadendorf, 
D.; Dummer, R.; Smylie, M.; Rutkowski, P.; Ferrucci, P. F.; Hill, A.; Wagstaff, J.; Carlino, M. S.; 
Haanen, J. B.; Maio, M.; Marquez-Rodas, I.; McArthur, G. A.; Ascierto, P. A.; et al. Combined 
Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015, 373, 
23–34. 
189. Pedicord, V. a; Montalvo, W.; Leiner, I. M.; Allison, J. P. Single Dose of Anti – CTLA-4 Enhances 
CD8 + T-Cell Memory Formation , Function , and Maintenance. PNAS 2011, 108, 266–271. 
190. Hugo, W.; Zaretsky, J. M.; Sun, L.; Song, C.; Moreno, B. H.; Hu-Lieskovan, S.; Berent-Maoz, B.; 
Pang, J.; Chmielowski, B.; Cherry, G.; Seja, E.; Lomeli, S.; Kong, X.; Kelley, M. C.; Sosman, J. 
A.; Johnson, D. B.; Ribas, A.; Lo, R. S. Genomic and Transcriptomic Features of Response to Anti-
PD-1 Therapy in Metastatic Melanoma. Cell 2016, 165, 35–44. 
191. Van Allen, E. M.; Miao, D.; Schilling, B.; Shukla, S. A.; Blank, C.; Zimmer, L.; Sucker, A.; Hillen, 
U.; Geukes Foppen, M. H.; Goldinger, S. M.; Utikal, J.; Hassel, J. C.; Weide, B.; Kaehler, K. C.; 
Loquai, C.; Mohr, P.; Gutzmer, R.; Dummer, R.; Gabriel, S.; et al. Genomic Correlates of 
Response to CTLA-4 Blockade in Metastatic Melanoma. Science (80-. ). 2015, 350, 207–211. 
277 
 
192. Jahan, N.; Talat, H.; Curry, W. T. Agonist OX40 Immunotherapy Improves Survival in Glioma-
Bearing Mice and Is Complementary with Vaccination with Irradiated GM-CSF–expressing Tumor 
Cells. Neuro. Oncol. 2017, 20, 44–54. 
193. Tyrsin, D.; Chuvpilo, S.; Matskevich, A.; Nemenov, D.; Römer, P. S.; Tabares, P.; Hünig, T. From 
TGN1412 to TAB08: The Return of CD28 Superagonist Therapy to Clinical Development for the 
Treatment of Rheumatoid Arthritis. Clin. Exp. Rheumatol. 2016, 34, 45–48. 
194. Polu, K. R.; Lowman, H. B. Probody Therapeutics for Targeting Antibodies to Diseased Tissue. 
Expert Opin. Biol. Ther. 2014, 14, 1049–1053. 
195. Kermer, V.; Hornig, N.; Harder, M.; Bondarieva, A.; Kontermann, R. E.; Muller, D. Combining 
Antibody-Directed Presentation of IL-15 and 4-1BBL in a Trifunctional Fusion Protein for Cancer 
Immunotherapy. Mol. Cancer Ther. 2014, 13, 112–121. 
196. Yasunaga, M.; Manabe, S.; Matsumura, Y. Immunoregulation by IL-7R-Targeting Antibody-Drug 
Conjugates: Overcoming Steroid-Resistance in Cancer and Autoimmune Disease. Sci. Rep. 2017, 7, 
1–14. 
197. Lerner, R. A. Combinatorial Antibody Libraries: New Advances, New Immunological Insights. 
Nature Reviews Immunology, 2016, 16, 498–508. 
198. Packer, M. S.; Liu, D. R. Methods for the Directed Evolution of Proteins. Nature Reviews Genetics, 
2015, 16, 379–394. 
199. Holliger, P.; Hudson, P. J. Engineered Antibody Fragments and the Rise of Single Domains. Nature 
Biotechnology, 2005, 23, 1126–1136. 
200. Owens, B. Faster, Deeper, Smaller—the Rise of Antibody-like Scaffolds. Nat. Biotechnol. 2017, 
35, 602–603. 
201. Xie, J. H.; Yamniuk, A. P.; Borowski, V.; Kuhn, R.; Susulic, V.; Rex-Rabe, S.; Yang, X. X.; Zhou, 
X. D.; Zhang, Y. F.; Gillooly, K.; Brosius, R.; Ravishankar, R.; Waggie, K.; Mink, K.; Price, L.; 
Rehfuss, R.; Tamura, J.; An, Y.; Cheng, L.; et al. Engineering of a Novel Anti-CD40L Domain 
Antibody for Treatment of Autoimmune Diseases. J. Immunol. 2014, 192, 4083–4092. 
202. Strohl, W. R. Current Progress in Innovative Engineered Antibodies. Protein Cell 2017, 9, 1–35. 
203. Chelius, D.; Ruf, P.; Gruber, P.; Plöscher, M.; Liedtke, R.; Gansberger, E.; Hess, J.; Wasiliu, M.; 
278 
 
Lindhofer, H.; Chelius, D.; Ruf, P.; Gruber, P.; Plöscher, M.; Liedtke, R.; Gansberger, E.; Hess, J.; 
Wasiliu, M.; Structural, H. L.; Chelius, D.; et al. Structural and Functional Characterization of the 
Trifunctional Antibody Catumaxomab Structural and Functional Characterization of the 
Trifunctional Antibody Catumaxomab. 2016, 0862, 309–319. 
204. Huehls, A. M.; Coupet, T. A.; Sentman, C. L. Bispecific T Cell Engagers for Cancer 
Immunotherapy. Immunol. Cell Biol. 2015, 93, 290–296. 
205. Klinger, M.; Brandl, C.; Zugmaier, G.; Hijazi, Y.; Bargou, R. C.; Topp, M. S.; Gökbuget, N.; 
Neumann, S.; Goebeler, M.; Viardot, A.; Stelljes, M.; Hoelzer, D.; Degenhard, E.; Nagorsen, D.; 
Baeuerle, P. a; Wolf, A.; Kufer, P.; Dc, W.; Go, N. Immunopharmacologic Response of Patients 
with B-Lineage Acute Lymphoblastic Leukemia to Continuous Infusion of T Cell − Engaging 
Immunopharmacologic Response of Patients with B-Lineage Acute Lymphoblastic Leukemia to 
Continuous Infusion of T Cell – Engagi. 2013, 119, 6226–6233. 
206. Yuraszeck, T.; Kasichayanula, S.; Benjamin, J. E. Translation and Clinical Development of 
Bispecific T-Cell Engaging Antibodies for Cancer Treatment. Clin. Pharmacol. Ther. 2017, 101, 
634–645. 
207. Lee, K. J.; Chow, V.; Weissman, A.; Tulpule, S.; Aldoss, I.; Akhtari, M. Clinical Use of 
Blinatumomab for B-Cell Acute Lymphoblastic Leukemia in Adults. Ther. Clin. Risk Manag. 
2016, 12, 1301–1310. 
208. Kantarjian, H.; Stein, A.; Gökbuget, N.; Fielding, A. K.; Schuh, A. C.; Ribera, J.-M.; Wei, A.; 
Dombret, H.; Foà, R.; Bassan, R.; Arslan, Ö.; Sanz, M. A.; Bergeron, J.; Demirkan, F.; Lech-
Maranda, E.; Rambaldi, A.; Thomas, X.; Horst, H.-A.; Brüggemann, M.; et al. Blinatumomab 
versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl. J. Med. 2017, 376, 
836–847. 
209. Mack, M.; Riethmuller, G.; Kufer, P. A Small Bispecific Antibody Construct Expressed as a 
Functional Single-Chain Molecule with High Tumor Cell Cytotoxicity. Proc. Natl. Acad. Sci. 1995, 
92, 7021–7025. 
210. Hipp, S.; Tai, Y. T.; Blanset, D.; Deegen, P.; Wahl, J.; Thomas, O.; Rattel, B.; Adam, P. J.; 
Anderson, K. C.; Friedrich, M. A Novel BCMA/CD3 Bispecific T-Cell Engager for the Treatment 
279 
 
of Multiple Myeloma Induces Selective Lysis in Vitro and in Vivo. Leukemia 2017, 31, 1743–
1751. 
211. Iwahori, K.; Kakarla, S.; Velasquez, M. P.; Yu, F.; Yi, Z.; Gerken, C.; Song, X.-T.; Gottschalk, S. 
Engager T Cells: A New Class of Antigen-Specific T Cells That Redirect Bystander T Cells. Mol. 
Ther. 2014. 
212. Ross, S. L.; Sherman, M.; McElroy, P. L.; Lofgren, J. A.; Moody, G.; Baeuerle, P. A.; Coxon, A.; 
Arvedson, T. Bispecific T Cell Engager (BiTE®) Antibody Constructs Can Mediate Bystander 
Tumor Cell Killing. PLoS One 2017, 12, 1–24. 
213. Ryan, J. M.; Mittal, P.; Menoret, A.; Svedova, J.; Wasser, J. S.; Adler, A. J.; Vella, A. T. A Novel 
Biologic Platform Elicits Profound T Cell Costimulatory Activity and Antitumor Immunity in 
Mice. Cancer Immunol. Immunother. 2018, 0, 0. 
214. Chen, Y.; Xu, Y. Pharmacokinetics of Bispecific Antibody. Current Pharmacology Reports, 2017, 
3, 126–137. 
215. Sedykh, S. E.; Prinz, V. V.; Buneva, V. N.; Nevinsky, G. A. Bispecific Antibodies: Design, 
Therapy, Perspectives. Drug Design, Development and Therapy, 2018, 12, 195–208. 
216. Fischer, J. A. A.; Hueber, A. J.; Wilson, S.; Galm, M.; Baum, W.; Kitson, C.; Auer, J.; Lorenz, S. 
H.; Moelleken, J.; Bader, M.; Tissot, A. C.; Tan, S.-L.; Seeber, S.; Schett, G. Combined Inhibition 
of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid 
Arthritis: Development and Characterization of a Novel Bispecific Antibody. Arthritis Rheumatol. 
2015, 67, 51–62. 
217. Lyman, M.; Lieuw, V.; Richardson, R.; Timmer, A.; Stewart, C.; Granger, S.; Woods, R.; Silacci, 
M.; Grabulovski, D.; Newman, R. A Bispecific Antibody That Targets IL-6 Receptor and IL-17A 
for the Potential Therapy of Patients with Autoimmune and Inflammatory Diseases. J. Biol. Chem. 
2018, jbc-M117. 
218. Huang, Y.; Yu, J.; Lanzi, A.; Yao, X.; Andrews, C. D.; Tsai, L.; Gajjar, M. R.; Sun, M.; Seaman, 
M. S.; Padte, N. N.; Ho, D. D. Engineered Bispecific Antibodies with Exquisite HIV-1-
Neutralizing Activity. Cell 2016, 165, 1621–1631. 
219. Steinhardt, J. J.; Guenaga, J.; Turner, H. L.; McKee, K.; Louder, M. K.; O’Dell, S.; Chiang, C. I.; 
280 
 
Lei, L.; Galkin, A.; Andrianov, A. K.; Doria-Rose, N. A.; Bailer, R. T.; Ward, A. B.; Mascola, J. 
R.; Li, Y. Rational Design of a Trispecific Antibody Targeting the HIV-1 Env with Elevated Anti-
Viral Activity. Nat. Commun. 2018, 9. 
220. Pang, X.; Ma, F.; Zhang, P.; Zhong, Y.; Zhang, J.; Wang, T.; Zheng, G.; Hou, X.; Zhao, J.; He, C. 
Treatment of Human B-Cell Lymphomas Using Minicircle DNA Vector Expressing Anti-
CD3/CD20 in a Mouse Model. Hum. Gene Ther. 2017, 28, 216–225. 
221. Oelke, M.; Schneck, J. P. Overview of a HLA-Ig Based “Lego-like System” for T Cell Monitoring, 
Modulation and Expansion. Immunol. Res. 2010, 47, 248–256. 
222. Perica, K.; Kosmides, A. K.; Schneck, J. P. Linking Form to Function: Biophysical Aspects of 
Artificial Antigen Presenting Cell Design. Biochim. Biophys. Acta (BBA)-Molecular Cell Res. 
2015, 1853, 781–790. 
223. Dudley, M. E.; Rosenberg, S. a. Adoptive-Cell-Transfer Therapy for the Treatment of Patients with 
Cancer. Nat. Rev. Cancer 2003, 3, 666–675. 
224. Rosenberg, S. A.; Restifo, N. P. Adoptive Cell Transfer as Personalized Immunotherapy for Human 
Cancer. Science (80-. ). 2015, 348, 62–68. 
225. Busch, D. H.; Fräßle, S. P.; Sommermeyer, D.; Buchholz, V. R.; Riddell, S. R. Role of Memory T 
Cell Subsets for Adoptive Immunotherapy. Semin. Immunol. 2016, 28, 28–34. 
226. Della Bella, S.; Gennaro, M.; Vaccari, M.; Ferraris, C.; Nicola, S.; Riva, A.; Clerici, M.; Greco, M.; 
Villa, M. L. Altered Maturation of Peripheral Blood Dendritic Cells in Patients with Breast Cancer. 
Br. J. Cancer 2003, 89, 1463. 
227. Satthaporn, S.; Robins, A.; Vassanasiri, W.; El-Sheemy, M.; Jibril, J. a; Clark, D.; Valerio, D.; 
Eremin, O. Dendritic Cells Are Dysfunctional in Patients with Operable Breast Cancer. Cancer 
Immunol. Immunother. 2004, 53, 510–518. 
228. Ye, F.; Yu, Y.; Hu, Y.; Lu, W.; Xie, X. Alterations of Dendritic Cell Subsets in the Peripheral 
Circulation of Patients with Cervical Carcinoma. J. Exp. Clin. Cancer Res. 2010, 29, 78. 
229. Curtsinger, J.; Deeths, M. J.; Pease, P.; Mescher, M. F. Artificial Cell Surface Constructs for 




230. Mescher, M. F. Surface Contact Requirements for Activation of Cytotoxic T Lymphocytes. J. 
Immunol. 1992, 149, 2402–2405. 
231. Oelke, M.; Maus, M. V; Didiano, D.; June, C. H.; Mackensen, A.; Schneck, J. P. Ex Vivo Induction 
and Expansion of Antigen-Specific Cytotoxic T Cells by HLA-Ig–coated Artificial Antigen-
Presenting Cells. Nat. Med. 2003, 9, 619–625. 
232. Tham, E. L.; Jensen, P. L.; Mescher, M. F. Activation of Antigen-Specific T Cells by Artificial Cell 
Constructs Having Immobilized Multimeric Peptide-Class I Complexes and Recombinant B7-Fc 
Proteins. J. Immunol. Methods 2001, 249, 111–119. 
233. Motta, I.; Lone, Y. C.; Kourilsky, P. In Vitro Induction of Naive Cytotoxic T Lymphocytes with 
Complexes of Peptide and Recombinant MHC Class I Molecules Coated onto Beads: Role of 
TCR/Ligand Density. Eur. J. Immunol. 1998, 28, 3685–3695. 
234. Hinrichs, C. S.; Borman, Z. a; Gattinoni, L.; Yu, Z.; Burns, W. R.; Klebanoff, C. a; Johnson, L. a; 
Kerkar, S. P.; Yang, S.; Muranski, P.; Palmer, D. C.; Scott, C. D.; Morgan, R. a; Robbins, P. F.; 
Rosenberg, S. a; Restifo, N. P.; Huang, J. Human Effector CD8 + T Cells Derived from Naive 
Rather than Memory Subsets Possess Superior Traits for Adoptive Immunotherapy. October 2011, 
117, 808–814. 
235. Steenblock, E. R.; Fahmy, T. M. A Comprehensive Platform for Ex Vivo T-Cell Expansion Based 
on Biodegradable Polymeric Artificial Antigen-Presenting Cells. Mol. Ther. 2008, 16, 765–772. 
236. Perica, K.; De León Medero, A.; Durai, M.; Chiu, Y. L.; Bieler, J. G.; Sibener, L.; Niemöller, M.; 
Assenmacher, M.; Richter, A.; Edidin, M.; Oelke, M.; Schneck, J. Nanoscale Artificial Antigen 
Presenting Cells for T Cell Immunotherapy. Nanomedicine 2014, 10, 119–129. 
237. Schamel, W. W. A.; Arechaga, I.; Risueño, R. M.; van Santen, H. M.; Cabezas, P.; Risco, C.; 
Valpuesta, J. M.; Alarcón, B. Coexistence of Multivalent and Monovalent TCRs Explains High 
Sensitivity and Wide Range of Response. J. Exp. Med. 2005, 202, 493–503. 
238. Delcassian, D.; Depoil, D.; Rudnicka, D.; Liu, M.; Davis, D. M.; Dustin, M. L.; Dunlop, I. E. 
Nanoscale Ligand Spacing Influences Receptor Triggering in T Cells and NK Cells. Nano Lett. 
2013, 13, 5608–5614. 
239. Matic, J.; Deeg, J.; Scheffold, A.; Goldstein, I.; Spatz, J. P. Fine Tuning and Efficient T Cell 
282 
 
Activation with Stimulatory ACD3 Nanoarrays. Nano Lett. 2013, 13, 5090–5097. 
240. Fang, J.; Nakamura, H.; Maeda, H. The EPR Effect: Unique Features of Tumor Blood Vessels for 
Drug Delivery, Factors Involved, and Limitations and Augmentation of the Effect. Adv. Drug 
Deliv. Rev. 2011, 63, 136–151. 
241. Helle, M.; Rampazzo, E.; Monchanin, M.; Marchal, F.; Guillemin, F.; Bonacchi, S.; Salis, F.; 
Prodi, L.; Bezdetnaya, L. Surface Chemistry Architecture of Silica Nanoparticles Determine the 
Efficiency of in Vivo Fluorescence Lymph Node Mapping. ACS Nano 2013, 7, 8645–8657. 
242. Astete, C. E.; Sabliov, C. M. Synthesis and Characterization of PLGA Nanoparticles. J. Biomater. 
Sci. Polym. Ed. 2006, 17, 247–289. 
243. Danhier, F.; Ansorena, E.; Silva, J. M.; Coco, R.; Le Breton, A.; Préat, V. PLGA-Based 
Nanoparticles: An Overview of Biomedical Applications. J. Control. Release 2012, 161, 505–522. 
244. Perica, K.; Tu, A.; Richter, A.; Bieler, J. G.; Edidin, M.; Schneck, J. P. Magnetic Field-Induced T 
Cell Receptor Clustering by Nanoparticles Enhances T Cell Activation and Stimulates Antitumor 
Activity. ACS Nano 2014, 8, 2252–2260. 
245. Ye, Q.; Song, D.-G.; Poussin, M.; Yamamoto, T.; Best, A.; Li, C.; Coukos, G.; Powell, D. J. 
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in 
Tumor. Clin. Cancer Res. 2014, 20, 44–55. 
246. Hernandez-chacon, J. A.; Li, Y.; Wu, R. C.; Bernatchez, C.; Weber, J.; Hwu, P.; Radvanyi, L. Co-
Stimulation through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-Infiltrating 
Lymphocytes from Activation-Induced Cell Death and Enhances Anti-Tumor Effector Function. 
2012, 34, 236–250. 
247. Zhang, H.; Snyder, K. M.; Suhoski, M. M.; Maus, M. V; Kapoor, V. 4-1BB Is Superior to CD28 
Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy. 2013, 
179, 4910–4918. 
248. Tay, N. Q.; Lee, D. C. P.; Chua, Y. L.; Prabhu, N.; Gascoigne, N. R. J.; Kemeny, D. M. CD40L 
Expression Allows CD8+ T Cells to Promote Their Own Expansion and Differentiation through 
Dendritic Cells. Front. Immunol. 2017, 8. 
249. Singh, M.; Vianden, C.; Cantwell, M. J.; Dai, Z.; Xiao, Z.; Sharma, M.; Khong, H.; Jaiswal, A. R.; 
283 
 
Faak, F.; Hailemichael, Y.; Janssen, L. M. E.; Bharadwaj, U.; Curran, M. A.; Diab, A.; Bassett, R. 
L.; Tweardy, D. J.; Hwu, P.; Overwijk, W. W. Intratumoral CD40 Activation and Checkpoint 
Blockade Induces T Cell-Mediated Eradication of Melanoma in the Brain. Nat. Commun. 2017, 8, 
1–10. 
250. Kosmides, A. K.; Necochea, K.; Hickey, J. W.; Schneck, J. P. Separating T Cell Targeting 
Components onto Magnetically Clustered Nanoparticles Boosts Activation. Nano Lett. 2018, 18. 
251. Poon, I. K. H.; Lucas, C. D.; Rossi, A. G.; Ravichandran, K. S. Apoptotic Cell Clearance: Basic 
Biology and Therapeutic Potential. Nat. Rev. Immunol. 2014, 14, 166–180. 
252. Bruns, H.; Bessell, C.; Varela, J. C.; Haupt, C.; Fang, J.; Pasemann, S.; Mackensen, A.; Oelke, M.; 
Schneck, J. P.; Schütz, C. CD47 Enhances in Vivo Functionality of Artificial Antigen-Presenting 
Cells. Clin. Cancer Res. 2015, 21, 2075–2083. 
253. LEVINE, B. L.; COTTE, J.; SMALL, C. C.; CARROLL, R. G.; RILEY, J. L.; BERNSTEIN, W. 
B.; VAN EPPS, D. E.; HARDWICK, R. A.; JUNE, C. H. Large-Scale Production of CD4+ T Cells 
from HIV-1-Infected Donors after CD3/CD28 Costimulation. J. Hematother. 1998, 7, 437–448. 
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